

Gut

*Journal of the British Society of Gastroenterology which
is a registered charity*

Editor: R N Allan

Technical Editor: Jackie Foulds

Review Editor: D L Wingate

Editorial Assistant: Michelle Dimler

EDITORIAL BOARD

| | | | |
|----------------|-------------|---------------|---|
| D C C Bartolo | T G Cooke | P Quirke | S J W Evans (<i>Statistical adviser</i>) |
| M F Bassendine | C A Hart | D Rampton | |
| R M Batt | C J Hawkey | W D W Rees | Editor <i>British Medical Journal</i> |
| I S Benjamin | J Neuberger | D Swallow | |
| J Calam | D Nolan | I C Talbot | |
| D C A Candy | H O'Connor | B J R Whittle | |
| R Chapman | M E Parsons | | |

INTERNATIONAL ADVISORY BOARD

| | | |
|---|------------------------|--------------------------|
| B S Anand (USA) | D Y Graham (USA) | R Modigliani (France) |
| C Arvanitakis (Greece) | J Hansky (Australia) | T Muto (Japan) |
| G P van Berge Henegouwen (Netherlands) | J Heathcote (Canada) | G Paumgartner (Germany) |
| G Bianchi-Porro (Italy) | R H Hunt (Canada) | E W Pomare (New Zealand) |
| A L Blum (Switzerland) | J R Jass (New Zealand) | D Rachmilewitz (Israel) |
| M van Blankenstein (Netherlands) | S-J Jiang (China) | J Rask-Madsen (Denmark) |
| J P Delmont (France) | S J Konturek (Poland) | E Rene (France) |
| J Dent (Australia) | S K Lam (Hong Kong) | A Torsoli (Italy) |
| | M M Levine (USA) | |
| | J-R Malagelada (Spain) | |

AUTHOR INDEX – MAIN HEADINGS, 1993

- Abad-Lacruz A *see* Esteve-Comas M *et al*
 González-Huix F *et al*
- Abraham P *see* Nagral AS *et al*
- Acer D *see* González-Huix F *et al*
- Acharya S *see* Davies MH *et al*
- Adams DH *see* Ayres RCS *et al*
- Adams G *see* Ogden JM *et al*
- Adams RF *see* Murray KE *et al*
- Adrian TE *et al.* Deoxycholate is an important releaser of peptide YY and enteroglucagon from the human colon, 1219
- Affie E *see* Grobler SP *et al*
- Afschrift M *see* Elewaut A *et al*
- Agarwal DP *see* Seitz HK *et al*
- Aggarwal A *see* Hammer J *et al*
- Ahlistedt S *see* Raab Y *et al*
- Aiso S *see* Hibi T *et al*
- Akazawa F *see* Takahashi M *et al*
- Akkermans LMA *see* van der Sijp JRM *et al*
- Al Jumaili BJ *see* Burke D *et al*
- Al Mardini H *see* Burke D *et al*
- Alderson D *see* Barham CP *et al*
- Aleotti A *see* Caselli M *et al*
- Alexander GJM *see* de Silva DGH *et al*
- Alison MR *see* Goodlad RA *et al*
- Allan RN *see* Stainsby KJ *et al*
 Tan WC and Allan RN
- Allison MC *see* Angerson WJ *et al*
- Almasio P *see* Provenzano G *et al*
- Almer S *et al.* Increased absorption of polyethylene glycol 600 deposited in the colon in active ulcerative colitis, 509
see also Peen E *et al*
- Alvisi V *see* Caselli M *et al*
- Amouyal P *see* Fléjou J-F *et al*
- Anderson JR *see* Leen E *et al*
- Anderson JV *see* Catnach SM *et al*
- Anderson NH *see* Gardiner KR *et al*
- Andrews J. Gastric mucosal phospholipids and gastroduodenal diseases: correspondence, 1741
- Angelin B *see* Eusufzai S *et al*
- Angerson WJ *et al.* Neoterminal ileal blood flow after ileocolonic resection for Crohn's disease, 1531
- Annese V *see* Janssens J *et al*
- Anthony A *see* Sankey EA *et al*
- Anti M *et al.* Rectal epithelial cell proliferation patterns as predictors of adenomatous colorectal polyp recurrence, 525
- Ardill JES *see* El-Omar E *et al*
 McColl KEL *et al*
 Mulholland G *et al*
- Armelao F *see* Anti M *et al*
- Armstrong D *et al.* Prospective multicentre study of risk factors associated with delayed healing of recurrent duodenal ulcers (RUDER), 1319
see also Castiglione F *et al*; Inauen W *et al*
- Armstrong DN *et al.* Bile salt inhibition of motility in the isolated perfused rabbit terminal ileum, 483
- Armstrong JG *see* Evans DGR *et al*
- Arnold R *see* Armstrong D *et al*
- Arranz E *see* Ferguson A *et al*
- Arthurs K *see* Deans GT *et al*
- Asquith P *see* Moran A *et al*
 Panos MZ *et al*
- Atkinson M *see* Robertson CS *et al*
- Attra A *see* Yu RCH *et al*
- Attwood SEA *et al.* Role of intragastric and intraoesophageal alkalinisation in the genesis of complications in Barrett's columnar lined lower oesophagus, 11
- Axelson M *see* Eusufzai S *et al*
- Axon A *see* Thornton J and Axon A
 Cowan RE *et al*
 Lewis WG *et al*
 Lobo AJ *et al*
 Lynch DAF *et al*
- Axon ATR *see* Sobala GM *et al*
- Ayliffe GAJ *see* Cowan RE *et al*
- Ayres RCS *et al.* Intercellular adhesion molecule-1 and MHC antigens on human intrahepatic bile duct cells: effect of pro-inflammatory cytokines, 1245
- Azuma T *et al.* Pepsinogen C gene polymorphisms associated with gastric body ulcer, 450
- Baba S *see* Nakamura S *et al*
- Babbs C *see* Evans DGR *et al*
- Baettig B *et al.* Dieulafoy's disease: endoscopic treatment and follow up, 1418
- Bagshaw JA *see* McColm AA *et al*
- Bailey S *see* Madden MV *et al*
- Bain I *see* Keighley MRB *et al*
- Baker L *see* Tovey FI *et al*
- Bakker CM *see* van Leeuwen ML *et al*
- Ball CS *see* Attwood SEA *et al*
- Ballantyne GH *see* Adrian TE *et al*
 Armstrong DN *et al*
- Ballinger AB *see* Catnach SM *et al*
- Balsitis M *see* Hudson N *et al*
- Bamford KB *et al.* *Helicobacter pylori*: comparison of DNA fingerprints provides evidence for intrafamilial infection, 1348
- Bamonti-Catena F *see* Peracchi M *et al*
- Banerjee S *et al.* Treatment of achalasia: correspondence, 861
- Barbara L *see* Belluzzi A *et al*
- Barber DC *see* Giaffer MH *et al*
- Barbera R *see* Basilisco G *et al*
- Barbier F *see* Elewaut A *et al*
- BardeLLA MT *see* Peracchi M *et al*
- Bardhan KD *see* Hawkey CJ *et al*
 Wodzinski MA *et al*
- Bareggi B *see* Peracchi M *et al*
- Barham CP *et al.* Pressure events surrounding oesophageal acid reflux episodes and acid clearance in ambulant healthy volunteers, 444
- Barlow AP *see* Attwood SEA *et al*
- Baron JH *see* Bowling TE *et al*
- Bartesaghi B *see* Penagini R *et al*
- Bartolo DCC *see* Warren BF *et al*
- Barton CM *et al.* The RB1 tumour suppressor gene in human pancreatic cancer, 1296 abs
- Basile C *see* Sciarretta G *et al*
- Basilisco G *et al.* Acid clearance and oesophageal sensitivity in patients with progressive systemic sclerosis, 1487
- Basson MD *see* Adrian TE *et al*
- Bassotti G, Crowell MD, Whitehead WE. Contractile activity of the human colon: lessons from 24 hour studies, 129
- Battistel M *et al.* Chronic nicotine intake causes vascular dysregulation in the rat gastric mucosa, 1688
- Bauerfeind P *see* Castiglione F *et al*
- Baumer P *see* Schwartz J-C and Baumer P
- Baxter JN *see* Angerson WJ *et al*
 McKay CJ *et al*
- Bayston R *see* Hardy SP *et al*
- Bazzocchi G *see* Di Lorenzo C *et al*
- Bearzi I *see* Catassi C *et al*
- Beattie S *see* Cahill RJ *et al*
- Beglinter C *see* Mossi S *et al*
- Bell SM *see* Scott N *et al*
- Belluzzi A *et al.* Polyunsaturated fatty acid pattern and fish oil treatment in inflammatory bowel disease: correspondence, 1289
- Beneduce F *see* Loguerio C *et al*
- Benhamou JP *see* Marcellin P *et al*
 Lettéron P *et al*
- Beningfield SJ *see* Madden MV *et al*
- Bennett JR *see* Dakkak M *et al*
- Benson M *see* Martin JE *et al*
- Benveniste J *see* Sobhani I *et al*
- Berg P *see* Calès P *et al*
- Bergin A *see* Daly J *et al*
- Bergmann H *see* Stacher G *et al*
- Bernades P *see* Fléjou J-F *et al*
- Berson A *see* Lettéron P *et al*
- Bertrán X *see* Esteve-Comas M *et al*
- Besancón P *see* Zambonino Infante JL *et al*
- Bessent R *see* McColl KEL *et al*
- Besser GM *see* Catnach SM *et al*
- Betschen HU *see* Inauen W *et al*
- Bevers G *see* Porschen R *et al*
- Bhandarkar DS. Endoscopic injection therapy: correspondence, 1150
- Bharucha AE *et al.* Autonomic dysfunction in gastrointestinal motility disorders, 397
- Bhatia SJ *see* Nagral AS *et al*
- Bianchi P *see* Basilisco G *et al*
- Bianchi PA *see* Penagini R *et al*
 Peracchi M *et al*

- Bianchi Porro G et al.** Short and long term outcome of *Helicobacter pylori* positive resistant duodenal ulcers treated with colloidal bismuth subcitrate plus antibiotics or sucralphate alone, 466: correspondence, 1646
- Bickley J** see Bamford KB et al
- Bielanski W** see Konturek SJ et al
- Biemond I et al.** Diagnostic value of serum pepsinogen C in patients with raised serum concentrations of pepsinogen A, 1315
see also Meijer JL et al
- Bijman J** see Wolvekamp MCJ et al
- Bilchik AJ** see Adrian TE et al
- Bilotta J** see Subramani K et al
- Bishop DT** see Stephenson BM et al
- Bjarnason I** see Pearson M et al
Teahon K and Bjarnason I
- Bjerke K et al.** Distribution of macrophages and granulocytes expressing L1 protein (calprotectin) in human Peyer's patches compared with normal ileal lamina propria and mesenteric lymph nodes, 1357
- Blackman G** see Sergeant IR et al
- Blair GE** see Scott N et al
- Blamire AM** see Evans DF et al
- Blann AD.** von Willebrand factor in upper gastrointestinal tract inflammation: correspondence, 288
- Blanshard C** see Forbes A et al
- Blecker U, Vandendras Y.** Serological diagnosis of *Helicobacter pylori*: correspondence, 1467
- Bloomberg B** see Rautelin H et al
- Bloom E** see Cals P et al
- Bloom S et al.** Inappropriate expression of blood group antigens on biliary and colonic epithelia in primary sclerosing cholangitis, 977
- Bloom SL et al.** Adhesion molecule expression in primary sclerosing cholangitis (PSC), 718 abs
- Bloom SR** see Goodlad RA et al
- Blum AL** see Armstrong D et al
Castiglione F et al
Inauen W et al
- Bodemar G** see Peen E et al
- Bodian C** see Subramani K et al
- Boeing H** see Weisgerber UM et al
- Bogentoft C** see Tomlin J et al
- Bok B** see Marcellin P et al
- Boldrini P** see Caselli M et al
- Bonfante F** see Chiarioni G et al
- Bonnière P** see Lescut D et al
- Bontempo I** see Ricci R et al
- Book reviews**
- Adler G, Beglinger C, editors. Cholecystokinin antagonists in gastroenterology, 1991, 863
 - Barrison IG, Anderson MG, McIntyre PB. Gastroenterology in practice, 1992, 864
 - Braga PC, Guslandi M, editors. Drugs in gastroenterology, 1991, 141
 - Brunner G, Mito M, editors. Artificial liver support, 1992, 1468
 - Castell DO. The esophagus, 1992, 141
 - Cotton PB, Tytgat GNJ, Williams CB. Annual of gastrointestinal endoscopy 1992, 864
 - Cuschieri A, Berci G. Laparoscopic biliary surgery, 1992, 1293
 - Davenport HW. A history of gastric secretion and digestion: experimental studies to 1975, 1992, 1151
 - Drossman D, editor. Manual of gastrointestinal procedures, 1992, 863
 - Fuller R, editor. Probiotics: the scientific basis, 1992, 863
 - Givel J-C, Oates GD, Thomson JPS. Updates in coloproctology, 1993, 1468
 - Grant JP. Handbook of total parenteral nutrition, 1992, 863
 - Johnson AG, Triger DR. Liver disease and gallstones: the facts, 1992, 1151
 - Kaplowitz N, editor. Liver and biliary diseases, 1992, 715
 - Kelly MP. Colitis, 1992, 715
 - Lennard-Jones J, Truelove S, editors. Inflammatory bowel disease, 1992, 1152
 - Lessoof MH. Food intolerance, 1992, 864
 - McIntyre N, Benhamou J-P, Bircher J, Rizzetto M, Rodes J, editors. Oxford textbook of clinical hepatology, 1991, 141
 - Marsh M, editor. Coeliac disease, 1992, 715
 - Mitchell DG, Stark DD. Hepatobilary MRI, 1992, 1151
 - Navarro J, Schmitz J. Paediatric gastroenterology, 1992, 142
 - Prieto J, Rodes J, Shafritz DA, editors. Hepatobilary diseases, 1992, 1150
 - Reddick EJ, editor. Atlas of laparoscopic surgery, 1993, 1151
 - Sanford PA. Digestive system physiology, 1992, 864
 - Scarpignato C, editor. Advances in drug therapy of gastro-esophageal reflux disease, 1992, 716
 - Starzl TE. The puzzle people: memoirs of a transplant surgeon, 1992, 862
 - Taylor MB, editor. Gastrointestinal emergencies, 1992, 141
 - Veidenheimer MC, Roberts PL. Colonic diverticular disease, 1991, 141
 - Yeomans ND, editor. Inhibition of gastric secretion. Baillière's Clinical Gastroenterology. Vol 7. No 1. 1993, 1648
- Zollinger RM Jr, Zollinger RM.** Atlas of surgical operations, 7th ed, 1993, 1467
- Booker SV** see Giardiello FM et al
- Booth IW** see Calder CJ et al
- Boothmann P** see Taha AS et al
- Borch K** see Chu M et al
- Borchard F** see Porschen R et al
- Börsch G** see Labenz J et al
- Bose PP** see Broor SL et al
- Bosma NB** see Noach LA et al
- Boston V** see Bamford KB et al
- Bouchier IAD** see Plevris JN et al
Simpson KJ et al
- Bourne BE** see Goggin PM et al
- Bowling TE et al.** Effects of supplemental oxygen on cardiac rhythm during upper gastrointestinal endoscopy: a randomised controlled double blind trial, 1492
- Bown RL** see Catnach SM et al
- Bown SG** see Sergeant IR et al
- Bowyer RC et al.** Effect of a satiating meal on the concentrations of procolipase propeptide in the serum and urine of normal and morbidly obese subjects, 1520
- Bradburn DM, Rhodes M.** Overview of screening and management of familial adenomatous polyposis: correspondence, 575
- Bradburn DM et al.** Colonic fermentation of complex carbohydrates in patients with familial adenomatous polyposis, 630
- Bradfield JWB** see Warren BF et al
- Brading A** see O'Kelly T et al
- Bradley LA** see Singh S et al
- Braegger CP** see Murch SH et al
- Braghetto I** see Csendes A et al
- Bramble MG et al.** Organising unrestricted open access gastroscopy in South Tees: special report, 422: correspondence, 1290
- Brandtzæg P** see Bjerke K et al
Halstensen TS et al
- Breed H** see Pool MO et al
- Breumelhof R** see Timmer R et al
- Brighi S** see Antí M et al
- Brignola C** see Belluzzi A et al
- Bril H** see Pool MO et al
- British-Belgian Gall Stone Study Group** see Hood KA et al
- Brito MJ et al.** DNA ploidy in early gastric carcinoma (T1): a flow cytometric study of 100 European cases, 230
- Britton KE** see Nightingale JMD et al
van der Sijp JRM et al
- Brodrrib AJM** see Roe AM et al
- Broeckaert L** see Rutgeerts P et al
- Broor SL et al.** Long term results of endoscopic dilatation for corrosive oesophageal strictures, 1498
- Brousse N** see Kutlu T et al
- Broussy P** see Calès P et al
- Brown C** see Roe AM et al
- Brown CM et al.** Measurement of bicarbonate output from the intact human oesophagus, 872
- Brown N** see Tomlin J et al
- Brunke G** see Herzig K-H et al
- Brunn PW** see Naji SA et al
- Brzozowski T** see Konturek SJ et al
- Budillon G** see Nardone G et al
- Burditt LJ et al.** Alphafetoprotein variants in hepatocellular carcinoma and benign liver disease, 719 abs
- Burke A** see O'Brien S et al
- Burke D et al.** Culture negative cytotoxin positive stools in community acquired diarrhoea, 192
- Burke DA** see Hawthorne AB et al
- Burke MD** see McKay JA et al
- Burn J** see Bradburn DM et al
- Burnham R** see Farthing MJG et al
- Burroughs A** see Farthing MJG et al
- Burroughs AK** see Lauri A et al
Thompson NP et al
- Butler P et al.** Primary biliary cirrhosis (PBC) specific M2 autoantibodies in patients with recurrent urinary tract infection using an ELISA and purified pyruvate dehydrogenase, 717 abs
- Byrne DJ** see Tait IS et al
- Caballero M** see Martínez-Salmerón JF et al
- Cabré E** see Esteve-Comas M et al
González-Huix F et al
- Cahill RJ et al.** Effects of vitamin antioxidant supplementation on cell kinetics of patients with adenomatous polyps, 963
- Calam J** see Moss SF and Calam J
- Calder CJ et al.** Crohn's disease with pulmonary involvement in a 3 year old boy: case report, 1636
- Calès P et al.** Diffuse vascular ectasia of the antrum, duodenum, and jejunum in a patient with nodular regenerative hyperplasia. Lack of response to portosystemic shunt or gastrectomy: case report, 558

- Camilleri M** see Bharucha AE *et al*
 Hammer J *et al*
 Oosterbosch L *et al*
- Campbell AP** *et al.* Cap polyposis – an unusual cause of diarrhoea: *case report*, 562
- Campbell FC** *et al.* Transplantation of cultured small bowel enterocytes: *leading article*, 1153
- Campieri M** see Belluzzi A *et al*
- Camps J** *et al.* Prediction of the response of chronic hepatitis C to interferon alfa: a statistical analysis of pretreatment variables, 1714
- Candy DCA** see de Silva DGH *et al*
- Cann PA** see Bramble MG *et al*
- Carlsson A** see Tomlin J *et al*
- Carmona C** see Jaramillo JL *et al*
- Carnaby S** see Thillainayagam AV *et al*
- Caselli M** *et al.* Ultrastructural patterns of *Helicobacter pylori*, 1507
- Casey M** see O'Brien S *et al*
- Castagnani R** see Catassi C *et al*
- Castiglione F** *et al.* Nocturnal oesophageal motor activity is dependent on sleep stage, 1653
- Catassi C** *et al.* Dose dependent effects of protracted ingestion of small amounts of gliadin in coeliac disease children: a clinical and jejunal morphometric study, 1515
- Catnach SM** *et al.* Colorectal carcinoma in patients with ulcerative colitis and recent colonoscopy: *case report*, 1148
- Effect of octreotide on gall stone prevalence and gall bladder motility in acromegaly, 270
- Erythromycin induces supranormal gall bladder contraction in diabetic autonomic neuropathy, 1123
- Catterall AP** *et al.* Factors predicting a response to IFN alpha treatment of chronic hepatitis B infection, 717 *abs*
- Causton JS** see Cowan RE *et al*
- Celle G** see Picciotto A *et al*
- Cerf-Bensussan N** see Kutlu T *et al*
- Cevallos AM** see Char S *et al*
- Chalmers N** see Simpson KJ *et al*
- Chao C-F** see Cheng J-Y *et al*
- Chapman PD** see Bradburn DM *et al*
- Chapman RW** see Bloom S *et al*
- Chapman RWG** see Campbell AP *et al*
 Lo SK *et al*
- Char S** *et al.* Impaired IgA response to *Giardia* heat shock antigen in children with persistent diarrhoea and giardiasis, 38
- Chari S** *et al.* Alcohol and gastric acid secretion in humans: *progress report*, 843
- Charlton CPJ** see Lo SK *et al*
- Chart H** see de Silva DGH *et al*
- Chatterton BE** see Yeoh EK *et al*
- Chaussade S, Sogni P.** Concentrations of 5-ASA and AC-5-ASA in human ileocolonic biopsy homogenates: *correspondence*, 713
- Chawla YK** see Chugh S *et al*
- Cheeseman P** see Lo SK *et al*
- Cheng J-Y** *et al.* Human papillomavirus 16 DNA in NIH3T3 cells transformed by colonic cancer cellular DNA, 1710
- Chiarioli G** *et al.* Liquid stool incontinence with severe urgency: anorectal function and effective biofeedback treatment, 1576
- Chijiwa K** see Nakano K and Chijiwa K
- Ching CK** *et al.* Comparison of two sialosyl-Tn binding monoclonal antibodies (MLS102 and B72.3) in detecting pancreatic cancer, 1722
- Chittajallu RS** see McColl KEL *et al*
 Mulholland G *et al*
- Choudari CP, Palmer KR.** Endoscopic injection therapy: *correspondence*, 1150
see also Eastwood MA *et al*
- Christian J** see Hawkey CJ *et al*
- Christiansen KJ** see Cullen DJE *et al*
- Christi SU** *et al.* Methanogenesis in the human large intestine: *correspondence*, 573
- Chu AC** see Yu RCH *et al*
- Chu M** *et al.* Pancreatic hypertrophy with acinar cell nodules after longterm fundectomy in the rat, 988
- Chugh S** *et al.* Polymyositis associated with ulcerative colitis: *case report*, 567
- Cianciosi P** see Picciotto A *et al*
- Cicala M** see Pauletzki J *et al*
- Civeira MP** see Camps J *et al*
- Civiletti C** see Nardone G *et al*
- Clancy T** see Evans DGR *et al*
- Clark ML** see Gorard DA *et al*
 Thillainayagam AV *et al*
- Clarke D** see Bramble MG *et al*
- Classen M** see Armstrong D *et al*
 Neuhaus H *et al*
- Clausen MR** see Hove H *et al*
- Clayton NM** see Trevethick MA *et al*
- Clements D, Rhodes J.** Hormone replacement therapy in chronic active hepatitis: *case report*, 1639
- Clements D** *et al.* Hormone replacement therapy prevents bone loss in patients with inflammatory bowel disease, 1543
- Clingan PR** see Morris DL *et al*
- Cobb CA** see Campbell AP *et al*
- Cochran KM** see Hawkey CJ *et al*
- Cochran M** *et al.* Absorbed aluminium is found with two cytosolic protein fractions, other than ferritin, in the rat duodenum, 643
- Coddington R** see Gillen CD *et al*
- Codoceo R** see Fernandez-Calle P *et al*
- Cole AT, Hawkey CJ.** Acetophan and diarrhoea: *correspondence*, 432
- Cole AT** *et al.* In vivo rectal inflammatory mediator changes with radiotherapy to the pelvis, 1210
- Collins JSA** see Dickey W *et al*
- Collazos J** *et al.* Serum concentrations of laminin in cirrhosis of the liver, 974
- Collins BJ** see Cullen DJE *et al*
 Johnston PW *et al*
- Collins DA** see Goggin PM *et al*
- Collins JSA** see Bamford KB *et al*
 Johnston PW *et al*
- Colombel JF** see Lescut D *et al*
- Compston JE** see Clements D *et al*
- Connell WR** *et al.* Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience, 1081
- Contractor B** see Bramble MG *et al*
- Conway PL** see Murray KE *et al*
- Cook I** see Willing J *et al*
- Cooke TG** see Leen E *et al*
- Cooke WM** see Bramble MG *et al*
- Cooper P** see Wodzinski MA *et al*
- Coppa GV** see Catassi C *et al*
- Corazziari E** see Ricci R *et al*
- Corbett WA** see Bramble MG *et al*
- Corbisley CM** see Goggin PM *et al*
- Cortot A** see Lescut D *et al*
- Costigan DC** see Ryan J and Costigan DC
- Cotton PB.** Biliary endoprosthesis and common bile duct stones: *correspondence*, 574
- Cotton W** see Davies MH *et al*
- Cowan RE** *et al.* Aldehyde disinfectants and health in endoscopy units: *special report*, 1641
- Coxon R** see Evans DF *et al*
- Crabtree JE** *et al.* Systemic and mucosal humoral responses to *Helicobacter pylori* in gastric cancer, 1339
- Crape A** see Elewaut A *et al*
- Craven JL** see Dyke GW *et al*
- Craxi A** see Provenzano G *et al*
- Cripps H** see Heaton KW *et al*
- Cripps NF** see Cowan RE *et al*
- Crisóstomo S** see Camps J *et al*
- Critchley M** see Galil MA *et al*
- Crnojevic L** see Scott-Coombes DM *et al*
- Crobach LFSJ** see Meijer JL *et al*
- Cronin CC** see Gibson GE *et al*
- Crotty B** see Sachdev GK *et al*
- Crowell MD** see Bassotti G *et al*
- Cruickshank A** see Heath DI *et al*
- Cruickshank G** see Reinbach DH *et al*
- Csendes A** *et al.* Location of the lower oesophageal sphincter and the squamous columnar mucosal junction in 109 healthy controls and 778 patients with different degrees of endoscopic oesophagitis, 21
- Csendes P** see Csendes A *et al*
- Cullen DJE** *et al.* When is *Helicobacter pylori* infection acquired? 1681
- Cullen KJ** see Cullen DJE *et al*
- Cummings JH** see Christl SU *et al*
 Gibson GR *et al*
- Curley P** *et al.* Interleukin-2 treatment improves survival in murine acute pancreatitis, 1295 *abs*
- Cuschieri A** see Vander Velpen GC *et al*
- Czernichow B** see Galluser M *et al*
- D'Agostino G** see Anti M *et al*
- Dahill S** see Taha AS *et al*
- Dahill SW** see McColl KEL *et al*
- Dakkak M** *et al.* Oesophagitis is as important as oesophageal stricture diameter in determining dysphagia, 152
- Dalekos GN** *et al.* Soluble interleukin-2 receptors, antineutrophil cytoplasmic antibodies, and other autoantibodies in patients with ulcerative colitis, 658
- Dall FH** *et al.* Biomechanical wall properties of the human rectum. A study with impedance planimetry, 1581
- Dalton HR** see Sachdev GK *et al*
- Daly J** *et al.* Effect of food and anti-cholinergic drugs on the pattern of rectosigmoid contractions, 799
- Dang N** see Chugh S *et al*
- Danielsson D** see Rautelin H *et al*
- Das KM** see Halstensen TS *et al*

- Davids PHP et al.** Bile duct injury after laparoscopic cholecystectomy: the value of endoscopic retrograde cholangiopancreatography, 1250
- Davidson BR.** Progress in determining the nature of bile duct strictures: leading article, 725
- Davidson BR** see also Lauri A et al
- Davidson G** see Lowsky R et al
- Davidson GP** see Willing J et al
- Davies DR** see Evans DGR et al
- Davies JD** see Warren BF and Davies JD
- Davies MH** et al. GSTM1 null polymorphism at the glutathione S-transferase M1 locus: phenotype and genotype studies in patients with primary biliary cirrhosis, 549
- Davies N** et al. Transforming growth factor alpha is trophic to pancreatic cancer in vivo, 1097
- de Boer SY** et al. Effect of acute hyperglycaemia on gall bladder contraction induced by cholecystokinin in humans, 1128
- de Boer WA.** Riedel's thyroiditis, retroperitoneal fibrosis, and sclerosing cholangitis: diseases with one pathogenesis? correspondence, 714
- de Bruin WI** see Stolk MFJ et al
- de Cannière L** see De Ronde Th et al
- De Gando M** see Solis-Herruzo JA et al
- de Jonge HR** see Wolvekamp MCJ et al
- de la Mata M** see Jaramillo JL et al
- De La Torre MP** see Solis-Herruzo JA et al
- de León R** see González-Huix F et al
- De Ronde Th** et al. Thrombosis of splenic artery pseudoaneurysm complicating pancreatitis: case report, 1271
- de Silva DGH, Mendis LN, Sheron N, Alexander GJM, Candy DCA, Charr H, Rowe B.** Concentrations of interleukin 6 and tumour necrosis factor in serum and stools of children with *Shigella dysenteriae* 1 infection, 194
- de Sola C** see Martínez-Salmeron JF et al
- de Teresa J** see Martínez-Salmeron JF et al
- de Vincentiis A** see Loguerio C et al
- De Vitis I** see Antí M et al
- de Vos M.** Concentrations of 5-ASA and AC-5-ASA in human ileocolonic biopsy homogenates: correspondence, 713
see also Elewaut A et al
- de Wit LTh** see Davids PHP et al
- Deans GT** et al. DNA densitometry of colorectal cancer, 1566
- Déchelotte P** et al. Conjugation of 1-naphthol in human gastric epithelial cells, 177
- Deehan DJ** et al. Carcinoid tumour of the gall bladder: two case reports and a review of published works, 1274
- Deen KI** et al. The prevalence of anal sphincter defects in faecal incontinence: a prospective endosonic study, 685
- Degott C** see Lettéron P et al
- Dehn TCB.** Surgery for uncomplicated gastro-oesophageal reflux: correspondence, 428
- Dejong CHC** et al. Intestinal glutamine and ammonia metabolism during chronic hyperammonaemia induced by liver insufficiency, 1112
- Dekker W** see Pool MO et al
- del Vecchio Blanco C** see Loguerio C et al
- Delmotte JS** see Lescut D et al
- Denizot Y** see Sobhani I et al
- Dent J** see Fraser R et al
Ireland AC et al
Willing J et al
- Desjeux JF** see Hiribarren A et al
- Deutschmann C** see Ziegler K et al
- Deutz NEP** see Dejong CHC et al
- Dewsnup PA** see Gomborone JE et al
- Dharwal A** see Plevris JN et al
- Dhillon AP** see Hudson M et al
Lim SG et al
Sankey EA et al
- Di Lorenzo C** et al. Colonic manometry in children with chronic intestinal pseudo-obstruction, 803
- Di Mario F** see Battistel M et al
- Dias JA** see Thillainayagam AV et al
- Díaz F** see Collazos J et al
- Dick R** see Farthing MJG et al
Thompson NP et al
- Dickey W** et al. Secretor status and *Helicobacter pylori* infection are independent risk factors for gastroduodenal disease, 351
- Dilawari JB** see Chugh S et al
- Dilley AV** see Morris DL et al
- DiPaolo MC** see Sachdev GK et al
- Dippold W** et al. Expression of intercellular adhesion molecule 1 (ICAM-1, CD54) in colonic epithelial cells, 1593
- Diquattro O** see Provenzano G et al
- Dixon MF** see Lynch DAF et al
Scott N et al
Sobala GM et al
Stephenson BM et al
- Djurhuus JC** see Dall FH et al
- Dockray GJ** see Nemeth J et al
- Dodd C** see Evans DGR et al
- Dodge JA** see Farthing MJG et al
- Doffoel M** see Galluser M et al
- Doherty DG** et al. DNA polymorphisms in the complement C4 genes in patients with autoimmune hepatitis, 718 abs
- Dolman KM** see Pool MO et al
- Domschke W** see Konturek JW et al
- Donald JJ** see Gillams A et al
- Donnelly RJ** see Gray MR et al
- Dooley JS** see Lauri A et al
- Dorrian CA** see El-Omar E et al
McColl KEL et al
- Dowling RH** see Hood KA et al
Howard PJ et al
- Doyle GJ** et al. Pleural lymphoma in a patient presenting with malabsorption: an illustration of the clinicopathological behaviour in a case of enteropathy associated T cell lymphoma: case report, 1463
- Drain J** see McColl KEL et al
- Dreyfus H** see Galluser M et al
- Driver M** see Tan CEL et al
- Drury PL** see Catnach SM et al
- Duchatelle V** see Lettéron P et al
- Dunne JB** et al. S-Adenosylmethionine improves hepatic function during liver perfusion after sequential cold and warm ischaemic injury, 720 abs
- Durante NMC** see Wolvekamp MCJ et al
- Durkin M** see Sedghi S et al
- Dusheiko G** et al. Hepatitis C virus genotypes: an investigation of type specific differences in geographic origin and disease, 717 abs
- Dyke GW** et al. DNA damage in the stomach after vagotomy measured by ³²P-postlabelling, 1683
- Dykes PW** see Hall C et al
- Eastham EJ** see Thomas JE et al
- Eastwood JB** see Rhodes A et al
- Eastwood MA** et al. Antibodies to *Mycobacterium paratuberculosis*: correspondence, 1291
see also Ghosh S et al
- Eckey R** see Seitz HK et al
- Egerer G** see Seitz HK et al
- Einarsson K** see Eusufzai S et al
- Ekblom A** see Stefánsson T et al
- El-Nujumi AM** see McColl KEL et al
- El-Omar E** et al. Eradicating *Helicobacter pylori* infection lowers gastrin mediated acid secretion by two thirds in patients with duodenal ulcer, 1060
see also McColl KEL et al; Penman ID et al
- Elewaut A** et al. Results of extracorporeal shock wave lithotripsy of gall bladder stones in 693 patients: a plea for restriction to solitary radiolucent stones, 274: correspondence, 1292
- Eliakim R** et al. Octreotide effectively decreases mucosal damage in experimental colitis, 264
see also Ferraris L et al
- Elias E, Laitt R.** Riedel's thyroiditis, retroperitoneal fibrosis, and sclerosing cholangitis: diseases with one pathogenesis? correspondence, 714
see also Davies MH et al
- Ellerbroek PM** see Pool MO et al
- Ellis A** see Tomlin J et al
- Eltringham WK** et al. A laparoscopic technique for full thickness intestinal biopsy and feeding jejunostomy, 122
- Emde C** see Castiglione F et al
Inauen W et al
- Ensari A** et al. Morphometric analysis of intestinal mucosa. V Quantitative histological and immunocytochemical studies of rectal mucosae in gluten sensitivity, 1225
- Epis J** see Cullen DJE et al
- Eremi O** see Deehan DJ et al
- Erwin PJ** see Gardiner KR et al
- Espinier HJ** see Eltringham WK et al
- Esteve-Comas M** et al. Abnormal plasma polyunsaturated fatty acid pattern in non-active inflammatory bowel disease, 1370
Polyunsaturated fatty acid pattern and fish oil treatment in inflammatory bowel disease: correspondence, 1289
- Esteve M** see González-Huix F et al
- Eto T** see Takahashi M et al
- EUROGAST Study Group.** Epidemiology of, and risk factors for, *Helicobacter pylori* infection among 3194 asymptomatic subjects in 17 populations, 1672
- Eusufzai S** et al. Serum 7alpha-hydroxy-4-cholesteno-3-one concentrations in the evaluation of bile acid malabsorption in patients with diarrhoea: correlation to SeHCAT test, 698
- Evans BK** see Pullan RD et al
- Evans D** see Varty K et al

- Evans DF et al.** Prolonged monitoring of the upper gastrointestinal tract using echo planar magnetic resonance imaging: technique, 848
- Evans DGR et al.** Non-penetrance and late appearance of polyps in families with familial adenomatous polyposis, 1389
- Evans GS** see Campbell FC *et al*
- Evans WD** see Clements D *et al*
- Everitt S** see Hudson N *et al*
- Ewen SWB** see McKay JA *et al*
- Extermann M** see Hayoz D *et al*
- Facchinetto D** see Lanzini A *et al*
- Faggioli P** see Peracchi M *et al*
- Fairclough PD** see Catnach SM *et al*
- Farthing MJG *et al*
- O'Donnell LJD and Fairclough PD
- Faris F, Sampliner RE.** Barrett's oesophagus and development of dysplasia and adenocarcinoma: correspondence, 1292
- Farmery SM** see Miller GV *et al*
- Taylor GR and Farmery SM
- Farthing MJG** *et al.* Nature and standards of gastrointestinal and liver services in the United Kingdom: special report, 1728
see also Char S *et al*; Gomborone JE *et al*; Gorard DA *et al*; Thillaianayagam AV *et al*
- Faulder GC** see Davies MH *et al*
- Fawcett J** *et al.* Detection of K ras oncogene mutations in pancreatic juice - a potential diagnostic test for pancreatic adenocarcinoma, 1296 *abs*
- Fékété F** see Fléjou J-F *et al*
- Felsenberg D** see Ziegler K *et al*
- Fenlon H** see O'Brien S *et al*
- Fenton-Lee D** *et al.* PMN-elastase as a prognostic indicator in acute pancreatitis, 1294 *abs*
The relationship of epidermal growth factor receptor (EGF-R), ploidy and S-phase fraction in gastric cancer, 1470 *abs*
- Ferguson A** *et al.* Clinical and pathological spectrum of coeliac disease - active, silent, latent, potential: leading article, 150: correspondence reply, 1740
- Fernández-Bañares F** see Esteve-Comas M *et al*
González-Huix F *et al*
- Fernandez-Boya B** see Solis-Herruzo JA *et al*
- Fernandez-Calle P** *et al.* Is an intestinal permeability test a valid marker for slight dietary transgressions in adolescents with coeliac disease? 774
- Ferraris L** *et al.* Intestinal epithelial cells contribute to the enhanced generation of platelet activating factor in ulcerative colitis, 665
- Ferrer MP** see Solis-Herruzo JA *et al*
- Ferriss JB** see Gibson GE *et al*
- Ficarelli R** see Anti M *et al*
- Fields JZ** see Sedghi S *et al*
- Fierens H** see Van Outryve MJ *et al*
- Figa M** see González-Huix F *et al*
- Filipe MI** see Brito MJ *et al*
- Filipowicz F** see Hudson N *et al*
- Fillmore D** see Mulholland G *et al*
- Finan PJ** see Stephenson BM *et al*
- Finlayson NDC** see Simpson KJ *et al*
- Finnie IA** *et al.* Ileal and colonic epithelial metabolism in quiescent ulcerative colitis: increased glutamine metabolism in distal colon but no defect in butyrate metabolism, 1552: correspondence, 1646
- Fiocchi C** see Ferraris L *et al*
- Fiorentino G** see Provenzano G *et al*
- Fisch C** see Lettéron P *et al*
- Fischer M** see Armstrong D *et al*
- FitzGerald MX** see O'Brien S *et al*
- Fitzsimons EJ** see McColl KEL *et al*
- Fléjou J-F** *et al.* Cystic dystrophy of the gastric and duodenal wall developing in heterotopic pancreas: an unrecognised entity, 343
- Fleming K** see Bloom S *et al*
- Fleming KA** see Lo SK *et al*
- Flores AF** see Di Lorenzo C *et al*
- Florin T.** Methanogenesis in the human large intestine: correspondence, 573
- Foale RA** see Bowring TE *et al*
- Fogg K** see Sande GI *et al*
- Fölsch UR** see Herzog K-H *et al*
- Fone D** see Fraser R *et al*
- Forbes A, Blanshard C, Gazzard B.** Natural history of AIDS related sclerosing cholangitis: a study of 20 cases, 116
- Ford DV** see Williams JG *et al*
- Formela LJ** *et al.* Further characterisation of a new model of acute pancreatitis, 1294 *abs*
- Forrester JC** see Tait IS *et al*
- Foster CS** see Jalleh RP *et al*
- Foster GR, Thomas HC.** Recent advances in the molecular biology of hepatitis B virus: mutant virus and the host response: leading article, 1
- Fowler CJ** see Lemieux M-C *et al*
- Franceschini R** see Picciotto A *et al*
- Franzén L** see Almer S *et al*
Chu M *et al*
- Fraser AG** *et al.* Effect of ranitidine bismuth citrate on postprandial plasma gastrin and pepsinogens, 338
- Fraser G** see Sande GI *et al*
- Fraser R** *et al.* Cholecystokinin octapeptide stimulates phasic and tonic pyloric motility in healthy humans, 33
- Fredlund H** see Rautelin H *et al*
- Fredstrom SB** see Lampe JW *et al*
- Fretland D** see Sedghi S *et al*
- Fromenty B** see Lettron P *et al*
- Fryer AA** see Davies MH *et al*
- Fujimoto H** see Ohkusa T *et al*
- Fujishima M** see Tada S *et al*
- Fullarton GM** see McColl KEL and Fullarton GM
Mulholland G *et al*
- Furno A** see Sciarretta G *et al*
- Galil MA** *et al.* Isotope gastric emptying tests in clinical practice: expectation, outcome, and utility, 916
- Gallacher B** see Sobala GM *et al*
- Galloway SW** see Eltringham WK *et al*
- Gallusser M** *et al.* Comparison of different lipid substrates on intestinal adaptation in the rat, 1069
- Gálvez C** see Jaramillo JL *et al*
- Gamboni G** see Mossi S *et al*
- Ganesh S** see Pullan RD *et al*
Sier CFM *et al*
- Gans ROB** see Pool MO *et al*
- García-Granero M** see Camps J *et al*
- Garcia-Montero M** see Martínez-Salmerón JF *et al*
- Gardiner KR** *et al.* Adsorbents as antiendotoxin agents in experimental colitis, 51
- Garibaldi A** see Picciotto A *et al*
- Garnier RC** see Dyke GW *et al*
- Gassull MA** see Esteve-Comas M *et al*
González-Huix F *et al*
- Gau S-D** see Cheng J-Y *et al*
- Gaupmann G** see Stacher G *et al*
- Gazzard B** see Forbes A *et al*
- Geddes C** see Madden MV *et al*
- Gelernt IM** see Subramani K *et al*
- Gemmell CG** see Taha AS *et al*
- GEMUD** see Ruszniewski Ph *et al*
- Genollá J** see Collazos J *et al*
- Gent AE** see Hartley MG *et al*
- Geoghegan JG** *et al.* Insulinoma: accurate localisation by selective angiography and surgical management, 1296 *abs*
- Gerdin B** see Raab Y *et al*
- Germer C** see Ziegler K *et al*
- Gespach CP** see McKenna P *et al*
- Gevers AM** see Rutgeerts P *et al*
- Ghatei MA** see Goodlad RA *et al*
- Ghosh S** *et al.* Acute gastric dilatation – a delayed complication of percutaneous endoscopic gastrostomy: case report, 859
- Giaffer MH** *et al.* Quantification of disease activity in Crohn's disease by computer analysis of Tc-99m hexamethyl propylene amine oxime (HMPAO) labelled leucocyte images, 68
see also Hawthorne AB *et al*
- Giardiello FM** *et al.* Increased risk of thyroid and pancreatic carcinoma in familial adenomatous polyposis, 1394
- Gibbs P** see Evans DF *et al*
- Gibson GE** *et al.* Reversible bilateral ureteric obstruction due to a pancreatic pseudocyst: case report, 1267
- Gibson GR** *et al.* Sulphate reducing bacteria and hydrogen metabolism in the human large intestine: leading article, 437
see also Christl SU *et al*
- Gibson PR** see McIntyre A *et al*
- Gil A** see Esteve-Comas M *et al*
- Gilat T** see Halpern Z *et al*
- Gilbertson JA** see Jalleh RP *et al*
- Gilliams A** *et al.* The percutaneous rotary lithotrite: a new approach to the treatment of symptomatic cholezystolithiasis, 837
- Gillen CD** *et al.* Extraintestinal lymphoma in association with Whipple's disease: case report, 1627
- Gillespie J** see Davies N *et al*
- Gillespie S** see Lim SG *et al*
- Gionchetti P** see Belluzzi A *et al*
- Giorgi PL** see Catassi C *et al*
- Giorgiannis K** see Ladas SD *et al*
- Gleeson D** see Hood KA *et al*
- Goddard G** see Cochran M *et al*
- Godwin P** see Lobo AJ *et al*
- Goebell H** *et al.* Oroileal transit of slow release 5-aminosalicylic acid, 669
see also Armstrong D *et al*
- Goedde HW** see Seitz HK *et al*

- Goggins PM** *et al.* Prevalence of *Helicobacter pylori* infection and its effect on symptoms and non-steroidal anti-inflammatory drug induced gastrointestinal damage in patients with rheumatoid arthritis, 1677
- Goldacre MJ** *see* Vessey MP *et al*
- Goldberg JA** *see* Leen E *et al*
- Goldschmeding R** *see* Pool MO *et al*
- Gomborone JE** *et al.* Selective affective biasing in recognition memory in the irritable bowel syndrome, 1230
- Gomez-Cerezo J** *see* Fernandez-Calle P *et al*
- González-Huix F** *et al.* Polymeric enteral diets as primary treatment of active Crohn's disease: a prospective steroid controlled trial, 778
see also Esteve-Cornas M *et al*
- Goodlad RA** *et al.* Evaluation of a proposed technique to assess unscheduled DNA synthesis and genotoxicity, 235
- Goodwin CS**. *Helicobacter pylori*: 10th anniversary of its culture in April 1982: *leading article*, 293
- Gorard DA** *et al.* Initial response and subsequent course of Crohn's disease treated with elemental diet or prednisolone, 1198
- Gossé F** *see* Galluser M *et al*
- Gotley DC** *see* Barham CP *et al*
- Goulding H** *see* Gray MR *et al*
- Goussia AC** *see* Dalekos GN *et al*
- Govers MJAP, Van der Meer R.** Effects of dietary calcium and phosphate on the intestinal interactions between calcium, phosphate, fatty acids, and bile acids, 365
- Grace RH** *see* Hartley MG *et al*
- Graham H** *see* McColl KEL *et al*
- Graham S** *see* Adrian TE *et al*
- Granser-Vacariu GV** *see* Stacher G *et al*
- Gray A** *see* Martin JE *et al*
- Gray M.** Assessment of proliferation of squamous, Barrett's, and gastric mucosa in patients with columnar lined Barrett's oesophagus: *correspondence*, 575
- Gray MR** *et al.* Mucosal polyamine metabolism in the columnar lined oesophagus, 584
The role of smoking and alcohol in metaplasia and cancer risk in Barrett's columnar lined oesophagus, 727
- Greaves JL** *see* Washington N *et al*
- Green JRB.** Nasal oxygen during endoscopy: *correspondence*, 288
- Greenfield SM** *et al.* Inhibition of leucocyte adhesion molecule upregulation by tumour necrosis factor alpha: a novel mechanism of action of sulphasalazine, 252
- Greenwall TJ** *et al.* Indocyanine green potentiation of 805 nm diode laser tissue interactions for palliative radiotherapy of advanced carcinoma of the gastric antrum, 1471 *abs*
- Gregersen H** *see* Dall FH *et al*
- Gregor M** *see* Stölzel U *et al*
- Griffin J** *see* Hall C *et al*
- Griffioen G** *see* Sier CFM *et al*
- Griffiths AM** *et al.* Growth and clinical course of children with Crohn's disease, 939
- Grobler S** *see* Keighley MRB *et al*
- Grobler SP** *et al.* Outcome of restorative proctocolectomy when the diagnosis is suggestive of Crohn's disease, 1384
- Grönroos JM** *see* Nevalainen TJ *et al*
- Gruener N** *see* Lerner A *et al*
- Guarner F** *see* Guarner L *et al*
Lugea A *et al*
Mourelle M *et al*
- Guarner L** *et al.* Fate of oral enzymes in pancreatic insufficiency, 708
- Gudjeon M** *see* Heath DI *et al*
- Guérard B** *see* Galluser M *et al*
- Guilera M** *see* González-Huix F *et al*
- Guillou PJ** *see* Davies N *et al*
- Gumaste V.** Serum amylase levels and acute pancreatitis: *correspondence*, 429
- Gunn A** *see* Bradburn DM *et al*
- Guslandi M.** *Helicobacter pylori* positive resistant duodenal ulcers: *correspondence*, 1646
- Gustavsson S** *see* Meyer-Rosberg K and Gustavsson S
- Guy SP** *see* Evans DGR *et al*
- Gyenes E** *see* Labenz J *et al*
- Haddad AM** *see* Hammer J *et al*
- Hadjiminas CL** *see* Bowring TE *et al*
- Haeckl W** *see* Baettig B *et al*
- Hagen S** *see* Naji SA *et al*
- Hall C, Griffin J, Dykes PW, Williams JA, Keighley MRB.** Haemoccult does not reduce the need for colonoscopy in surveillance after curative resection for colorectal cancer, 227
- Hall L** *see* Wardle TD *et al*
- Hall R** *see* Cowan RE *et al*
Dyke GW *et al*
- Hällgren R** *see* Raab Y *et al*
- Halliday J** *see* Cochran M *et al*
- Halliday MI** *see* Gardiner KR *et al*
- Hallissey MT** *et al.* Prognostic factors in gastric cancer, 1471 *abs*
- Halpern Z** *et al.* Effect of phospholipids and their molecular species on cholesterol solubility and nucleation in human and model bile, 110
- Halstensen TS** *et al.* Epithelial deposits of immunoglobulin G1 and activated complement colocalise with the M, 40 kD putative autoantigen in ulcerative colitis, 650
see also Bjerke K *et al*
- Halter F** *et al.* Non-steroidal anti-inflammatory drug-induced jejunal and colonic diaphragm disease: *correspondence*, 715
see also Inauen W *et al*
- Hamblin AS** *see* Greenfield SM *et al*
- Hamilton G** *see* Thompson NP *et al*
- Hamilton H** *see* Cahill RJ *et al*
- Hamilton P** *see* Deans GT *et al*
- Hamilton SR** *see* Giardiello FM *et al*
- Hammer HF.** Colonic hydrogen absorption: quantification of its effect on hydrogen accumulation caused by bacterial fermentation of carbohydrates, 818
- Hammer J** *et al.* Does the ileocolonic junction differentiate between solids and liquids? 222
- Hampton SM** *see* Lovegrove JA *et al*
- Hanson PJ** *see* McKenna P *et al*
- Hanson PJV** *see* Cowan RE *et al*
- Haoot BJ** *see* Campbell AP *et al*
- Hardcastle JD** *see* Evans DF *et al*
Harrison JD *et al*
Watson SA *et al*
- Harding LJ** *see* Notghi A *et al*
- Hardy SP** *et al.* Electrogenic colonic ion transport in Hirschsprung's disease: reduced secretion to the neural secretagogues acetylcholine and iloprost, 1405
- Harman IW** *see* Trevethick MA *et al*
- Harpaz N** *see* Subramani K *et al*
- Harris R** *see* Evans DGR *et al*
- Harrison DJ** *see* Plevris JN *et al*
- Harrison J** *see* Cowan RE *et al*
- Harrison JD** *et al.* Screening for gastric carcinoma in coal miners, 494
- Harrison PM** *et al.* Hepatocyte growth factor mRNA detected in normal and fulminant liver by ribonuclease protection assay, 719 *abs*
- Hart MT** *see* Webberley MJ *et al*
- Hartley MG** *et al.* Adhesive and hydrophobic properties of *Escherichia coli* from the rectal mucosa of patients with ulcerative colitis, 63
- Hatfield ARW** *see* Gilliams A *et al*
- Hawkey CJ** *et al.* Improved symptom relief and duodenal ulcer healing with lansoprazole, a new proton pump inhibitor, compared with ranitidine: *clinical trial*, 1458
see also Cole AT *et al*; Cole AT and Hawkey CJ; Hawthorne AB *et al*; Hudson N *et al*
- Hawthorne AB** *et al.* Double blind trial of oral fluticasone propionate v prednisolone in the treatment of active ulcerative colitis, 125
- Hayakumo T** *see* Azuma T *et al*
- Hayashi A** *see* Hibi T *et al*
- Hayashi K** *see* Azuma T *et al*
- Hayes N** *et al.* Influence of open access endoscopy on the stage of detection of gastric cancer, 1471 *abs*
- Hayes PC** *see* Plevris JN *et al*
Simpson KJ *et al*
- Hayoz D** *et al.* Familial primary gastric lymphoma: *case report*, 136
- Heading RC** *see* Farthing MJG *et al*
- Healey CJ** *see* Shepherd NA *et al*
- Heath DI** *et al.* Role of interleukin-6 in mediating the acute phase protein response and potential as an early means of severity assessment in acute pancreatitis, 41
- Heatley M** *see* Deans GT *et al*
- Heaton KW** *et al.* Bowel function and irritable bowel symptoms after hysterectomy and cholecystectomy – a population based study, 1108
- Heaton ND, Howard ER.** Complications and limitations of injection sclerotherapy in portal hypertension: *leading article*, 7; *correspondence*, 861
- Hegarty JE** *see* O'Brien S *et al*
- Hegele RA** *see* Lowsky R *et al*
- Heidemann M** *see* Jodal M *et al*
- Heinemann E** *see* Wolvekamp MCJ *et al*
- Hellier MD** *see* Hartley MG *et al*
- Henriquez A** *see* Csendes A *et al*
- Hermon-Taylor J** *see* Bowyer RC *et al*
- Hernandez Muñoz I** *see* Solis-Herruzo JA *et al*
- Heryet A** *see* Bloom S *et al*
- Herzig K-H** *et al.* Mechanism of Galanin's inhibitory action on pancreatic enzyme secretion: modulation of cholinergic transmission – studies *in vivo* and *in vitro*, 1616
- Heyman M** *see* Hiribarren A *et al*
- Heymans HSA** *see* van Elburg RM *et al*
- Heys SD** *see* Deehan DJ *et al*
- Hibi T** *et al.* Interleukin 2 and interferon-gamma augment anticolon antibody dependent cellular cytotoxicity in ulcerative colitis, 788
- Hiele M** *see* Rutgeerts P *et al*

- Hift RJ** *et al.* Hepatoerythropoietic porphyria precipitated by viral hepatitis: *case report*, 1632
- Hillan KJ** *see* Penman ID *et al*
- Hills BA**. Gastric mucosal barrier: evidence for *Helicobacter pylori* ingesting gastric surfactant and deriving protection from it, 588
- Hiribarren A** *et al.* Effect of cytokines on the epithelial function of the human colon carcinoma cell line HT29 cl 19A, 616
- Hoang P** *see* Campbell AP *et al*
- Sachdev GK *et al*
- Hoare RC** *see* Dakkak M *et al*
- Hochlaf S** *see* Sobhani I *et al*
- Hodgson HJF** *see* Vesey DA *et al*
- Hoffman J** *see* Gray MR *et al*
- Hoffmann W** *see* Neuhaus H *et al*
- Holdsworth CD** *see* Giaffer MH *et al*
- Hawthorne AB *et al*
- Holdsworth PJ** *see* Lewis WG *et al*
- Holl J** *see* Pauletzki J *et al*
- Holloway RH** *see* Ireland AC *et al*
- Holly JMP** *see* Thomas AG *et al*
- Holmes G** *see* Scott B and Holmes G
- Holmes GKT** *see* Ching CK *et al*
- Holmes SW** *see* Ching CK *et al*
- Holzer P** *see* Battistel M *et al*
- Pabst MA *et al*
- Hood KA** *et al.* Gall stone recurrence and its prevention: the British/Belgian gall stone study group's post-dissolution trial: *special report*, 1277
- Horowitz M** *see* Fraser R *et al*
- Yeoh EK *et al*
- Horton MDA'C** *see* Morris DL *et al*
- Horton RC** *see* Lauri A *et al*
- Hosie KB** *see* Grobler SP *et al*
- Hosoda Y** *see* Hibi T *et al*
- Hosoi H** *see* Ohkusa T *et al*
- Houe D** *see* Dall FH *et al*
- Hove H** *et al.* Lactate and pH in faeces from patients with colonic adenomas or cancer, 625
- Howard ER** *see* Heaton ND and Howard ER
- Tan CEL *et al*
- Howard PJ** *et al.* New theories based on inappropriate application of high technology: *correspondence*, 430
- Howdle P** *see* Wong V *et al*
- Huber T** *see* Inauen W *et al*
- Huber TH** *see* Halter F *et al*
- Hudson M** *et al.* Factor XIIIa subunit and Crohn's disease, 75
see also Fraser AG *et al*; Sankey EA *et al*
- Hudson MJ** *see* Hartley MG *et al*
- Hudson N** *et al.* Effect of *Helicobacter pylori* colonisation on gastric mucosal eicosanoid synthesis in patients taking non-steroidal anti-inflammatory drugs, 748
Enhanced gastric mucosal leukotriene B₄ synthesis in patients taking non-steroidal anti-inflammatory drugs, 742
- Hughes AO** *see* Probert CSJ *et al*
- Huibregtsse K** *see* Davids PHP *et al*
- Hungin AS** *see* Bramble MG *et al*
- Hunt JB** *see* Gorard DA *et al*
- Hunter JO** *see* Middleton SJ *et al*
- Husband EM** *see* Tovey FI *et al*
- Hutton RA** *see* Hudson M *et al*
- Hyman PE** *see* Di Lorenzo C *et al*
- Iancu TC** *see* Lerner A *et al*
- Ibbotson JP** *see* Stainsby KJ *et al*
- Ichikawa H** *see* Yoshikawa T *et al*
- Iftikhar SY, Steel RJC**. Barrett's oesophagus and development of dysplasia and adenocarcinoma: *correspondence*, 1292
- Iftikhar SY** *et al.* Assessment of proliferation of squamous, Barrett's, and gastric mucosa in patients with columnar lined Barrett's oesophagus: *correspondence*, 575
- Iida M** *see* Tada S *et al*
- Iinuma S** *see* Yoshikawa T *et al*
- Imrie CW** *see* Heath DI *et al*
- McKay CJ *et al*
- Inauen W** *et al.* Effects of ranitidine and cisapride on acid reflux and oesophageal motility in patients with reflux oesophagitis: a 24 hour ambulatory combined pH and manometry study, 1025
- Inokuchi H** *see* Azuma T *et al*
- Ireland AC** *et al.* Mechanisms underlying the antireflux action of fundoplication, 303
- Isolauri J** *see* Luostarinen M *et al*
- Iwao Y** *see* Hibi T *et al*
- Jaakkola M, Nordback I**. Pancreatitis in Finland between 1970 and 1989, 1255
- Jackson PA** *see* Goggin PM *et al*
- Jacyna MR** *see* Phull PS and Jacyna MR
- Jahnsen F** *see* Bjerke K *et al*
- Jalleh RP** *et al.* Expression of major histocompatibility antigens in human chronic pancreatitis, 1452
- James PD** *see* Iftikhar SY *et al*
- Jameson JS, Misiewicz JJ**. Colonic motility: practice or research? *leading article*, 1009
- Jankowski J**. Gene expression in Barrett's mucosa: acute and chronic adaptive responses in the oesophagus: *leading article*, 1649
- Janowitz HD** *see* Subramani K *et al*
- Jansen JBMJ** *see* Biemond I *et al*
- de Boer SY *et al*
- Meijer JL *et al*
- Stolk MFJ *et al*
- Janssens J** *et al.* Bursts of non-delutitive simultaneous contractions may be a normal oesophageal motility pattern, 1021
- Jansson M** *see* Jodal M *et al*
- Jaramillo JL** *et al.* Efficacy of the heater probe in peptic ulcer with a non-bleeding visible vessel. A controlled, randomised study, 1502
- Järnerot G** *see* Rautelin H *et al*
- Järvinen H** *see* Sjöblom SM *et al*
- Jaspersen D**. Dieulafoy's disease controlled by Doppler ultrasound endoscopic treatment: *case report*, 857
- Jayanthi V, Mayberry JF**. Oral submucous fibrosis – a chronic disseminated intravascular coagulation syndrome with local coagulopathy: *correspondence*, 713
see also Probert CSJ *et al*
- Jayaraj AP** *see* Tovey FI *et al*
- Jazrawi RP** *see* Goggin PM *et al*
- Jebbink MCW** *see* de Boer SY *et al*
- Jeejeebhoy KN** *see* Lowsky R *et al*
- Jehanli A** *see* Heath DI *et al*
- Jehanli AMT** *see* Bowyer RC *et al*
- Jenkins AP, Thompson RPH**. Does the fatty acid profile of dietary fat influence its trophic effect on the small intestinal mucosa? 358
- Jenkinson L** *see* Attwood SEA *et al*
- Jewell DP** *see* Campbell AP *et al*
- Morita H *et al*
- Sachdev GK *et al*
- Jeyasingham K** *see* Pappas G *et al*
- Jocic M** *see* Battistel M *et al*
- Jodal M** *et al.* Nerve involvement in fluid transport in the inflamed rat jejunum, 1526
- Johnson AG, Ross B**. Extracorporeal shock wave lithotripsy and gall bladder stones: *correspondence*, 1291
see also Kerrigan DD *et al*; Smythe A *et al*
- Johnson MA** *see* Lim SG *et al*
- Johnston BT** *see* Bamford KB *et al*
- Johnston PW *et al*
- Johnston D** *see* Lewis WG *et al*
- Lobo AJ *et al*
- Johnston IDA** *see* Bradburn DM *et al*
- Johnston PW** *et al.* Audit of the role of oesophageal manometry in clinical practice, 1158
- Jones DB** *see* Katelaris PH *et al*
- Jones DEJ** *et al.* T-cell response to the major human mitochondrial autoantigen in primary biliary cirrhosis, 718 *abs*
- Jones R** *see* Farthing MJG *et al*
- Joplin R** *see* Ayres RCS *et al*
- Jorgensen CS** *see* Dall FH *et al*
- Joshi AS** *see* Nagral AS *et al*
- Jost R** *see* Baettig B *et al*
- Joypaul BV** *et al.* Serodiagnostic values of CA 72-4 and CA 19-9 in the monitoring of patients with gastric carcinoma, 1470 *abs*
- Kachelhofer J** *see* Galluser M *et al*
- Kamm MA** *see* Connell WR *et al*
- Lemieux M-C *et al*
- Nightingale JMD *et al*
- Speakman CTM and Kamm MA
- van der Sijp JRM *et al*
- Kanai T** *see* Hibi T *et al*
- Kaneko T** *see* Yoshikawa T *et al*
- Kapila L** *see* Varty K *et al*
- Kapoor VK**. Colonic tuberculosis: *correspondence*, 429
- Kapur P** *see* Davies N *et al*
- Karanja ND** *et al.* The compartment syndrome of chronic pancreatitis, 1295 *abs*
- Karmeli F** *see* Eliakim R *et al*
- Ferraris L *et al*
- Kataoka K** *see* Ohkusa T *et al*
- Katelaris PH** *et al.* Effect of age, *Helicobacter pylori* infection, and gastritis with atrophy on serum gastrin and gastric acid secretion in healthy men, 1032
- Kawai K** *see* Azuma T *et al*

- Kawser CA** *et al.* Regulation of lipocyte derived alpha2-macroglobulin and 72 kDa type IV collagenase/gelatinase by Kupffer cell medium and dexamethasone, 719 *abs*
- Keech ML** *see* Hawthorne AB *et al*
- Keighley MRB** *et al.* An audit of restorative proctocolectomy, 680
see also Deen KI *et al*; Grobler SP *et al*; Hall C *et al*
- Kelley NC** *see* Giardiello FM *et al*
- Kelly EJ** *et al.* Immunocytochemical localisation of parietal cells and G cells in the developing human stomach, 1057
- Kent PW** *see* Morita H *et al*
- Kenyon WE** *see* Gray MR *et al*
- Kernohan N** *see* Deegan DJ *et al*
- Kerrigan DD** *et al.* Acid, motility, and ulcers: a comparison of cisapride with placebo in the prevention of duodenal ulcer relapse, 1042
- Keshavarzian A** *see* Sedghi S *et al*
- Kesteven PJL** *see* Doyle GJ *et al*
- Kettlewell M** *see* Campbell AP *et al*
- Kettlewell MGW** *see* Morita H *et al*
- Keyriläinen O** *see* Luostarinen M *et al*
- Kingsnorth AN** *see* Gray MR *et al*
- Kino I** *see* Nakamura S *et al*
- Kishi A** *see* Yoshikawa T *et al*
- Kitamoto T** *see* Tada S *et al*
- Kitano A** *see* Oshitani N *et al*
- Klamut M** *see* Sedghi S *et al*
- Klein J** *see* Ferraris L *et al*
- Klotz U** *see* Goebell H *et al*
- Knecht H** *see* Hayoz D *et al*
- Kobayashi K** *see* Oshitani N *et al*
- Kodama T** *see* Azuma T *et al*
- Kondo M** *see* Yoshikawa T *et al*
- Konishi T** *see* Takahashi M *et al*
- Konturek JW** *et al.* Cholecystokinin in the control of gastric acid secretion in man, 321
- Konturek SJ** *et al.* Fibroblast growth factor in gastroprotection and ulcer healing: interaction with sucralfate, 881
see also Konturek JW *et al*
- Koppeschaar HPF** *see* Stolk MFJ *et al*
- Korolkiewicz R** *see* Lambrecht N *et al*
- Kortesuo PT** *see* Nevalainen TJ *et al*
- Koskinen M** *see* Luostarinen M *et al*
- Kost LJ** *see* Oosterbosch L *et al*
- Koszka C** *see* Störlzel U *et al*
- Krausz T** *see* Yu RCH *et al*
- Krenz HK** *see* Armstrong DN *et al*
- Kreuning J** *see* Biemond I *et al*
- Krige JEJ** *see* Madden MV *et al*
- Krishnamurthy GT**. New theories based on inappropriate application of high technology: *correspondence*, 430
- Krush AJ** *see* Giardiello FM *et al*
- Kugi A** *see* Stacher G *et al*
- Kumar A** *see* Broor SL *et al*
- Kumar D** *see* Deen KI *et al*
Notghi A *et al*
- Kutlu T** *et al.* Numbers of T cell receptor (TCR) alpha-beta+ but not of TCR gamma-delta+ intraepithelial lymphocytes correlate with the grade of villous atrophy in coeliac patients on a long term normal diet, 208
- Kyoi T** *see* Ohkusa T *et al*
- La Bella A** *see* Ricci R *et al*
- Labenz J** *et al.* Amoxicillin plus omeprazole *versus* triple therapy for eradication of *Helicobacter pylori* in duodenal ulcer disease: a prospective, randomized, and controlled study, 1167
- Laccetti P** *see* Nardone G *et al*
- Lacey JH** *see* Bowyer RC *et al*
- Lacy D** *see* Calder CJ *et al*
- Ladas SD** *et al.* Complex carbohydrate malabsorption in exocrine pancreatic insufficiency, 984
- Lagopoulos M** *see* Kelly EJ *et al*
- Lahoti D** *see* Broor SL *et al*
- Laitinen J** *see* Luostarinen M *et al*
- Laitt R** *see* Elias E and Laitt R
- Lam WM** *see* Fraser AG *et al*
- Lambrecht N** *et al.* Role of eicosanoids, nitric oxide, and afferent neurons in antacid induced protection in the rat stomach, 329
- Lamers CBHW** *see* Biemond I *et al*
de Boer SY *et al*
Meijer JL *et al*
Sier CFM *et al*
Stolk MFJ *et al*
- Lammer F** *see* Baettig B *et al*
- Lamont G** *see* Evans DF *et al*
- Lampe JW** *et al.* Sex differences in colonic function: a randomised trial, 531
- Langman MJS** *see* Singh S *et al*
- Lanzini A** *et al.* Postprandial biliary and pancreatic secretion during profound inhibition of gastric secretion in humans, 1607
- Larusso NF** *see* Sandborn WJ *et al*
- Larvin M** *et al.* A prospective, multicentre, controlled, randomised trial of intraperitoneal trasylol treatment for acute pancreatitis, 1295 *abs*
- Laufer H** *see* Halpern Z *et al*
- Lauri A** *et al.* Endoscopic extraction of bile duct stones: management related to stone size, 1718
- Layer P** *see* Goebell H *et al*
- Lazzaroni M** *see* Bianchi Porro G *et al*
- Le Diest F** *see* Kutlu T *et al*
- Lecomte-Houcke M** *see* Lescut D *et al*
- Lee CA** *see* Lim SG *et al*
- Lee CY** *see* Goodlad RA *et al*
- Lee DH** *see* Giardiello FM *et al*
- Lee FD** *see* Taha AS *et al*
- Lee S-D** *see* Lin H-J *et al*
- Leen E** *et al.* Hepatic perfusion changes in patients with liver metastases: comparison with those patients with cirrhosis, 554
- Lees WR** *see* Gillams A *et al*
- Lehtinen E** *see* Luostarinen M *et al*
- Leicester R** *see* Farthing MJG *et al*
- Leicester RJ** *see* Cowan RE *et al*
- Lemieux M-C** *et al.* Bowel dysfunction in young women with urinary retention, 1397
- Lemkes HHPJ** *see* de Boer SY *et al*
- Lemoine NR** *see* McLellan EA *et al*
- Lennard-Jones JE** *see* Connell WR *et al*
Nightingale JMD *et al*
van der Sijp JRM *et al*
- Lerner A** *et al.* Serum creatinine concentrations in coeliac disease, 933
- Lescut D** *et al.* Perioperative endoscopy of the whole small bowel in Crohn's disease, 647: *correspondence*, 1741
- Lettéron P** *et al.* Increased ethane exhalation, an in vivo index of lipid peroxidation, in alcohol-abusers, 409
- Levi AJ** *see* Pearson M *et al*
- Lewin MJ** *see* Sobhani I *et al*
- Lewis F** *see* Wong V *et al*
- Lewis WG** *et al.* Restorative proctocolectomy with end to end pouch-anastomosis in patients over the age of fifty, 948
- L'Helgouac'h A** *see* Hiribarren A *et al*
- Libby GW** *see* Gomborone JE *et al*
- Lim SG** *et al.* Audit of endoscopic surveillance biopsy specimens in HIV positive patients with gastrointestinal symptoms, 1429
- Lin BPC** *see* Ketelaars PH *et al*
- Lin H-J** *et al.* Is sclerosant injection mandatory after an epinephrine injection for arrest of peptic ulcer haemorrhage? A prospective, randomised, comparative study, 1182
- Lin J-C** *see* Cheng J-Y *et al*
- Linhart NC** *see* Marcellin P *et al*
- Lipman MC** *see* Lim SG *et al*
- Lippe IT** *see* Battistel M *et al*
- Liszskay M** *see* Lambrecht N *et al*
- Lo SK** *et al.* Antineutrophil antibody: a test for autoimmune primary sclerosing cholangitis in childhood? 199
- Lobo AJ** *et al.* Carriage of adhesive *Escherichia coli* after restorative proctocolectomy and pouch anal anastomosis: relation with functional outcome and inflammation, 1379
see also Lynch DAF *et al*
- Loening-Baucke V**. Constipation in early childhood: patient characteristics, treatment, and longterm follow up, 1400
- Loft DE** *see* Ensari A *et al*
- Loguercio C** *et al.* Glutathione prevents ethanol induced gastric mucosal damage and depletion of sulphydryl compounds in humans, 161
- Loizou LA** *see* Sargeant IR *et al*
- Long RG** *see* Ching CK *et al*
Hawkey CJ *et al*
McIntyre AS and Long RG
Sayer JM and Long RG
- Longo WE** *see* Adrian TE *et al*
- Longstreth GF**. Hysterectomy and the irritable bowel: *correspondence*, 429
- Lonsdale RN**. Microvascular abnormalities in the mucosal prolapse syndrome, 106: *correspondence*, 714
- Louw JA** *see* Ogden JM *et al*
- Love AHG** *see* Johnston PW *et al*
- Lovegrove JA** *et al.* Transfer of cow's milk beta-lactoglobulin to human serum after a milk load: a pilot study, 203
- Low PA** *see* Bharucha AE *et al*
- Lowes JR** *see* Stainsby KJ *et al*
- Lowsky R** *et al.* Familial visceral myopathy associated with a mitochondrial myopathy: *case report*, 279
- Lucarotti M** *et al.* Patient selection and timing of dynamic computed tomography in acute pancreatitis, 1294 *abs*
- Ludwigson N** *see* Cochran M *et al*
- Lugea A** *et al.* Influence of dietary fat on duodenal resistance to acid, 1303

- Luk YW *see* Fraser AG *et al*
 Lundgren O *see* Jodal M *et al*
 Luostarinen M *et al*. Fate of Nissen fundoplication after 20 years. A clinical, endoscopic, and functional analysis, 1015
 Lynch DAF *et al*. Failure of colonoscopic surveillance in ulcerative colitis, 1075
see also Sobala GM *et al*
- McArdle CS *see* Leen E *et al*
 McCaigue MD *see* Gardiner KR *et al*
 McColl KEL, Fullarton GM. Duodenal ulcer pain – the role of acid and inflammation: *leading article*, 1300
see also El-Omar E *et al*; Mulholland G *et al*; Penman ID *et al*; Reinbach DH *et al*
 McColl KEL *et al*. A study of the pathogenesis of *Helicobacter pylori* negative chronic duodenal ulceration, 762
 McColm AA, Bagshaw JA, O'Malley CF. Development of a ^{14}C -urea breath test in ferrets colonised with *Helicobacter mustelae*: effects of treatment with bismuth, antibiotics, and urease inhibitors, 181
 McCruden EAB *et al*. Viral hepatitis in intravenous drug misusers dying from heroin overdose, 717 *abs*
 McCulloch P. Health education in the early detection of gastric cancer, 1471 *abs*
 McDermott V. Bleeding varices in the elderly: *correspondence*, 576
 MacDonald TT *see* Murch SH *et al*
 McElree C *see* Yang H *et al*
 Macfarlane GT *see* Gibson GR *et al*
 McGregor JR *see* Penman ID *et al*
 McIntyre A *et al*. Butyrate production from dietary fibre and protection against large bowel cancer in a rat model, 386
 McIntyre AS, Long RG. Prospective survey of investigations in outpatients referred with iron deficiency anaemia, 1102
 MacIntyre M *see* Eastwood MA *et al*
 McKay C *et al*. Monocyte production of tumour necrosis factor in acute pancreatitis is related to outcome, 1294 *abs*
 McKay CJ *et al*. Somatostatin and somatostatin analogues – are they indicated in the management of acute pancreatitis? 1622
 McKay JA *et al*. Xenobiotic metabolising enzyme expression in colonic neoplasia, 1234
 McKenna P *et al*. Protein kinase C inhibits cyclic adenosine monophosphate generation by histamine and truncated glucagon like peptide 1 in the human gastric cancer cell line HGT-1, 953
 Mackie CR *see* Galil MA *et al*
 McLellan EA *et al*. High frequency of K-ras mutations in sporadic colorectal adenomas, 392
 MacMillan JH *see* Griffiths AM *et al*
 Madden MV *et al*. Randomised trial of targeted chemotherapy with lipiodol and 5-epidoxorubicin compared with symptomatic treatment for hepatoma, 1598
 Maeda Y *see* Takahashi M *et al*
 Majka J *see* Konturek SJ *et al*
 Malagelada J-R *see* Guarner L *et al*
Lugea A et al
Mourelle M et al
 Malagutti P *see* Sciarretta G *et al*
 Maluenda F *see* Csédes A *et al*
 Mani V *see* Pullan RD *et al*
 Manning AP *see* Cowan RE *et al*
 Manoussakis MN *see* Dalekos GN *et al*
 Mansfield P *see* Evans DF *et al*
 Marcellin P *et al*. Thyroid function and interferon treatment in chronic hepatitis C: *correspondence*, 574
 Marino L *see* Provenzano G *et al*
 Markkula H *see* Luostarinen M *et al*
 Marks IN *see* Ogden JM *et al*
 Marquet RL *see* Wolvekamp MCJ *et al*
 Marra G *see* Anti M *et al*
 Marsh MN. Clinical and pathological spectrum of coeliac disease: *correspondence*, 1740
see also Ensari A *et al*
 Marshall J *see* Cochran M *et al*
 Martin BAB *see* Robertson CS *et al*
 Martin JE *et al*. Myofibroblasts in hollow visceral myopathy: the origin of gastrointestinal fibrosis? *case report*, 999
 Martínez-Salmerón JF *et al*. Epidemiology of inflammatory bowel disease in the Province of Granada, Spain: a retrospective study from 1979-1988, 1207
 Martins EBG *et al*. Positive association between gamma/delta T-lymphocytes and autoimmune liver disease, 718 *abs*
 Masaoka Y *see* Takahashi M *et al*
 Masclee AAM *see* de Boer SY *et al*
 Maslin SC *see* Dakkak M *et al*
 Mathan VI *see* Ramakrishna BS and Mathan VI
 Mather SJ *see* Nightingale JMD *et al*
van der Sijp JRM et al
 Mathers JC *see* Bradburn DM *et al*
- Mathias PM *see* Cahill RJ *et al*
 Matsugu Y *see* Takahashi M *et al*
 Matsumoto T *see* Oshitani N *et al*
 Mayberry JF *see* Jayanthi V and Mayberry JF
Probert CSJ et al
 Mayet W *see* Dippold W *et al*
 Mazzoni M *see* Sciarretta G *et al*
 Mearin ML *see* Mulder CJJ *et al*
 Mehai WZ *et al*. Primary HLA DRw52a and Dw2 associations in a primary sclerosing cholangitis (PSC) population, 718 *abs*
 Meijer JL *et al*. Inhibition of omeprazole induced hypergastrinaemia by SMS 201-995, a long acting somatostatin analogue in man, 1186
 Meissner PN *see* Hift RJ *et al*
 Melange M *see* De Ronde Th *et al*
 Melia NP *see* Farthing MJG *et al*
 Melikian V *see* Webberley MJ *et al*
 Melvin WT *see* McKay JA *et al*
 Mendis LN *see* de Silva DGH *et al*
 Meng C-L *see* Cheng J-Y *et al*
 Mentha G *see* Robert JH *et al*
 Merki HS *see* Inauen W *et al*
Mossi S et al
 Meuwissen SGM *see* Pool MO *et al*
 Meyer HJ *see* Déchélotte P *et al*
 Meyer-Rosberg K, Gustavsson S. ^{13}C -urea breath test for diagnosis of experimental *Helicobacter pylori* infection in barrier born pigs, 594
 Meyer-Wyss B *see* Mossi S *et al*
 Meyer zum Büschelenfeld K-H *see* Dippold W *et al*
 Meyssen MAC *see* Wolvekamp MCJ *et al*
 Middleton SJ *et al*. Relaxation of distal colonic circular smooth muscle by nitric oxide derived from human leucocytes, 814
 Mieli-Vergani G *see* Lo SK *et al*
 Miglioli M *see* Belluzzi A *et al*
 Mignoni M *see* Russniewski Ph *et al*
Sobhani I et al
 Miller G *see* Crabtree JE *et al*
 Miller GV *et al*. Somatostatin binding in human gastrointestinal tissues: effect of cations and somatostatin analogues, 1351
 Miller R *see* Barham CP *et al*
 Miller V *see* Thomas AG *et al*
 Mills A *see* Barham CP *et al*
 Miño G *see* Jaramillo JL *et al*
 Misiewicz JJ *see* Gorard DA *et al*
Jameson JS and Misiewicz JJ
Rogers J et al
 Mistry FP *see* Nagral AS *et al*
 Modlin IM *see* Adrian TE *et al*
Armstrong DN et al
 Molas G *see* Fléjou J-F *et al*
 Molero X *see* Mourelle M *et al*
 Molgora M *see* Basilisco G *et al*
 Molteni N *see* Peracchi M *et al*
 Moncada S *see* Mourelle M *et al*
 Monteith PG *see* Gillen CD *et al*
 Moore K *et al*. Increased lipid peroxidation in hepatorenal syndrome, 719 *abs*
 Moran A *et al*. *Helicobacter pylori* positive resistant duodenal ulcers: *correspondence*, 1646
 More L *see* Hudson M *et al*
Sankey EA et al
 Morgan AG *see* Crabtree JE *et al*
 Morgan JB *see* Lovegrove JA *et al*
 Morgan S *see* Ensari A *et al*
 Moriarty K *see* Ensari A *et al*
 Morita H *et al*. Glycosylation and sulphation of colonic mucus glycoproteins in patients with ulcerative colitis and in health subjects, 926
 Morris DL *et al*. Treatment of hepatic metastases by cryotherapy and regional cytotoxic perfusion: *leading article*, 1156
see also Harrison JD *et al*
 Morris GP *see* Nightingale JMD *et al*
van der Sijp JRM et al
 Morris J *see* Pullan RD *et al*
 Mortensen N *see* O'Kelly T *et al*
 Mortensen PB *see* Hove H *et al*
 Moshkowitz M *see* Halpern Z *et al*
 Moss HA *see* Washington N *et al*
 Moss SF, Calam J. Acid secretion and sensitivity to gastrin in patients with duodenal ulcer: effect of eradication of *Helicobacter pylori*, 888
 Mossi S *et al*. Influence of *Helicobacter pylori*, sex, and age on serum gastrin and pepsinogen concentrations in subjects without symptoms and patients with duodenal ulcer, 752
 Moule B *see* Leen E *et al*
 Moules IK *see* Hawkey CJ *et al*
 Mountford RA *see* Eltringham WK *et al*
 Mourelle M *et al*. Regulation of gall bladder motility by the arginine-nitric oxide pathway in guinea pigs, 911

- Moutsopoulos HM** see Dalekos GN *et al*
- Mowat NAG** see Naji SA *et al*
- Muecke T** see Yeoh EK *et al*
- Mulcahy H** see O'Brien S *et al*
- Mulcahy HE, O'Donoghue DP.** Molecular biology. Setting the stage in colorectal cancer? *leading article*, 1476
- Mulder AH** see van Leeuwen ML *et al*
- Mulder CJJ** *et al.* Clinical and pathological spectrum of coeliac disease: *correspondence*, 1740
see also van Berge-Henegouwen GP and Mulder CJJ; van Elburg RM *et al*
- Mulholland G** *et al.* *Helicobacter pylori* related hypergastrinaemia is the result of a selective increase in gastrin 17, 757
- Muñoz-Yague MT** see Solis-Herruzo JA *et al*
- Murch SH** *et al.* Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease, 1705
- Murday VA** see Stephenson BM *et al*
- Murphy GM** see Howard PJ *et al*
- Murray GI** see McKay JA *et al*
- Murray KE** *et al.* Presence of N-acyl and acetoxy derivatives of putrescine and cadaverine in the human gut, 489
- Murray-Lyon IM** see Tan CEL *et al*
- Murthy KVR** see Rao SSC and Murthy KVR
- Nadorp JHSM** see Timmer R *et al*
- Nagral AS** *et al.* Congestive jejunopathy in portal hypertension, 694
- Naito Y** see Yoshikawa T *et al*
- Naji SA** *et al.* Improving the selection of patients for upper gastrointestinal endoscopy, 187
- Nakajima M** see Azuma T *et al*
- Nakamura S** *et al.* Nuclear DNA content of isolated crypts of background colonic mucosa from patients with familial adenomatous polyposis and sporadic colorectal cancer, 1240
see also Oshitani N *et al*
- Nakano K, Chijiwa K.** Reduced cholesterol metastability of hepatic bile and its further decline in gall bladder bile in patients with cholesterol gall stones, 702
- Nakshabendi I** see Taha AS *et al*
- Napoli J** see Katalaris PH *et al*
- Nardi G** see Loguercio C *et al*
- Nardone G** *et al.* Phospholipid composition of human gastric mucosa: a study of endoscopic biopsy specimens, 456: *correspondence reply*, 1741
- Nauta JJ** see Pool MO *et al*
- Neale G, Williams R.** Consultant staffing and career prospects in gastroenterology for England and Wales: *special report*, 284
see also Char S *et al*; Farthing MJG *et al*
- Negri G** see Penagini R *et al*
- Nehlsen B** see Goebell H *et al*
- Nemeth J** *et al.* Identification of progastrin derived peptides in colorectal carcinoma extracts, 90
- Nemitz R** see Weisgerber UM *et al*
- Neoptolemos JP.** Adjuvant radiochemotherapy after resection of pancreatic adenocarcinoma: preliminary results, 1296 *abs*
Serum amylase levels and acute pancreatitis: *correspondence*, 429
- Neuberger J** see Shorrock C and Neuberger J
- Neuberger JM** see Ayres RCS *et al*
- Neuhaus H** *et al.* Laser lithotripsy of difficult bile duct stones under direct visual control, 415
- Neumann C** see Cowan RE *et al*
- Nevalainen TJ** *et al.* Pancreatic and synovial type phospholipases A2 in serum samples from patients with severe acute pancreatitis, 1133
- Ngu MC** see Katalaris PH *et al*
- Nguyen P** see Griffiths AM *et al*
- Nightingale JMD** *et al.* Disturbed gastric emptying in the short bowel syndrome. Evidence for a 'colonic brake', 1171
see also van der Sijp JRM *et al*
- Noach LA** *et al.* Gastric metaplasia and *Helicobacter pylori* infection, 1510
- Nogueras F** see Martínez-Salmerón JF *et al*
- Nordback I** see Jaakkola M and Nordback I
- Norris TL** see Attwood SEA *et al*
- Northfield TC** see Goggins PM *et al*
- Notghi A** *et al.* Radioisotope determination of regional colonic transit in severe constipation: *correspondence*, 1289
- Nugent KP** *et al.* Iatrogenic pancreatitis in familial adenomatous polyposis: *case report*, 1269
see also Spigelman AD *et al*
- Núñez MC** see Esteve-Comas M *et al*
- O'Brien S** *et al.* Intestinal bile acid malabsorption in cystic fibrosis, 1137
- O'Broin A** see O'Brien S *et al*
- Odermatt BF** see Hayoz D *et al*
- O'Donnell LJD, Fairclough PD.** Gall stones and gall bladder motility: *leading article*, 440
- O'Donoghue DP** see Mulcahy HE and O'Donoghue DP
- O'Dwyer PJ** see Penman ID *et al*
- Offerhaus GJA** see Giardiello FM *et al*
- Ogata H** see Hibi T *et al*
- Ogden JM** *et al.* Duodenal juice total protein and pancreatic enzyme synthesis, turnover, and secretion in patients after acute pancreatitis, 1261
- Ohara M** see Hibi T *et al*
- Ohkusa T** *et al.* Electron microscopic study of intercellular junctions in human gastric mucosa with special reference to their relationship to gastric ulcer, 86
- Okabe H** see Oshitani N *et al*
- Okada K** see Takahashi M *et al*
- Okajima M** see Takahashi M *et al*
- O'Keefe SJD** see Ogden JM *et al*
- O'Kelly T** *et al.* Nerve mediated relaxation of the human internal anal sphincter: the role of nitric oxide, 689
- Okon E** see Eliakim R *et al*
- Olaision G** see Almer S *et al*
- O'Leary D.** Mucus synthesis by the human gall bladder: *correspondence*, 861
see also Smythe A *et al*
- Olliff J** see Deen KI *et al*
- Olyaeem S** see Sedghi S *et al*
- O'Mahony S** see Ferguson A *et al*
- O'Malley CF** see McColm AA *et al*
- O'Morain C** see Cahill RJ *et al*
- Oosterbosch L** *et al.* Effects of serotonin on rat ileocolonic transit and fluid transfer in vivo: possible mechanisms of action, 794
- Oosting J** see Noach LA *et al*
- Ormerod MG** see Brito MJ *et al*
- Orsi M** see Fernandez-Calle P *et al*
- Oshitani N** *et al.* Location of superoxide anion generation in human colonic mucosa obtained by biopsy, 936
- Osmann DL** see Lovegrove JA *et al*
- O'Sullivan KR** see Cahill RJ *et al*
- Otte M** see Siegers C-P *et al*
- Otto W** see Konturek SJ *et al*
- Owen C** see Patel S *et al*
- Owen RA** see McLellan EA *et al*
- Owen RJ** see Bamford KB *et al*
- Pabst MA** *et al.* Ablation of capsaicin sensitive afferent nerves impairs defence but not rapid repair of rat gastric mucosa, 897
- Pagliaro L** see Provenzano G *et al*
- Pahlman L** see Stefansson T *et al*
- Palmer KR** see Choudari CP and Palmer KR
Ghosh S *et al*
Gorard DA *et al*
- Panos MZ** *et al.* Toxic megacolon: the knee-elbow position relieves bowel distension: *case report*, 1726
see also Moran A *et al*
- Pappo M** see Ruszniewski Ph *et al*
- Parente F** see Bianchi Porro G *et al*
- Paris JC** see Lescut D *et al*
- Parker D** see Heaton KW *et al*
- Parker E** see Catnach SM *et al*
- Parks TG** see Deans GT *et al*
- Pascal J-P** see Calès P *et al*
- Patankar RV** *et al.* Effect of pancreatic enzyme supplementation on the management of acute pancreatitis, 1294 *abs*
- Patel S** *et al.* Study of the proliferation in human gastric mucosa after in vivo bromodeoxyuridine labelling, 893
- Patterson CC** see Deans GT *et al*
- Pauletzki J** *et al.* Correlation between gall bladder fasting volume and postprandial emptying in patients with gall stones and healthy controls, 1443
- Paumgartner G** see Pauletzki J *et al*
- Pauwels S** see Nemeth J *et al*
- Pauwels W** see Elewaut A *et al*
- Payen J-L** see Calès P *et al*
- Payne HR** see Pappas G *et al*
- Payne-James JJ** see Gorard DA *et al*
- Pearson M** *et al.* Food intolerance and Crohn's disease, 783
- Peen E** *et al.* Anti-lactoferrin antibodies and other types of ANCA in ulcerative colitis, primary sclerosing cholangitis, and Crohn's disease, 56
- Peeters TL** see Stacher G *et al*
- Pelckmans PA** see Van Outryve MJ *et al*
- Peled Y** see Halpern Z *et al*
- Peña AS** see Mulder CJJ *et al*
Pool MO *et al*
- Penagini R** *et al.* Lower oesophageal sphincter hypersensitivity to opioid receptor stimulation in patients with idiopathic achalasia, 16
- Penman I** see El-Omar E *et al*
- McColl KEL** *et al*

- Penman ID** *et al.* Omeprazole inhibits colorectal carcinogenesis induced by azoxymethane in rats, 1559
- Peppas G** *et al.* Ambulatory motility patterns of the transposed short segment colon, 1572
- Peracchi M** *et al.* Duodenal mucosa and extracellular cyclic nucleotide pattern in coeliac disease, 769
- Percesepe A** *see* Antí M *et al*
- Perng C-L** *see* Lin H-J *et al*
- Peskar BM** *see* Lambrecht N *et al*
- Pessaire D** *see* Lettéron P *et al*
- Peters R** *see* Westaby D and Peters R
- Phatak AG**. Oral submucous fibrosis – a chronic disseminated intravascular coagulation syndrome with local coagulopathy: correspondence, 713
- Phillips RKS** *see* Nugent KP *et al*
- Spigelman AD *et al*
- Phillips SF** *see* Hammer J *et al*
- Oosterbosch L *et al*
- Phull PS, Jacyna MR**. Inflammatory bowel disease in Asians: correspondence, 714
- Picciotto A** *et al.* Thyroid function and interferon treatment in chronic hepatitis C: correspondence, 574
- Pigozzi MG** *see* Lanzini A *et al*
- Pilarski LM** *see* Yacyshyn BR and Pilarski LM
- Pillay D** *see* Lim SG *et al*
- Pinzello G** *see* Provenzano G *et al*
- Pisani E** *see* Catassi C *et al*
- Planas R** *see* González-Huix F *et al*
- Plebani M** *see* Battistel M *et al*
- Plevris JN** *et al.* Primary culture of bovine gall bladder epithelial cells, 1612
- Polanco I** *see* Fernandez-Calle P *et al*
- Polson RJ** *see* Bowling TE *et al*
- Pool MO** *et al.* Serum antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease are mainly associated with ulcerative colitis. A correlation study between perinuclear antineutrophil cytoplasmic autoantibodies and clinical parameters, medical and surgical treatment, 46
- Porschen R** *et al.* Influence of preoperative radiotherapy on DNA ploidy in squamous cell carcinomas of the oesophagus, 1086
- Porter KG** *see* Dickey W *et al*
- Poston GJ** *see* Davies N *et al*
- Potet F** *see* Fléjou J-F *et al*
- Potten CS** *see* Patel S *et al*
- Potter JD** *see* Lampe JW *et al*
- Potts S** *see* Bamford KB *et al*
- Pounder RE** *see* Fraser AG *et al*
- Hudson M *et al*
- Lim SG *et al*
- Sankey EA *et al*
- Pouteau M** *see* Marcellin P *et al*
- Pradère B** *see* Calès P *et al*
- Prangnell DR** *see* Sahay R *et al*
- Preston FE** *see* Wodzinski MA *et al*
- Preston SR** *see* Miller GV *et al*
- Prieto J** *see* Camps J *et al*
- Primrose JN** *see* Crabtree JE *et al*
- Kelly EJ *et al*
- Miller GV *et al*
- Probert CSJ** *et al.* Prevalence and family risk of ulcerative colitis and Crohn's disease: an epidemiological study among Europeans and South Asians in Leicestershire, 1547
- Provenzano G** *et al.* Immunoblotting as a confirmatory test for antimitochondrial antibodies in primary biliary cirrhosis, 544
- Pugh S, Sissons G**. Injection sclerotherapy in portal hypertension: correspondence, 861
- see also* Banerjee S *et al*
- Pugin P** *see* Hayoz D *et al*
- Pulford K** *see* Bjerke K *et al*
- Pullan RD** *et al.* Comparison of bismuth citrate and 5-aminosalicylic acid enemas in distal ulcerative colitis: a controlled trial, 676
- Punchard NA** *see* Greenfield SM *et al*
- Quandalle P** *see* Lescut D *et al*
- Quesada MS** *see* Csendes A *et al*
- Quinn CM** *see* Yu RCH *et al*
- Quirke P** *see* Lobo AJ *et al*
- Scott N *et al*
- Scott N and Quirke P
- Stephenson BM *et al*
- Raab Y** *et al.* Neutrophil mucosal involvement is accompanied by enhanced local production of interleukin-8 in ulcerative colitis, 1203
- Raafat F** *see* Calder CJ *et al*
- Rachmilewitz D** *see* Eliakim R *et al*
- Ferraris L *et al*
- Radotra BD** *see* Chugh S *et al*
- Raedsch R *see* Weisgerber UM *et al*
- Raimundo AH** *see* Rogers J *et al*
- Raju GS** *see* Broor SL *et al*
- Ramakrishna BS, Mathan VI**. Colonic dysfunction in acute diarrhoea: the role of luminal short chain fatty acids, 1215
- Rambaud C** *see* Kutlu T *et al*
- Ramesh GN** *see* Broor SL *et al*
- Ramm G** *see* Cochran M *et al*
- Rampton D** *see* Sergeant IR *et al*
- Rampton DS** *see* Simmonds NJ and Rampton DS
- Rao SSC, Murthy KVR**. Post-bulbar and coexisting ulceration: unique features of peptic ulcer in Hyderabad, 1327
- Rapaccini GL** *see* Antí M *et al*
- Raptis SA** *see* Ladas SD *et al*
- Rassam S** *et al.* A quantitative comparison of circulating hepatitis C virus during ribavirin and alpha interferon treatment of chronic hepatitis C, 717 *abs*
- Rätsch I-M** *see* Catassi C *et al*
- Raul F** *see* Galluser M *et al*
- Rautelin H** *et al.* Incidence of *Helicobacter pylori* strains activating neutrophils in patients with peptic ulcer disease, 599
- Rauws EAJ** *see* Davids PHP *et al*
- Noach LA *et al*
- Read NW** *see* Daly J *et al*
- Kerrigan DD *et al*
- Tomlin J *et al*
- Record CO** *see* Burke D *et al*
- Hawthorne AB *et al*
- Reddy SN** *see* Di Lorenzo C *et al*
- Redhead DN** *see* Simpson KJ *et al*
- Rees RGP** *see* Gorard DA *et al*
- Rees WDW** *see* Brown CM *et al*
- Regamey C** *see* Hayoz D *et al*
- Rehfeld JF** *see* Chu M *et al*
- Reid J** *see* Taha AS *et al*
- Reilly JT** *see* Wodzinski MA *et al*
- Reinbach DH** *et al.* Acute perforated duodenal ulcer is not associated with *Helicobacter pylori* infection, 1344
- Remy U** *see* Porschen R *et al*
- Renner EL** *see* Mossi S *et al*
- Rew DA** *see* Patel S *et al*
- Rhodes A** *et al.* Early acute hepatitis with parenteral amiodarone: a toxic effect of the vehicle? case report, 565
- Rhodes J** *see* Clements D *et al*
- Clements D and Rhodes J
- Pullan RD *et al*
- Rhodes JM** *see* Finnie IA *et al*
- Rhodes M**. Mucus synthesis by the human gall bladder: correspondence, 861
- see also* Bradburn DM and Rhodes M
- Ricci R** *et al.* Real time ultrasonography of the gastric antrum, 173
- Ricciuto GM** *see* Antí M *et al*
- Richardson AJ** *see* Eastwood MA *et al*
- Richman PI** *see* Shepherd NA *et al*
- Richter JE** *see* Singh S *et al*
- Ridwan BU** *see* Pool MO *et al*
- Riecken EO** *see* Stölzel U *et al*
- v Lampe B *et al*
- Ziegler K
- et al*
- Rieu-Boi JI** *see* Camps J *et al*
- Rigaud D** *see* Sobhani I *et al*
- Rinaldi F** *see* Provenzano G *et al*
- Ringers J** *see* Davids PHP *et al*
- Ritchie JK** *see* Connell WR *et al*
- Robb T** *see* Yeoh EK *et al*
- Robert JH** *et al.* Ischaemic colitis: two distinct patterns of severity: leading article, 4
- Robert SA** *see* Patel S *et al*
- Robertson CS** *et al.* R1 subtotal v R3 total gastrectomy for operable antral cancer: a prospective randomised trial, 1471 *abs*
- Varicella-zoster virus DNA in the oesophageal myenteric plexus in achalasia, 299
- Robertson GSM** *et al.* Mode of digest release into the magnetic field significantly affects immunomagnetic islet purification, 1296 *abs*
- Robertson J** *see* Leen E *et al*
- Robertson JFR** *see* Watson SA *et al*
- Rodrigo M** *see* Martínez-Sámero JF *et al*
- Rodríguez R** *see* Guarner L *et al*
- Roe AM** *et al.* Diversion colitis and involution of the defunctioned anorectum, 382
- see also* Eltringham WK *et al*
- Roediger WEW**. Colonic epithelial metabolism in ulcerative colitis: correspondence, 1646
- Rogers J** *et al.* Cephalic phase of colonic pressure response to food, 537

- Rohner A** see Robert JH *et al*
Rolf TM see Noach LA *et al*
Rolston DDK. Colonic tuberculosis: *correspondence*, 429
Romanoff M see Loguercio C *et al*
Rose JDG see Doyle GJ *et al*
Rosenberg J. Nasal oxygen during endoscopy: *correspondence*, 288
Ross B see Johnson AG and Ross B
Rossini M see Catassi C *et al*
Roth M-P see Yang H *et al*
Rothwell J see Lobo AJ *et al*
Rotter JI see Yang H *et al*
Rouanet JM see Zambonino Infante JL *et al*
Rowe B see de Silva DGH *et al*
Rowlands BJ see Deans GT *et al*
 Gardiner KR *et al*
Rowlands DC *et al.* Epstein-Barr virus infection in gastric carcinoma, 1471 *abs*
Rowston WM see Bowyer RC *et al*
Rubin PH see Subramani K *et al*
Ruchti CH see Halter F *et al*
RUDER Study Group see Armstrong D *et al*
Rühl GH see Labenz J *et al*
Ruina M see Caselli M *et al*
Ruppel DC see Hood KA *et al*
Russell IT see Naji SA *et al*
Russell RCG see Gillams A *et al*
Russell RI see Angerson WJ *et al*
 Farthing MJG *et al*
 Taha AS *et al*
 Taha AS and Russell RI
Russo A see Yeoh EK *et al*
Ruszyniewski Ph *et al.* Two year maintenance treatment of duodenal ulcer disease with ranitidine 150 mg: a prospective multicentre randomised study, 1662
Rutgeerts P *et al.* Endoscopic injection therapy to prevent rebleeding from peptic ulcers with a protruding vessel: a controlled comparative trial, 348; *correspondence*, 1150
Rutter KRP see Catnach SM *et al*
Ryan J, Costigan DC. Determination of the histological distribution of insulin like growth factor 1 receptors in the rat gut, 1693
Rydén B-O see Peen E *et al*
- Sachar DB** see Subramani K *et al*
Sachdev GK *et al.* Human colonic intraepithelial lymphocytes suppress in vitro immunoglobulin synthesis by autologous peripheral blood lymphocytes and lamina propria lymphocytes, 257
Sagar P see Scott N *et al*
Sagar PM *et al.* The effects of major surgery and nutritional support on pancreatic function and morphology in critically ill gastroenterological patients, 1295 *abs*
 see also Lewis WG *et al*; Lobo AJ *et al*
Sahay R, Scott BB. Iron deficiency anaemia – how far to investigate? 1427
Sahay R *et al.* Inflammatory bowel disease and refractory anaemia (myelodysplasia): *case report*, 1630
Saito Y see Ohkusa T *et al*
Salas A see Lugea A *et al*
Saleri A see Lanzini A *et al*
Salian N *et al.* Is diagnostic endoscopic retrograde pancreatography (ERP) now a necessary investigation? 1296 *abs*
Salih V see Martin JE *et al*
Salmeron J see Martínez-Salmeron JF *et al*
Salvesen H see Svanes C *et al*
Samloff IM see Fraser AG *et al*
Sampliner RE see Faris F and Sampliner RE
Sandborn WJ *et al.* Ulcerative colitis disease activity following treatment of associated primary sclerosing cholangitis with cyclosporin, 242
Sandle GI *et al.* Properties of a potassium channel in cultured human gastric cells (HGT-1) possessing specific omeprazole binding sites, 1331
Sandle LN see Brown CM *et al*
Sanft C see Ziegler K *et al*
Sanidas EE *et al.* Expression of c-erbB in gastric carcinoma and adjacent mucosa, 1470 *abs*
 Expression of p53 protein and prognosis in gastric carcinoma, 1470 *abs*
Sankey EA *et al.* Early mucosal changes in Crohn's disease, 375
 see also Hudson M *et al*; Lim SG *et al*
Santinelli A see Catassi C *et al*
Sargeant IR *et al.* Laser ablation of upper gastrointestinal vascular ectasias: long term results, 470
 Radiation enhancement of laser palliation for advanced rectal and rectosigmoid cancer: a pilot study, 958
Sarraf CE see Goodlad RA *et al*
Sasabe M see Ohkusa T *et al*
Sasaki N see Ohkusa T *et al*
Sauerbruch T see Pauletzki J *et al*
- Saunders BP** see Trewby PN and Saunders BP
Sawhney IMS see Chugh S *et al*
Sawyerr AM see Fraser AG *et al*
 Sankey EA *et al*
Sayer JM, Long RG. A perspective on iron deficiency anaemia: *leading article*, 1297
Scattolini C see Chiarioni G *et al*
Schäffer M see Herzig K-H *et al*
Schafmayer A see Pauletzki J *et al*
Schauseil S see Porschen R *et al*
Scheuer PJ see Thompson NP *et al*
Scheurer U see Inauen W *et al*
Schipper J see de Boer SY *et al*
Schmitz J see Kutlu T *et al*
Schneider B see Siegers C-P *et al*
Schneider C see Castiglione F *et al*
 Stacher G *et al*
Schön I see Herzig K-H *et al*
Schönnike E see Pabst MA *et al*
Schorah CJ see Sobala GM *et al*
Schwaeble W see Dippold W *et al*
Schwartz J-C, Baumer P. Acetorphan and diarrhoea: *correspondence*, 432
Schwartz MP see Noach LA *et al*
Schwenk M see Déchelotte P *et al*
Sciarretta G *et al.* Technetium-99m hexamethyl propylene amine oxime granulocyte scintigraphy in Crohn's disease: diagnostic and clinical relevance, 1364
Scott B, Holmes G. Perforation from endoscopic small bowel biopsy: *case report*, 134
Scott BB see Sahay R *et al*
 Sahay R and Scott BB
 Scott EM and Scott BB
Scott-Coombes DM *et al.* Fibrinolytic activity of ascites caused by alcoholic cirrhosis and peritoneal malignancy, 1120
Scott EM, Scott BB. Painful rib syndrome – a review of 76 cases, 1006
Scott N, Quirke P. Molecular biology of colorectal neoplasia: *leading article*, 289
Scott N *et al.* p53 expression and K-ras mutation in colorectal adenomas, 621
Seagroatt v see Vessey MP *et al*
Sedghi S *et al.* Increased production of luminol enhanced chemiluminescence by the inflamed colonic mucosa in patients with ulcerative colitis, 1191
Seitz HK *et al.* Human gastric alcohol dehydrogenase activity: effect of age, sex, and alcoholism, 1433
Selden AC see Vesey DA *et al*
Senior S see Giaffer MH *et al*
Seow F see Katelaris PH *et al*
Sercome J see Fraser AG *et al*
Shakoor ZS see Greenfield SM *et al*
Shanahan F see Yang H *et al*
Shaw J see Ayres RCS *et al*
Shaw KJ see Murray KE *et al*
Sheffield JP see McLellan EA *et al*
Shenkin A see Heath DI *et al*
Shepherd NA *et al.* Distribution of mucosal pathology and an assessment of colonic phenotypic change in the pelvic ileal reservoir, 101
 see also Warren BF *et al*
Sheppard MC see Singh S *et al*
Sherman PM see Griffiths AM *et al*
Sheron N see de Silva DGH *et al*
Shimi SM see Vander Velzen GC *et al*
Shires S see Sobala GM *et al*
Shmueli E *et al.* Growth hormone and insulin resistance in cirrhosis, 719 *abs*
Shorrock C, Neuberger J. The changing face of liver transplantation: *leading article*, 295
Shorthouse M see Middleton SJ *et al*
Shorvon PJ. Perioperative endoscopy of the whole small bowel in Crohn's disease: *correspondence*, 1741
Siegers C-P *et al.* Anthranoid laxative abuse – a risk for colorectal cancer? 1099
Sier CFM *et al.* Plasminogen activators in normal tissue and carcinomas of the human oesophagus and stomach, 80
Silk DBA see Gorard DA *et al*
Sim R see Hudson M *et al*
 Sankey EA *et al*
Simanowski UA see Seitz HK *et al*
Simmonds NJ, Rampton DS. Inflammatory bowel disease – a radical view: *leading article*, 865
Simpson KJ *et al.* Transjugular intrahepatic portasystemic stent shunting for control of acute and recurrent upper gastrointestinal haemorrhage related to portal hypertension, 968
Sinclair TS see Naji SA *et al*
Singer MV see Chari S *et al*

- Singh S et al.** Determinants of oesophageal 'alkaline' pH environment in controls and patients with gastro-oesophageal reflux disease, 309
 Sex differences in the incidence of colorectal cancer: an exploration of oestrogen and progesterone receptors, 611
- Sipponen P** see Sjöblom SM et al
- Sissons G** see Pugh S and Sissons G
- Sjöblom SM et al.** Gastroscopic follow up of pernicious anaemia patients, 28
- Sjölin C** see Peen E et al
- Skogh T** see Peen E et al
- Slama A** see Ruszniewski Ph et al
- Slater K** see Cole AT et al
- Slater SD** see Jalleh RP et al
- Slavin JL** see Lampe JW et al
- Slee B** see Brown CM et al
- Sloan JM** see Bamford KB et al
 Dickey W et al
- Sloan P** see Evans DGR et al
- Smedh K** see Almer S et al
- Smith C** see Griffiths AM et al
- Smith PM** see Banerjee S et al
 Hardy SP et al
- Smith SA** see Rhodes A et al
- Smout AJPM** see Timmer R et al
- Smythe A et al.** Duodenogastric reflux after gastric surgery and in gastric ulcer disease: continuous measurement with a sodium ion selective electrode, 1047
- Snape WJ** see Di Lorenzo C et al
- Snowdon CF** see Brown CM et al
- Sobala GM et al.** Effect of eradication of *Helicobacter pylori* on gastric juice ascorbic acid concentrations, 1038
 see also Crabtree JE et al; Lynch DAF et al
- Sobhani I et al.** Gastric secretion of platelet activating factor and precursors in healthy humans: effect of pentagastrin, 1051
- Soeters PB** see Dejong CHC et al
- Sofaer J.** Crohn's disease: the genetic contribution: *leading article*, 869
- Sogni P** see Chaussade S and Sogni P
- Sokal M** see Cole AT et al
- Solis-Herruzo JA et al.** Reversal of carbon tetrachloride induced changes in microviscosity and lipid consumption of liver plasma membrane by colchicine in rats, 1438
- Somers R** see Taal BG et al
- Sood GK** see Broor SL et al
- Soreide O** see Svanes C et al
- Sparén P** see Stefánsson T et al
- Speakman CTM, Kamm MA.** Abnormal visceral autonomic innervation in neurogenic faecal incontinence, 215
- Spence RAJ** see Deans GT et al
- Spencer J.** Achalasia cardia: dilatation or operation? *leading article*, 148; *correspondence*, 861
- Spigelman AD et al.** Screening and management of familial adenomatous polyposis: *correspondence*, 1292
 see also Nugent KP et al
- Spitz L** see Hardy SP et al
- Squire S** see Lim SG et al
- Stacher G et al.** Erythromycin effects on gastric emptying, antral motility and plasma motilin and pancreatic polypeptide concentrations in anorexia nervosa, 166
 see also Castiglione F et al
- Stachura J** see Konturek SJ et al
- Stainsby KJ et al.** Antibodies to *Mycobacterium paratuberculosis* and nine species of environmental mycobacteria in Crohn's disease and control subjects, 371: *correspondence*, 1291
- Stallmach A** see v Lampe B et al
- Stangeland L** see Svanes C et al
- Steele RJC** see Iftikhar SY et al
 Washington N et al
- Stefánsson T et al.** Increased risk of left sided colon cancer in patients with diverticular disease, 499
- Stehling MK** see Evans DF et al
- Stein H** see Ziegler K et al
- Stephenson BM et al.** Feasibility of family based screening for colorectal neoplasia: experience in one general surgical practice, 96
- Stepniewska KA** see McLellan EA et al
- Stevens M** see Catnach SM et al
- Stewart CS** see Eastwood MA et al
- Stolk MFJ et al.** Postprandial gall bladder motility and hormone release during intermittent and continuous subcutaneous octreotide treatment in acromegaly, 808
- Stoll R** see Konturek JW et al
- Stölzel U et al.** Lithotripsy of an impacted calcified stone in the cystic duct accompanied by cholecystitis in severe Crohn's disease: *case report*, 1145
- Strange RC** see Davies MH et al
- Ström M** see Almer S et al
- Strong P** see Trevethick MA et al
- Sturrock RD** see Taha AS et al
- Subramani K et al.** Refractory pouchitis: does it reflect underlying Crohn's disease? 1539
- Sullivan PB** see Char S et al
- Sullivan S** see Chu M et al
- Sun WM** see Daly J et al
- Surveyor I** see Cullen DJE et al
- Svanes C et al.** Perforated peptic ulcer over 56 years. Time trends in patients and disease characteristics, 1666
- Svanes K** see Svanes C et al
- Swan CHJ** see Farthing MJG et al
- Swarbrick ET** see Farthing MJG et al
 Hartley MG et al
- Swash M** see Martin JE et al
- Szalachcic A** see Konturek SJ et al
- Taal BG et al.** Isolated primary oesophageal involvement by lymphoma: a rare cause of dysphagia: two case histories and a review of other published data, 994
- Tada S et al.** Intestinal pseudo-obstruction in patients with amyloidosis: clinicopathologic differences between chemical types of amyloid protein, 1412
- Taggart RT** see Azuma T et al
- Taha AS, Russell RI.** *Helicobacter pylori* and non-steroidal anti-inflammatory drugs: uncomfortable partners in peptic ulcer disease: *leading article*, 580
- Taha AS et al.** Duodenal histology, ulceration, and *Helicobacter pylori* in the presence or absence of non-steroidal anti-inflammatory drugs, 1162
- Tait IS et al.** Overview of screening and management of familial adenomatous polyposis: *correspondence*, 575
 see also Campbell FC et al
- Takahashi M et al.** Use of the conjugate of disulphated ursodeoxycholic acid with p-aminobenzoic acid for the detection of intestinal bacteria, 823
- Takahishi S** see Yoshikawa T et al
- Takaishi H** see Hibi T et al
- Tamura Y** see Ohkusa T et al
- Tan CEL et al.** Non-communicating multiseptate gall bladder and choledochal cyst: a case report and review of publications, 853
- Tan WC, Allan RN.** Diffuse jeunoileitis of Crohn's disease, 1374
- Tang TMH** see Naji SA et al
- Tanner AG et al.** Pancreatic disease in AIDS patients, 1295 *abs*
- Taranto D** see Loguercio C et al
- Targan SR** see Yang H et al
- Taylor B** see Nemeth J et al
- Taylor BA** see Finnie IA et al
- Taylor F** see Thomas AG et al
- Taylor GR, Farmery SM.** Single gene disorders affecting the gastrointestinal tract: *leading article*, 433
- Taylor I** see Patel S et al
- Taylor ME** see Kerrigan DD et al
- Taylor RH** see Gillen CD et al
- Taylor TV** see Evans DGR et al
- Teahon K, Bjarnason I.** Comparison of leukocyte excretion and blood loss in inflammatory disease of the bowel, 1535
 see also Pearson M et al
- Teare JP** see Greenfield SM et al
- Tejje K** see Peen E et al
- Tenias JM** see Fernandez-Calle P et al
- Teramae N** see Azuma T et al
- Terblanche J** see Madden MV et al
- Tersmette AC** see Giardiello FM et al
- Teyssen S** see Chari S et al
- Thakker N** see Evans DGR et al
- Thillainayagam AV et al.** Evidence of a dominant role for low osmolality in the efficacy of cereal based oral rehydration solutions: studies in a model of secretory diarrhoea, 920
- Thomas AG et al.** Insulin like growth factor-I, insulin like growth factor binding protein-1, and insulin in childhood Crohn's disease, 944
- Thomas HC** see Foster GR and Thomas HC
- Thomas JE et al.** New non-invasive test of gastric acid secretion for use in children, 738
- Thompson H** see Brito MJ et al
 Grobler SP et al
- Thompson JN** see Scott-Coombes DM et al
- Thompson JR** see Probert CSJ et al
- Thompson NP et al.** Intraperitoneal ivalon mimicking peritoneal malignancy after plugged percutaneous liver biopsy: *case report*, 1635
- Thompson RPH** see Greenfield SM et al
 Jenkins AP and Thompson RPH
- Thomson WHF** see Shepherd NA et al
- Thornton J, Axon A.** Towards safer endoscopic retrograde cholangio-pancreatography: *leading article*, 721

- Thorpe S** see Sergeant IR *et al*
Tiernan E see Gibson GE *et al*
Tierney RP see Adrian TE *et al*
Timmer R *et al.* Oesophageal motor response to reflux is not impaired in reflux oesophagitis, 317
Tindale WB see Giaffer MH *et al*
Titley J see Brito MJ *et al*
Tjiang HL see van Leeuwen ML *et al*
Tobias JS see Sergeant IR *et al*
Toda K see Hibi T *et al*
Todd G see Hift RJ *et al*
Tokoi S see Ohkusa T *et al*
Tomii T see Yoshikawa T *et al*
Tomlin J *et al.* The effect of liquid fibre on gastric emptying in the rat and humans and the distribution of small intestinal contents in the rat, 1177
Tompkins DS see Crabtree JE *et al*
Toouli J see Ireland AC *et al*
Torsoli A see Ricci R *et al*
Tovey FI *et al.* *Helicobacter pylori* positive resistant duodenal ulcers: correspondence, 1646
Tran DD. Interleukin-6 in the early assessment of acute pancreatitis: correspondence, 1467
Trautmann M see Lambrecht N *et al*
Tremaine WJ see Sandborn WJ *et al*
Trembath RC see Catnach SM *et al*
Trevethick MA *et al.* Do infiltrating neutrophils contribute to the pathogenesis of indomethacin induced ulceration of the rat gastric antrum? 156
Trewby PN, **Saunders BP**. Open access gastroscopy: correspondence, 1290
Trigaux JP see De Ronde Th *et al*
Triger DR. Bleeding varices in the elderly: correspondence, 576
Tsiaras EV see Dalekos GN *et al*
Tsuchiya M see Hibi T *et al*
Tulloch M see Sergeant IR *et al*
Turnberg LA see Wardle TD *et al*
Tytgat GNJ see Davids PHP *et al*
 Noach LA *et al*
- Uchida K** see Takahashi M *et al*
Ueda F see Ohkusa T *et al*
Uil JJ see van Elburg RM *et al*
Urban G see Sedghi S *et al*
Usitalo A see Luostarinen M *et al*
- v Lampe B** *et al.* Altered glycosylation of integrin adhesion molecules in colorectal cancer cells and decreased adhesion to the extracellular matrix, 829
Valdovinos MA see Oosterbosch L *et al*
Valenti A see Anti M *et al*
Van Beers B see De Ronde Th *et al*
van Berge-Henegouwen GP, **Mulder CJJ**. Pioneer in the gluten free diet: Willem-Karel Dicke 1905-1962, over 50 years of gluten free diet: leading article, 1473
 see also Stolk MFJ *et al*
van Blankenstein M see van Leeuwen ML *et al*
van der Heyde MN see Davids PHP *et al*
Van der Meer R see Govers MJAP and Van der Meer R
van der Sijp JRM *et al.* Radioisotope determination of regional colonic transit in severe constipation: comparison with radio opaque markers, 402: correspondence, 1289
 see also Nightingale JMD *et al*
van Elburg RM *et al.* Intestinal permeability in patients with coeliac disease and relatives of patients with coeliac disease, 354
van Erpecum KJ see Stolk MFJ *et al*
van Hattum J see Wismans PJ and van Hattum J
Van Heerde P see Taal BG *et al*
van Leeuwen ML *et al.* Phlegmonous gastritis: an unusual presenting symptom of Sjögren's syndrome: case report, 1142
Van Maercke YM see Van Outryve MJ *et al*
Van Outryve MJ *et al.* Transrectal ultrasound study of the pathogenesis of solitary rectal ulcer syndrome, 1422
Vanco D see Lescut D *et al*
Vandenplas Y see Blecker U and Vandenplas Y
Vander Velzen GC *et al.* Outcome after cholecystectomy for symptomatic gall stone disease and effect of surgical access: laparoscopic v open approach, 1448
Vanoli M see Basilisco G *et al*
Vantini I see Chiarioni G *et al*
Vantrappen G. Non-deglutitive motor activity of the oesophagus: leading article, 1013
 see also Janssens J *et al*; Rutgeerts P *et al*
Varagona G see Picciotto A *et al*
Varrentrapp M see Déchelotte P *et al*
- Varro A** see Nemeth J *et al*
Varty K *et al.* Paediatric gastro-oesophageal reflux: prognostic indicators from pH monitoring, 1478
Vatier J see Sobhani I *et al*
Vecchio FM see Anti M *et al*
Venables CW see Farthing MJG *et al*
Verspaget HW see Sier CFM *et al*
Vesey DA *et al.* Down regulation of epidermal growth factor receptors in liver proliferation induced by a mixture of triiodothyronine, amino acids, glucagon, and heparin (TAGH), 1601
Vessey MP *et al.* Peptic ulcer, cimetidine, and motor neurone disease – a record linkage study, 1660
Vinel J-P see Calès P *et al*
Vipond MN see Scott-Coombes DM *et al*
Vloedgraven HJM see Sier CFM *et al*
Voigt J-J see Calès P *et al*
von Blomberg BME see Pool MO *et al*
von der Ohe M see Oosterbosch L *et al*
von Hertzberg-Lottin E see Siegers C-P *et al*
von Wartburg J-P see Seitz HK *et al*
Vora IM see Nagral AS *et al*
- Wakefield AJ** see Hudson M *et al*
 Sankey EA *et al*
Waldherr R see Seitz HK *et al*
 Weisgerber UM *et al*
Walker ER see Nightingale JMD *et al*
Walker-Smith JA see Lo SK *et al*
 Murch SH *et al*
Walker SW see Plevris JN *et al*
Wallace HM see Gray MR *et al*
Wardle TD *et al.* Inter-relationships between inflammatory mediators released from colonic mucosa in ulcerative colitis and their effects on colonic secretion, 503
Warhurst G see Sandle GI *et al*
Warlters A see Morris DL *et al*
Warnes T see Evans DGR *et al*
Warren BF, **Davies JD**. Microvascular abnormalities in the mucosal prolapse syndrome: correspondence, 714
Warren BF *et al.* Pathology of the defunctioned rectum in ulcerative colitis, 514
 see also Roe AM *et al*; Shepherd NA *et al*
Warren JR see Cullen DJE *et al*
Washington C see Washington N *et al*
Washington N *et al.* Non-invasive detection of gastro-oesophageal reflux using an ambulatory system, 1482
Wass JAH see Catnach SM *et al*
Watanabe M see Hibi T *et al*
Watanabe N see Hibi T *et al*
Watkins PJ see Catnach SM *et al*
Watson A. Surgery for uncomplicated gastro-oesophageal reflux: correspondence, 428
 see also Attwood SEA *et al*
Watson RGP see Dickey W *et al*
Watson S see Iftilkar SY *et al*
Watson SA *et al.* Effect of histamine on the growth of human gastrointestinal tumours: reversal by cimetidine, 1091
Weaver LT see Thomas JE *et al*
Weaver RJ see McKay JA *et al*
Webberley MJ *et al.* Thromboembolism in inflammatory bowel disease: role of platelets, 247
Weber B see Inauen W *et al*
Weisgerber UM *et al.* Proliferation cell nuclear antigen (clone 19A2) correlates with 5-bromo-2-deoxyuridine labelling in human colonic epithelium, 1587
Weller PH see Calder CJ *et al*
Werner ID see Madden MV *et al*
Westaby D, **Peters R**. Biliary endoprosthesis and common bile duct stones: correspondence, 574
Whowell SA see Scott-Coombes DM *et al*
Whitehead WE see Bassotti G *et al*
Wicks ACB see Probert CSJ *et al*
Wicks J see Cowan RE *et al*
Wiesnagrotzki S see Stacher G *et al*
Wiesner RH see Sandborn WJ *et al*
Wilkinson LJ see Watson SA *et al*
Wilkinson SP see Shepherd NA *et al*
Williams CB see Nugent KP *et al*
Williams GT see Brito MJ *et al*
 Pullan RD *et al*
 Wright PA and Williams GT
Williams JA see Hall C *et al*
Williams JG *et al.* Capturing clinical activity – coming to terms with information: leading article, 1651
 see also Deen KI *et al*
Williams JM see McKenna P *et al*

- Williams R** see Farthing MJG *et al*
 Neale G and Williams R
- Williamson K** see Deans GT *et al*
- Williamson RCN** see Jalleh RP *et al*
- Willing J** *et al.* Effect of gastro-oesophageal reflux on upper oesophageal sphincter motility in children, 904
- Wilson CG** see Washington N *et al*
- Wilson PAJ** see Catnach SM *et al*
- Wingren S** see Chu M *et al*
- Wingren U** see Jodal M *et al*
- Winship D** see Sedghi S *et al*
- Winwood PJ** *et al.* Regulation of Kupffer cell derived 95 kDa type IV collagenase/gelatinase; a mediator of liver injury, 719 *abs*
- Wismans PJ, van Hattum J.** Strategies for hepatitis B infection: correspondence, 575
- Wittig B** see Dippold W *et al*
- Wodzinski MA** *et al.* Reduced tissue type plasminogen activator activity of the gastroduodenal mucosa in peptic ulcer disease, 1310
- Wolman S** see Lowsky R *et al*
- Wolvekamp MCJ** *et al.* The value of in vivo electrophysiological measurements for monitoring functional adaptation after massive small bowel resection in the rat, 637
- Wong V** *et al.* Gold induced enterocolitis complicated by cytomegalovirus infection: a previously unrecognised association: *case report*, 1002
- Wood MJ** see Panos MZ *et al*
- Woodhouse LF** see Miller GV *et al*
- Wormsley KG** see Hawkey CJ *et al*
- Wright NA.** Trefoil peptides and the gut: *leading article*, 577
see also Goodlad RA *et al*
- Wright PA, Williams GT.** Molecular biology and gastric carcinoma: *leading article*, 145
- Wührer A** see Lanzini A *et al*
- Wurtz A** see Lescut D *et al*
- Wyatt J** see Wong V *et al*
- Wyatt JI** see Crabtree JE *et al*
- Yacyshyn BR, Pilarski LM.** Expression of CD45RO on circulating CD19+ B-cells in Crohn's disease, 1698
- Yamamoto M** see Ohkusa T *et al*
- Yamson P** see Char S *et al*
- Yang H** *et al.* Familial empirical risks for inflammatory bowel disease: differences between Jews and non-Jews, 517
- Yao T** see Tada S *et al*
- Yapp TR** see Williams JG *et al*
- Yasuda K** see Azuma T *et al*
- Yasuda M** see Yoshikawa T *et al*
- Yeates D** see Vessey MP *et al*
- Yeooh EK** *et al.* Gastrointestinal function in chronic radiation enteritis – effects of loperamide-N-oxide, 476
- Yiu YC** see Tovey FI *et al*
- Yoshikawa T** *et al.* Role of active oxygen, lipid peroxidation, and antioxidants in the pathogenesis of gastric mucosal injury induced by indomethacin in rats, 732
- Young GP** see McIntyre A *et al*
- Yu RCH** *et al.* Multisystem Langerhans' cell histiocytosis with pancreatic involvement: *case report*, 570
- Zambonino Infante JL** *et al.* Mathematical correlation between villus height and the nutritional state in Sprague-Dawley rats, I, 1066
- Zannini P** see Penagini R *et al*
- Zeitz M** see Ziegler K *et al*
- Ziegler K** *et al.* Comparison of computed tomography, endosonography, and intraoperative assessment in TN staging of gastric carcinoma, 604
see also Stölzel U *et al*
- Zillinger C** see Neuhaus H *et al*
- Zimmer T** see Stölzel U *et al*
- Ziegler K** *et al*
- Zinsmeister AR** see Bharucha AE *et al*

SUBJECT INDEX – MAIN HEADINGS, 1993

- Acetophan** and diarrhoea: *correspondence*, 432
- Acetylcholine**, reduced secretion to, and electrogenic colonic ion transport in Hirschsprung's disease, 1405
- Achalasia**
treatment: *correspondence*, 861
varicella-zoster virus DNA in oesophageal myenteric plexus, 299
- Achalasia cardia**, dilatation or operation: *leading article*, 148; *correspondence*, 861
- Acid**
clearance, and oesophageal sensitivity, in progressive systemic sclerosis, 1487
duodenal resistance to, influence of dietary fat, 1303
and inflammation, role in duodenal ulcer pain: *leading article*, 1300
- Acinar cell nodules**, and pancreatic hypertrophy, after longterm fundectomy, rat, 988
- Acromegaly**
effect of octreotide on gall stone prevalence and gall bladder motility, 270
octreotide treatment, postprandial gall bladder motility and hormone release, 808
- Adenocarcinoma**, dysplasia, and Barrett's oesophagus: *correspondence*, 1292
- Adenomas**, colorectal, sporadic, high frequency of K-ras mutations, 392
- Adenomatous colorectal polyp**, rectal epithelial cell proliferation patterns as predictors of recurrence, 525
- Adenomatous polyps**, effects of vitamin antioxidant supplementation on cell kinetics, 963
- S-Adenosylmethionine**, improves hepatic function during liver perfusion after sequential cold and warm ischaemic injury, 720 *abs*
- Adsorbents** as antiendotoxin agents in experimental colitis, 51
- Age**, effect on serum gastrin and gastric acid secretion, 1032
- AIDS**
and pancreatic disease, 1295 *abs*
related sclerosing cholangitis, natural history, 116
- Alcohol**
abusers, increased ethane exhalation and in vivo index of lipid peroxidation, 409
and gastric acid secretion: *progress report*, 843
role in metaplasia and cancer risk in Barrett's columnar lined oesophagus, 727
- Alcohol dehydrogenase**, gastric activity, effect of age, sex, and alcoholism, 1433
- Aldehyde disinfectants** and health in endoscopy units: *special report*, 1641
- Alkalisation**, role in complications in Barrett's columnar lined lower oesophagus, 11
- Alpha, antitrypsin deficiency**, affecting gastrointestinal tract, 434
- Alphafetoprotein variants** in hepatocellular carcinoma and benign liver disease, 719 *abs*
- Aluminium**, absorbed, found with two cytosolic protein fractions, in rat duodenum, 643
- 5-Aminosalicylic acid**
and AC-5-ASA concentrations, in ileocolonic biopsy homogenates: *correspondence*, 713
and bismuth citrate enemas compared, in UC, 676
slow release, orioleal transit, 669
- Amiodarone**, parenteral, and early acute hepatitis, toxic effect of vehicle: *case report*, 565
- Ammonia** and glutamine metabolism, intestinal, during chronic hyperammonaemia, induced by liver insufficiency, 1112
- Amoxicillin** plus omeprazole *versus* triple therapy, for *H. pylori* eradication in duodenal ulcer disease, 1167
- Amylase**, serum levels, and acute pancreatitis: *correspondence*, 429
- Amyloidosis**, and intestinal pseudo-obstruction, 1412
- Anal sphincter**
defects, prevalence in faecal incontinence, endosonography, 685
nerve mediated relaxation, role of NO, 689
- Anorectum**, defunctioned, involution, and diversion colitis, 382
- Anorexia nervosa**, erythromycin effects on gastric emptying, antral motility, and plasma motilin and pancreatic polypeptide concentrations, 166
- Antacid induced protection**, role of eicosanoids, nitric oxide, and afferent neurons, rat stomach, 329
- Antranoid laxative abuse**, risk for colorectal cancer?, 1099
- Anti-cholinergic drugs**, and food, effect on pattern of rectosigmoid contractions, 799
- Anti-lactoferrin antibodies** and other types of ANCA in UC, primary sclerosing cholangitis, and Crohn's disease, 56
- Anti-neutrophil cytoplasm antibodies**, in UC, primary sclerosing cholangitis, and Crohn's disease, 56
- Antiendotoxin agents**, adsorbents as, in experimental colitis, 51
- Antimitochondrial antibodies** in primary biliary cirrhosis, immunoblotting, 544
- Antineutrophil antibody**, as test for autoimmune primary sclerosing cholangitis, childhood, 199
- Antineutrophil cytoplasmic antibodies**, in UC, 658
- Antineutrophil cytoplasmic autoantibodies**, serum, in IBD, are mainly associated with UC, 46
- Antioxidants**, oxygen, and lipid peroxidation, and indomethacin-induced injury in rats, 732
- Antireflux action**, of fundoplication, mechanisms underlying, 303
- Antral cancer**, R1 subtotal *v* R3 total gastrectomy, prospective randomised trial, 1471 *abs*
- Antral motility**, in anorexia nervosa, effects of erythromycin, 166
- Arginine-nitric oxide pathway**, in gall bladder motility regulation, guinea pigs, 911
- Ascites**, caused by alcoholic cirrhosis and peritoneal malignancy, fibrinolytic activity, 1120
- Ascorbic acid**, gastric juice concentrations, effect of eradication of *H. pylori*, 1038
- Audit**
of endoscopic surveillance biopsy specimens in HIV positive patients with gastrointestinal symptoms, 1429
of restorative proctocolectomy, 680
of role of oesophageal manometry in clinical practice, 1158
- Autonomic dysfunction** in gastrointestinal motility disorders, 397
- Azathioprine**, in IBD, causing bone marrow toxicity, 27 years experience, 1081
- Azoxymethane** induced colorectal carcinogenesis, omeprazole inhibits, rats, 1559
- B cells**, CD19+, circulating, in Crohn's disease, expression of CD45RO, 1698
- Barrett's columnar lined lower oesophagus**, complications, role of alkalinisation, 11
- Barrett's columnar lined oesophagus**, role of smoking and alcohol in metaplasia and cancer risk, 727
- Barrett's mucosa**, gene expression, adaptive responses in the oesophagus: *leading article*, 1649
- Barrett's oesophagus**, and development of dysplasia and adenocarcinoma: *correspondence*, 1292
- Beta-lactoglobulin**, cow's milk, transfer to human serum after milk load, 203
- Bicarbonate**, measurement of output from intact human oesophagus, 872
- Bile acid**
calcium and phosphate, effects of dietary calcium and phosphate on intestinal interactions between, 365
intestinal malabsorption, in cystic fibrosis, 1137
malabsorption, serum 7alpha-hydroxy-4-cholest-3-one concentrations, in diarrhoea, 698
- Bile duct**
injury after laparoscopic cholecystectomy, value of ERCP, 1250 stones
difficult, laser lithotripsy under direct visual control, 415
endoscopic extraction, management related to stone size, 1718
strictures, progress in determining nature: *leading article*, 725
- Bile salt inhibition** of motility in isolated perfused rabbit terminal ileum, 483
- Biles**, effect of phospholipids and their molecular species on cholesterol solubility and nucleation, 110
- Biliary endoprosthesis**, and common bile duct stones: *correspondence*, 574
- Biliary and pancreatic secretion**, postprandial, during profound inhibition of gastric secretion, 1607
- Bismuth citrate**, and 5-ASA enemas compared, in UC, 676
- Bleeding varices**, in the elderly: *correspondence*, 576
- Blood group antigens**, inappropriate expression on biliary and colonic epithelia in PSC, 977
- Blood groups** and *H. pylori* infection, risk factors for gastroduodenal disease, 351
- Blood loss** and leukocyte excretion in inflammatory disease of the bowel, comparison, 1535
- Bone loss**, in patients with IBD, HRT prevents, 1543
- Bone marrow toxicity** caused by azathioprine in IBD, 27 years experience, 1081

- Bowel**
 distension, in toxic megacolon, knee-elbow position relieves: *case report*, 1726
 dysfunction, in young women with urinary retention, 1397
 function, and irritable bowel symptoms after hysterectomy and cholecystectomy, 1108
Breath test, 14C-urea, ferrets with *H. mustelae*, bismuth, antibiotics, and urease inhibitors, effects, 181
British Association for the Study of the Liver, 1993 Spring Meeting, London, February 1993, abstracts, 717
5-Bromo-2-deoxyuridine labelling, correlation with PCNA (clone 19A2), colonic epithelium, 1587
Bromodeoxyuridine labelling, *in vivo*, proliferation in human gastric mucosa after, 893
Butyrate and glutamine metabolism in quiescent UC, 1552: *correspondence*, 1646
Butyrate production from dietary fibre and protection against large bowel cancer, rat model, 386
- c-erbB**, expression in gastric carcinoma and adjacent mucosa, 1470 *abs*
14C-urea breath test, ferrets with *H. mustelae*, bismuth, antibiotics, and urease inhibitors, effects, 181
CA 72-4 and CA 19-9, serodiagnostic values, in monitoring of patients with gastric carcinoma, 1470 *abs*
Cadaverine, N-acyl and acetoxy derivatives, presence in gut, 489
Calcified impacted stone in cystic duct, lithotripsy, and cholecystitis, in Crohn's disease: *case report*, 1145
Calcium, dietary, effects on intestinal interactions between calcium, phosphate, fatty acids, and bile acids, 365
Calprotectin, distribution of macrophages and granulocytes expressing, Peyer's patches compared with ileal lamina propria and lymph nodes, 1357
Cap polypsis, unusual cause of diarrhoea: *case report*, 562
Capsaicin sensitive afferent nerves, ablation, impairs defence but not rapid repair of rat gastric mucosa, 897
Carbohydrates
 complex, colonic fermentation, in familial adenomatous polyposis, 630
 malabsorption, complex, in exocrine pancreatic insufficiency, 984
13-Carbon-urea breath test, for *H. pylori* diagnosis, pigs, 594
Carcinoid tumour, gall bladder, two case reports and review, 1274
Cardiac rhythm, during upper gastrointestinal endoscopy, effects of supplemental oxygen, 1492
Carnitine concentrations, serum, in coeliac disease, 933
CD45RO, expression on circulating CD19+ B-cells in Crohn's disease, 1698
Cells, small bowel, transplantation: *leading article*, 1153
Cephalic phase of colonic pressure response to food, 537
Chemiluminescence, luminol enhanced, increased production by inflamed colonic mucosa in UC, 1191
Chloride diarrhoea, affecting gastrointestinal tract, 435
Cholecystectomy
 and hysterectomy, bowel function and irritable bowel symptoms after, 1108
 for symptomatic gall stone disease, outcome after, and effect of surgical access, laparoscopic v open approach, 1448
Cholecystokinin
 in control of gastric acid secretion, 321
 induced acute hyperglycaemia, effect on gall bladder contraction, 1123
Cholecystokinin octapeptide stimulates phasic and tonic pyloric motility in healthy humans, 33
Cholezystolithiasis, symptomatic, percutaneous rotary lithotrite, new approach, 837
Choledochal cyst, and non-communicating multiseptate gall bladder: *case report*, 853
Cholesterol
 metastability, reduced, of hepatic bile, 702
 solubility, effect of phospholipids and their molecular species, human and model biles, 110
Cholinergic transmission, modulation, and inhibition of pancreatic enzyme secretion, 1616
Cimetidine
 in gastrointestinal tumour growth reversal, effect of histamine, 1091
 peptic ulcer, and motor neurone disease, record linkage study, 1660
Cirrhosis
 alcoholic, ascites caused by, fibrinolytic activity, 1120
 growth hormone and insulin resistance, 719 *abs*
 hepatic perfusion changes, comparison with liver metastases, 554
Cirrhosis of the liver, laminin serum concentrations, 974
Cisapride
 with placebo compared, in prevention of duodenal ulcer relapse, 1042
 and ranitidine, effects on oesophageal motility in reflux oesophagitis, 1025
Clinical terms project, and information within NHS: *leading article*, 1651
- Coal miners**, screening for gastric carcinoma, 494
Coeliac disease
 clinical and pathological spectrum, active, silent, latent, potential: *leading article*, 150: *correspondence*, 1740
 duodenal mucosa and extracellular cyclic nucleotide pattern, 769
 intestinal permeability, 354
 intestinal permeability test as valid marker for slight dietary transgressions, 774
 normal diet patients, TCRs, alpha-beta+/gamma-delta+ intraepithelial numbers, and villous atrophy grade, 208
 serum carnitine concentrations, 933
Colchicine, reversal of carbon tetrachloride induced changes of liver plasma membrane, 1438
Colitis
 diversion, and involution of defunctioned anorectum, 382
 experimental
 adsorbents as antiendotoxin agents, 51
 octreotide effectively decreases mucosal damage, 264
 ischaemic, two distinct patterns of severity: *leading article*, 4
Colloidal bismuth subcitrate, for *H. pylori* positive resistant duodenal ulcers, 466: *correspondence*, 1646
Colon, colonic
 adenomas, lactate and pH in faeces, 625
 'brake' to gastric emptying, in short bowel syndrome, 1171
 cancer
 cellular DNA, HPV 16 DNA in NIH3T3 cells transformed by, 1710
 left sided, increased risk in diverticular disease, 499
 carcinoma, cell line HT29 cl 19A, effect of cytokines on epithelial function, 616
 contractile activity, 24 hour studies: *progress report*, 129
 diaphragm disease, NSAID-induced: *correspondence*, 715
 dysfunction, in acute diarrhoea, role of luminal short chain fatty acids, 1215
 epithelial cells, expression of ICAM-1, 1593
 epithelial metabolism, in quiescent UC, butyrate and glutamine metabolism, 1552: *correspondence*, 1646
 epithelium, PCNA (clone 19A2) correlates with 5-bromo-2-deoxyuridine labelling, 1587
 fermentation of complex carbohydrates in FAP, 630
 function, sex differences, randomised trial, 531
 hydrogen absorption, quantification of its effect on hydrogen accumulation caused by bacterial fermentation of carbohydrates, 818
 intraepithelial lymphocytes suppress Ig synthesis by autologous peripheral blood and lamina propria lymphocytes, 257
 ion transport, electrogenic, in Hirschsprung's disease, reduced secretion to neural secretagogues acetylcholine and iloprost, 1405
 manometry, in children with intestinal pseudo-obstruction, 803
 motility, practice or research? *leading article*, 1009
 mucosa
 inter-relationships between inflammatory mediators from, in ulcerative colitis, effects on colonic secretion, 503
 location of superoxide anion generation obtained by biopsy, 936
 neoplasia, xenobiotic metabolising enzyme expression, 1234
 pressure response to food, cephalic phase, 537
 short segment, transposed, ambulatory motility patterns, 1572
 transit, regional, in severe constipation, radioisotope determination and radio opaque markers compared, 402: *correspondence*, 1289
 tuberculosis: *correspondence*, 429
Colonoscopic surveillance, failure, in ulcerative colitis, 1075
Colonoscopy
 after curative resection for colorectal cancer, Haemoccult does not reduce need, 227
 recent, and colorectal carcinoma in ulcerative colitis: *case report*, 1148
Colorectal adenomas
 p53 expression and K-ras mutation, 621
 sporadic, high frequency of K-ras mutations, 392
Colorectal cancer
 cells, altered glycosylation of integrin adhesion molecules and decreased adhesion to extracellular matrix, 829
 curative resection, Haemoccult does not reduce need for colonoscopy after, 227
 DNA densitometry, 1566
 family based screening, feasibility, 96
 molecular biology involved in screening and diagnosis: *leading article*, 1476
 risk of anthranoid laxative abuse, 1099
 sex differences, oestrogen and progesterone receptors, 611
 sporadic, DNA content of isolated crypts of background colonic mucosa, 1240
Colorectal carcinogenesis, induced by azoxymethane, omeprazole inhibits, rats, 1559
Colorectal carcinoma
 extracts, identification of gastrin derived peptides, 90
 in ulcerative colitis, and recent colonoscopy: *case report*, 1148
Colorectal mucosal prolapse, microvascular abnormalities, 106: *correspondence*, 714

- Colorectal neoplasia, molecular biology:** *leading article*, 289
- Columnar lined Barrett's oesophagus**, proliferation of squamous, Barrett's and gastric mucosa, assessment: *correspondence*, 575
- Columnar lined oesophagus**, mucosal polyamine metabolism, 584
- Common bile duct stones**, biliary endoprosthesis: *correspondence*, 574
- Compartment syndrome** of chronic pancreatitis, 1295 *abs*
- Complement C4 genes**, in autoimmune hepatitis, DNA polymorphisms, 718 *abs*
- Computed tomography**
dynamic, in acute pancreatitis, patient selection and timing, 1294 *abs*
endosonography, and intraoperative assessment compared, in TN staging of gastric carcinoma, 604
- Constipation**
in early childhood, patient characteristics, treatment, and longterm follow up, 1400
severe, regional colonic transit, radioisotope determination and radio opaque markers compared, 402: *correspondence*, 1289
- Consultant staffing** and career prospects, gastroenterology, England and Wales: *special report*, 284
- Contractile activity** of human colon, 24 hour studies: *progress report*, 129
- Correction**, 1648
- Cow's milk beta-lactoglobulin**, transfer to human serum after milk load, 203
- Crohn's disease**
99mTc-HMPAO granulocyte scintigraphy, 1364
active, polymeric enteral diets as primary treatment, prospective steroid controlled trial, 778
anti-lactoferrin antibodies and other types of ANCA, 56
antibodies to *M. paratuberculosis* and nine species of environmental mycobacteria, 371: *correspondence*, 1291
childhood, insulin, insulin like growth factor-I, and insulin like growth factor binding protein-1, 944
children, growth and clinical course, 939
cholecystitis, lithotripsy of impacted calcified stone in cystic duct: *case report*, 1145
diagnosis suggestive of, and outcome of restorative proctocolectomy, 1384
diffuse jeunoileitis, 1374
early mucosal changes, 375
expression of CD45RO on circulating CD19+ B-cells, 1698
and factor XIIIa subunit, 75
food intolerance, 783
genetic contribution: *leading article*, 869
initial response and subsequent course after elemental diet or prednisolone, 1198
neoterminal ileal blood flow after ileocolonic resection, 1531
perioperative endoscopy of whole small bowel, 647: *correspondence*, 1741
with pulmonary involvement, 3 year old boy: *case report*, 1636
quantification of activity by computer analysis of Tc-99m HMPAO labelled leucocytes, 68
and refractory pouchitis, 1539
and ulcerative colitis, in Europeans and South Asians in Leicestershire, 1547
- Cryotherapy**, and regional cytotoxic perfusion, in treatment of hepatic metastases: *leading article*, 1156
- Cyclic adenosine monophosphate** inhibited by protein kinase C in HGT-1, 953
- Cyclic nucleotide**, extracellular, and duodenal mucosa, in coeliac disease, 769
- Cyclosporin**, for primary sclerosing cholangitis, ulcerative colitis disease activity following, 242
- Cystic dystrophy** of gastric and duodenal wall developing in heterotopic pancreas, unrecognised entity, 343
- Cystic fibrosis**
affecting gastrointestinal tract, 433
intestinal bile acid malabsorption, 1137
- Cytochrome P450 1 A and 3A**, as markers in colonic neoplasia, 1234
- Cytokines**
effect on epithelial function of human colon carcinoma cell line HT29 cl 19A, 616
pro-inflammatory, effect of ICAM-1 and MHC antigens on human intrahepatic bile duct cells, 1245
- Cytomegalovirus infection**, complicating gold induced enterocolitis, previously unrecognised association: *case report*, 999
- Cytotoxin positive stools**, culture negative, in community acquired diarrhoea, 192
- Deoxycholate**, an important releaser of peptide YY and enteroglucagon from human colon, 1219
- Depression**, and IBS, word recognition memory studies, 1230
- Dexamethasone suppression** of 72 kDa C/G activity, 719 *abs*
- Diabetic autonomic neuropathy**, erythromycin induces supranormal gall bladder contraction, 1123
- Diarrhoea**
and acetylphorin: *correspondence*, 432
acute, colonic dysfunction, role of luminal short chain fatty acids, 1215
community acquired, culture negative cytotoxin positive stools, 192
persistent, and giardiasis, impaired IgA response to *Giardia* heat shock antigen, children, 38
serum 7alpha-hydroxy-4-cholest-3-one concentrations in bile acid malabsorption evaluation, 698
syndromes, affecting gastrointestinal tract, 435
unusual cause, cap polyposis: *case report*, 562
- Dicke, Willem-Karel**, 1905-1962, pioneer, gluten free diet: *leading article*, 1473
- Dietary fat**
influence on duodenal resistance to acid, 1303
influence on its trophic effect on small intestinal mucosa, 358
- Dietary fibre**, butyrate production from, and protection against large bowel cancer, rat model, 386
- Dietary trials**, sex differences in colonic function, 531
- Dieulafoy's disease**
controlled by Doppler ultrasound endoscopic treatment: *case report*, 857
endoscopic treatment and follow up, 1418
- Disaccharidase deficiencies**, affecting gastrointestinal tract, 435
- Distal colonic circular smooth muscle**, relaxation by NO derived from human leucocytes, 814
- Diversion colitis** and involution of defunctioned anorectum, 382
- Diverticular disease**, increased risk of left sided colon cancer, 499
- DNA**
damage in stomach after vagotomy measured by ³²P-postlabelling, 1683
densitometry, of colorectal cancer, 1566
HPV 16, in NIH3T3 cells, transformed by colonic cancer cellular DNA, 1710
ploidy
in early gastric carcinoma (T1), flow cytometry, 100 cases, 230
in oesophageal carcinoma, influence of preoperative radiotherapy, 1086
polymorphisms, in complement C4 genes in autoimmune hepatitis, 718 *abs*
synthesis, unscheduled, and genotoxicity, proposed technique to assess, evaluation, 235
- Doppler ultrasound endoscopic treatment** controlling Dieulafoy's disease: *case report*, 857
- Duodenal histology**, ulceration, and *H. pylori*, in presence or absence of NSAIDs, 1162
- Duodenal juice total protein** and pancreatic enzyme synthesis, turnover, and secretion, after acute pancreatitis, 1261
- Duodenal mucosa**, and extracellular cyclic nucleotide pattern, in coeliac disease, 769
- Duodenal resistance to acid**, influence of dietary fat, 1303
- Duodenal ulcer**
acid secretion and gastrin sensitivity, effect of *H. pylori* eradication, 888
acute perforated, is not associated with *H. pylori* infection, 1344
cisapride with placebo compared in prevention of relapse, 1042
disease, *H. pylori* eradication, amoxicillin plus omeprazole versus triple therapy, 1167
eradicating *H. pylori* infection lowers gastrin mediated acid secretion, 1060
pain, role of acid and inflammation: *leading article*, 1300
recurrent, prospective multicentre study of risk factors associated with delayed healing, 1319
symptom relief and healing, lansoprazole and ranitidine compared: *clinical trial*, 1458
- Duodenal ulcer disease**, ranitidine 150 mg, two year maintenance treatment, 1662
- Duodenal ulceration**, *H. pylori* negative, chronic, pathogenesis, 762
- Duodenogastric reflux** after gastric surgery and in gastric ulcer disease, continuous measurement with a sodium ion selective electrode, 1047
- Dysphagia**
caused by isolated primary oesophageal involvement by lymphoma: *case report*, 994
oesophagitis is as important as oesophageal stricture diameter in determining, 152
- Dysplasia**
and adenocarcinoma, and Barrett's oesophagus: *correspondence*, 1292
arteriohepatic, affecting gastrointestinal tract, 435
- Echo planar magnetic resonance imaging**, for prolonged monitoring of the upper gastrointestinal tract: *technique*, 848
- Ectasia, vascular**
diffuse, of antrum, duodenum, and jejunum, associated with nodular regenerative hyperplasia: *case report*, 558
upper gastrointestinal, laser ablation, long term results, 470

- Eicosanoids**
gastric mucosal, synthesis, effect of *H. pylori* and NSAIDs, 748
role in antacid induced protection, rat stomach, 329
- Elderly**, bleeding varices: *correspondence*, 576
- Elemental diet**, in Crohn's disease, initial response and subsequent course, 1198
- Endoscopic dilatation** for corrosive oesophageal strictures, long term results, 1498
- Endoscopic extraction** of bile duct stones, management related to stone size, 1718
- Endoscopic injection**
to prevent rebleeding from peptic ulcers with a protruding vessel, 348: *correspondence*, 1150
for ulcer bleed, 1182
- Endoscopic oesophagitis**, location of lower oesophageal sphincter and squamous columnar mucosal junction, 21
- Endoscopic retrograde cholangiopancreatography**
safer: *leading article*, 721
value in bile duct injury after laparoscopic cholecystectomy, 1250
- Endoscopic retrograde pancreatography**, diagnostic, is it a necessary investigation? 1296 *abs*
- Endoscopic small bowel biopsy**, perforation from: *case report*, 134
- Endoscopy**
nasal oxygen during: *correspondence*, 288
open access, influence on stage of detection of gastric cancer, 1471 *abs*
perioperative, of whole small bowel, in Crohn's disease, 647: *correspondence*, 1741
units, aldehyde disinfectants and health: *special report*, 1641
upper gastrointestinal audit, in HIV positive patients, 1429
effects of supplemental oxygen on cardiac rhythm during, 1492
improving patient selection, 187
- Endosonography**, CT, and intraoperative assessment compared, in TN staging of gastric carcinoma, 604
- Enteritis**, radiation, chronic, effects of loperamide-N-oxide, gastrointestinal function, 477
- Enteroglucagon**, deoxycholate is an important releaser of from human colon, 1219
- Epidermal growth factor receptor**
down regulation, in liver proliferation induced by TAGH solution, 1, 1601
ploidy, and S-phase fraction, relationship in gastric cancer, 1470 *abs*
- 5-Epidoxorubicin** and lipiodol compared with symptomatic treatment for hepatoma, 1598
- Epithelial cell proliferation patterns**, rectal, as predictors of adenomatous colorectal polyp recurrence, 525
- Epstein-Barr virus infection**, in gastric carcinoma, 1471 *abs*
- Erythromycin**
effects on gastric emptying, antral motility, and plasma motilin and pancreatic polypeptide concentrations, anorexia nervosa, 166
induces supranormal gall bladder contraction in diabetic autonomic neuropathy, 1123
- Escherichia coli**
adhesive, carriage after restorative proctocolectomy and pouch anal anastomosis, 1379
from rectal mucosa in ulcerative colitis, adhesive and hydrophobic properties, 63
- Ethane exhalation**, increased, an in vivo index of lipid peroxidation in alcohol abusers, 409
- Ethanol induced gastric mucosal damage**, and depletion of sulphydryl compounds, glutathione prevents, 161
- Exocrine pancreatic insufficiency**, complex carbohydrate malabsorption, 984
- Extracorporeal shock wave lithotripsy**, gall bladder stones, 693 patients, plea for restriction to solitary radiolucent stones, 274: *correspondence*, 1291
- Factor XIIIa subunit** and Crohn's disease, 75
- Faecal incontinence**
liquid stool, with severe urgency, anorectal function and biofeedback treatment, 1576
neurogenic, abnormal visceral autonomic innervation, 215
prevalence of anal sphincter defects, endosonography, 685
- Familial adenomatous polyposis**
colonic fermentation of complex carbohydrates, 630
DNA content of isolated crypts of background colonic mucosa, 1240
and iatrogenic pancreatitis: *case report*, 1269
increased risk of thyroid and pancreatic carcinoma, 1394
non-penetrance and late appearance of polyps, 1389
pelvic ileal reservoir, mucosal changes, 101
screening and management, overview: *correspondence*, 575, 1292
- Familial primary gastric lymphoma**: *case report*, 136
- Familial visceral myopathy**, associated with mitochondrial myopathy: *case report*, 279
- Fatty acid profile** of dietary fat, influence on its trophic effect on small intestinal mucosa, 358
- Fatty acids**, calcium and phosphate, effects of dietary calcium and phosphate on intestinal interactions between, 365
- Feeding jejunostomy**, laparoscopic technique, 12
- Fibre**, dietary, butyrate production from, and protection against large bowel cancer, rat model, 386
- Fibrinolytic activity** of ascites caused by alcoholic cirrhosis and peritoneal malignancy, 1120
- Fibroblast growth factor** in gastroprotection and ulcer healing, interaction with sucralfate, 881
- Fish oil** treatment in inflammatory bowel disease, and polyunsaturated fatty acid pattern: *correspondence*, 1289
- Fluid transport**, in inflamed rat jejunum, nerve involvement, 1526
- Fluticasone propionate v prednisolone**, oral, in active ulcerative colitis, double blind trial, 125
- Food**
and anti-cholinergic drugs, effect on pattern of rectosigmoid contractions, 799
colonic pressure response, cephalic phase, 537
intolerance, in Crohn's disease, 783
- Free radicals**, role in inflammatory bowel disease: *leading article*, 865
- Full thickness intestinal biopsy**, laparoscopic technique, 12
- Functional adaptation** after massive small bowel resection, 637
- Fundectomy**, longterm, pancreatic hypertrophy with acinar cell nodules after, rat, 988
- Fundoplication**, antireflux action, mechanisms underlying, 303
- G cells** and parietal cells in developing human stomach, immunocytochemical localisation, 1057
- Galanin**, inhibitory action on pancreatic enzyme secretion, mechanism, and cholinergic transmission, 1616
- Gall bladder**
bile, decline of reduced cholesterol metastability, 702
carcoid tumour, two case reports and review, 1274
emptying, inappropriate application of high technology: *correspondence*, 430
epithelial cells, bovine, primary culture, 1612
fasting volume and postprandial emptying, correlation between, in patients with gall stones and healthy controls, 1443
motility
and gall stones: *leading article*, 440
regulation by arginine-nitric oxide pathway, guinea pigs, 911
mucus synthesis: *correspondence*, 861
non-communicating multiseptate, and choledochal cyst: *case report*, 853
stones, extracorporeal shock wave lithotripsy, 693 patients, plea for restriction to solitary radiolucent stones, 274: *correspondence*, 1291
supranormal contraction induced by erythromycin, in diabetic autonomic neuropathy, 1123
- Gall stone disease**, symptomatic, outcome after cholecystectomy and effect of surgical access, laparoscopic v open approach, 1448
- Gall stones**
and gall bladder motility: *leading article*, 440
prevalence, and gall bladder motility in acromegaly, effect of octreotide, 270
recurrence, and its prevention, British/Belgian gall stone study group's post-dissolution trial: *special report*, 1277
- Gamma/delta T-lymphocytes**, and autoimmune liver diseases, positive association between, 718 *abs*
- Gastrectomy**, R1 subtotal v R3 total, for operable antral cancer, prospective randomised trial, 1471 *abs*
- Gastric acid secretion**
and alcohol: *progress report*, 843
cholecystokinin in control, 321
effect of age, *H. pylori* infection, and gastritis with atrophy, 1032
new non-invasive test for use in children, 738
- Gastric alcohol dehydrogenase activity**, effect of age, sex, and alcoholism, 1433
- Gastric antrum**
carcinoma, indocyanine green potentiation, laser palliation, 1471 *abs*
real time ultrasonography, 173
- Gastric body ulcer**, and pepsinogen C gene polymorphisms, 450
- Gastric cancer (carcinoma)**
and adjacent mucosa, expression of c-erbB, 1470 *abs*
coal miners, screening, 494
early detection, health education, 1471 *abs*
early (T1), DNA ploidy, flow cytometry, 100 cases, 230
EBV infection, 1471 *abs*
influence of open access endoscopy on stage of detection, 1471 *abs*
molecular biology: *leading article*, 145
p53 protein expression, and prognosis, 1470 *abs*
plasminogen activators, 80
prognostic factors, 1471 *abs*
relationship of EGF-R, ploidy, and S-phase fraction, 1470 *abs*
serodiagnostic values of CA 72-4 and CA 19-9 in monitoring patients, 1470 *abs*
systemic and mucosal humoral responses to *H. pylori*, 1339
- TN staging**, CT, endosonography, and intraoperative assessment compared, 604

- Gastric cells**, human (HGT-1), possessing specific omeprazole binding sites, 1331
- Gastric dilatation**, acute, delayed complication of percutaneous endoscopic gastrostomy: *case report*, 859
- Gastric emptying**
in anorexia nervosa, effects of erythromycin, 166
disturbed, in short bowel syndrome, evidence for a 'colonic brake', 1171
effect of liquid fibre on rats and humans, 1177
- Gastric epithelial cells**, conjugation of 1-naphthol, 177
- Gastric metaplasia**, and *H. pylori* infection, 1510
- Gastric mucosa**
chronic nicotine intake causes vascular dysregulation, rat, 1688
intercellular junctions, relation to gastric ulcer, electron microscopic study, 86
phospholipid composition, endoscopic biopsy, 456: *correspondence*, 1741
- Gastric mucosal barrier**, evidence for *H. pylori* ingesting gastric surfactant and deriving protection from it, 588
- Gastric mucosal eicosanoid synthesis**, in patients taking NSAIDs, effect of *H. pylori* colonisation, 748
- Gastric mucosal leukotriene B₄ synthesis**, enhanced, in patients taking NSAIDs, 742
- Gastric secretion**, profound inhibition, postprandial biliary and pancreatic secretion during, 1607
- Gastric surfactant**, ingested by *H. pylori*, protection derived, 588
- Gastric ulcer**
healing, fibroblast growth factor, interaction with sucralfate, 881
relation to intercellular junctions in gastric mucosa, electron microscopic study, 86
- Gastrin**
concentrations, influence of *H. pylori*, sex, and age, 752
effect of age, *H. pylori* infection, and gastritis with atrophy, 1032
plasma, postprandial, effect of ranitidine bismuth citrate, 338
sensitivity, in duodenal ulcer, effect of *H. pylori* eradication, 888
- Gastrin 17**, selective increase, *H. pylori* related hypergastrinaemia as result, 757
- Gastritis**, phlegmonous, unusual presenting symptom of Sjögren's syndrome: *case report*, 1142
- Gastro-oesophageal reflux**
disease, oesophageal alkaline pH environment, determinants, 309
effect on upper oesophageal sphincter motility in children, 904
motor response not impaired in reflux oesophagitis, 317
non-invasive detection using ambulatory system, 1482
paediatric, prognostic indicators from pH monitoring, 1478
uncomplicated, surgery: *correspondence*, 428
- Gastroduodenal disease**, secretor status and *H. pylori* infection are independent risk factors, 351
- Gastroduodenal mucosa**, reduced tissue type plasminogen activator activity, in peptic ulcer disease, 1310
- Gastroenterology**, consultant staffing and career prospects, England and Wales: *special report*, 284
- Gastrointestinal fibrosis**, myofibroblasts in hollow visceral myopathy a possible origin: *case report*, 999
- Gastrointestinal and liver services**, nature and standards, UK: *special report*, 1728
- Gastrointestinal motility disorders**, autonomic dysfunction, 397
- Gastrointestinal tract**
single gene disorders affecting: *leading article*, 433
upper, inflammation, von Willebrand factor: *correspondence*, 288
- Gastroprotection** and ulcer healing, fibroblast growth factor, interaction with sucralfate, 881
- Gastroscopy**
follow up of pernicious anaemia patients, 28
open access, unrestricted, organising, South Tees: *special report*, 422: *correspondence*, 1290
- Gene expression** in Barrett's mucosa, adaptive responses in the oesophagus: *leading article*, 1649
- Genotoxicity**, and unscheduled DNA synthesis, proposed technique to assess, evaluation, 235
- Giardia** heat shock antigen, impaired IgA response in persistent diarrhoea and giardiasis, children, 38
- Giardiasis**, and persistent diarrhoea, impaired IgA response to *Giardia* heat shock antigen, children, 38
- Gliadin**, small amounts, in coeliac disease, 1515
- Glutamine** and ammonia metabolism, intestinal, during chronic hyperammonaemia, induced by liver insufficiency, 1112
- Glutamine and butyrate metabolism** in quiescent UC, 1552: *correspondence*, 1646
- Glutathione**, prevents ethanol induced gastric mucosal damage and depletion of sulphydryl compounds, 161
- Glutathione S-transferase M1 locus**, GSTM1 null polymorphism, in primary biliary cirrhosis, 549
- Gluten free diet**, pioneer, Willem-Karel Dicke 1905-1962, over 50 years of gluten free diet: *leading article*, 1473
- Gluten sensitivity**, rectal mucosae, quantitative histological and immunocytochemical studies, 1225
- Glycosylation** and sulphation of colonic mucus glycoproteins in UC and healthy subjects, 926
- Gold induced enterocolitis** complicated by CMV infection, previously unrecognised association: *case report*, 999
- Growth factor**, hepatocyte, mRNA detected in normal and fulminant liver by ribonuclease protection assay, 719 *abs*
- Growth hormone**, and insulin resistance in cirrhosis, 719 *abs*
- GSTM1 null polymorphism** at glutathione S-transferase M1 locus, in primary biliary cirrhosis, 549
- Haemoccult** does not reduce need for colonoscopy after curative resection for colorectal cancer, 227
- Haemochromatosis**, idiopathic, affecting gastrointestinal tract, 435
- Haemorrhage**, peptic ulcer, is sclerosant injection mandatory after epinephrine injection?, 1182
- Heater probe** in peptic ulcer with non-bleeding visible vessel, efficacy, 1502
- Helicobacter mustelae**, ferrets, 14C-urea breath test, bismuth, antibiotics, and urease inhibitors, effects, 181
- Helicobacter pylori**
10th anniversary of its culture in April 1982: *leading article*, 293
colonisation, effect on gastric mucosal eicosanoid synthesis, and NSAIDs, 748
comparison of DNA fingerprints provides evidence for intrafamilial infection, 1348
duodenal histology, and ulceration, in presence or absence of NSAIDs, 1162
effect on serum gastrin and gastric acid secretion, 1032
eradication
in duodenal ulcer disease, amoxicillin plus omeprazole *versus* triple therapy, 1167
effect on gastric juice ascorbic acid concentrations, 1038
effect on gastrin sensitivity in duodenal ulcer, 888
four serological tests, presence/absence NSAIDs, 461: *correspondence*, 1467
infection
epidemiology of and risk factors for, 3194 asymptomatic subjects, 17 populations, 1672
eradicating lowers gastrin mediated acid secretion, 1060
and gastric metaplasia, 1510
no association with acute perforated duodenal ulcer, 1344
prevalence, and effects on symptoms and NSAID induced gastropathy in RA, 1677
and secretor status, are independent risk factors of gastroduodenal disease, 351
when is it acquired?, 1681
ingesting gastric surfactant, protection derived, 588
negative chronic duodenal ulceration, pathogenesis, 762
NSAIDs, and peptic ulcer disease: *leading article*, 580
positive resistant duodenal ulcers, colloidal bismuth subcitrate plus antibiotics or sucralfate alone, 466: *correspondence*, 1646
related hypergastrinaemia is result of selective increase in gastrin 17, 757
sex, and age, influence on gastrin and pepsinogen concentrations, 752
strains activating neutrophils in peptic ulcer disease, 599
systemic and mucosal humoral responses to, in gastric cancer, 1339
ultrastructural patterns, 1507
- Hepatic bile**, decline of reduced cholesterol metastability, 702
- Hepatic metastases**, treatment by cryotherapy and regional cytotoxic perfusion: *leading article*, 1156
- Hepatic perfusion changes** in liver metastases compared with cirrhosis, 554
- Hepatitis**
autoimmune, DNA polymorphisms in complement C4 genes, 718 *abs*
chronic active, and HRT: *case report*, 1639
early acute, with parenteral amiodarone, toxic effect of vehicle: *case report*, 565
in intravenous drug misusers dying from heroin overdose, 717 *abs*
- Hepatitis B infection**
factors predicting response to IFN alpha treatment, 717 *abs*
strategies for: *correspondence*, 575
- Hepatitis B virus**, molecular biology, mutant virus and host response, recent advances: *leading article*, 1
- Hepatitis C**
chronic
interferon, thyroid function: *correspondence*, 574
response prediction to interferon alfa, pretreatment variables, 1714
ribavirin and alpha interferon treatment, 717 *abs*
- Hepatitis C virus genotypes**, type specific differences, 717 *abs*
- Hepatocellular carcinoma**, alphafetoprotein variants, 719 *abs*
- Hepatoerythropoietic porphyria**, precipitated by viral hepatitis: *case report*, 1632
- Hepatoma**, lipiodol and 5-epidoxorubicin compared with symptomatic treatment, 1598
- Hepatorenal syndrome**, increased lipid peroxidation, 719 *abs*
- Heroin overdose**, viral hepatitis in intravenous drug misusers dying from, 717 *abs*

- Heterotopic pancreas**, development of cystic dystrophy of gastric and duodenal wall, 343
- Hexamethyl propylene amine oxime**, technetium-99m, granulocyte scintigraphy, in Crohn's disease, 1364
- Hirschsprung's disease**, electrogenic colonic ion transport, reduced secretion to neural secretagogues acetylcholine and iloprost, 1405
- Histamine**, effect on gastrointestinal tumour growth, and reversal by cimetidine, 1091
- HIV positive patients** with gastrointestinal symptoms, audit of endoscopy, 1429
- HLA DRw52a and Dw2 associations** in primary sclerosing cholangitis, 718 *abs*
- Hollow visceral myopathy**, myofibroblasts, possible origin of gastrointestinal fibrosis: *case report*, 999
- Hormone replacement therapy**
in chronic active hepatitis: *case report*, 1639
prevents bone loss in IBD, 1543
- Human gastric cells (HGT-1)**, possessing specific omeprazole binding sites, properties of potassium channel, 1331
- Human papillomavirus** 16 DNA in NIH3T3 cells transformed by colonic cancer cellular DNA, 1710
- Hydrogen metabolism**, and sulphate reducing bacteria, large intestine: *leading article*, 437
- 7alpha-Hydroxy-4-cholesten-3-one** serum concentrations, bile acid malabsorption, in diarrhoea, correlation to SeHCAT test, 698
- Hyperammonaemia**, chronic, induced by liver insufficiency, intestinal glutamine and ammonia metabolism during, 1112
- Hypergastrinaemia**, omeprazole induced, inhibition by SMS 201-995, 1186
- Hyperglycaemia**, acute, induced by cholecystokinin, effect on gall bladder contraction, 1123
- Hysterectomy**
and cholecystectomy, bowel function and irritable bowel symptoms after, 1108
and the irritable bowel: *correspondence*, 429
- '**Ileal brake**' mechanism, and bile salt inhibition of motility, rabbit, 483
- Ileocolonic biopsy homogenates**, 5-ASA and AC-5-ASA concentrations: *correspondence*, 713
- Ileocolonic junction**, does it differentiate between solids and liquids? 222
- Ileocolonic resection** for Crohn's disease, neoterminal ileal blood flow after, 1531
- Ileocolonic transit and fluid transfer in vivo**, effects of serotonin, rat, 794
- Iloprost**, reduced secretion to, and electrogenic colonic ion transport in Hirschsprung's disease, 1405
- Immunoblotting**, for antimitochondrial antibodies in primary biliary cirrhosis, 544
- Immunoglobulin A**, impaired response to *Giardia* heat shock antigen, persistent diarrhoea and giardiasis, children, 38
- Immunohistochemistry**, location of TNF alpha in chronic inflammatory bowel disease, 1705
- Immunomagnetic islet purification**, mode of digest release into magnetic field significantly affects, 1296 *abs*
- Indocyanine green** potentiation of 805 nm diode laser palliation for gastric antrum carcinoma, 1471 *abs*
- Indomethacin-induced injury in rats**, role of oxygen, lipid peroxidation, and antioxidants, 732
- Indomethacin** induced ulceration, contribution of infiltrating neutrophils, 156
- Inflammation**
and acid, role in duodenal ulcer pain: *leading article*, 1300
in UC, increased production of luminol enhanced chemiluminescence, 1191
- Inflammatory bowel disease**
in Asians: *correspondence*, 714
azathioprine causing bone marrow toxicity, 27 years experience, 1081
chronic, location of TNF alpha by immunohistochemistry, 1705
epidemiology, Province of Granada, Spain, 1979 to 1988, 1207
familial empirical risks, Jews/non-Jews, 517
- HRT prevents bone loss, 1543
- leukocyte excretion and blood loss compared, 1535
- non-active, abnormal plasma polyunsaturated fatty acid pattern, 1370
- pANCA are mainly associated with UC, 46
- polyunsaturated fatty acid pattern and fish oil treatment: *correspondence*, 1289
- radical review: *leading article*, 865
- and refractory anaemia (myelodysplasia): *case report*, 1630
- thromboembolism, platelet role, 247
- Information systems**, clinical terms project: *leading article*, 1651
- Injection therapy** for peptic ulcer haemostasis, 348: *correspondence*, 1150
- Insulin like growth factor 1 receptors**, determination of histological distribution, rat gut, 1693
- Insulin like growth factor-I**, insulin like growth factor binding protein-1, and insulin in childhood Crohn's disease, 944
- Insulin resistance** in cirrhosis, and growth hormone, 719 *abs*
- Insulinoma**, accurate localisation by selective angiography and surgical management, 1296 *abs*
- Integrin adhesion molecules**, altered glycosylation in colorectal cancer cells and decreased adhesion to extracellular matrix, 829
- Intercellular adhesion molecule 1**, expression in colonic epithelial cells, 1593
- Intercellular adhesion molecule-1**, and MHC antigens, on human intrahepatic bile duct cells, effect of pro-inflammatory cytokines, 1245
- Intercellular junctions**, gastric mucosa, relation to gastric ulcer, electron microscopic study, 86
- Interferon**, chronic hepatitis C, thyroid function: *correspondence*, 574
- Interferon alfa**
in chronic hepatitis B infection, factors predicting response, 717 *abs*
response prediction of chronic hepatitis C, pretreatment variables, 1714
and ribavirin, in chronic hepatitis C, 717 *abs*
- Interleukin-2**
and IFN-gamma, augment anticolon antibody dependent cellular cytotoxicity in ulcerative colitis, 788
receptors, in UC, 658
treatment improves survival in murine acute pancreatitis, 1295 *abs*
- Interleukin-6**
role in mediating acute phase protein response and potential as early means of severity assessment in acute pancreatitis, 41: *correspondence*, 1467
- serum and stool, measurement, *Shigella dysenteriae* 1 infection, children, 194
- Interleukin-8**, enhanced local production and neutrophil mucosal involvement, in ulcerative colitis, 1203
- Intestine, intestinal**
adaptation, comparison of different lipid substrates, rat, 1069
bacteria, PABA-UDCA disulphate for detection, 823
biopsy, full thickness, laparoscopic technique, 12
defects, affecting gastrointestinal tract, 436
- epithelial cells, and platelet activating factor generation, in UC, 665
- mucosa, morphometric analysis, quantitative histological and immunocytochemical studies of rectal mucosae in gluten sensitivity, 1225
- permeability, in coeliac disease and relatives of patients with coeliac disease, 354
- permeability test, as valid marker for slight dietary transgressions in adolescents with coeliac disease, 774
- pseudo-obstruction
children, colonic manometry, 803
in patients with amyloidosis, 1412
- Intraepithelial lymphocytes**
colonic, suppress Ig synthesis by autologous peripheral blood and lamina propria lymphocytes, 257
- see also* T cell receptors
- Intraoperative assessment**, CT, and endosonography compared, in TN staging of gastric carcinoma, 604
- Iron deficiency anaemia**
how far to investigate? 1427
perspective: *leading article*, 1297
prospective survey of investigations in outpatients referred with, 1102
- Irritable bowel**
and hysterectomy: *correspondence*, 429
symptoms, and bowel function, after hysterectomy and cholecystectomy, 1108
- Irritable bowel syndrome**, selective affective biasing in recognition memory, 1230
- Ischaemic colitis**, two distinct patterns of severity: *leading article*, 4
- Islet purification**, immunomagnetic, mode of digest release into magnetic field significantly affects, 1296 *abs*
- Isotope gastric emptying tests** in clinical practice, expectation, outcome, and utility, 916
- Ivalon**, intraperitoneal, mimicking peritoneal malignancy after plugged percutaneous liver biopsy: *case report*, 1635
- Jejunal diaphragm disease**, NSAID-induced: *correspondence*, 715
- Jeunoileitis**, diffuse, of Crohn's disease, 1374
- Jejunostomy**, congestive, in portal hypertension, 694
- Jejunum**, inflamed, nerve involvement in fluid transport, rat, 1526
- Jews/non-Jews, familial empirical risks for inflammatory bowel disease, 517
- K-ras mutations**, and p53 expression, in colorectal adenomas, 621
- K-ras mutations**, high frequency in sporadic colorectal adenomas, 392
- K ras mutations**, detection in pancreatic juice, potential diagnostic test for pancreatic adenocarcinoma, 1296 *abs*

- Knee-elbow position** relieves bowel distension, in toxic megacolon: *case report*, 1726
- Kupffer cell** derived 95 kDa type IV collagenase/gelatinase regulation, and liver injury, 719 *abs*
- Lactate** and pH in faeces from patients with colonic adenomas or cancer, 625
- Laminin**, serum concentrations, in cirrhosis of the liver, 974
- Langerhans' cell histiocytosis**, multisystem, with pancreatic involvement: *case report*, 570
- Lansoprazole**, and ranitidine compared, in duodenal ulcer healing and relief: *clinical trial*, 1458
- Laparoscopic cholecystectomy**, bile duct injury after, value of ERCP, 1250
- Laparoscopic technique** for full thickness intestinal biopsy and feeding jejunostomy, 12
- Large bowel**
cancer, protection against, butyrate production from dietary fibre, rat model, 386
methanogenesis: *correspondence*, 573
sulphate reducing bacteria and hydrogen metabolism: *leading article*, 437
- Laser ablation** of upper gastrointestinal vascular ectasias, long term results, 470
- Laser endoscopic palliation**, indocyanine green potentiation of 805 nm, gastric antrum carcinoma, 1471 *abs*
- Laser lithotripsy** of difficult bile duct stones under direct visual control, 415
- Laser palliation**, radiation enhancement, for advanced rectal and rectosigmoid cancer, pilot study, 958
- Laxatives**, anthranoid, abuse, risk for colorectal cancer? 1099
- Leucocyte adhesion molecule** upregulation, inhibition by TNF-alpha, novel mechanism of action of sulphasalazine, 252
- Leucocytes**
excretion, and blood loss, in inflammatory disease of the bowel, comparison, 1535
labelled (Tc-99m HMPAO), in analysis of Crohn's disease activity, 68 NO derived from, and relaxation of distal colonic circular smooth muscle, 814
- Leukotriene B₄**, gastric mucosal synthesis and NSAIDs, 742
- Lipid peroxidation**
and alcohol abusers, 409
increased, in hepatorenal syndrome, 719 *abs*
oxygen, and antioxidants, and indomethacin-induced injury in rats, 732
- Lipid substrates**, different, comparison, intestinal adaptation, rat, 1069
- Lipiodol** and 5-epidoxorubicin compared with symptomatic treatment for hepatoma, 1598
- Lipocyte** derived alpha2-macroglobulin and 72 kDa type IV collagenase/felinase, regulation by Kupffer cell medium and dexamethasone, 719 *abs*
- Liquid fibre**, effect on gastric emptying in rat and humans and distribution of small intestinal contents, rat, 1177
- Liquid stool incontinence** with severe urgency, anorectal function and effective biofeedback treatment, 1576
- Lithotripsy**, laser, of difficult bile duct stones under direct visual control, 415
- Lithotripsy** of impacted calcified stone in cystic duct, and cholecystitis, in Crohn's disease: *case report*, 1145
- Lithotrite**, percutaneous rotary, new approach to symptomatic cholezystolithiasis, 837
- Liver**
biopsy, plugged percutaneous, intraperitoneal ivalon mimicking peritoneal malignancy after: *case report*, 1635
disease
autoimmune, and gamma/delta T-lymphocytes, positive association between, 718 *abs*
benign, alphafetoprotein variants, 719 *abs*
and gastrointestinal services, nature and standards, UK: *special report*, 1728
metastases, hepatic perfusion changes, comparison with cirrhosis, 554
perfusion, after sequential cold and warm ischaemic injury, S-adenosylmethionine improves hepatic function during, 720 *abs*
plasma membrane, reversal of carbon tetrachloride induced changes by colchicine, 1438
transplantation, changing face: *leading article*, 295
see also Hepatic: Hepatitis
- Loperamide-N-oxide**, effects on gastrointestinal function in chronic radiation enteritis, 477
- Lower oesophageal sphincter**
hypersensitivity to opioid receptor stimulation in idiopathic achalasia, 16
- and squamous columnar mucosal junction, location in different degrees of endoscopic oesophagitis, 21
- Luminal short chain fatty acids**, role in colonic dysfunction in acute diarrhoea, 1215
- Luminol enhanced chemiluminescence**, increased production by inflamed colonic mucosa in ulcerative colitis, 1191
- Lymphoma**
extraintestinal, in association with Whipple's disease: *case report*, 1627
gastric, familial primary: *case report*, 136
pleural, in patient presenting with malabsorption, enteropathy associated T cell lymphoma: *case report*, 1463
- Major histocompatibility antigens**
expression in human chronic pancreatitis, 1452
and ICAM-1, on human intrahepatic bile duct cells, effect of pro-inflammatory cytokines, 1245
- Malabsorption**, and pleural lymphoma, enteropathy associated T cell lymphoma: *case report*, 1463
- Manometry**, oesophageal, in clinical practice, audit, 1158
- Megacolon**, toxic, knee-elbow position relieves bowel distension: *case report*, 1726
- Methanogenesis**, in large intestine: *correspondence*, 573
- MHC**, *see* Major histocompatibility
- Mitochondrial myopathy**, and familial visceral myopathy: *case report*, 279
- Molecular biology**
of colorectal neoplasia: *leading article*, 289
and gastric carcinoma: *leading article*, 145
setting the stage in colorectal cancer? *leading article*, 1476
- Monoclonal antibodies**, sialosyl-Tn binding, MLS102 and B72.3 compared, in detecting pancreatic cancer, 1722
- Motilin**, plasma concentrations, in anorexia nervosa, effects of erythromycin, 166
- Motor neurone disease**, peptic ulcer, and cimetidine, record linkage study, 1660
- M**, 40 kD autoantigen involved with IgG1 mediated complement action in UC, 650
- Mucosae**, rectal, gluten sensitivity, quantitative histological and immunocytochemical studies, 1225
- Mucosal changes**, early, in Crohn's disease, 375
- Mucosal damage** in experimental colitis, octreotide effectively decreases, 264
- Mucosal polyamine metabolism** in columnar lined oesophagus, 584
- Mucosal prolapse syndrome**, microvascular abnormalities, 106: *correspondence*, 714
- Mucus synthesis**, by gall bladder: *correspondence*, 861
- Mycobacterium paratuberculosis**, antibodies, and nine species of environmental mycobacteria, in Crohn's disease and control subjects, 371: *correspondence*, 1291
- Myelodysplasia**, and inflammatory bowel disease: *case report*, 1630
- Myofibroblasts** in hollow visceral myopathy, possible origin of gastrointestinal fibrosis: *case report*, 999
- N-acetyl and acetoxy derivatives** of putrescine and cadaverine, presence in gut, 489
- 1-Naphthol**, conjugation in gastric epithelial cells, 177
- Nasal oxygen** during endoscopy: *correspondence*, 288
- Neoterminal ileal blood flow**, after ileocolonic resection for Crohn's disease, 1531
- Nerve involvement** in fluid transport in inflamed jejunum, rat, 1526
- Neurons**, afferent, role in antacid induced protection, rat stomach, 329
- Neutrophil** mucosal involvement is accompanied by enhanced local production of IL-8 in ulcerative colitis, 1203
- Neutrophils**, infiltrating, contribution to indomethacin induced ulceration, 156
- Nicotine**, chronic intake causes vascular dysregulation, gastric mucosa, rat, 1688
- Nissen fundoplication**, fate after 20 years, clinical, endoscopical, and functional analysis, 1015
- Nitric oxide**
derived from human leucocytes, and relaxation of distal colonic circular smooth muscle, 814
role in antacid induced protection, rat stomach, 329
role in nerve mediated relaxation of anal sphincter, 689
- Nocturnal oesophageal motor activity**, is dependent on sleep stage, 1653
- Nodular regenerative hyperplasia**, associated with diffuse vascular ectasia of antrum, duodenum, and jejunum: *case report*, 558
- Non-communicating multiseptate gall bladder**, and choledochal cyst: *case report*, 853
- Non-deglutitive motor activity**, oesophagus: *leading article*, 1013
- Non-deglutitive simultaneous contractions**, bursts may be a normal oesophageal motility pattern, 1021
- Non-steroidal anti-inflammatory drug(s)**
-induced gastropathy, prevalence of *H. pylori* infection and its effect on symptoms in RA, 1677
and effect of *H. pylori* colonisation on gastric mucosal eicosanoid synthesis, 748
and enhanced gastric mucosal leukotriene B₄ synthesis, 742

- H. pylori*, and peptic ulcer disease: *leading article*, 580
 -induced jejunal and colonic diaphragm disease: *correspondence*, 715
 presence or absence, duodenal histology, ulceration, and *H. pylori*, 1162
 presence/absence, diagnosis of *H. pylori*, four serological tests, 461: *correspondence*, 1467
- Notes**, 142, 432, 576, 716, 1152, 1293, 1468, 1648
- Nutritional state** and villus height, mathematical correlation between, Sprague-Dawley rats, 1066
- Nutritional support** after major surgery, effect on pancreatic function, 1295 *abs*
- Octreotide**
 in acromegaly, postprandial gall bladder motility and hormone release, 808
 effect on gall stone prevalence and gall bladder motility in acromegaly, 270
 effectively decreases mucosal damage in experimental colitis, 264
- Oesophagitis**
 endoscopic, location of lower oesophageal sphincter and squamous columnar mucosal junction, 21
 as important as oesophageal stricture diameter in determining dysphagia, 152
- Oesophagus, oesophageal**
 acid reflux episodes, pressure events surrounding, and acid clearance, healthy volunteers, 444
 adaptive responses, gene expression in Barrett's mucosa: *leading article*, 1649
 alkaline pH environment, in gastro-oesophageal reflux disease, determinants, 309
 Barrett's columnar lined lower, complications, role of alkalinisation, 11
 carcinoma
 influence of preoperative radiotherapy on DNA ploidy, 1086
 plasminogen activators, 80
 intact, measurement of bicarbonate output, 872
 involvement, isolated primary, by lymphoma, causing dysphagia: *case report*, 994
 lower sphincter, *see* Lower oesophageal sphincter
 manometry, in clinical practice, audit, 1158
 motility
 normal pattern, and bursts of non-deglutitive simultaneous contractions, 1021
 in reflux oesophagitis, effects of ranitidine and cisapride, 1025
 motor activity
 nocturnal, is dependent on sleep stage, 1653
 non-deglutitive: *leading article*, 1013
 motor response to reflux is not impaired in reflux oesophagitis, 317
 myenteric plexus, in achalasia, varicella-zoster virus DNA, 299
 sensitivity, and acid clearance, in progressive systemic sclerosis, 1487
 strictures, corrosive, endoscopic dilatation, long term results, 1498
- Oestrogen** and progesterone receptors, sex differences in colorectal cancer, 611
- Omeprazole**
 binding sites, properties of potassium channel in cultured human gastric cells (HGT-1) possessing, 1331
 induced hypergastrinaemia, inhibition by SMS 201-995, 1186
 inhibits colorectal carcinogenesis induced by azoxymethane, rats, 1559
- Opioid receptor stimulation** in idiopathic achalasia, LOS hypersensitivity, 16
- Oral enzymes**, fate in pancreatic insufficiency, 708
- Oral rehydration solutions**, cereal based, dominant role for low osmolality, 920
- Oral submucous fibrosis**, a chronic disseminated intravascular coagulation syndrome with local coagulopathy: *correspondence*, 713
- Oroileal transit** of slow release 5-ASA, 669
- Oxygen**
 lipid peroxidation, and antioxidants, and indomethacin-induced injury in rats, 732
 nasal, during endoscopy: *correspondence*, 288
 supplemental, effects on cardiac rhythm during upper gastrointestinal endoscopy, 1492
- p53 expression** and K-ras mutation in colorectal adenomas, 621
- p53 protein**, expression, and prognosis in gastric carcinoma, 1470 *abs*
- PABA-UDCA disulphate**, for intestinal bacteria detection, 823
- Paediatric gastro-oesophageal reflux**, prognostic indicators from pH monitoring, 1478
- Painful rib syndrome**, review of 76 cases, 1006
- Pancreas, pancreatic**
 adenocarcinoma
 adjuvant radiochemotherapy after resection, preliminary results, 1296 *abs*
 detection of K ras oncogene mutations in pancreatic juice as potential diagnostic test, 1296 *abs*
- and biliary secretion, postprandial, during profound inhibition of gastric secretion, 1607
- cancer**
 detection, sialosyl-Tn binding monoclonal antibodies MLS102 and B72.3 compared, 1722
 RB1 tumour suppressor gene, 1296 *abs*
 in vivo, TGF alpha is trophic to, 1097
- carcinoma**, increased risk in FAP, 1394
- disease**, in AIDS patients, 1295 *abs*
- enzyme secretion**, mechanism of galanin's inhibitory action, and cholinergic transmission, 1616
- enzyme supplementation**, effect on management of acute pancreatitis, 1294 *abs*
- enzyme synthesis**, turnover, and secretion, after acute pancreatitis, 1261
- function**, after major surgery, nutritional support, 1295 *abs*
- genetic disorders**, affecting gastrointestinal tract, 435
- heterotopic**, development of cystic dystrophy of gastric and duodenal wall, 343
- hypertrophy**, with acinar cell nodules after longterm fundectomy, rat, 988
- insufficiency**, fate of oral enzymes, 708
- polypeptide concentrations**, in anorexia nervosa, effects of erythromycin, 166
- pseudocyst**, causing bilateral ureteric obstruction: *case report*, 1267
- Pancreatitis**
 acute
 are somatostatin and somatostatin analogues indicated?, 1622
 duodenal juice total protein and pancreatic enzyme synthesis, turnover, and secretion after, 1261
 dynamic computed tomography, patient selection and timing, 1294 *abs*
 effect of pancreatic enzyme supplementation on management, 1294 *abs*
 further characterisation of new model, 1294 *abs*
 IL-2 treatment improves survival, mouse, 1295 *abs*
 IL-6 role in mediating acute phase protein response and potential in severity assessment, 41: *correspondence*, 1467
 intraperitoneal trasylol, prospective, multicentre, controlled, randomised trial, 1295 *abs*
 monocyte production of TNF, relation to outcome, 1294 *abs*
 PMN-elastase as prognostic indicator, 1294 *abs*
 serum amylase levels: *correspondence*, 429
- chronic
 compartment syndrome, 1295 *abs*
 expression of MHC antigens, 1452
- Finland, 1970-1989, 1255
- iatrogenic**, in FAP: *case report*, 1269
- severe acute, pancreatic and synovial type phospholipase A2 in serum samples, 1133
- thrombosis of splenic artery pseudoaneurysm complicating: *case report*, 1271
- Parietal cells** and G cells in developing human stomach, immunocytochemical localisation, 1057
- Pelvic ileal reservoir**, distribution of mucosal pathology and assessment of colonic phenotypic change, 101
- Pelvis**, radiotherapy, in vivo rectal inflammatory mediator changes, 1210
- Pentagastrin**, effect on gastric secretion of PAF and precursors, 1051
- Pepsinogen C**
 gene polymorphisms, associated with gastric body ulcer, 450
 serum, diagnostic value in patients with raised serum concentrations of pepsinogen A, 1315
- Pepsinogens**
 concentrations, influence of *H. pylori*, sex, and age, 752
 plasma, postprandial, effect of ranitidine bismuth citrate, 338
- Peptic ulcer**
 cimetidine, and motor neurone disease, record linkage study, 1660
 disease
 H. pylori and NSAIDs, synergistic reaction between: *leading article*, 580
 H. pylori strains activating neutrophils, 599
 reduced tissue type plasminogen activator activity of gastroduodenal mucosa, 1310
 haemorrhage, is sclerosant injection mandatory after epinephrine injection? 1182
 with non-bleeding visible vessel, efficacy of heater probe, 1502
 perforated, over 56 years, time trends in patients and disease characteristics, 1666
 rebleeding, prevention by endoscopic injection therapy, 348: *correspondence*, 1150
- Peptic ulceration**, and post-bulbar ulceration, Hyderabad, 1327
- Peptide YY**, deoxycholate is an important releaser of from human colon, 1219
- Percutaneous endoscopic gastrostomy**, acute gastric dilatation a delayed complication: *case report*, 859
- Percutaneous rotary lithotrite**, new approach to symptomatic cholezystolithiasis, 837

- Perforated peptic ulcer** over 56 years, time trends in patients and disease characteristics, 1666
- Perforation**, from endoscopic small bowel biopsy: *case report*, 134
- Perioperative endoscopy** of whole small bowel in Crohn's disease, 647: *correspondence*, 1741
- Peritoneal malignancy**, ascites caused by, fibrinolytic activity, 1120
- Pernicious anaemia**, gastroscopic follow up of patients, 28
- Peyer's patches**, macrophages and granulocytes expressing L1 protein, distribution, compared with ileal lamina propria and lymph nodes, 1357
- pH**
and lactate, in faeces from patients with colonic adenomas or cancer, 625
monitoring, of paediatric gastro-oesophageal reflux, 1478
- Phlegmonous gastritis**, unusual presenting symptom of Sjögren's syndrome: *case report*, 1142
- Phosphate**, dietary, effects on intestinal interactions between calcium, phosphate, fatty acids, and bile acids, 365
- Phospholipase A2**, pancreatic and synovial type, in severe acute pancreatitis serum samples, 1133
- Phospholipid composition** of gastric mucosa, endoscopic biopsy, 456: *correspondence*, 1741
- Phospholipids** and their molecular species, effect on cholesterol solubility and nucleation, human and model biles, 110
- Phosphorus-32 postlabelling**, measuring DNA damage in stomach after vagotomy, 1683
- Plasminogen activators** in normal tissue and oesophageal and gastric carcinomas, 80
- Platelet activating factor**
generation in UC, contribution of intestinal epithelial cells, 665
and precursors, gastric secretion, effect of pentagastrin, 1051
- Pleural lymphoma**, in patient presenting with malabsorption, enteropathy associated T cell lymphoma: *case report*, 1463
- Ploidy**, EGF-R, and S-phase fraction, relationship in gastric cancer, 1470 *abs*
- Polyethylene glycol 600**, deposited in colon in active ulcerative colitis, increased absorption, 509
- Polymeric enteral diets** as primary treatment of active Crohn's disease, prospective steroid controlled trial, 778
- Polymorphonuclear-elastase**, as prognostic indicator in acute pancreatitis, 1294 *abs*
- Polymyositis**, associated with ulcerative colitis: *case report*, 567
- Polyp**
adenomatous colorectal, rectal epithelial cell proliferation patterns as predictors of recurrence, 525
non-penetrance and late appearance in families with FAP, 1389
- Polyposis**, cap, unusual cause of diarrhoea: *case report*, 562
- Polyunsaturated fatty acid**
pattern, and fish oil treatment, in inflammatory bowel disease: *correspondence*, 1289
plasma, abnormal pattern in non-active inflammatory bowel disease, 1370
- Portal hypertension**
and congestive jejunopathy, 694
injection sclerotherapy, complications and limitations: *leading article*, 7; *correspondence*, 861
related acute and recurrent upper gastrointestinal haemorrhage, TIPSS, 968
- Post-bulbar** and coexisting ulceration, unique features of peptic ulcer, Hyderabad, 1327
- Potassium channel**, in cultured human gastric cells (HGT-1) possessing specific omeprazole binding sites, properties, 1331
- Pouchitis**
and carriage of adhesive *E. coli*, 1379
refractory, does it reflect underlying Crohn's disease?, 1539
- Prednisolone**
in Crohn's disease, initial response and subsequent course, 1198
v fluticasone propionate, oral, in active ulcerative colitis, double blind trial, 125
- Primary biliary cirrhosis**
GSTM1 null polymorphism at glutathione S-transferase M1 locus, 549
immunoblotting for antimitochondrial antibodies, 544
specific M2 autoantibodies, and UTI, 717 *abs*
T-cell response to major human mitochondrial autoantigens, 718 *abs*
- Primary sclerosing cholangitis**
adhesion molecule expression, 718 *abs*
anti-lactoferrin antibodies and other types of ANCA, 56
autoimmune, childhood, antineutrophil antibody as test, 199
cyclosporin, ulcerative colitis disease activity following, 242
inappropriate expression of blood group antigens on biliary and colonic epithelia, 977
primary HLA DRw52a and Dw2 associations, 718 *abs*
- Procolipase propeptide concentrations**, effect of satiating meal, normal and morbidly obese subjects, 1520
- Proctocolectomy**, restorative, audit, 680
- Progastrin derived peptides**, identification in colorectal carcinoma extracts, 90
- Proliferation cell nuclear antigen (clone 19A2)**, correlates with 5-bromo-2-deoxyuridine labelling in colonic epithelium, 1587
- Proliferation** in human gastric mucosa after *in vivo* bromodeoxyuridine labelling, 893
- Protein kinase C** inhibits cAMP in HGT-1, 953
- Pseudoaneurysm**, splenic artery, thrombosis, complicating pancreatitis: *case report*, 1271
- Pulmonary involvement** in Crohn's disease, 3 year old boy: *case report*, 1636
- Putrescine**, N-acyl and acetoxy derivatives, presence in gut, 489
- Pyloric motility**, phasic and tonic, cholecystokinin octapeptide stimulates, healthy humans, 33
- R1 subtotal v R3 total gastrectomy**, for operable antral cancer, prospective randomised trial, 1471 *abs*
- Radiation enhancement** of laser palliation for advanced rectal and rectosigmoid cancer, pilot study, 958
- Radiation enteritis**, chronic, effects of loperamide-N-oxide, gastrointestinal function, 477
- Radioisotope determination** and radio opaque markers compared, in regional colonic transit in severe constipation, 402: *correspondence*, 1289
- Radiotherapy**
preoperative, influence on DNA ploidy in squamous cell carcinomas of the oesophagus, 1086
to the pelvis, *in vivo* rectal inflammatory mediator changes, 1210
- Ranitidine**
and cisapride, effects on oesophageal motility in reflux oesophagitis, 1025
and delayed healing of recurrent duodenal ulcers, multicentre study, 1319
in duodenal ulcer disease, two year maintenance treatment, 1662
and lansoprazole compared, in duodenal ulcer healing and relief: *clinical trial*, 1458
- Ranitidine bismuth citrate**, effect on postprandial plasma gastrin and pepsinogens, 338
- RB1 tumour suppressor gene**, in human pancreatic cancer, 1296 *abs*
- Reactive oxygen metabolites** in inflammatory bowel disease: *leading article*, 865
- Real time ultrasonography**, gastric antrum, 173
- Recognition memory**, selective affective biasing, in IBS, 1230
- Rectosigmoid cancer**, advanced, radiation enhancement of laser palliation, pilot study, 958
- Rectosigmoid contractions**, effect of food and anti-cholinergic drugs, 799
- Rectum, rectal**
cancer, advanced, radiation enhancement of laser palliation, pilot study, 958
defunctioned, in ulcerative colitis, pathology, 514
human, biomechanical wall properties, impedance planimetry, 1581
inflammatory mediator changes, *in vivo*, with radiotherapy to pelvis, 1210
mucosa, in UC, *E. coli* from, adhesive and hydrophobic properties, 63
- Reflux oesophagitis**
oesophageal motility, effects of ranitidine and cisapride, 1025
oesophageal motor response to reflux not impaired, 317
- Refractory anaemia**, and inflammatory bowel disease: *case report*, 1630
- Restorative proctocolectomy**
with end to end pouch-anal anastomosis, in patients over fifty, 948
outcome when diagnosis is suggestive of Crohn's disease, 1384
and pouch anal anastomosis, carriage of adhesive *E. coli* after, 1379
- Retropertitoneal fibrosis**, Riedel's thyroiditis, and sclerosing cholangitis, diseases with one pathogenesis? *correspondence*, 714
- Rheumatoid arthritis**, NSAID induced gastropathy, and prevalence of *H. pylori* infection, 1677
- Ribavirin**, and alpha interferon, in chronic hepatitis C, 717 *abs*
- Ribonuclease protection assay**, detecting hepatocyte growth factor mRNA in normal and fulminant liver, 719 *abs*
- Riedel's thyroiditis**, retroperitoneal fibrosis, and sclerosing cholangitis, diseases with one pathogenesis? *correspondence*, 714
- S-phase fraction**, EGF-R, and ploidy, relationship in gastric cancer, 1470 *abs*
- Satiety signal**, procolipase propeptide concentrations in normal and morbidly obese subjects, 1520
- Sclerosant injection**, is it mandatory after an epinephrine injection for arrest of peptic ulcer haemorrhage? 1182
- Sclerosing cholangitis**
AIDS related, natural history, 116
Riedel's thyroiditis, and retroperitoneal fibrosis, diseases with one pathogenesis? *correspondence*, 714
- Sclerotherapy**, injection, in portal hypertension, complications and limitations: *leading article*, 7; *correspondence*, 861
- Screening**, family based, for colorectal cancer, feasibility, 96
- Secretor status** and *H. pylori* infection are independent risk factors for gastroduodenal disease, 351

- Serotonin**, effect on ileocolonic transit and fluid transfer in vivo, rat, 794
Sex differences in colonic function, randomised trial, 531
Shigella dysenteriae 1 infection, IL-6 and TNF serum and stool concentrations, children, 194
Short bowel syndrome, disturbed gastric emptying, evidence for a 'colonic brake', 1171
Sialosyl-Tn binding monoclonal antibodies, MLS102 and B72.3 compared, in detecting pancreatic cancer, 1722
Single gene disorders, affecting the gastrointestinal tract: *leading article*, 433
Sjögren's syndrome, presenting unusually with phlegmonous gastritis: case report, 1142
Sleep stage, nocturnal oesophageal motor activity is dependent on, 1653
Small bowel (intestine)
 biopsy, endoscopic, perforation from: *case report*, 134
 contents, distribution, effect of liquid fibre, rat, 1177
 enterocytes, cultured, transplantation: *leading article*, 1153
 mucosa, influence of fatty acid profile of dietary fat on its trophic effect, 358
 resection, massive, in vivo electrophysiological measurements for functional adaptation, 637
Smoking, role in metaplasia and cancer risk in Barrett's columnar lined oesophagus, 727
SMS 201-995, in inhibition of omeprazole induced hypergastrinaemia, 1186
Sodium ion selective electrode, in continuous measurement of duodenogastric reflux after gastric surgery and in gastric ulcer disease, 1047
Solitary rectal ulcer syndrome, transrectal ultrasound study of pathogenesis, 1422
Somatostatin
 binding, in human gastrointestinal tissues, effect of cations and somatostatin analogues, 1351
 and somatostatin analogues, are they indicated in management of acute pancreatitis? 1622
Splenic artery pseudoaneurysm, thrombosis, complicating pancreatitis: *case report*, 1271
Squamous cell carcinomas of the oesophagus, influence of preoperative radiotherapy on DNA ploidy, 1086
Squamous columnar mucosal junction, and lower oesophageal sphincter, location in different degrees of endoscopic oesophagitis, 21
Steroids, compared with polymeric enteral diets, in Crohn's disease, 778
Sucralfate, and fibroblast growth factor in gastroprotection and ulcer healing, interaction, 881
Sucralphate, for *H. pylori* positive resistant duodenal ulcers, 466: *correspondence*, 1646
Sulphydryl compounds, depletion, glutathione prevents, 161
Sulphasalazine, novel mechanism of action in inhibitor of LAM upregulation by TNF-alpha, 252
Sulphate reducing bacteria and hydrogen metabolism, large intestine: *leading article*, 437
Sulphation of colonic mucus glycoproteins in UC and healthy subjects, 926
Superoxide anion generation, location in human colonic mucosa obtained by biopsy, 936
Systemic sclerosis, progressive, acid clearance and oesophageal sensitivity, 1487
- T cell receptors**
 alpha-beta+ not gamma-delta+ intraepithelial lymphocyte numbers, and villous atrophy grade, normal diet coeliac patients, 208
see also Intraepithelial lymphocytes
- T-cell response** to major human mitochondrial autoantigen in primary biliary cirrhosis, 718 *abs*
- TAGH**-induced down regulation of EGF receptors in liver proliferation, 1601
- Technetium 99m HMPAO** labelled leucocytes in analysis of Crohn's disease activity, 68
- Test meal** for detection of gastro-oesophageal reflux, 1482
- Thromboembolism** in inflammatory bowel disease, platelet role, 247
- Thrombosis** of splenic artery pseudoaneurysm complicating pancreatitis: *case report*, 1271
- Thyroid carcinoma**, increased risk in FAP, 1394
- Thyroid function** and interferon treatment in chronic hepatitis C: *correspondence*, 574
- Tissue type plasminogen activator** activity of gastroduodenal mucosa, reduced, in peptic ulcer disease, 1310
- TN staging** of gastric carcinoma, CT, endosonography, and intraoperative assessment compared, 604
- Transforming growth factor alpha**, is trophic to pancreatic cancer in vivo, 1097
- Transjugular intrahepatic portasystemic stent shunting** for control of acute and recurrent upper gastrointestinal haemorrhage related to portal hypertension, 968
- Transplantation**, of cultured small bowel enterocytes: *leading article*, 1153
- Transposed short segment colon**, ambulatory motility patterns, 1572
- Transrectal ultrasound study** of pathogenesis of solitary rectal ulcer syndrome, 1422
- Trasylol**, intraperitoneal, for acute pancreatitis, prospective, multi-centre, controlled, randomised trial, 1295 *abs*
- Trefoil peptides** and the gut: *leading article*, 577
- Triple therapy**, versus amoxicillin plus omeprazole, for *H. pylori* eradication in duodenal ulcer disease, 1167
- Tuberculosis**, colonic: *correspondence*, 429
- Tumour necrosis factor**
 monocyte production, in acute pancreatitis, relation to outcome, 1294
abs
 serum and stool, measurement, *Shigella dysenteriae* 1 infection, children, 194
- Tumour necrosis factor-alpha**
 inhibition of LAM upregulation, novel mechanism of action of sulphasalazine, 252
 location by immunohistochemistry in chronic inflammatory bowel disease, 1705
- Ulcerative colitis**
 active
 increased absorption of polyethylene glycol 600 deposited in colon, 509
 oral fluticasone propionate v prednisolone, double blind trial, 125
 adhesive and hydrophobic properties of *E. coli* from rectal mucosa, 63
 anti-lactoferrin antibodies and other types of ANCA, 56
 association of perinuclear antineutrophil cytoplasmic autoantibodies, 46
 bismuth citrate and 5-ASA enemas compared, 676
 colorectal carcinoma, and recent colonoscopy: *case report*, 1148
 and Crohn's disease, in Europeans and South Asians in Leicestershire, 1547
 defunctioned rectum, pathology, 514
 disease activity following cyclosporin for associated primary sclerosing cholangitis, 242
 failure of colonoscopic surveillance, 1075
 glycosylation and sulphation of colonic mucus glycoproteins, 926
 IL-2 and IFN-gamma augment anticancer antibody dependent cellular cytotoxicity, 788
 inter-relationships between inflammatory mediators from colonic mucosa, effects on colonic secretion, 503
 M₁ 40 kD autoantigen involved with IgG1 mediated complement action, 650
 neutrophil mucosal involvement is accompanied by enhanced local production of IL-8, 1203
 pelvic ileal reservoir, mucosal changes, 101
 and polymyositis: *case report*, 567
 quiescent, ileal and colonic epithelial metabolism, increased glutamine but no butyrate defect, 1552: *correspondence*, 1646
 soluble IL-2 receptors, antineutrophil cytoplasmic antibodies, 658
- Ultrasound**, inappropriate use for measuring gall bladder emptying: *correspondence*, 430
- Upper gastrointestinal haemorrhage**, acute and recurrent, related to portal hypertension, TIPS, 968
- Upper gastrointestinal tract**, prolonged monitoring using echo planar MRI: *technique*, 848
- Upper oesophageal sphincter motility**, effect of gastro-oesophageal reflux, children, 904
- Urinary retention**, and bowel dysfunction, young women, 1397
- Vagotomy**, DNA damage in stomach after measured by ³²P-postlabelling, 1683
- Varicella-zoster virus** DNA in oesophageal myenteric plexus in achalasia, 299
- Vascular dysregulation**, gastric mucosa, caused by chronic nicotine intake, rat, 1688
- Vascular ectasia**
 diffuse, of antrum, duodenum, and jejunum, associated with nodular regenerative hyperplasia: *case report*, 558
 upper gastrointestinal, laser ablation, long term results, 470
- Villus height** and nutritional state, mathematical correlation between, Sprague-Dawley rats, 1066
- Viral hepatitis**, precipitating hepatocellular porphyria: *case report*, 1632
- Visceral autonomic innervation**, abnormal, in neurogenic faecal incontinence, 215
- Visceral myopathy**, familial, associated with mitochondrial myopathy: *case report*, 279
- Vitamin antioxidant supplementation**, effect on cell kinetics in adenomatous polyps, 963
- von Willebrand factor**, in upper gastrointestinal tract inflammation: *correspondence*, 288
- Whipple's disease**, and extraintestinal lymphoma: *case report*, 1627
- Wilson's disease**, affecting gastrointestinal tract, 435
- Xenobiotic metabolising enzyme** expression in colonic neoplasia, 1234

AUTHOR INDEX – SUPPLEMENTS, 1–4, 1993

- Abbas AM, Talbot IC, Chester K, Forbes A: S4.F266, S4.F268
 Ackroyd R, Hosie KB, Pollock K, Cowen V, Stoddard CH: S1.W8
 Adam IJ, Mohamdee MO, Martin IG, Scott N, Dixon MF, Johnston D, Finan PJ, Quirke P: S4.W33
 Adam IJ, Sue-Ling H, Finan PJ, Boylston A, Johnston D: S1.F244
 Adler A, Veltzke W, Felix R, Neuhaus P, Hampel KE, Hintze RE: S3.OXIV/3 1097
 Aggarwal R, Naik SR: S3.OV/8 1029
 Ahluwalia NK, Mani V, Goodman MJ, Thompson DG, Dane G, Laing S: S1.W42
 Ahmed HA, Petroni ML, Lauffer GL, Jazrawi RP, Hamdiyyah MA, Northfield TC: S1.F200
 Alter MJ: S2.17
 Anderson DN, Rothnie I, Broom J, Keenan R, Whiting PJ: S3.OX/1 632
 Anderson JT, Murray FE, Gallacher C, Ross PE, Milne G, Hopwood D: S4.W64
 Anggiansah A, Bright N, Wang J, Jones AR, Owen WJ: S4.F258
 Anggiansah A, Wang J, Owen WA, Zhang Q, Jones AR, Owen WJ: S4.F256
 Anthony A, Dhillon AP, Fidler H, McFadden JJ, Nygard G, Pounder RE, Wakefield AJ: S4.F226
 Anthony A, Dhillon AP, Nygard G, Piasecki C, Hudson M, Pounder RE, Wakefield AJ: S1.F280
 Anthony A, Dhillon AP, Nygard G, Pounder RE, Wakefield AJ: S1.T193
 Anti M, Marra G, Armelao F, Percesepe A, Valente EM, Bartoli GM, Parrella P, Ponz De Leon M: S1.T152
 Antolín M, García-Lafuente A, Videla S, Vilaseca J, Crespo E, Guarner F, Malagelada J-R: S3.PDI/5 1068
 Antonica G, Sabbà C, Berardi E, Buonomico P, Pugliese D, Ferraioli G: S3.OIII/6 985
 Arnold MM, McKenna F, Rees WDW: S1.W65
 Arredondo-Cortes E, Gonzalez-Gonzalez JA, Bosques-Padilla F, Elizondo Riojas G, Barragan-Villarreal RF: S3.OXIX/4 1049
 Ashwood P, Chinery R, Alison M, Jeffery RE, Poulsom R, Wright NA: S4.F200
 Atherton JC, Cockayne A, Balsitis M, Hawkey CJ, Spiller RC: S1.T140
 Atherton JC, Jenkins D, Kirk GE, Hull MA, Cullen DJE, Cockayne A, Spiller RC, Hawkey CJ: S4.T168
 Atherton JC, Washington N, Bracewell MA, Sutton LJ, Greaves JL, Perkins AC, Spiller RC: S4.F253
 Auwerda JJA, Schouten WR: S3.OXI/8 330
 Aziz Q, Rothwell JC, Barlow J, Hobson A, Thompson DG: S4.W53
- Bai JC, Martinez C, Mauriño E, Boerr L, Vazquez H: S3.OXI/2 318
 Bain IM, Deen K, Patel R, Keighley MRB: S3.OIV/4 641
 Bain IM, Neoptolemos JP, Keighley MRB: S4.T159
 Baker DM, Steele RJC, Hardcastle JD: S1.W79
 Balan KK, Grime SJ, Sutton R, Roberts N, Yiannakou Y, Critchley M, Jenkins SA: S1.T87
 Ballinger AB, McLoughlin L, Medbak S, Clark ML: S4.T101
 Bañares R, Laiz JM, Clements G, Casado M, Echenaguia A, Camuñez F, Aguirre A, Jaime B, Cos E: S3.OIII/3 1030
 Banerjee S, Ardill JES, Beattie AD, McColl KEL: S1.F224
 Banerjee S, Hawksby K, Dahill SW, Miller S, Beattie AD, McColl KEL: S1.W13
 Bangaru B, Schacht RG, Gallo G: S3.OIV/4 790
 Barber R, Feinle C, Read NW: S3.OXVIII/1 063
 Barham CP, Gotley DC, Mills A, Alderson D: S1.W4, S3.OI/1 179
 Barham CP, Mills A, Alderson D: S4.F255
 Barker GM, Tadley S, Bain I, Davis A, Lawson AM, Keighley MRB, Neoptolemos JP: S4.W34
 Barlow AP, Eyre-Brook IA: S4.T134
 Barone M, Romanello D, Angelini A, Francavilla A: S3.OII/8 222
 Barrachina MD, Calatayud S, Moreno L, Piqué JM, Whittle BJR, Esplugues JV: S3.PDI/12 113
 Barton R, Hatfield ARW, Theis B, Russell RCG: S1.F204
 Bartram H-P, Gostner A, Scheppach W, Dusel G, Richter F, Kasper H: S3.OVI/2 396
 Baskin G, DiNello R, Polito A, Quan S, Lee WS, Wu J, Nelles M, Lee S: S2.61
 Bassano N, Fiocca F, Meteria A, Fantini A, Silecchia G, Spaziani E, Genco A, Caruso C, Pizzuto G, De Leo A: S3.OXIV/7 729
 Bateson MC: S4.T139
 Bateson MC, Gedling P, Senidhira T: S4.T141
 Bayerdörffer E, Mannes GA, Höchter W, Weingart J, Sommer A, Klann H, Heldewein W, Hatz R, Simon T, Eimiller A, Miehlke S, Bästlein E, Ruckdeschel G, Lehn N, Stolte M: S3.PYI/1 847
 Bayraktar Y, Uzunalimoglu B, Arslan S, Koseoglu T, Kayhan B, Telatar H: S2.101
 Bazzoli F, Morelli MC, Fossi S, Taroni F, Pozzato P, Zagari RM, Simoni P, Roda A, Roda E: S3.OVI/7 339
 Bearcroft CP, Andre EA, Mourad FH, Farthing MJG: S4.F216
 Bedossa P, Poynard T, Mathurin P, Lemaigne G, Chaput JC: S2.146
 Bell GD, Powell KU, Burridge SM, Rameh B, Bolton G, Purser K, Harrison G, Gant PW, Jones PH, Trowell JE: S1.T146
 Ben-Ari (Shpirer) Z, Booth JD, Rolles K, Dhillon AP, Burroughs AK: S1.T172
 Benelux Multicentre Trial Study Group: S2.119
 Benhamou J-P: S2.IV
 Benini L, Brightenti F, Castellani G, Brentegani MT, Sembenini C, Pellegrini N, Casiraghi MC, Vantini I: S4.W46
 Benson MJ, van Someren RNM, Ainley CC, Glynn MJ: S1.T180
 Berenquer M, Olaso V, Córdoba J, Benages R: S3.OV/5 931
 Bergin A, Abitbol J-L, Daly J, Méric G, Lopez M, Fraitag B, Read NW: S3.PDII/9 1370
 Bhattacharya S, Bradley NJ, Dhillon AP, Fuller BJ, Winslet MC, Hobbs KEF: S4.W22
 Binmoeller KF, Goebell E, Soehendra N: S3.OXIV/5 1286
 Bjarnason I, Keating J, Smith T, Macpherson A, Posniac A, Gazzard B: S1.F289
 Blanc P, Couderc M, Peray P, Liautard J, Larrey D, Michel H: S3.PDIII/8 1034
 Blanshard C, Ellis DS, Chauhan D, Gazzard BG: S1.F290
 Bloom S, Fleming K, Chapman R, Neuberger J, Hubscher S: S4.T87
 Bloom S, Piggott R, Simmons D, Jewell DP: S4.T106
 Boermeester MA, Van Leeuwen PAM, Wesdorp RIC, Rodrick ML, Wilmore DW: S3.OX/3 589
 Bonino F, Colloredo Mels G, Bellati G, Ideo G, Oliveri F, Colombatto P, Brunetto MR: S2.36
 Bourgeois N, Devière J, Bourgeois F, Van de Stadt J, Gelin M, Adler M, Cremer M: S3.OX/8 621
 Bourgeois N, Szajner Y, Botembe N, Liesnard C, Moonens F, Peny MO, Deprez C, Van de Stadt J, Gelin M, Adler M: S3.OX/6 1004
 Bowling TE, Raimundo AH, Grimble GK, Silk DBA: S4.T100
 Bowling TE, Raimundo AH, Jameson JS, Rogers J, Silk DBA: S1.F254
 Bowling TE, Raimundo AH, Silk DBA: S1.T130
 Boyle TJ, Bean AG, Roddie ME, Scott HJ, Williamson RCN, Habib NA: S4.T135
 Bramley P, Masson J, Herd K, Sinclair TS, McKinlay AW, Brunt PW, Mowat NAG: S4.F219
 Bramley PN, Masson J, Walshe D, Souter M, Park K, Anderson D, Thomas P, Sinclair TS, McKinley AW, Brunt PW, Mowat NAG: S1.F236
 Bréchot C: S2.39
 Bresters D, Mauser-Bunschoten EP, Cuypers HTM, Han JH, Jansen PLM, Chamuleau RAFM, Houghton M, Reesink HW: S2.124
 Brown CM, Snowdon CF, Slee B, Sandle LN, Rees WDW: S1.W68
 Bryant B, Filipowicz B, Cole AT, Hawkey CJ: S4.F250
 Buchman AL, Moukarzel AA, Ament ME, Eckhert C, Bhuta S: S3.OIV/8 778
 Buchman AL, Moukarzel AA, Ament ME, Hollander DL: S3.PDII/6 777
 Butler P, Hamilton-Miller JMT, Baum H, Burroughs AK: S1.T118
 Byrne PJ, Caldwell MTP, Lawlor P, Walsh TN, Hennessy TPJ: S1.W46
- Cadière GB, Bruyns J, Himpens J, Houben JJ, Gelin M, Lemper JC, Panzer JM: S3.OVII/3 1311
 Cahill RJ, Gilvarry J, Beattie S, Hamilton H, O'Morain CA: S3.OXVIII/7 128
 Calam J, Golodner EH, Walsh JH, Soll AH: S1.W11
 Caldwell MTP, Byrne PJ, Lawlor P, Attwood SEA, Walsh TN, Hennessy TPJ: S4.F254
 Caldwell MTP, McDermott M, Jazrawi S, Byrne PJ, Walsh TN, Hourihane DOB, Hennessy TPJ: S1.T141
 Caliari S, Benini L, Brentegani MT, Fioretta A, Sembenini C, Bardelli E, Castellani G, Vantini I: S1.F263
 Camilleri M, Balm RK, Zinsmeister AR: S3.PDII/11 410
 Camilleri M, von der Ohe MR, Scolapio JS, Hanson RB: S3.OXI/3 409
 Canadian Inflammatory Bowel Disease Study Group: S4.F210
 Carpani M, Rentsch R, Keirnan S, Levi S, Hodgson HJF: S4.F199
 Casellas F, Mourelle M, Guarner F, Papo M, Malagelada J-R: S3.OXII/2 1064
 Castellani G, Benini L, Sembenini C, Bardelli E, Caliari S, Fioretta A, Brentegani MR, Vantini I: S1.W62
 Catnach SM, Hinds CJ, Fairclough PD: S1.F202

- Catterall AP, Zuckerman A, Murray-Lyon IM, Harrison TJ: S4.W31
 Cevallos AM, Anderson C, Farthing MJG: S1.F285
 Cevallos AM, Savva N, Farthing MJG: S4.F275
 Chapman L, Poston GJ: S4.T149
 Char S, Katelaris PH, Rovertson G, Tippett G, Hoa DQ, Farthing MJG: S4.T128
 Chen YK, Santoro MJ, Foliente RL, Walter MH, Collen MJ: S3.OXIV/2 767
 Chiaramonte M, Ngatchu T, Bertin T, Altinier G, Naccarato R: S4.F272
 Ching CK, Parker N, Hand C, Charney R, Long RG: S1.T110
 Choudari CP, Palmer KR: S1.T115, S1.T183
 Choudari CP, Raigopal C, Palmer KR: S1.T182
 Clements B, Ennis M, Halliday I, Campbell G, Rowlands BJ: S4.T132
 Clements B, Erwin P, Halliday I, Barclay R, Rowlands BJ, Moorehead RJ: S1.F271
 Clements B, Halliday I, Erwin P, McCaigue M, Barclay GR, Rowlands BJ: S4.F223
 Clements WDB, Halliday MI, Barclay GR, Rowlands BJ: S4.W29
 Cole AT, Nassim MA, Hawkey CJ: S1.T92
 Collier JD, Bennett MK, Bassendine MF, Lendrum R: S1.T111
 Collington GK, Shaw RK, Knutton S, Booth IW: S4.F224
 Collins CE, Benson MJ, Burnham WR, Rampton DS: S4.T114
 Collins CE, Cahill MR, Macey MG, Newland AC, Rampton DS: S1.T195
 Collins CE, Cahill MR, Rampton DS: S4.F249
 Collins CE, Cahill MR, Syndercombe-Court D, Rampton DS: S1.T90
 Colombo M, Lampertico P, Rumi M: S2.141
 Connell WR, Kamm MA, Ritchie JK, Hawley PR, Lennard-Jones JE: S1.T154
 Conte D, Barisani D, Fraquelli M, Casarin P, Bodini P, Borzio M, Aimo GP, Mandelli C: S3.OXIII/1 691
 Cooper P, Rowles PM, Sim R, Dhillon AP, Pittilo RM, Pounder RE, Wakefield AJ: S4.T112
 Corder AP, Jones RH, Johnson CD: S1.W6
 Corleteo V, Delle Fave G, Scopinaro F, Schillaci O, Di Macio L, Poletti E, Gualdi G, Marignani M, Annibale B: S3.OVIII/7 511
 Cottrill MRB, Mani V: S1.T145
 Couzigou P, Richard L, Dumas F, Schouler L, Fleury H: S2.59
 Covic D, Higham AD, Barlow J, Thompson DG: S1.F216
 Cox MR, Huang J, Saccone GTP, Harvey JR, Baker RA, Tooili J: S4.W2
 Cox MR, Kent AL, Wilson TG, Padbury RTA, Tooili J: S4.T156
 Craxì A, Di Marco V, Lo Iacono O, Almasio P, Bruno R, Cammà C, Volpe R, Pagliaro L: S3.PYI/5 130
 Crean StJ, Ballinger AB, Scott G, Clark ML: S1.F234
 Cullen DJE, Collins BJ, Christiansen KJ, Epsi J, Warren JR, Cullen KJ: S1.F284
 Curless R, Srivastava ED, French JM, Williams GV, James OFW: S4.T121
- Dakkak M, Patching A, Bennett JR: S1.F233
 Dapoigny M, Homerin M, Scherrer B, Fraitag B: S3.PDII/12 1369
 Davidson B, Lauri A, Horton R, Burroughs A, Dooley JS: S1.F203
 Davies GR, Banatvala N, Rampton DS: S1.T143
 Davies GR, Collins CE, Banatvala N, Rampton DS: S1.F288
 Davies GR, Gertner DJ, Benson MJ, Rampton DS, Swain CP: S1.T116
 Davies N, Kynaston H, Yates J, Jenkins SA, Taylor BA: S1.T164
 Davies N, Yates J, Kynaston H, Taylor B, Cooke T, Hamad H, Bamford CH, Jenkins SA: S1.F238, S3.OII/5 977
 Davies R, Evans DGR, Guy SP, Armstrong JG, Clancy T, Babbs C, Warnes T, Harris R: S1.F211
 Davis GL: S2.109
 Davison SM, Murphy MS, Adeodu OO, Kelly DA: S3.OX/7 612, S4.T127
 Dawson K, Osborne M, Dooley J, Burroughs A, Rolles K, Davidson B: S1.F277
 De Angelis C, Gindro T, Arrigoni A, Indiogine C, Andriulli A, Recchia S, Pera A, Verme G: S3.OVII/3 198
 De Bac C, Grimaldi F, Clementi C, Duca F, Livoli D, Taliani G: S2.135
 De Boni M, De Boni M, Bellumati A, Di Mario F, Battaglia G, Plebani M, Cielo R, Naccarato R: S1.W50
 De Conca V, Mesiti S, Vallarino E, Mornese A, Dodero M: S2.126
 De Giacomo C, Gianatti A, Perotti P, Bawa P, Fiocca R: S3.OIV/3 1249
 De Giorgio R, Brecha NC, Tucci A, Cordinaldesi R, Franzoso L, Go VLW, Sternini C: S3.OVII/4 570
 De Giorgio R, Parodi JE, Barbara G, Brecha NC, Ricci Maccarini M, Stanghellini V, Becker JM, Go VLW, Sternini C: S3.OXV/4 336
 de Man RA, Schalm SW, Main J, Thomas HC, Fevery J, Nevens F, Staley H: S4.W19
 De Santis A, Riggio O, Merli M, Servi R, Stati T, Rossi P, Capocaccia L: S3.OIII/5 949
 de Weerth A, Pisegna JR, Wank SA: S3.OXIII/4 663
 Deen KI, Williams G, Grant E, Kumar D, Keighley MRB: S1.W75
 Del Buono R, Wright NA: S4.T107
 Denton GWL, Perkins AC, Wastie MW, Hardcastle JD: S4.F182
- Di Marco V, Lo Iacono O, Capra M, Grutta S, Ciaccio C, Gerardi C, Maggio A, Renda D, Almasio P, Pisa R, Craxì A: S2.142
 di Paolo MC, Merrett MN, Jewell DP: S4.F265
 Di Sebastiano P, Buechler M, Fink T, Schaefer MKH, Weihe E, Friess H, Beger HG: S3.OXV/1 1126
 Dianzani F: S2.74
 Dickey W, Wylie JDC, Collins JSA, Porter KG, Watson RGP, McLoughlin JC: S4.T90
 Dillon J, Simpson K, Hayes PC: S1.T185
 Dimopoulos M, Fafoutis K, Basiliou K, Ketikoglou J, Karvountzis G: S2.104
 D'Inca R, Di Leo V, Martines D, Minotto M, Venturi C, Sturniolo GC, Naccarato R: S1.F241
 Ding S-F, Delhantry JDA, Carrillo A, Dalla Serra G, Zografos G, Bowles L, Dooley JS, Wood CB, Habib NA: S1.W30
 Dobson H, Hopwood D, D'Arrigo C: S1.W33
 Dodds SR, Thompson MR: S1.T104
 Doppl WE, Schnell-Kretschmer H, Sziegoleit A, Schäfer H, Klör HU, Federlin K: S3.OVIII/2 520
 Doppl WE, Weber HP, Temme A, Klör HY, Federlin K: S3.OXVII/6 768
 Douds A, Weldon MJ, Poulton T, Maxwell JD: S4.W32
 Douds AC, Finlayson C, Maxwell JD: S4.F229
 Duffy JP, Allen SM, Walker SJ, Darnton SJ, Cullen MH, Matthews HR: S1.W60
 Duthie GS, Miller R, Bartolo DCC: S4.F189
 Dwarakanath AD, O'Dowd JM, Beasley C, Tsai HH, Hart CA, Rhodes JM: S3.T111
 Dwarakanath AD, Tsai HH, Hart CA, Rhodes JM: S4.F244
 Dwarakanath AD, Tsai HH, Sunderland D, Hart CA, Crabtree JE, Figura N, Rhodes JM: S1.T121
- Ebert R, Höper C, Ramadori G: S3.OVIII/2 013
 Ekundayo AA, Lee CY, Goodlad RA: S4.F261
 El-Omar E, Penman I, Ardill JES, McColl KEL: S1.W48, S1.T136, S4.F194
 El-Omar E, Penman I, McColl KEL: S4.F195
 Eleftheriades E, Kotzampassi K, Karkavelas G, Tzioufa V, Papadimitriou K, Aletras H: S3.PDIII/9 989
 Ellis HJ, Doyle AP, Day P, Sturgess RP, Wieser H, Ciclitira PJ: S1.F251
 Engel AF, Kamm MA: S1.F239
 Engel AF, Sultan AH, Kamm MA, Nicholls RJ, Bartram CI: S1.T156
 Epstein O, Cave J, Lineham J: S1.F198
 Esplugues JV, Martinez-Cuesta MA, Barrachina MD, Moreno L, Piqué JM, Whittle BJR: S3.OIX/2 112
 Esteban R: S2.77
 Evans D, Wright J, Gowland P, Mansfield P: S1.F212
 Evans DF, Venson MJ, Williams S, Wingate DL: S1.F217
 Evans GS, Flint N, Tait I, Campbell FC: S1.W25
 Ewer AK, Durbin GM, Morgan MEI, Booth IW: S4.T126
- Fan XJ, Chua A, Fan XG, Kelleher D, Keeling PWN: S3.OVIII/8 051
 Fan XJ, Chua A, Shahi CN, O'Farrelly C, Keeling PWN, Kelleher D: S1.T120
 Farinati F, Savastano S, De Maria N, Marafin C: S1.T163
 Fell JME, Lindley K, Milla PJ: S4.T98
 Fenton-Lee D, Riach E, Cooke TG, Baxter JN: S1.T105
 Ferenci P: S2.69
 Fernández-Rodríguez CM, Andrade A, Zozaya JM, Quiroga J, Mallo R, Penas J, Rodríguez-Martínez D, Prieto J: S3.OIII/8 260
 Fernández-Rodríguez CM, Zozaya JM, Gutián R, Quiroga J, Pallarés A, Prieto JS: S3.PDIII/5 261
 Ferrana M, Battaglia G, Dotto P, Dal Bo N, Salandin S, Vianello F, Rugge M, Vigneri S, Leandro G, Di Mario F, Naccarato R: S4.T179
 Ferri C, Marzo E, Longombardo G, La Civita L, Lombardini F, Giuggioli D, Vanacore R, Liberati AM, Mazzoni A, Greco F, Bombardieri S: S2.144
 Festen H, Klinkenberg-Knol E, Kuipers E, Lamers C, Jansen J, Biemond I, Teroolen J, Meuwissen S: S1.F225
 Fidler HM, Thurrell W, Johnson NMCI, Rook GAW, McFadden JJ (introduced by Barton R): S4.F227
 Figura N, Bugnoli M, Armellini D, Bayeli PF, Rappuoli R, Crabtree JE: S1.T134
 Finn IA, Taylor BA, Rhodes JM: S4.T110
 Flint N, Evans GS: S1.W24
 Floreani A, Infantolino D, De Lazzari F, Biasin MR, Venturi C, Zappala F, Naccarato R, Chiaramonte M: S4.W23
 Formela L, Kingsnorth AN: S1.T107
 Formela LJ, McLaughlin PJ, Flanagan BF, Southern SN, Giles TE, McDicken IF, Kingsnorth AN: S4.W6
 Formela LJ, Whittaker M, Kingsnorth AN: S4.T161
 Fox AD, Baigrie RJ, Cobb R, Dowling BL: S4.T130
 Francavilla A, Barone M, Ierardi E, De Lorenzis A, Coppolecchia P: S3.PDIII/1 221

- Freeman TC, Pascall J, Coadwell WJ, Brown K: S1.W14B
 Freeman TC, Shirazi-Beechey SP: S1.W14A
 Fregonese D, Di Toma F: S4.T75
 Fries W, Giacomin D, Plebani M, Martin A, Naccarato R: S1.W36
 Fries W, Masiero M, Plebani M, Martin A, Naccarato R: S1.W37
 Friess H, Yamanaka Y, Büchler M, Kobrin MS, Beger HG, Korc M: S3.OVIII/6 561
 Friis-Andersen H, Rokkjaer M, Kruse A: S3.OXVII/8 531
 Froehlich F, Thorens J, Schwizer W, Köhler M, v.Melle P, Gonvers JJ, Fried M (introduced by Lennard-Jones JE): S4.T158
 Fullarton GM, Bell G, West of Scotland Laparoscopic Cholecystectomy Study Group: S1.F274
- Gagliardi G, Hershman MJ, Thompson IW, Jordan S, Hawley PR, Talbot IC: S1.F237
 Gane E, Ramage J, Portmann B, Williams R: S1.T173
 Gane E, Sutton M, Pybus J, Hamilton I: S1.F227
 Garner A, Chandranath I, Hassan MY, Bastaki SMA, Al-Tahir GK, Schmiedmann A: S4.F214
 Garner A, Hunter AC, Wilkes JM, Tanira MO, Dib R, Bastaki SA, Abu-Hijleh G: S4.W65
 Gasbarrini A, Caraceni P, Bernardi M, Facchini A, Gasbarrini G, Farghali H, Borle AB, Van Thiel DH: S3.OII/6 1245
 Gattuso JM, Kamm MA, Abassi M, Talbot IC: S4.F191
 Genesca J, Esteban JI, Quer J, Viladomiu LL, Gonzalez A, Esteban R, Guardia J: S2.63
 Ghosh S, Dalvi H, Gillespie T, Palmer KR: S4.W15
 Ghosh S, Moussa S, Palmer KR: S1.F270
 Ghosh S, Palmer KR: S1.F273
 Gillen CD, Prior P, Andrews HA, Allan RN: S1.T150, S4.F260
 Gilvarry J, Leen E, Sant S, Sweeney E, O'Morain C: S1.W14
 G.I.S.U. (Interdisciplinary Group for Ulcer Disease): S4.T170
 Glasbrenner B, Nelson DK, Dahmen G, Riepl RL, Malfertheiner P, Adler G: S3.OXIII/5 705
 Godkin A, Petros AJ, Bennett ED, Farthing MJG: S1.W47
 Goggins MG, Mahmud N, Hall N, O'Connell M, Weir D, Kelleher D: S4.F242
 Goggins MG, Mahmud N, Hall N, O'Connell M, Weir DG, Kelleher D: S3.OXII/1 460
 Goggins MG, O'Brien S, Kelleher B, Scott JM, Weir DG: S1.W51
 Goldberg PA, Kamm MA, Setti-Carraro P, van der Sijs JRM, Roth C: S4.F217
 Goldberg PA, Nicholls RJ, Kamm MA: S1.F245
 Goldin E, Huibregtse K, Safra T, Beyar M, Smits ME, Globerman O: S3.OXIV/4 732
 Gomborone JE, Dewsnup PA, Libby GW, Farthing MJG: S1.F221, S1.F230
 Goody R, O'Carroll RE, Bzeizi K, Bouchier IAD, Hayes PC: S4.W17
 Gorard DA, Dewsnup PA, Medbak SH, Libby GW, Farthing MJG: S1.F219
 Gorard DA, Healy JC, O'Donnell LJD, Farthing MJG: S4.W47
 Graziadei I, Kaserbacher R, Böhm A, Vogel W: S3.OII/4 247
 Greenfield SM, Punchard NA, Boswell DJ, Thompson RPH: S4.F208
 Greenfield SM, Punchard NA, Thompson RPH: S4.F209
 Greig JD, John TG, Miles WFA, Garden OJ: S1.T168
 Greig JD, Mahadaven M, John TG, Garden OJ: S1.T112
 Grellier L, Tanner P, Grainger SL: S1.T135
 Gribble SM, Pinches SA, Campbell FC, Shirazi-Beechey SP: S1.W22
 Griffith J, Sue-Ling H, Salter G, King R, Scott S, Johnston D: S1.W57
 Gröger G, Goebell H, Holst JJ, Layer P: S3.PYI/3 417
 Guglietta A, Lesch CA, Sanchez B: S3.OXVII/8 466
 Gupta S, Evans DF, Benson MJ, Gardner BP, Short D, Frankel H, Cochrane P, Wingate DL: S1.F228
 Gupta S, Evans DF, Jamous A, Nuseibeh I, Savage P, Cochrane P, Wingate DL: S4.W44
 Gupta S, Lee C-D, Aragona E, Burk RD, Yerneni PR, Bessin M: S3.OII/3 313
 Guslandi M, Sorghi M, Tittobello A: S4.T169
 Gut A, Kay PM, Schofield D, Shiel N, Braganza JM, Segal I: S4.W5
 Gut A, Schofield D, Shiel N, Rieley F, Purmasir M, Braganza JM, Segal I: S4.W7
 Gwee KA, Celik AF, Read NW: S4.W43
- Haggett PJ, Moore NR, Shearman JD, Travis SPL, Jewell DPL: S4.F187
 Hall MA, Sturgess RP, Lanchbury JS, Ciclitira PJ: S1.F250
 Halter F, Brignoli R, Omega-project group: S3.OI6 169
 Hambling CE, McWhirter JP, Pennington CR: S4.F233
 Hardo PG, Hassan F, Lynch DAF, Mapstone NP, Tugnait A, West AP, Axon ATR, Chalmers DM, Kowalik MJ: S4.F277
 Hardwick RH, Shepherd NA, Moorgren M, Newcomb PV, Alderson D: S4.F262
 Hardwick RH, Shepherd NA, Newcomb PV, Savage P, Alderson D: S1.W61
 Harrison JD, Mayer AD, Buckels JAC, McMaster P: S4.T86, S4.T131
- Harvey CB, Wang Y, Barton R, Thurrell W, Lanzon-Millar S, Loke R, Hughes L, Swallow DM, Sams VR, Sarner M: S1.T124
 Harvey R, Galvagas M, Myers J, Ainley CC, Glynn MJ: S1.F235
 Hauser F, Poulsom R, Chinery R, Rogers LA, Hanby AM, Wright NA, Hoffmann W: S4.T164
 Hawkey CJ, Hudson N, Wilson JV, Logan RFA: S3.OI/7 889
 Hay JE, Porayko MK, Dickson ER, Gores GJ, Steers J, Krom RAF, Wiesner RH: S3.PYI/4 598
 Hayes N, Scott D, Raimes SA, Griffin SM: S4.W63
 Heading RC: S3.OI/5 015
 Hendrickse C, Youngs D, Thompson H, Keighley MRB, Neoptolemos JP: S4.F181
 Hess G: S2.1
 Higham AD, Owen F, Kirkman E, Thompson DG: S1.F215
 Hintze RE, Adler A, Veltzke W, Hampel KE: S3.OXIV/8 1185
 Hoffmann R, Henninger H-P, Schulze-Specking A, Decker K: S3.OII/2 291
 Hope AJ, Winwood PJ, Arthur MJP: S4.W30
 Houdijk APJ, van Leeuwen PAM, Boermeester MA, Teerlink T, Wesdorp RIC: S3.OIV/7 1197
 Houdijk APJ, van Leeuwen PAM, Boermeester MA, Wesdorp RIC: S3.OVII/8 590
 Houghton LA, Rogers J, Whorwell PJ, Campbell FC, Raimundo A, Goka H: S4.W14
 Houghton LA, Wych J, Whorwell PJ: S4.W11
 Houghton T, Houghton DM, Redmond P, Watson RWG, Watson RGK, Bouchier-Hayes D: S3.OVII/1 1226
 Howard A, Legon S, Walters JRF: S1.T125
 Howard PJ, Maher L, Pryde A, Heading RC: S1.W1, S3.PDII/7 072
 Hull MA, Cullen DJE, Atherton JC, Hawkey CJ: S4.F201
 Hunt JB, Taylor GP, Thomas HJW, Wilkins MJ, Goldin R, Summerfield JA: S4.T136
 Hunt LM, Rooney PS, Gifford K-A, Mascari RJ, Hardcastle JD, Armitage NC: S4.T69
 Hurllman S, Abbuhl B, Halter F, Inauen W: S3.OI/3 833
 Husebye E, Skar V, Hoverstad T, Iversen T, Melby K: S3.OXI/5 321
 Hussain A, Cox JGC: S4.F230
 Hussaini SH, Pereira SP, Kennedy C, Murphy GM, Dowling RH: S1.F199
 Hutchinson R, Mostafa AB, Deen KI, Harding LK, Kumar D: S1.T158
 Hutchinson R, Mostafa AB, Harding LK, Kumar D: S4.W45
 Hutchinson R, Notghi A, Harding LK, Kumar D: S4.W13
 Hutchinson R, Notghi A, Mostafa AB, Harding LK, Kumar D: S4.W49
- Iino S: S2.114
 Iqbal TH, Lewis KO, Cooper BT: S4.T167
 Iqbal TH, Neumann CS, Cooper BT: S1.W73
 Iredale JP, Benyon RC, Goddard S, Ferris WF, Arthur MJP: S1.T80
 Iredale JP, Goddard S, Ferris WF, Kawser CA, Winwood PJ, Arthur MJP: S1.T82
- Jaffer A, Castagliuolo I, Kelly CP, LaMont JT, Pothoulakis C: S3.OXV/7 415
 Jaffray B, Angerson WJ, Anderson JR, Baxter JN: S4.T78
 Jalan R, Plevris J, Finlayson NDC, Hayes PC: S4.T85
 Jameson JS, Chia YW, Kamm MA, Speakman CTM, Henry MM: OXI/7 578
 Jameson JS, Rogers J, Raimundo AH, Feyerabend C, Henry MM, Misiewicz JJ: S1.F220, S3.OXI/4 411
 Jankowski JA, Newham PM, Kandemir O, Pignatelli MN: S4.T104
 Jazrawi RP, de Caestecker JS, Brittain A, Joseph AEA, Maxwell JD, Northfield TC: S1.T176
 Jazrawi RP, Pazzi P, Petroni ML, Adam J, Northfield TC: S4.W1
 Jehle EC, Starlinger MJ, Gross ML, Jenss H, Becker HD: S3.OXII/8 1070
 Jenkins SA, Shields R, Kingsnorth AN, Sutton R, Ellenbogen S: S1.T85
 Jewell DP, Lennard-Jones JE, Cyclosporin Study Group of Great Britain and Ireland: S4.F211
 Jeziorska M, Haboubi NY, Schofield PF, Woolley DE: S1.W18
 John K-D, Modlin IM, Ballentyne GH: S1.T99
 Johnston BT, Carre IJ, Thomas PS, Collins BJ: S1.W70
 Johnston BT, Collins JSA, Sloan JM, O'Morain C, Gilvary J, O'Connor HJ: S1.T144
 Johnston BT, Lewis SA, Love AHG: S1.W66, S1.W67
 Johnston BT, O'Connor FA: S4.T138
 Jones AL, Finlayson NDC, Hayes PC: S4.T80
 Jones AL, Hayes PC: S1.T167
 Jones RH, Tait CL: S1.F223
 Jones SC, Banks RE, Gearing AJH, Hemingway IK, Axon ATR: S1.W45
 Jones SC, Crabtree JE, Dixon MF, Axon ATR: S1.T93
 Jones SC, Crabtree JE, Rembacken BJ, Axon ATR, Whicher JT, Trejdosiewicz LK: S1.W44
 Joypaul BV, Browning MK, Newman EL, Cuschieri A: S4.W62
 Joypaul BV, Newman EL, Hopwood D, Cuschieri A: S4.W58
 Judmaier G, Prior Chr, Propst A, Vogel W, Kathrein H: S3.OXIX/1 965

- Kadirkamanathan SS, Evans DF, Brown G, Gong F, Scott M, Yazaki E, Swain CP: S1.W63
- Kane KF, Williams GR, Docherty K, Sheppard MC, Langman MJS: S1.W27
- Kane M, Alter M, Esteban R, Rizzetto M: S2.45
- Kane MA: S2.10
- Kar Purkayastha S, Hogan J, Krasner N: S4.F259
- Karagiozoglou-Lampoudi T, Lamy M, Otte JB, Sokal E: S3.OX/5 620
- Karatapanis S, McCormick PA, Phillips A, Hobbs KEF, McIntyre N, Burroughs AK: S1.T88
- Karmeli F, Eliakim R, Rachmilewitz D: S3.OXVI/7 450
- Kashida H, Minowa K, Tochio H, Shimada K, Hamada M, Tomita S: S3.OXIX/7 946
- Katelaris PH, Seow F, Lin BPS, Ngu MC, Jones DB: S1.T113
- Katelaris PH, Wocial T, Patchett S, Salam I, Farthing MJG: S1.F283
- Keating J, Somasundaram S, Francis N, Menzies IS, Bjarnason I, Gazzard B: S4.F225
- Kelly EJ, Newell SJ, Brownlee KG, Primrose JN: S4.T124
- Kelly P, Thillainayagam AV, Keating J, Smithson J, Gazzard B, Forbes A, Farthing MJG: S4.F274
- Kelly SM, Borland SE, Tuffnell Q, Hunter JO: S4.F238
- Kelly SM, Gibson GR, Cummings JH: S1.F287
- Kemmer TP, Duntas L, Muniz W, Malfertheiner P: S3.OVIII/3 513
- Keshavarzian A, Tierney L, Steinbach S, Winship D, Fields J: S3.PDI/4 452
- Keshavarzian A, Wasylw R, Fiedler J, Urban G, Winship D, Fields J: S3.OIX/3 802
- Khakoo SI, Lobo AJ, Shepherd NA, Wilkinson SP: S1.T114
- Khin CC, Simmonds NJ, Norton B, Gertner DJ, Burnham WR: S1.T181
- Khoo UY, Macpherson AJS, Philpott-Howard J, Forgacs I, Bjarnason I: S1.W35
- Khulusi S, Ahmed HA, Mendall MA, Patel P, Levy J, Northfield TC: S3.OIX/7 007
- Khulusi S, Ahmed HA, Mendall MA, Patel P, Northfield TC: S4.W66, S4.F273
- Khulusi S, Mendall MA, Badve S, Patel P, Finlayson C, Northfield TC: S4.F198
- Khulusi S, Mendall MA, Patel P, Levy J, Goggin PM, Northfield TC: S4.F196
- Kitis G, Wright HI, Abu-Elmagd K, Gavaler JS, Fung J, Starzl TE, Van Thiel DH: S3.OXII/4 1069
- Kmiot W, Perry EP, Donovan I, Harding LK, Neoptolemos J: S4.W3
- Kmiot W, Stonelake P, Baragwanath P, Donovan I, Harding LK, Neoptolemos J: S4.F264
- Kobayashi H, O'Briain DS, Puri P: S1.W59, S1.T161
- Kontakou M, Sturgess RP, Przemioslo RT, Limb GA, Nelufre JM, Ciclitira PJ: S4.T93
- Konturek JW, Dembinski A, Konturek M, Stoll R, Domschke W: S1.F222
- Konturek JW, Gabryelewicz A, Stoll R, Domschke W: S1.T106
- Konturek JW, Stoll R, Fischer H, Domschke W: S1.W3, S3.OXVIII/6 019
- Konturek JW, Thor P, Stoll R, Domschke W: S1.F213
- Konturek JW, Thor P, Stoll R, Maczka M, Domschke W, Konturek SJ: S1.W58
- Konturek SJ, Brzozowski T, Slomiany B, Drozdowicz, Garner A: S3.PDI/10 026
- Körner Th, Jaspersen D, Schorr W, Hammar C-H, Kropf J, Gressner AM: S3.PDII/5 698
- Kotzampassi K, Kapanidis N, Kazamias P, Eleftheriadis E: S3.OVII/5 605
- Kouroumalis E, Koutroubakis I, Manousos ON: S4.T81
- Kreuzpaintner G, Acker G, Kölble R, Wallner A, Hesterberg R, Grotjahn R, Thomas L, Stremmel W, Strohmeyer G: S3.OXII/7 1362
- Kuroki T, Nishiguchi S, Fukuda K, Ikeoka N, Murata R, Isshiki G, Tomoda S, Ogita S, Monna T, Kobayashi K: S2.52
- Kurzawinski T, Davidson B, Bhattacharya S, Burroughs A, Rolles K: S1.174
- Kyriacou E, Bouchier IAD, Ashley RH: S1.F267
- Ladas SD, Katsogridakis J, Giannopoulou H, Malamou H, Kesse-Elia M, Raptis SA: S4.T178
- Lama R, Olivares P, Tovar J, Polanco I: S3.OIV/6 776
- Lamarque D, Whittle BJR: S4.W59
- Lanas A, Nerin J, Serrano MT, Sáinz R: S3.OIX/4 920
- Lance P, Andersen V, Li M: S1.W34
- Lansdown M, Diament R, Quirke P, Dixon M, Johnston D: S4.W60
- Laszlo F, Varga Cs, Karacsony G, Whittle BJR, Laszlo FA: S4.F241
- Laszlo F, Whittle BJR: S4.T109
- Lauri A, Davidson B, Horton R, Burroughs A, Dooley JS: S1.F276
- Law NM, Lim CC, Ng HS, Cheng J: S3.OXIV/6 765
- Lee H-S, Han CJ, Kim CY: S3.OV/7 277
- Levi S, Legon S, Davis J, Rentsch R, Beales I, Lovat L, Carpani-deKaski M, Patel K, Elia G, Wright NA, Hodgson HJF: S4.F202
- Levi S, Poulsom R, Davis J, Hanby A, Stamp G, Longcroft JM, Rentsch R, Beales R, Lovat L, Carpani-deKaski M, Patel K, Elia G, Hodgson HJF, Wright NA: S4.F203
- Lewis WG, Williamson MER, Kuzu A, Stephenson BM, Holdsworth PJ, Finan PJ, Johnston D: S1.W77
- Lifshitz S, Schwaartz B, Mikhailowski R, Niv Y, Lamprecht SA: S3.OVI/3 1337
- Lim AG, Ahmed HA, Jazrawi RP, Northfield TC: S1.T84, S1.T175, S3.PDII/2 1026
- Lim AG, Ahmed HA, Northfield TC: S4.W28
- Lindley KJ, Muller DPR, Phillips AD, Millar PJ: S4.T99
- Lipp RW, Hammer HF, Schnedl W, Passath A, Leb G, Krejs GJ: S3.PDII/8 836
- Lisciandriano D, Baldassari AR, Tanzi T, Campanini MC, Perucchini M, Dal Lago A: S3.PDI/1 453
- Liu D, Nigam AK, Lalani E-N, Stamp GWH, Pignatelli M (introduced by Prof. NA Wright): S4.T105
- Lobo AJ, Barlow A, Bhonsle U, Gear MWL, Wilkinson SP: S1.W64
- Lobo AJ, Braithwaite B, Probert CS, Barr H, Gear MWL, Wilkinson SP: S4.F220
- Loder PB, Kamm MA, Nicholls RJ, Philips RKS: S1.T96
- Löfberg R, Ostergaard-Thomsen O, Langholtz E, Schiöler R, Danielsson , Suhr Å, Olsson O, Graffner H, Pählin L, Raab Y, Matzen P, Andersen T, Moller-Pedersen JF, Halvorsen L, Hovdenak N, Malchow-Møller A, Willén R, Persson T, Seidegaard C, Nordström H: S1.T162
- Logan RFA, Little J, Hawtin P, Hardcastle JD: S1.F205
- Loh CS, Bliss P, Bown SG, Krasner N: S1.T153
- Losi L, Lanza G, Di Gregorio C, Fante R, Maestri I, Roncucci L, Pedroni M, Ponz De Leon M: S4.W37
- Loudon MA, Small PK, Waldron B, Smith D, Campbell FC: S1.F218
- Lowes JR, Chahal H, Zewde M, Allan RN, Ibbotson JP: S1.T89
- Luman W, Gray RS, Palmer KR: S4.F212
- Lunniss PJ, Kamm MA, Phillips RKS: S4.W36
- Lynch DAF, Clarke AMT, Jackson P, Dixon MF, Quirke P, Axon ATR: S1.12
- Lynch DAF, Mapstone NP, Clarke AMT, Jackson P, Sobala GM, Dixon MF, Quirk P, Axon ATR: S4.F197
- MacAuley S, Asso D, Forbes A: S4.W54
- McCormick PA, Chin J, Greenslade L, Karatapanis S, Dick R, McIntrye N, Burroughs AK: S1.T166
- McCourtney JS, Finlay IG: S1.T101, S1.F240
- MacDonald A, Baxter JN, Findlay IG: S4.F190
- MacDonald A, Carter K, Baxter JN, Wright R, Finlay IG: S4.W10
- MacDonald A, Craig J, Finlay IG, Baxter JN, Muir TC: S1.T95
- MacDonald A, Poon F, Baxter JN, Finlay IG: S1.T157
- MacFarlane X, Bhalla A, Robertson DAF: S4.T96
- McIlroy BS, Norris TL, Mackie CR: S3.OXVIII/3 049
- McIntosh D, Cooke R: S1.W16
- McIntyre AS, Marshall R, Perkins A, Spiller RC: S4.W12
- McKay C, Gallagher G, Imrie CW, Baxter JN: S3.PDII/3 553
- McKiernan PJ, Beath SV, Ballantine N, Walt RP, Kelly DA: S3.OIV/1 792
- McLindon JP, Babbs C, Yates AJ, Love EM, McMahon R, Craske J, Warnes TW: S1.T171
- McMahon AJ, Ross S, Russell IT, Baxter JN, Anderson JR, Morran C, Ramsay G, Galloway D, Sunderland G, O'Dwyer PJ: S1.F268
- McMahon AJ, Russell IT, Baxter JN, O'Dwyer PJ: S1.F269
- McManus R, Moloney M, Chuan YT, Weir DG, Kelleher D: S1.F249
- McNamee R, Braganza JM, Cherry N: S1.T109
- Maehiro K, Watanabe S, Hirose M, Niwayaki A, Ohkura R, Kobayashi O, Murai T, Sato N: S3.PDI/11 190
- Mahmud N, Stinson J, O'Connell M, Feely J, Weir DG, Kelleher D: S1.T91
- Makowiec F, Jehle EC, Weinlich M, Starlinger M, Becker HD: S3.OXII/6 1071
- Makris M, Preston FE, Triger DR, Underwood JCE, Westlake L, Adelman MI: S2.121
- Malliwa JA, Tabaqchali MA, Watson J, Venables CW: S4.T176
- Mambriani P, Perreard M, Gérolami A: S3.OXIII/7 648
- Mann RJ, Probert CSJ, Tizard EJ, Mountford RA, Maybery JF, Lock RJ: S1.W40
- Mansfield JC, Giaffer MH, Tindale WB, Holdsworth CD: S4.F245
- Mansfield JC, Holden H, Tarlow JK, McDowell TL, Holdsworth CD, Duff GW: S4.T115
- Mansfield JC, Holden H, Wilson AG, di Giovine FS, Holdsworth CD, Duff GW: S1.F282
- Mansfield JC, Holden J, Wilson AG, Holdsworth CD, Duff GW: S4.T91
- Marcellin P, Boyer N, Colin JF, Martinot-Peignoux M, Lefort V, Matheron S, Erlinger S, Benhamou J-P: S2.106
- Marotta F, Wu CC, Benetti L, Bassi C, Suzuki K, Idéo G: S3.PDII/4 593
- Marrero JM, de Caestecker JS, McCormick CJ, Savalgi RS, Corbishley CM, Northfield TC: S4.F205

- Marrero JM, Goggin PM, Finch P, Savalgi RS, McCormick CJ, Corbishley CM, Northfield TC: S1.W31
- Maroni N, Casadevall M, Panés J, Piera C, Jou JM, Piqué JM: S3.PDI/7 144
- Marteau C, Ducroc R, Gérolami A: S3.PDII/2 523
- Martelli B, Goldberg PA, Nicholls RJ, Talbot IC: S3.OVII/7 603
- Martin A, Leone L, Naccarato R: S4.W55
- Martin I, Sue-Ling H, Dixon MF, Johnston D: S1.W54
- Martin KC, Messer G, Mauthe B, Rämisch S, Kind P, Classen M, Deuschi K: S3.OXVI/1 1082
- Marui A, Imoto M, Fukuda Y, Koyama Y, Nakano I, Urano F, Kanda N, Isobe K, Yamada M, Katano Y: S3.PDIII/12 248
- Marway JS, Preedy VR: S4.T163
- Masson J, Bramley P, Herd K, Sinclair TS, McKinlay AW, Brunt PW, Mowar NAG: S4.T153
- Matthew JA, Pell JD, Prior A, Kennedy HJ, Fellows IW, Gee JM, Burton J, Johnson IT: S1.W19
- Mauracher E: S2.99
- Maxton DG, Tweedle DEF, Martin DF: S1.T189
- Mazlam MZ, Hodgson HJF: S1.W43
- Mee AS, Przemioslo R, Williams L: S1.F197
- Mendall MA, Goggin PM, Molineaux N, Levi J, Strachan D, Northfield TC: S1.W9
- Menken PLuymers MBE, Hop WCJ, Mulder AH, Tilanus HW, The Rotterdam Oesophageal Tumour Study Group, van Blankenstein M: S1.W71, S1.W72
- Mennan J, Jansen J, Tytgat GN, Devanter SV: S1.T94
- Menon DK, Harris M, Sargentoni J, Taylor-Robinson SD, Cox IJ, Morgan MY: S1.T177
- Mesquita MA, Thompson DG, Ahluwalia NK, Hindle J, Mamtoro H: S1.F229
- Métreau JM: S2.112
- Meyenberger Ch, Marincek B, Schaer R, Bertschinger Ph, Wirth HP, Bischof Th, Jost R, Ammann R, Altorfer J: S3.OVIII/8 555
- Middleton SJ, Shorthouse M, Hunter JO: S4.W40
- Millar AD, Chander C, Claxton A, Blake DR, Rampton DS: S4.F207
- Mitchison HC, Kelly PJ, Bassendine MF, James OFW: S3.OXIX/6 251
- Monte MJ, Barbero ER, Herrera MC, Marin JJJG: S3.PDIII/10 297
- Moody GA, Gillespie C, Mayberry JF: S4.F222
- Moody GA, Mayberry JF: S1.W74, S1.F232, S4.W56
- Moody GA, Probert CS, Jayanthi V, Wicks ACB, Mayberry JF: S4.F247
- Moran A, Robinson M, Lawson N, Stanley J, Jones A, Asquith P, Hardcastle J: S4.F270
- Morris AJ, Nakshabendi I, Park RHR, Quin JD, Davidson F, Cruickshank A, Beastall G, Russell RI: S1.F256
- Morris PA, Tanner MS: S4.T129
- Morton B, Day T, Engel B, Fawcett HV, Benson MJ, Lakeman M, Powell-Tuck J: S4.T102
- Mössner J, Mühlfordt A, Secknus R, Fischbach W: S3.PDII/1 563
- Mössner J, Wessig C, Fischbach W: S3.OVIII/5 564
- Mourad FH, Andre EA, O'Donnell LJD, Clark ML, Farthing MJG: S4.F240
- Mourad FH, O'Donnell LJD, Cevallos AM, Clark ML, Farthing MJG: S4.T108
- Mourad FH, O'Donnell LJD, Clark ML, Farthing MJG: S1.F259
- Mourad FH, O'Donnell LJD, Owen RA, Clark ML, Farthing MJG: S1.T126, S3.OVX/5 328
- Moy RJD, Marshall TFde, Choto RGAB, McNeish AS, Booth IW: S4.F239
- Mulcahy H, Jeffers M, O'Dowd G, Stagg M, Toner M, O'Donoghue DP: S4.F185
- Mulder HD, Felt-Bersma RJF, Koorevaar M, van Baren R, Cuesta MA, Meuwissen SGM, Wesdorp RIC: S4.F186
- Müller AF, Toghill PJ: S4.W18
- Müller R, Baumgarten R, Markus R, Schulz M, Wittenberg H, Hintsche-Kilger B, Fengler J-D, von Wussow P, Meisel H, Klein H, Malmus K, Schmidt FW: S2.97
- Mullins PD, Youngs GR: S4.T74
- Muls V, Makhoul E, Urbain D, Ham HR: S3.PDIII/11 1346
- Murch SH, MacDonald TT, Phillips AD, Levin M, Walker-Smith JA, Lionetti P, Klein NJ: S1.T194
- Murphy PP, Johnston BT, Collins JSA: S1.W5
- Murphy RP, Horan R, O'Gorman T, Headon DR: S4.F184
- Murray FE, Hudson N, Atherton JC, Cole AT, Hawkey CJ: S4.F215
- Mutimer D, Shaw J, Harrison R, Ala F, Neuberger J, Elias E: S2.54
- Naaeder SB, Evans DF, Pye G, Baker N, Hardcastle JD, Archampong EQ: S1.F246
- Nakolpoulou L, Giannopoulou I, Koureas A, Psycharis I, Archimadritis A: S3.OXIX/8 1045
- Nakshabendi IM, Obiedat W, Russell RI, Downie S, Rennie MJ: S1.T128
- Naom IS, Lee JCW, Hodgson SVH, Lennard-Jones JE, Mathew CG: S1.W39
- Naoumov NV, Antonov KA, Wong PYN, Doherty D, Rayner A, Portmann B, Williams R: S4.T88
- Neilly PJD, Anderson NH, Kirk SJ, Gardiner KR, Halliday MI, Rowlands BJ: S4.F237
- Nguyen HN, Silny J, Rau G, Matern S: S3.PDII/10 344
- Nicholls S, Dawnay A, Williams CB, MacDonald TT, Walker-Smith JA: S1.T192
- Nicholson ML, Dennis MJS, Marshall K, Doran J, Steele RJC: S4.T146
- Nigam AK, Liu D, Savage FJ, Stamp GWH, Boulos PB, Pignatelli M: S3.OVII/4 343
- Nigam AK, Wrba F, Durbin H, Boulos PB, Liu D, Bodmer WF, Pignatelli M: S4.F267
- Nugent KP, Phillips RKS, Hodgson SV, Cottrell S, Smith-Ravin J, Bodmer W: S4.T122
- Nwokolo CU, Fitzpatrick JD, Paul R, Dyal R, Smits BJ, Loft DE: S1.F226
- Nwokolo CU, Loft DE, Langman MJS: S4.F213
- O'Brien S, Craig PI, Harfield ARW: S1.F272
- O'Connell MA, Mahmud N, Long A, Keeling PWN, Weir DG, Kelleher D: S3.OXVI/2 461
- Oderda G, Kuvidi M, Garbo G, Altare F, Palladin D, Destro I, Ansaldi N: S1.T142
- Oderda G, Vaira D, Ponzetto A, Boero M, Altare F, Palladin D, Ansaldi N: S1.W10
- O'Farrell BJ, Shattock AG, Al-Bloushi S, Rajan L, Courtney NG, Fielding JF: S1.F281
- O'Riordan DK, Srai SKS, Debnam ES, Epstein O: S4.F232
- Overby LR: S2.6
- Ozeki T, Nakamura T, Nakamura: S3.OV/1 984
- Panella C, Francavilla A, Conte D, Tatulli I, Rubini F: S2.127
- Panella C, Guglielmi FW, Mastronuzzi T, Contento F, Siciliano N, Francavilla A: S3.OXIX/2 220
- Panos MZ, Langman MJS: S4.T171
- Papachrysostomou M, Smith AN: S1.T97, S3.OXI/6 610
- Parker D, Carlisle KM, Read AE, Wells PNT: S1.258
- Parrilla P, Ramirez P, Andreu F, Robles R, Bueno F, Escribano B, Miras M, Pons JA, Acosta F, Munar A: S3.OX/2 616
- Paspatis G, Basilakaki T, Zizi A, Xourgas B, Elemenoglou J, Karamanolis D: S1.F209
- Patanar R, Bailey IS, Sanderson A, Johnson CD: S1.F201
- Patchett SE, Katalaris PH, Zhang ZW, Alstead EM, Lowe D, Farthing MJG: S4.F204
- Patchett SE, Saunders BP, Harocopos C, Hodgson SV, Alstead EM, Farthing MJG: S1.F210
- Patel P, Mendall MA, Khulusi S, Molineaux N, Northfield TC: S1.T139
- Patel RT, Pall A, Adu A, Keighley MRB: S3.OXVI/3 444
- Patel RT, Youngs D, Keighley MRB: S1.T122
- Pawlotsky J-M, Deforges L, Bretagne S, André C, Métreau J-M, Thiers V, Zafrani E-S, Goossens M, Duval J, Mavier J-P, Dhumeaux D: S2.66
- Peano GM, Fenog LM, Ponzetto A, Rossi G: S3.PDIII/3 1046
- Pell J, Johnson IT, Goodlad RA: S4.F235
- Penman ID, El-Omar E, McGregor JR, Hillan KJ, O'Dwyer P, McColl KEL: S1.W29
- Peresepe A, Marra G, Coco C, Pahor M, Armelao F, Ficarelli R, Gentiloni N, Ponz de Leon M, Anti M: S4.T123
- Pereira SP, Ellul JPM, Keightley A, Kennedy C, Dick J, Dowling RH: S1.F278
- Pereira SP, Hussaini SH, Cassell TB, Murphy GM, Wass JAH, Dowling RH: S3.OXIII/8 653
- Pérez R, Pravia R, Linares A, González M, Rodríguez M, Lombraña JLS, Riestra S, Suárez A, Rodrigo L: S2.136
- Pérez R, Pravia R, Linares A, Rodríguez M, Lombraña JLS, Suárez A, Riestra S, Navascués CA, Rodrigo L: S2.139
- Perez V, Findor J, Tanno H, Sord J: S2.91
- Perrillo RP: S2.48, S2.95
- Persico M, Morisco F, Caporaso N, Tuccillo C, Romano M, Coltorti M: S3.OV/4 982
- Petrick AT, Meterissian S, Wagner HE, Harvey BE, Steele G, Thomas P: S1.W17
- Phull PS, Gower JD, Price AB, Green CJ, Jacyna MR: S1.T133, S4.F246
- Phull PS, Price AB, Halliday D, Jacyna MR: S4.F234
- Piasecki C, McCormick PA, Chin J, Greenslade N, McIntyre N, Burroughs AK: S3.OXVII/1 713
- Piazza M, Orlando R, Tosone G, Tiseo D, Conte MCD, Minervini F, Santoro G, Scordino F, Vitale D: S2.128
- Picarelli A, Ferretti E, Barone R, Greco M, Ronga G, Corazziari E, Pozzilli P, Signore A (introduced by Torsoli A): S4.T95
- Picarelli A, Greco M, Corazziari E, Di Giovambattista F, Cedrone C, Ramazzotti A, Anzini F, Torsoli A: S4.F236
- Pierzynowski SG, Thaela M-J, Weström BW, Svendsen J, Karlsson BW: S3.OVIII/1 518

- Pietropaolo V, Masoni L, Petruzzello L, Montori A: S3.OXVII/5 1350
 Piper IT, Thompson DG, Small B, Weston AJ: S4.W51
 Piquet MA, Dao T, Justum AM, Ballet JJ, Freymuth F, Galateau F, Verwaerde JC, Valla A: S3.OV/2 1039
 Plevris JN, Harrison DJ, Bell JE, Bouchier IAD: S4.T140
 Plevris JN, Jones AL, Dawkes R, Howie AF, Vouchier IAD, Hayes PC: S4.W26
 Plusa S, Farmery S, Peichl P, Lindley IJD, Primrose JN, Crabtree JE: S4.W57
 Plusa SM, Primrose JN, Webster N: S4.W4
 Porter RM, Holme TC, Newman EL, Hopwood D, Coghill G, Cuschieri A, Shirazi-Beechey SP: S1.W23
 Portincasa P, Di Ciaula A, Palmieri V, Palasciano G: S3.OXIII/2 687
 Prat F, Sibille A, Centarti M, Chapelon JY, Henry L, Cathignol D: S3.PDIII/4 217
 Preston SR, Primrose JN: S1.W56
 Preston SR, Woodhouse LF, Primrose JN: S1.T148
 Prieto M, Siles S, Benages R, Carrascop D, Berenguer M, Cordoba J, Mir J, Berenguer J: S3.OX/4 613
 Probert CSJ, Emmett PM, Heaton KW: S4.W9
 Probert CSJ, Quirk H, Mountford RA: S1.T187
 Przemioslo RT, Kontakou M, Nobili V, Sturgess R, Neleufer G, Ciclitira PJ: S4.T94
 Przemioslo RT, Wright NA, Elia G, Ciclitira PJ: S4.T92
 Pullan RD, Ganesh S, Mani V, Morris J, Williams GT, Thomas GAO, Russell MAH, Sawe U, Brown A, Rhodes J: S3.PYI/2 1074
 Pullan RD, Thomas GAO, Rhodes M, Williams GT, Allen A, Rhodes J: S3.PDI/3 471
 Purkiss SF, Rogers J, Williams NS: S1.F248
- Queneau PE, Mion F, Rousseau M, Brazier JL, Paliard P, Minaire Y: S3.OXIX/3 938
 Quine MA, Bell GD, McCloy RF: S1.T103
- Rábaqo LR, Gea F, Sarrion D, Jiminez J, Soler F, Agud JL, Ramos V: S3.PDIII/7 1006
 Radford-Smith G, Di Paolo MC, McGowan I, Jewell DP: S4.T103
 Radley S, Imray CHE, Davis A, Hendrickse CW, Lawson A, Donovan IA, Baker PR, Neoptolemos JP: S1.T151
 Rajan E, Albloushi S, O'Farrell B, Shattock A, Courtney MG, Fielding JF: S1.T170
 Raju GS, Bardham KD, Royston C, Beresford J: S4.W61
 Raju GS, Smith M, Morton D, Bardhan KD: S4.F193
 Ramage JK, Gimson AES, Panos M, Hayllar K, Harrison P, Westaby D, Williams R: S1.T86
 Ranger S, Martin P, Roussanne MC, Denis F: S2.50
 Raptopoulou M, Orphanou H, Vrettou H, Akribiadis E, Chadzikonstantinou L, Goulios G: S2.102
 Reed PI, Xu GP, Li DH, Mill MJ, Johnston BJ: S4.T118
 Regula J, MacRobert AJ, Bedwell J, Loh CS, Grant WE, Bown SG: S1.F206
 Regula J, MacRobert AJ, Buonaccorsi GA, Thorpe SM, Spencer GM, Bown SG: S4.T73
 Reill L, Erhardt F, Fischer R, Huber R, Londong W: S4.F251
 Reill L, Erhardt F, Fischer R, Rost KL, Roots I, Londong W: S4.F252
 Ricci Maccarini M, Stanghellini V, Barbara G, Franzoso L, Morselli Labate AM, De Giorgio R, Salvioli B, Ferri A, Corinaldesi R, Go VLW: S3.OXVIII/5 165
 Rizzi PM, Carpinelli L, Metivier E, Johnson PJ, Ryder SD, de Franchis R, Williams R: S4.W21
 Rizzi PM, Kane P, Ryder SD, Ramage JK, McPeake JR, Karani J, Portmann B, Ran KC, Williams R: S4.T84
 Roberts JP, Benson MJ, Rogers J, Deeks JJ, Wingate DL, Williams NS: S1.F231
 Robertson CS, Gurtner GC, Ip SM, Chung SCS, Ling TKW, Li AKC: S4.F276
 Robinson MHE, Berry DP, Vellacott KD, Moshakis V, Hardcastle JD: S1.T155
 Robinson MHE, Williams CB, Hardcastle JD: S1.F242
 Rode J, Lee CS, Ayberk H, Desmond P, Locarnini S, Bowden S, Lee JY: S1.T178
 Rokkas T, Mavrogeorgis A, Rallis E, Giannikos N: OI/4 188
 Ronayne C, Robertson G, Bray GP: S1.T169
 Roncucci L, Madenis N, Fante R, Di Gregorio C, Cassinadri MT, Ponz De Leon M: S4.W38
 Rooney PS, Gifford KA, Clarke PA, Hardcastle JD, Armitage NC: S4.W42
 Roseth AG, Kristinsson J, Aadland E, Schjonsby H, Nygaard K, Fagerhol MK: S3.OXVII/2 753
 Roudot-Thoraval F, Pawlotsky J-M, Deforges L, Firollet P-P, Dhumeaux D: S2.55
 Rowbotham DS, Mapstone NP, Trejdosiewicz LK, Howdle PD, Quirke P: S4.F228
 Rowntree AC, Allardice JT, Woods WW, Purkiss SF, Abulafi AM, Taylor HW, Williams NS: S1.T149
 Royston C, Lansdown M, Brough W: S4.T148
 Ruehl A, Collins SM: S3.OXV/3 1108
 Russell RCG, Theis BA, Hatfield ARW: S1.F264
 Ruszniewski P, Thomas F, Rougier P, Genestin E, Cloarec D, Gouerou H, Michel H, Modigliani R, Chayvialle JA: S3.OXV/8 1136
 Ryder SD, Jacyna MR, Levi AJ, Rhodes JM: S4.F269
 Ryder SD, Naoumov N, Williams R: S4.T89
 Ryder SD, O'Reilly S, Miller RJ, Jacyna MR, Levi AJ: S1.T102
- Sagar PM, Stoddard C, Kingsnorth AN: S1.W7
 Salemans JMJI, Nagengast FM, van Schaik A, Tangerman A, Jansen JBM: S3.OVII/6 1385
 Samson HJ, Pearson JP, Allen A, Srivastava ED, Record CO: S4.W39
 Sanyal AJ, Freedman AM, Schiffman ML, Luketic VA, Purdum PP, Tisnado J, Cole P: S3.OIII/4 216
 Sarsfield P, Bannister S, Goggins P, Bone A, Fine D, Okamoto H, Johnson C: S4.W8
 Satsangi J, Jewell DP: S4.W35
 Saunders BP, Fukumoto M, Halligan S, Masaki T, Williams CB: S4.T157
 Saunders BP, Halligan S, Jobling C, Fukumoto M, Moussa M, Williams CB: S4.T154
 Saunders BP, Halligan S, Zoli G, Catnach SM, O'Donnell LJD, Farthing MJG: S4.T137
 Saunders BP, Macrae FA, Williams CB: S1.T179
 Saunders BP, Williams CB: S1.T117
 Savidge TC, Freeman TC: S1.W15
 Savidge TC, Morey AL, Ferguson DJP, Fleming KA, Walker-Smith JA, Phillips AD: S4.T125
 Savidge TC, Walker-Smith JA, Phillips AD: S1.W20
 Schassmann A, Tarnawski A, Peskar BM, Varga L, Flogerzi B, Halter F: S3.OIX/6 832
 Schassmann A, Varga L, Flogerzi B, Sanner M, Halter F: S3.PDI/8 831
 Schaufelberger HD, Uhr MR, Misiewicz JJ: S3.OXVII/4 443
 Schaufelberger HD, Uhr MR, Smith AC, Logan RPH, Gordon-Smith EC, Misiewicz JJ: S1.T196
 Schiff ER: S2.148
 Schmilovitz-Weiss H, Levy M, Thompson N, Dusheiko G: S2.26
 Schölhorn K, Daum S, Wagner F, Classen M, Deusch K: S3.OVI/5 1103
 Schönfeld JV, Chong YY, Evans DF: S1.W2
 Schouten WR, Briel JW, Auwerda JJA, van Blankenstein M: S1.T98
 Schranz P, Renz M, Rednic H Schröter H, Seelig HP: S3.OV/3 1265
 Schuerer-Maly C-C, PLugin J, Maly F-E: S3.OXVI/6 494
 Scott-Coombes DM, Whowell SA, Thompson JN: S4.T147
 Sedman PC, May J, Brooks SG, Sagar P, Johnson D, Tring I, Mitchell CJ, Macfie J: S1.F252, S1.F286
 Setti-Carraro P, Strada G, Raad L, Belloni U, Nicholls RJ: S1.W76
 Setti-Carraro P, Talbot IC, Nicholls RJ: S1.F261
 Setti-Carraro P, Wilkinson KH, Ritchie JK, Nicholls RJ: S1.F247
 Shah K, Price AB, Talbot IC, Bardhan KD, Griffin W, Fenn CG, Bjarnason I: S4.T173
 Shah PM, Boulos PB, Pearce FL: S4.F206
 Shahin M, Schuppan D, Waldherr R, Savolainen ER, Zalpur F, Seitz HK: S3.OIX/5 246
 Shaikh S, Mills JG, Darekar B, Wood JR: S1.W52
 Shao O, Mei J, Chang WQ, Mei MH: S3.OII/7 1007
 Sharer NM, Lee S, Taylor PM, Schofield D, McIntosh J, Mei G, Braganza JM: S4.T160
 Sharer NM, Schofield D, Whiteley GSW, McCloy RF, Braganza JM: S1.T108
 Sherlock S, Hadziyanis S, Nishioka M, Perrillo RP, Schiff ER, Trépo C: S2.81
 Sherman DIN, Taylor NF, Williams R, Peters TJ: S4.W25
 Shidrawi RG, Przemioslo R, Ciclitira PJ: S4.T155
 Simkiss DE, Adams I, Myrdal I, Booth IW: S3.OIV/2 789
 Simpson KJ, Chalmers N, Redhead DN, Finlayson NDC, Hayes PC: S4.T82
 Simpson KJ, Jones A, Hayes PC: S1.T83
 Singh P, Taylor RJ, Colin-Jones DG: S4.T71
 Singh S, Paraskeva C, Gallimore PH, Sheppard MC, Langman MJS: S1.W28
 Singh S, Poulsom R, Jeffery R, Wright NA, Sheppard MC, Langman MJS: S4.T117
 Slomiany BL, Murty VLN, Piotrowski J, Czajkowski A, Slomiany A: S3.OIX/5 116
 Slomiany BL, Sengupta S, Piotrowski E, Murty VLN, Slomiany A: S3.PDI/9 119
 Small PK, Loudon M, Campbell FC: S4. W16
 Small PK, Loudon MA, Campbell FC: S4.T142
 Small PK, Smith DM, Waldron B, Campbell FC: S4.T174
 Smith GD, Eastwood MA, Palmer KR: S4.F221
 Smith MSH, Fox JD, Devos S, Taylor JE, Sweenie CH, Sim R, Sawyer AM, Pounder RE, Wakefield AJ: S4.F278
 Smith MW, Turvey A, Keable SJ: S1.W21

- Smith PM, Kerr GD, Cockel R, Ross BA, Bate CM, Brown P, Dronfield MW, Green JRB, Hislop WS, Theodossi A, McFarland RJ, Watts DA, Taylor MD, Richardson PDI, RESTORE Investigator Group: S4.T76
- Smith-Ravin J, England J, Talbot IC, Bodmer W: S1.F208
- Smith REA, McPeake JR, Gimson AES, Martin JF, Williams R, Moncada S: S4.T77
- Smith VV, Milla PJ: S4.W48
- Smythe A, Mangnall YF, Johnson AG: S4.W50
- Sobhani I, Lehy T, Cadiot G, Ruszniewski Ph, Lewin MJM, Mignon M: S3.OVI/8 437
- Sobola GM: S4.T119
- Sokal EM, Wirth S, Goyens P, Depreterre A, Cornu C: S2.87
- Soriano G, Novella MT, Mourelle M, Bulbena O, Tomás A, Roselló J, Ortiz J, Portorreal R, Guarner C, Moncada S, Vilardell F: S3.PDIII/6 969
- Spigelman AD, Penna C, Nugent KP, Phillips RKS: S1.W78
- Spigelman AD, Scates DK, Nugent KP, Venitt S, Phillips RKS: S1.W26
- Starzynska T, Marlicz K, Stern PL: S3.OVI/6 392
- Steele RJC, Marshall K, Lang M, Doran J: S4.T145
- Stiff G, Rhodes M, Kelly A, Telford K, Armstrong CP, Rees BI: S3.OVII/2 602
- Stretch GL, Campbell BJ, Dwarakanath AD, Rhodes JM: S1.W41
- Stubbs AP, Murphy GM, Wilkinson ML: S4.W24
- Sturges RP, Kontakou M, Spencer J, Hooper LB, Makgoba MW, Ciclitira PJ: S1.T119
- Sturniolo GC, D'Inca R, Lecis PE, Mestriner C, D'Odorico A, Venturi C, Naccarato R: S1.W38
- Sue-Ling H, Young S, Griffith J, Selby P, Johnston D: S1.W55
- Sultan AH, Kamm MA, Hudson CN, Bartram CI: S1.T159, S1.T160
- Sultan AH, Kamm MA, Talbot IC, Hudson CN, Bartram CI: S1.T100
- Sutton R, Williams EMI, Pellegrini G, Tedman S, Jenkins SA, Shields R: S3.OIII/1 1011
- Sweidan WH, Dakkak M, Sutton DR, Bennett JR: S4.T97
- Tabaqchali MA, Yapp T, Bancewicz J, Ford D, Venables CW, Williams J: S4.F231
- Tackeuchi N, Smilgin Humphries M, O'Kelly T, Mortensen N: S4.F192
- Taha AS, Nakshabendi I, Sturrock RD, Russell TI: S1.T137
- Tait IS, Evans GS, Flint N, Campbell FC: S1.T131, S1.T132
- Tait IS, Flint N, Evans GS, Hopwood D, Campbell FC: S4.T162
- Takeuchi N, Kakkamanis L, Campbell A, O'Kelly T, Mortensen N: S4.F183
- Tam F, Hillier K, Bunce KT, Grossman C: S3.OXV/2 1114
- Tan KC, Heaton ND, Vougas V, Rela M, Gane E, McPeake J, Wendon J, Williams R: S1.T165
- Tan WC, Andrews HA, Allan RN: S1.F262
- Tassopoulos NC, Koutelou MG, Papatheodoridis G, Polychronaki H, Delladetsima I, Giannikakis T, Todoulos A, Tolopoulos A, Hatzakis A: S2.130
- Teare JP, Sherman D, Greenfield SM, Bray GP, Catterall AP, Murray-Lyon IM, Peters TJ, Williams R, Thompson RPH: S1.T81
- Teare JP, Watkinson AF, Morris DC, Owen DA, Wolber R, Scudamore CH, Erb SR: S4.W27
- Teli MR, Cobden I: S4.T151
- Terada M, Matsubara Y, Todue H, Ito M, Sakurai Y, Takasu Y, Abe T, Ikegami F, Tanaka Y: S3.OV/6 1000
- Testoni PA, Cicardi M, Bergamaschini L, Guzzoni S, Castelli R, Cugno M, Buizza M, Agostoni A: S3.OXVII/7 757
- Thakeb F, Abdel Kader S, Salama Z, Abdel Hamid H, Salama H, Abdel Raouf T: S3.OXVII/4 766
- Tham TCK, Kennedy R, O'Connor FA: S4.T133
- Tham TCK, O'Connor FA, McLaughlin N, Hughes DF, Ferguson M, Crosbie JJ, Madden M, Namnyak S: S4.T68
- Thomsen OO, Andersen T, Langholz E, Malchow-Moller A, Matzen P, Persson T, Scandinavian Budesonide Study Group: S3.OXII/5 1075
- Thomson ABR, Lauritsen K, Rutgersson K, Bolling E, Brunner G, Eriksson S, Galimche JP, Walan A, Archambault A, Gudjónson H, Bailey R, Bianchi Porro G, Frison L, Havu N: S3.OI/2 184
- Tighe MR, Hall MA, Ashkenazi A, Siegler E, Lanchbury JS, Ciclitira PJ: S1.F260
- Tighe MR, Hall MA, Cardi E, Ashkenazi A, Lanchbury JS, Ciclitira PJ: S1.T123
- Travis SPL, A'Court C, Menzies IS, Stroud M, Edwards JSA: S4.T165
- Trépo C, Zoulim F, Alonso C, Petit M-A, Pichoud C, Vitvitski L: S2.20
- Trimble KC, Pryde A, Heading RC: S4.T72
- Tsai HH, Yiannakou JY, Gilmore IT, Morris AI: S1.F257
- Umana JP, Soin AS, Harrison JD, Gunson BK, Neuberger JM, Mayer AD, Buckels JAC, McMaster P: S4.T83
- Vafiadis I, Boletis J, Papastathi H, Delladetsima J, Stathakis C, Hatzakis A, Kostakis A, Vosnides G: S2.57
- Vaira D, Corbelli C, Brunetti G, Menegatti M, Levorato M, Grandineti G, Mulè P, Miglioli M, Barbara L: S1.W49
- Vaira D, Holton J, Miranda D, Menegatti M, Mulè P, Gusmaroli R, Mazzeo B, Biasco G, Rodi M, Milesi F, Giorcelli W, Casadei A, Miglioli M, Barbara L: S4.F263
- Vaira D, Miglioli M, Menegatti M, Holton J, Biasco G, Mulè P, Boschi S, Bisceglia G, Lombardi M, Vergura M, Azzarone P, Serra C, Copnte R, Barbara L: S3.OI/8 0754
- Vaira D, Miglioli M, Menegatti M, Holton J, Mulè P, Oderda G, Bisceglia G, Lombardi M, Biasco G, Vergura M, Altare F, Conte R, Barbara L: S1.T186
- van Buuren HR, Nix GAJJ, van Blankenstein M: S4.T67
- van Erpecum KJ, Go PMN, Stolk MFJ, Dirksen C, van der Elst DH, Ament A, Gouma DJ, van Berge Henegouwen GP: S1.F275
- van Someren RNM, Benson MJ, Ainley CC, Glynn MJ, Swain CP: S4.T150
- Varga G, Kisfalvi K, Scarpignato C: S3.OIX/8 883
- Videla S, Vilaseca J, Salas A, Guarner F, Crespo E, Antolin M, Malagelada J-R: S3.OXVI/5 469
- Villanueva C, Balanzó J, Martinez FJ, González D, Toro H, Vilardell F: S3.OIII/2 966
- Viond MN, Moshakis V: S1.T184
- Visco G, Alba L, Grisetti S, Guarascio P, Narciso P, Sette P, Sgurglia C, Tossini G, Tozzi V: S2.107
- Vlahcevic ZR, Jairath SK, Jones MP, Pandak WM, Hauman DM, Hylemon PB: S3.OII/1 1347
- Wagtmans MJ, van Hogezand RA, Biemond I, Griffioen G, Verspaget HW, Lamers CBHW: S4.F248
- Waldron B, Smith D, Campbell FC: S4.T175
- Wall ST, McFadden JJ, Sim R, Dhillon AP, Pounder RE, Wakefield AJ: S4.T113
- Wallace JL, McCafferty D-M, Granger DN, Kuves P: S3.OIX/1 1179
- Walters AM, Sarr MG (introduced by Primrose JN): S4.T166
- Wang J, Anggiansah A, Owen WA, Owen WJ: S4.F257
- Wang Y, Farnaud S, Selden AC, Hodgson HJF: S1.T127
- Wardle TD, Moriarty KJ: S1.T188
- Wardle TD, Turnberg LA: S1.T147
- Warren SJ, Burleigh D, Williams NS: S4.W52
- Watkin DS, Haworth JM, Leaper DJ, Thompson MJ: S1.F265
- Watkin DS, Warwick DJ, Thompson MJ: S1.F266
- Watson AJM, Askew JN: S1.W32
- Watson SA, Clifford T, Steele RJC, Hardcastle JD: S4.T120
- Watson SA, Michaeli D, Robertson JFR, Steele RJC, Hardcastle JD: S1.F207
- Watson SA, Robinson G, Morrell KJ, Nicholson S, Steele RJC, Turner DR, Hardcastle JD: S4.F271
- Wattchow DA, Brookes SJH, Kow L, Costa M, Bredt D, Snyder S: S1.F214
- Wegener M, Adamek RJ, Wedmann B, Pfaffenbach B: S3.OXIV/1 721
- Weldon MJ, Bond A, Alavi A, Hay FC, Maxwell JD, Axford JS: S4.F243
- Weldon MJ, Masoomi AM, Britten A, Joseph AEA, Maxwell JD: S1.T191, S3.PDI/2 485
- Weldon MJ, Saverymuttu SH, Findlayson C, Joseph AEA, Maxwell JD: S1.F243
- Whitehead MW, Powell JJ, Champion M, Lacey S, Thompson RPH: S4.T177
- Whiteley G, Pearson RC, Eddleston JM, Tooth JA, Vohra A, Doran B: S1.W53
- Whorwood CB, Stewart PM: S3.OXV/6 405
- Wicks C, Somasundaram S, Menzies IS, Bjarnason I, Williams R: S1.F255
- Wigmore SJ, Duthie GS, Young IE, Spalding EM, Rainey JB: S4.T144
- Wigmore SJ, Wood K, Macleod DAD: S4.T143
- Wilder-Smith CH, Scheuer U, Hurlmann S, Schmassman A, Grob HJ, Halter F, Merki HS: S3.OXI/1 356
- Wilkinson JM, Hosie KB, Johnson AG: S4.T172
- Williams D, Arnold R, Robinson P, Gleeson DC, Johnson AG: S4.T79
- Williams SGJ, Peters RA, Westaby D: S1.T190
- Williamson MER, Lewis WG, Sagar PM, Holdsworth PJ, Johnston D: S4.W41
- Wilson DC, Halliday HL, Reid M, McClure G, Dodge JA: S3.OIV/5 786
- Wilson JA, Pryde A, Grant R, Heading RC: S3.OXVIII/4 073
- Wilson JA, Pryde A, Maher L, Heading RC: S1.W69
- Wilson RJ, Weir HP, Maxwell P, Williamson KE, Rowlands BJ, Moorehead RJ: S3.OVI/1 399
- Winkelmann LG, Stenson WF, Zileuton study group: S3.OXII/3 476
- Winslet M, Mohsen Y, Hallisey M, Allum WH, Fielding JW: S4.T152
- Withey S, Millar DS, Tizard MLV, Ford J, Sanderson JD, Hermon-Taylor J: S3.PDI/6 1273
- Wong PYN, Hussain M, ROsol S, Gallati H, Portmann B, Vergani D, Naoumov NV, Williams R: S4.W20

Wright TA, Gray MR, Morris AI, Filmore IT, Smart HL, Ellis A, Kingsnorth AN: S4.T70
Wright TA, Kingsnorth AN, Gray MR: S4.T116
Wyeth JW, Eng KL, Fraser AG, Sankey EA, Dhillon AP, Pounder RE: S1.T138

Yamada G, Takahashi M, Endo H, Doi T, Miyamoto R, Shimomura H, Yamamoto K, Tsuji T: S2.133
Yano M, Yatsuhashi H, Inoue O, Inokuchi K, Koga M: S2.13
Yates J, Nott DM, Kynaston H, Davies N, JinLai L, Billington D, Shields R, Jenkins SA: S3.OIII/7 1012

Yokosuka O, Omata M, Ito Y, Ohto ML: S2.64
Yoong KF, Hubscher S, Gunson B, Harrison JD, Mayer AD, McMaster P, Buckels JAC: S4.F218
Young GP, St John DJB (introduced by Farthing M): S4.F180
Yu PR, Biancani P, Behar J: S3.OXIII/3 645

Zoli G, Ballinger A, Healy J, O'Donnell LJD, Clark ML, Farthing MJG: S1.F279, S3.OXIII/6 693
Zoli G, Corazza GR, Wood S, Farthing MJG: S1.T129
Zoli G, Katelaris PH, Garrow JS, Farthing MJG: S1.F253

SUBJECT INDEX – SUPPLEMENTS, 1–4, 1993

- Abdominal resection rectopexy** and perineal rectosigmoidectomy compared, S1.20
- Achalasia**, delayed gastric emptying, S1.16
- Achlorhydria**, omeprazole does not alter plasma gastrin, S1.57
- Acid-induced duodenal mucosal damage**, mechanism, S4.17
- Acid reflux**, and lower oesophageal sphincter relaxations, under ambulant conditions, S1.1
- Acid suppressing therapy**, long term, audit, S1.26
- Acid suppression**, and carcinoma development, in Barrett's oesophagus, S1.2
- Adenomas**, dietary calcium supplementation, double blind trial, S4.11
- Adenomatous polyposis coli gene**, and familial colorectal cancer, S4.46
- Adenomatous polyps** in first degree relatives of colon cancer patients, S3.15
- Adhesion molecules** in IBD, S1.12
soluble, in immune liver disease, S1.22
- Aganglionosis** may not only be due to Hirschsprung's disease, S4.12
- AIDS** diarrhoea not due to jejunal villus atrophy, S4.57
intestinal microsporidia, eliminated by albendazole, S1.73
-related cryptosporidiosis, jejunal water and electrolyte transport, S4.69
- Albumin**, intestinal loss, and reduction of sulphated glycosaminoglycans, S1.49
- Alcohol**, effects on gallbladder emptying in response to normal meal in healthy subjects, S3.32
- Alcoholic cirrhosis** action of isosorbide-5-mononitrate on azygos blood flow and portal pressure, S4.20
altered cortisol metabolism, S4.7
- Alcoholic liver disease** demonstration of IL-2 receptor expression on circulating lymphocytes using flow cytometry, S4.8
and functional hypersplenism, S4.5
procollagen III propeptide levels and PGA index, S1.21
serial hepatic 31P MRS, S1.45
ursodeoxycholic acid, S4.7
- Algorithms**, treatment, for hepatitis B and C, S2.148
- Alkali**, oesophageal and salivary secretory responses to topical oesophageal acidification, S1.18
- Allele loss** in colorectal liver metastases and its associated with clinical features, S1.8
- Alpha-1-antitrypsin** inhibits hepatic tumor cells HepG2, S3.3
- Altitudes above 5000m**, intestinal function, S4.42
- Aluminium**, tissue and CSF accumulation, S1.58
- Amoebic liver abscess**, treatment, S3.43
- Amino acids** bolus intravenous, gallbladder inertia, S4.35
rapid intravenous, promotion of gallbladder emptying and CCK release, S3.32
- 5-Aminolaevulinic acid** in photodynamic therapy of colon cancer, S1.52
in sensitisation and photodynamic therapy for oesophageal, duodenal and colorectal tumours, S4.19
- Aminopyrine breath test**, in alcoholic liver cirrhosis, prognostic value, S3.47
- 13C-Aminopyrine breath test**, simple and highly sensitive test for assessment of liver dysfunction, S3.43
- Aminosalicylate therapy** increases prostaglandin production in UC, S4.52
- 5-Aminosalicylic acid** enema, absorption, in ileorectal anastomosis for UC, S3.9
inhibits impaired epithelial barrier function induced by IFN-gamma, S4.67
serum, urinary acetylated and unacetylated compared, during administration of sulphasalazine, olsalazine or mesalazine, S1.11
- Amoxycillin/ cimetidine evasion** in *H. pylori* infection, PCR to locate site, S1.36
- Amyloidotic polyneuropathy**, familial, new indication for orthotopic liver transplant, S3.22
- Anal endosonography**, in faecal incontinence, new gold standard in diagnosing sphincter defects, S1.26
- Anal pressure**, and anodermal bloodflow, relationship between, S1.25
- Anal sphincters**, competent, in faecal incontinence, S3.25
- Anastomoses**, distal colon, pressure gradients and dehiscence, S1.59
- Androgen receptor expression**, quantitative expression in adult liver tissue by PCR, S4.6
- Anemia**, chronic normovolemic, increases gastric mucosal blood flow and protects against ethanol-induced gastric damage, S3.10
- Anorectal disease**, S4.47-48
- Anorectal function**, S1.25-26
effect of age, sex and parity, S3.25
- Anorectal manometry** ambulant, in slow transit constipation, S3.25
in postchildbirth/hysterectomy constipation, S4.48
- Anorectal physiology**, effect of acute diarrhoea, healthy volunteers, S4.3
- Anthropometric and quality of life measurements in specialist under-nutrition clinic**, S4.26
- Anti-endothelial cell antibody** in IBD, S3.37
- Anti-neutrophil cytoplasmic antibodies**, prevalence in South Asians and Europeans with UC, S1.11
- Anti-secretory drugs** acting via H⁺/K⁺ ATPase inhibition and CCK receptors, relative merits, S4.54
gastric acid, and increased incidence of bacterial diarrhoea, S4.54
- Antibody-cisplatin conjugates**, estimation of drug targeting indices, S1.5
- Antidepressants**, effect on IBS symptoms, S1.58
- Antigastrin antibodies** raised by Gastrimune inhibit growth of colorectal tumours, S1.53
- Antioxidant** blood, in fulminant pancreatitis, S1.28
blood profiles, in relation to pancreatic morphology in (non-gallstone) recurrent pancreatitis, S4.40
depletion, and protracted diarrhoea of infancy, S4.25
effects of new therapeutic agents in IBD, S4.52
and micronutrient intake, in dyspepsia, evidence for selenium deficiency, S4.59
- Antireflux surgery**, regression and progression of Barrett's oesophagus after, S1.2
- Antral nodularity**, macroscopic marker for *H. pylori* gastritis, S1.35
- Appendicitis**, acute, why does it happen and how is it managed? S4.36
- Aqueous cream**, for pruritus in patients with liver disease, S1.43
- Arachidonic acid-rich phospholipids** in gallbladder bile, octreotide increases proportions, S3.32
- L-Arginine**, unlike D-arginine, is a small intestinal secretagogue, animal model studies *in vivo*, S1.66, S4.60
- Ascitic fluid infection**, polymorphonuclear elastase, new test, S3.46
- Ascorbic acid** in gastric juice, effect of *H. pylori*, S1.4
- Ashkenazi Jews**, coeliac disease, and associations with polymorphisms of HLA class II genes, S1.66
- Aspirin** -induced mucosal damage, mechanism of effects, S1.56
may protect against colorectal cancer, S4.31
and NSAIDs use, risk of asymptomatic colorectal cancer, S1.52
prior use in upper gastrointestinal bleeding presenting to an open-access bleeding unit, S4.39
- Atrial natriuretic factor**, plasma, in cirrhosis, S3.6
- Atropine**, and gallbladder emptying, S4.4
- Audit**, S1.26-27, S1.59-60, S4.55-56, S4.58
- Autoimmune chronic active hepatitis**, type 1, and HCV infection, S2.66
- Azoxymethane-induced colorectal carcinogenesis**, omeprazole inhibits, rats, S1.8
- Bacterial translocation**, obstructive jaundice promotes, S1.69
- Barium enema audit**, colorectal outpatient clinic, S1.27
- Barrett's cancer**, is screening worth it? S4.18
- Barrett's oesophagus** acid suppression and carcinoma development, S1.2
c-erbB-2 dysfunction in dysplasia/carcinoma sequence, S4.66
DNA-ploidy, TNM-stage and grade as prognostic factors after resection, S1.19
omeprazole, S1.19
prognostic value of *c-erb B2* in adenocarcinomas, S4.29
and reflux symptoms in self medicating patients, S1.2
regression and progression after antireflux surgery, S1.2
value of flow cytometry for malignant change, S1.19
- Barrett's segment**, length, dependence on orad transport of refluxate, S4.18
- Basolateral membrane calcium pump**, distribution of different isoforms in GI tract, S1.32
- Bile**, and DNA adducts, *in-vitro* genotoxicity study, S1.7
- Bile acids** effect on DNA synthesis by regenerating perfused rat liver, S3.47
effect on hepatocyte mitochondria, S3.45
hydrophobic, do they damage specific human hepatocyte organelles? S4.7

- Bile duct**
 assessment prior to laparoscopic cholecystectomy, S1.67
 injury, iatrogenic, complicating laparoscopic cholecystectomy, S4.34
 obstruction, after orthotopic liver transplantation, endoscopic treatment, S3.33
- Bile duct stones**
 biliary endoprosthesis insertion, long term follow up, S1.70
 endoscopic removal, relationship to laparoscopic cholecystectomy, S1.66
 ESWL using piezoelectric lithotripter, S1.68
 lower rates of detection, S1.67
 salvage surgery, outcome, S1.52
- Bile vomiting**, postoperative, motor activity and intragastric pH changes associated with, S4.36
- Biliary**, S1.51-52
 bile acids, are they different in patients with familial adenomatous polyposis? S4.9
 decompression, restores Kupffer cell function in obstructive jaundice, S4.8
 disease, S4.1
 disorders, S4.33-35
 prosthesis, self-expandable (Endocoil), interim results, S3.33
 stent, blockage, prophylaxis using cyclical antibiotics and ursodeoxycholic acid, S1.69
 stones, endoscopic stenting, S3.34
 strictures, difficult, dilating, novel endoscopic method, S4.38
 tract, S1.67-71, S2.31-32
- Billroth-II gastric resection**, efficiency of transpapillary endoscopic treatment of biliary tract, S3.34
- Bismuth**
 non absorbable, is as effective as De-Nol in eradicating *H. pylori*, S4.45
 tissue and CSF accumulation, S1.58
- Black currant oil**, see N-3 and N-6 rich oils
- Bleeding units**, to reduce morbidity and mortality in lower GI bleeding, S4.55
- Blood donors**
 asymptomatic, high IgG, IgA, IgM to *H. pylori*, and serum PGI, S1.47
 HCV antibody positive, S2.54
- Blood group antigens**, inappropriate expression in hepatic allografts, S4.22
- Bombesin/gastrin releasing peptide receptors** on human gastric and colorectal cancer tissue, S1.38
- Bone metabolism**, effect of experimental colitis, rat, S1.10
- Bowel**
 decontamination, effect on inflammatory response in TNB induced colitis, S3.10
 disease, chronic, simple technique for abnormal mucosal cytokinetics, S1.6
 lymphocytic infiltration, in CD, in vivo imaging by 123I-interleukin 2, S4.24
 preparation not sedation influences tolerance of colonoscopy, S1.48
- Bran**, laxative effect on small bowel transit, due to its particulate nature, S4.3
- Bromodeoxyuridine** and PCNA immunohistochemistry, in proliferation analysis of preneoplastic colorectal mucosa, S3.14
- Budesonide**
 9 or 15 mg rapidly improves quality of life in active CD, S4.53
 enema treatment in UC, lack of adrenal gland suppression, S3.27
 versus prednisolone enema, in active distal UC, comparative eight week study, S1.41
- Butyl-2 cyanoacrylate** and ethanolamine oleate, combined use in bleeding esophagogastric varices, S3.39
- C1-inhibitor plasma concentrate**, efficacy in preventing hyperamylasemia induced by endoscopic papillosphincterotomy, S3.40
- C-erb B2**, prognostic value in adenocarcinomas arising in Barrett's oesophagus, S4.29
- CA 71-4** serum levels in gastric cancer patients, S4.16
- Cadherin**, E- and P-, cell adhesion molecules in colorectal carcinoma, S4.67, S4.26, S4.27
- Caecal diaphragms**, indomethacin-induced, in a chronic NSAID study, S1.49
- Caerulein-induced gallbladder contraction**, and PP release, inhibition by telenzepine, S3.32
- Calcium**, dietary supplementation, in adenomas, double blind trial, S4.11
- Calcium carbasalate**, effervescent, causes less gastroduodenal injury than plain aspirin, S4.54
- Calcium channel mucosal activity modulation** by gastric mucins, S3.21
- Calprotectin**, sensitive markers of gastrointestinal neoplasia, S3.39
- Cancer**, S4.65-68
- Capsaicin** amplified acetic acid induced colonic damage, decreased by Ketotifen, S3.38
- Capsaicin-sensitive sensory neurons**, involvement in intestinal effects of *Clostridium difficile* toxin A but not cholera toxin, S3.36
- Carbon tetrachloride**, and hepatic stimulator substance, stimulate oncogene expression, rat liver, S3.4
- Carcinoembryonic antigen**
 distribution in colorectal carcinoma, S4.67
 is modulator of adhesion in colorectal tumour cells, S4.67
- Carcinoid syndrome**, slow release lanreotide, S3.36
- Case studies**, in hepatology, S2.81
- CD3/CD4 cells**, gastric mucosal, before and after *H. pylori* treatment, S1.35
- Celiotomy**, replaced by EUS in predicting stage and resectability of gastric carcinoma? S3.39
- Cell biology**, S1.7-9
- Cell proliferation**
 after partial hepatectomy, S3.45
 coeliac disease, S1.6
 in *H. pylori* associated gastritis, Sydney system, S4.50
 intestinal epithelial
 heparinoids stimulate, S1.7
 mesenchymal interactions, S1.7
 simple technique, chronic bowel disease, S1.6
- Centralised unit** is part of 'state of the art' management for haematemesis and melaena, S4.55
- Chang cells**, in culture of HCV, S3.12
- Chemotherapy**, for oesophageal carcinoma, S1.16
- Chenodeoxycholic acid**, and ursodeoxycholic acid, effect on human hepatocyte and erythrocyte membranes, S1.45
- Cholangiography**
 intravenous, preoperative assessment for laparoscopic cholecystectomy, S4.36
 peroperative, through gall bladder, during laparoscopic cholecystectomy, S4.33
- Cholangiopathy**, HIV related, biliary tree abnormalities, S4.34
- Cholecystectomy**
 conventional and laparoscopic, and ESWL, cost-effectiveness, S1.70 and *H. pylori* infection, S1.36
 post-laparoscopic, bile leaks, place of endoscopic treatment, S1.52
 postoperative pain, less common after laparoscopy, S3.16
- Cholecysto-choledocholithiasis**, combined endoscopic-laparoscopic approach, S3.34
- Cholecytokinin**
 -B receptor, cloning and functional expression, S3.31
 in control of gastric secretory response to meal, S1.15
 in hormonal stimulation of pancreatic enzyme synthesis and secretion, S1.27
 is a satiety hormone at physiological post prandial concentrations, S4.26
 levels, and biliary motility, after truncal vagotomy, S1.51
 and PYY, effect on gastric secretion, motility and metabolic responses, S3.41
 release, and gallbladder emptying, promotion by rapid intravenous amino acids, S3.32
 stimulated gall bladder scintigraphy in acalculous biliary pain, chronic cholecystitis v cholesterolosis, S4.1
- Cholesterol 7alpha-hydroxylase**, paradoxical up-regulation following common bile duct ligation, S3.3
- Cholesterol crystal formation** in model bile, hydrophobic/hydrophilic balance of proteins is major determinant, S1.51
- Cholesterol crystal nucleation time**, and bile physical chemistry, in gallbladder stone recurrence, S1.51
- Cholesterol stones**, intracellular second messengers restore impaired gallbladder contractility, S3.31
- Cholestyramine**
 enteral, prevents fall in renal blood flow following surgery in obstructive jaundice, S3.17
 oral, effects on gallbladder and antral motility in obese and lean individuals, S3.31
- Cirrhosis**
 alcoholic and non-alcoholic, altered cortisol metabolism, S4.7
 aminopyrine breath test, prognostic value, S3.47
 changes in endotoxemia and endogenous vasoactive systems after colistin treatment, S3.46
 effect of intravenous N-acetylcysteine on cardiac output and oxygen utilisation, S1.43
 in hepatocellular carcinoma, S4.6
- intravenous octreotide, systemic haemodynamic effects, S1.42
 octreotide induced renal changes, Echodoppler to assess, S3.6
- plasma ANF, S3.6
 probability of developing gallstones and related risk factors, S3.31
 tissue hypoxia, role of arteriovenous shunting, S3.46
- Cisapride**
 determinants of response in adults with chronic intestinal pseudo-obstruction, S3.30
 segmental colonic motility with and without under fed and fasting conditions, S3.24
- Cisplatin**, decreases intestinal water absorption in rat jejunum by a 5-HT-dependent mechanism, S4.54
- Clinical pharmacology**, S4.53-55

- Clinical terms project, role in gastroenterology, S4.58**
- Clostridium difficile* toxin A, involvement of capsaicin-sensitive sensory neurons in intestinal effects, S3.36**
- CO₂, pneumoperitoneum, does it increase bacteraemia in peritonitis? S4.69**
- Cobalamin absorption**
during omeprazole treatment, S1.57
protein-bound, significantly impaired by omeprazole, S1.14
- Coeliac disease, S4.23-25**
among Ashkenazi Jews, and associations with polymorphisms of HLA class II genes, S1.66
cell proliferation, S1.6
and lymphocytic gastritis, children, S3.7
misdiagnosis, S4.39
suitability of foods, S1.64
susceptibility locus, S1.32
T cell receptor Vbeta usage, S1.63
TNF microsatellite polymorphisms, S1.63
total and segmental colonic transit, S3.24
- Colistin, in cirrhosis, changes in endotoxemia and endogenous vasoactive systems after, S3.46**
- Collagen turnover and undulin, circulating enzyme activities, in schistosomiasis and alcoholic liver cirrhosis, S3.44**
- Collagenase, interstitial expression in cultured human hepatic lipocytes and diseased human liver, S1.21**
- Colon, colonic, S3.24-25, S3.38**
adenocarcinomas, isolation and characterization of luminal and basolateral membrane vesicles, S1.6
carcinoma
cell line, transfection of E-Cadherin into induces differentiation and inhibits growth *in vitro*, S4.27
mast cell distribution and tumour cell proliferation, S1.5
cells, programmed death (apoptosis), S3.14
distal, effect of nicotine and its metabolites, S1.56
epithelial metabolism and mucin synthesis, in UC and controls, S4.28
factors, novel, in pathophysiology of UC, S3.9
motility
effect of enteral feeding, S1.64
human longitudinal, short chain fatty acids reduce, S4.13
in IBS, effect of zamefenacin, S4.4
patterns in postchildbirth/hysterectomy constipation, S4.3
mucus, adherent gel layer, relation to IBD, S3.9
pH in Ghanians, control subjects and colorectal cancer, S1.62
post-operative strictures, endoscopic dilation, S3.40
secretion, induced by enteral feeding, short chain fatty acids reverse, S4.25
secretory effect in response to enteral feeding in man, S1.33
transit
abnormalities, IBS symptoms do not correlate with, S4.4
segmental, in patients with spinal cord lesions, objective evaluation, S4.11
tumours, microfilament associated proteins in stromal cells, S1.7
- Colonoscopy**
bowel preparation not sedation influences tolerance, S1.48
difficulties identified, S1.46
entox as medication, S4.40
technical difficulty predicted from previous barium enema, S4.39
- Colorectal cancer, S1.38-40, S3.14-15, S4.45-47**
all patients should be offered surgery, S4.38
aspirin and NSAIDs may protect against, S4.31
cell lines, differentiation, sialic acid and hepatic metastasis, S1.5
determinants of prognosis, population-based study, S4.10
hereditary non-polyposis, ploidy, K-ras and p53 expression, S4.10
identification and endoscopic screening of first degree relatives of patients, S4.18
risk in Crohn's disease, S4.65
- Colorectal carcinoma, S1.8**
CEA distribution, S4.67
detection by haemoquant and faecal alpha-1-antitrypsin, S4.68
E- and P-cadherin cell adhesion molecule expression, S4.67
radioimmunoscintigraphy, S4.66
- Colorectal disorders, S1.60-63, S4.9-11**
- Colorectal mucosa, vitamin D receptor mRNA expression, S1.8**
- Colorectal polyps, malignant, local excision, S1.30**
- Colorectal tumour cells, CEA is modulator of adhesion, S4.67**
- Colorectal/anorectal, S1.52-54**
- Columnar-lined oesophagus, effect of acid sensitivity on salivary response, S1.2**
- Common bile duct ligation, paradoxical up-regulation of cholesterol 7alpha-hydroxylase following, S3.3**
- Community acquired viral hepatitis B and C, US, S2.17**
- Computed tomography-planimetry, percentage hepatic replacement of colorectal liver metastases, S1.63**
- Conscious sedation and pharyngeal anaesthesia, usefulness in gastroscopy, S4.40**
- Constipation**
childbirth and hysterectomy, S1.25, S1.40
- chronic idiopathic, transit abnormality, audit, S4.13
postchildbirth/hysterectomy, colonic motility patterns, S4.3
- Coping capacity and psychological distress, in functional and organic gastrointestinal disease, S4.14**
- Copper excretion, liver, retrorsine ingestion prevents, neonate, S4.33**
- Corticosteroids**
effects on regenerative repair in gastric mucosa, rats, S4.50
regulation of Na⁺/K⁺ ATPase subunit gene expression in colon, modulation by 11beta-hydroxysteroid dehydrogenase, S3.36
- Cortisol, altered metabolism in alcoholic and non-alcoholic cirrhosis, S4.7**
- Cost-effectiveness of ESWL, conventional and laparoscopic cholecystectomy, S1.70**
- Coughing, precipitates acute variceal haemorrhage, S3.5**
- CR2093, inhibitory effects on GF stimulated growth of pancreatic cell line, S4.30**
- CR-2194 and CR-2017, new tools to differentiate between CCK-A and CCK-B/gastrin receptors *in vivo*, S3.21**
- Cricopharyngeal dysfunction, resulting in hoarseness? S4.65**
- Crohn's disease, S3.27, S4.52-53**
assessment by MRI, S4.47
and carcinoma of lower gastrointestinal tract, S1.39
childhood, role of cyclosporin A as initial therapy, S1.49
clinical aspects, upper GI tract, S4.62
colorectal cancer risk, S4.65
diffuse jeunoileitis management, prognosis and outcome, S1.66
enhanced IL-6 production reflects quantitative not qualitative differences in monocyte function, S1.12
familial IBD in relatives of patients, S4.9
granulomatous tissue, S4.57
inactive, energy imbalance in growing adolescents, S1.64
M. paratuberculosis DNA not detected by PCR, S4.57
platelet activation and volume, S4.63
relapses, lactose/mannitol test to predict, S1.61
and UC, compared, for colorectal cancer risk, S1.38
see also Inflammatory bowel disease
- Cryoglobulinaemia**
and HCV, S3.12
mixed, IFN alfa-2b, controlled crossover trial, S2.144
- Crypt cell proliferation, site and level in CD, immunohistochemical analysis, S4.23**
- Cryptosporidiosis, AIDS-related, jejunal water and electrolyte transport, S4.69**
- Cyclosporin, oral, for chronic active CD, S4.53**
- Cyclosporin A, role as initial therapy for childhood Crohn's disease, S1.49**
- Cytokines**
gene polymorphisms on chromosome 2, and UC, S4.29
immunoregulatory, and epithelial cell growth factor expression, by intestinal intraepithelial lymphocytes, S3.15
- peritoneal response to surgery, S4.37**
- production and antigen expression by colon cell lines, S4.26**
- Cytomegalovirus and EBV infection**
following liver transplantation, children, S4.32
impact in children following liver transplantation, S3.23
- Day surgery audit, S1.27**
- Defaecography, in IBS, S4.12**
- Dexamethasone, effect on mucosal IL-6 secretion, S1.24**
- Diabetes, reduced intestinal iron transfer, S4.58**
- Diabetes type I, long-standing, disorders of gastric emptying, when to reckon with such events? S3.29**
- Diagnosing viral hepatitis, problems, S2.36**
- Diagnostic markers of viral hepatitis B and C, S2.20**
- Diarrhoea**
acute, effect on anorectal physiology, healthy volunteers, S4.3
bacterial, increased incidence in patients taking gastric acid anti-secretory drugs, S4.54
of infancy, protracted, and antioxidant depletion, S4.25
and malnutrition, in a developing country, S4.60
- Diclofenac treated arthritic patients, ranitidine prevents peptic ulceration, S1.14**
- DNA**
adducts, and bile, in-vitro genotoxicity study, S1.7
aneuploidy, gastric, in development of gastric dysplasia, S4.52
quantification, cellular, gastric carcinogenesis, S1.9
- Dopamine, effect on gastric intramucosal pH, S1.13**
- Drug targeting indices, for antibody-cisplatin conjugates, estimation, S1.5**
- Drugs, S1.56-58**
- Duodenal bile acids, secondary, increased, in colorectal cancer, S1.39**
- Duodenal biliary bile acid profiles, ileostomy/intact colon compared, S4.40**
- Duodenal histology, ulceration, and *H. pylori*, and NSAIDs, S1.35**
- Duodenal mucosal damage, acid-induced, mechanism, S4.17**

- Duodenal mucosal protein synthesis**, measurement in normal subjects after delivery of leucine and valine, S1.33
- Duodenal ulcer**
diseases, omeprazole, different doses for preventing relapses, S4.43
H. pylori infection density, urease activity, and pathogenicity, S4.49 and non-ulcer patients, and *H. pylori*, S4.49
omeprazole in treatment and prevention of relapse, S3.1 and pantoprazole, and serum gastrin, S4.63
- Duodenogastric reflux**
and *H. pylori* colonisation of the intact stomach, S4.45 and phasic peristaltic activity, simultaneous measurement in human stomach, S4.13
- Duodenotomy**, for duodenal polyposis in FAP, outcome, S1.20
- Duodenum**, S4.16-17
- Duodenum/stomach**, S1.12-16
- Dyspepsia**
acute, presenting to an Accident and Emergency Department, open access endoscopy, S1.60
antioxidant and micronutrient intake, evidence for selenium deficiency, S4.59
detection of *H. pylori* in faecal samples from patients, S1.73
functional
 and fat tolerance, S1.58
 gastroparesis, acid secretion and *H. pylori* colonisation, S4.44
high and medium dose of dietary fats worsen postprandial antral hypomotility, S3.42
multicentre UK study, S3.2
non-ulcer, effect of duodenal lipid infusion on distension, S3.41
non-ulcer, versus organic disease, S3.2
organic and functional, symptoms, clinical distinction, S4.44
- E2/NS1 protein**, HCV, antibody, in chronic liver disease, S2.64
- E-Cadherin**, S4.67
 different expression in normal, metaplastic, and dysplastic oesophageal mucosa, a putative biomarker, S4.26
transfection into colon carcinoma cell line induces differentiation and inhibits growth *in vitro*, S4.27
- Ebrotidine** gastroprotection, associated enhanced mucus phospholipid secretion, S3.11
- Echodoppler**
examination of portal circulation after TIPS, S3.6
to assess octreotide induced renal changes, cirrhosis, S3.6
- Emesis**, postoperative, effects of ondansetron on symptoms and motor correlates, S4.4
- Endoscopy(ic)**, S1.29-30, S1.46-48, S1.50, S4.38-40
anterior gastropexy for gastro-oesophageal reflux disease, S1.17
Congo Red test predicts presence and topographical extent of gastric atrophy, S1.29
gastroplasty, and anterior gastropexy, for gastro-oesophageal reflux disease, S1.17
general, S3.39-40
injection therapy for bleeding peptic ulcer, S1.30
interventional, S3.33-34
probe, novel, in measurement of oesophageal variceal pressure, S4.20
retrograde cholangiopancreatography
 diagnostic and operative, after liver transplantation, S3.23
 following liver transplantation, S1.70
sphincterotomy
 early complications and 8 year follow-up, young fit patients, S4.34
 and laparoscopic cholecystectomy, impact on gallstone management, S4.34
ultrasonography, can it replace celiotomy in predicting stage and resectability of gastric carcinoma? S3.39
upper GI, inappropriate use, S1.27
- Endosonography**, anorectal, demonstrates unsuspected sphincter defects after anorectal surgery, S4.47
- Endotoxaemia**
in biliary obstruction, conclusive evidence, S4.56
and endogenous vasoactive systems, changes after colistin treatment in cirrhosis, S3.46
- Endotoxin-induced acute gastrointestinal injury**, involvement of endogenous vasopressin, rat, S4.61
- Energy imbalance** in growing adolescents with inactive Crohn's disease, S1.64
- Enteral feeding**
colon secretory effect in response, S1.33
early full strength, in VLBW infants, S3.8
effect on colonic motility, S1.64
- Enteral nutrition**
does not protect against biliary sludge in critically ill patients, S1.51
postoperative, and intestinal function, following liver transplantation, S1.65
- Enteral refeeding**, short-term, jejunal mucosal thickness increases after, S3.8
- Enterocyte-specific gene expression**, suppression in Peyer's patch-associated epithelium, S1.5
- Enterocyte villus-specific genes**, are they controlled by a common mechanism? S1.4
- Enteropathogenic *Escherichia coli*** diarrhoea, pathophysiology, new insights using Caco-2 cells, S4.56
- Enteroscope**, push type, for small bowel examination, diagnostic, therapeutic and practical advantages, S1.30
- Entonox** as medication for colonoscopy, S4.40
- Eosinophils**
counts in human liver allografts, S1.44
mucosal, activation is early step in indomethacin-induced small intestinal enteropathy, S1.71
- Epidermal growth factor**
1-48, effect on TNBS-induced colonic damage, S3.38
and insulin, influence on wound repair, gastric ulcer disease, S3.11
ontogenetic role in developing human stomach, S4.31
receptor
 autocrine loop, in chronic pancreatitis, S3.19
 and intestinal trefoil peptides pS2 and hSP, enhanced expression at edges of human gastric ulcers, S4.51
spasmolytic polypeptide, intestinal trefoil factor and TGF-alpha mRNAs, are expressed sequentially during healing of cryoprobe-induced gastric ulcers, rats, S4.50
and TGF-alpha, hepatocyte expression alteration, in chronic liver disease and hepatocellular carcinoma, S4.23
- Epstein-Barr related lymphoproliferative disorders** in pediatric liver transplant recipients, S3.23
- Epstein-Barr virus and CMV infection**
following liver transplantation, children, S4.32
impact in children following liver transplantation, S3.23
- Erythromycin**, in infants with intestinal dysmotility, S3.7
- Ethanol**
-induced gastric damage, chronic normovolemic anemia increases gastric mucosal blood flow and protects against, S3.10
and NO, effects on muscle strip tension in cat lower esophageal sphincter, S3.20
- Ethnicity**, and *H. pylori* infection, S1.37
- Exocrine pancreas**, isolated acinar cells, influence of TRH on amylase secretion, S3.18
- Exocrine pancreatic secretion**, development of regulatory mechanisms, S3.18
- Extracorporeal shock wave lithotripsy**
for bile duct calculi, using piezoelectric lithotripter, S1.68
and conventional and laparoscopic cholecystectomy, cost-effectiveness, S1.70
- Faecal incontinence**
anal endosonography, new gold standard in diagnosing sphincter defects, S1.26
competent anal sphincters? S3.25
scleroderma (systemic sclerosis) an unrecognised cause, S1.61
- Faecal occult blood screening**, for colorectal cancer, S4.45
- Faecal occult blood test**, for those at high risk for colorectal cancer, S1.61
- Familial adenomatous polyposis**
are biliary bile acids different? S4.9
duodenotomy for duodenal polyposis, outcome, S1.20
mutation analysis, S4.31
non penetrance and late appearance of polyps in families, S1.54
- Familial hyperpepsinogenemia I** is related to intrafamilial spreading of *H. pylori* infection, S1.3
- Fat**
dietary, high and medium doses further worsen postprandial antral hypomotility in dyspeptic patients, S3.42
flora, and fibre, S4.59
tolerance, in functional dyspepsia, S1.58
- Fatty acid absorption**, effect of small bowel autotransplantation, S4.42
- Fatty acid inhibition of *H. pylori* growth in vitro**, S4.69
- Fatty meals** provoke gastro-oesophageal reflux in healthy volunteers, S1.1
- Fedotozine**
in IBD, S3.30
sleep deprivation, gastric emptying and food intake, S3.30
- Fibre**
fat, and flora, S4.59
role in pathogenesis of IBS, S4.60
- Fibroblast growth factor**, basic, and TGF alpha, in gastric ulceration, S4.51
- Fibronectin** in human bile fluid, new parameter for diagnosis of malignant biliary tract obstructions, preliminary results, S3.29
- First degree relatives** of colorectal cancer patients, identification and endoscopic screening, S4.18

Fish oil

dietary, decreases rectal cell proliferation in young healthy volunteers, involvement of prostaglandins, S3.14
supplements reduce rectal epithelial cell proliferation in colon cancer risk, S1.39
see also N-3 and N-6 rich oils

Flexible sigmoidoscopy

and haemoccult, vs haemoccult alone, in colorectal cancer population screening, randomised trial, S1.40
is direct access worthwhile? S1.47

Flora, fat, and fibre, S4.59**Flow cytometry**, value for malignant change in Barrett's oesophagus, S1.19**Flumazenil**, effects on cognitive function in latent hepatic encephalopathy, S4.5**5-Fluorouracil**

and levamisole, adjuvant, effects on T-cell proliferation, S1.62
targeting to liver
evaluation of novel disaccharide adduct, S1.60
using novel disaccharide adduct, S3.4

Free radical activity, heightened, evidence in South African blacks with chronic pancreatitis, S4.2**Fucosidase and neuraminidase production by *H. pylori*, S1.31****Fundal gastric varices**, thrombin an effective treatment? S1.48**Gallbladder**

emptying
and CCK release, promotion by rapid intravenous amino acids, S3.32
early phase, relationship to gastric emptying, influence of atropine and octreotide, S4.4
impaired by inhibition of 5-HT re-uptake, S4.12
promotion by rapid intravenous administration of amino acids, S1.71
in response to normal meal in healthy subjects, effects of alcohol, S3.32

epithelium, bovine, reconstitution of single potassium channels, S1.68
filling, postprandial, and turnover rate, in health and gallstone disease, S4.1
inertia to bolus intravenous amino acids in patients receiving intravenous nutrition, S4.35
innervation, immunocytochemical characteristics, S4.35

Gallstone basket impaction, management at ERCP, S1.46**Gallstones**, probability of developing and related risk factors, in cirrhosis, S3.31**Gastrectomy**, radical, for gastric cancer, quality of life after, S1.15**Gastric alkaline shift**, in presence of gastro-oesophageal acid reflux, S1.12**Gastric cancer, S1.14-15, S4.15-16****Gastric carcinogenesis**, cellular DNA quantification, S1.9**Gastric carcinoma**, can EUS replace celiotomy in predicting stage and resectability? S3.39**Gastric disorders, S4.15-17****Gastric emptying**
disorders, in long-standing diabetes (type I), when to reckon with such events? S3.29
and food intake, effects of sleep deprivation, healthy volunteers, action of fedotozine, S3.30
and glycemic response to next meal, effect of starch digestion, S4.12
in preterm infant, breast is best, S4.32
and small intestinal motility, abnormalities, in spinal cord lesions, S1.58
of solid meals, is delayed in achalasic patients after successful pneumatic dilatation, S1.16
validation by echo planar MRI, S1.54**Gastric injury, S4.50-52****Gastric metaplasia** of duodenum, *H. pylori* eradication reduces, S4.50**Gastric motility**, postprandial, regulation, and NO, S1.54**Gastric mucosa**
and cancers, oestrogen receptor and oestrogen inducible gene expression, S4.30
long-term effect of *H. pylori*, S1.4**Gastric mucosal blood flow**, chronic normovolemic anemia increases, and protects against ethanol-induced gastric damage, S3.10**Gastric releasing peptide** in DU, exaggerated acid response resolves following *H. pylori* eradication, S4.49**Gastric releasing peptide receptor expression** on human gastric cancer cell lines, S1.15**Gastric ulceration**
antibacterial treatment, S3.48
healed, outcome following selective endoscopic follow-up, S4.38**Gastrin**
and growth of gastrointestinal tract, S4.66
-mediated acid secretion, lowered by eradication of *H. pylori* infection, S1.35

receptors, on gastrointestinal tumours, detection using anti-gastrin receptor monoclonal antibody, 2CL, S4.68
release from cultured G-cells, S1.3
releasing peptide, for acid secretion-reproducibility data, S1.13
serum, and pantoprazole, S4.63
serum levels, and omeprazole, S1.13

Gastritis

chronic, alpha-tocopherol antioxidant levels, S1.34
endoscopic, Sydney classification, histological assessment, S1.29
H. pylori, antral nodularity a macroscopic marker, S1.35
H. pylori associated, cell proliferation, S1.3

Gastro-entero-pancreatic tumors, single and non invasive scintigraphic procedure to localize, S3.19**Gastro-oesophageal acid reflux**

gastric alkaline shift, S1.12
precipitating events, ambulant subjects, S3.1

Gastro-oesophageal reflux

provoked by fatty meals in healthy volunteers, S1.1
response to omeprazole, S1.17

Gastro-oesophageal reflux disease

anxiety and social support, S1.17
endoscopic gastroplasty and anterior gastropexy, S1.17
psychosocial factors influence acid sensitivity, S1.18

Gastrointestinal Bleeding Unit

Grampian region, impact, S1.60
open-access, prior use of aspirin, NSAIDs and ulcer healing drugs, S4.39

Gastrointestinal disease

chronic, effect on IGF-1, S1.65
functional and organic, psychological distress and coping capacity, S4.14

Gastrointestinal haemorrhage, acute, in anticoagulated patients, diagnosis and response to endoscopic therapy, S1.46**Gastrointestinal motility, S4.3-4****Gastrointestinal tract and IBD**, HHV-6 DNA, S4.70**Gastroparesis**, acid secretion and *H. pylori* colonisation in functional dyspepsia, S4.44**Gastroscopy**, usefulness of conscious sedation and pharyngeal anaesthesia, S4.40**Gene therapy**, gut, S4.27**Genetic linkage analysis**, in study of HLA region in IBD, S1.11**Giant gastric ulcer, S4.16****Giardia lamblia**

stool positivity and serum immunoreactivity, children, S4.32
strain-dependent variation in disaccharidase expression during experimental infection, S1.72

Giardia trophozoites, increasing ornithine decarboxylase activity in enterocyte-like cultured cells, S1.72**Giardiasis**, antibody response and parasite virulence, relationship between, S4.69**Glucocorticoids**, and prostaglandins, in regulation of Kupffer cell-derived 95kD type IV collagenase/gelatinase, S4.8**Glucose transport** into villus-attached enterocytes, postnatal inhibition, S1.6**Glucose in vitro**, *H. pylori* synthesis of fatty acids from, S4.17**Glutamine release**, skeletal muscle, following surgery in bile duct ligated rat, prevention by cholestyramine pretreatment, S3.8**Glycemic response to next meal**, and gastric emptying, effect of starch digestion, S4.12**Glyceryl trinitrate**, beneficial effect in diffuse esophageal spasm, S3.42**Glycosylation**, IgG, abnormal, in CD and UC, S4.61**Glycosyltransferases**, hepatic and intestinal expression, S1.9**Goseki grading system** in survival prediction, gastric cancer, S1.14**Graft function**, indocyanine green clearance an early predictor, S4.22**Granulomas**, rapid localisation in CD, S4.28**Granulomatous tissue**, in Crohn's disease, S4.57**Growth factors**

epidermal, *see* Epidermal growth factor

fibroblast, *see* Fibroblast growth factor

hepatocyte, *see* Hepatocyte growth factor

mucosal receptor expression and gastroprotective activity, S3.11

Growth response of colonic carcinoma to oestrogen, S1.8**Gut translocation**

prevalence in general surgical patients, S1.72

TPN does not predispose to, S1.64

H₂ antagonist treatment, long term, for *H. pylori* infection, S1.37**H₂-receptor antagonist treatment**, high dose, loss of acid suppression occurs within two days, S3.1**Haematemesis**, centralised unit is part of 'state of the art' management, S4.55**Haemophilias**

with chronic hepatitis C, long-term treatment with IFN alfa-2b, S2.124

IFN alfa-2b for chronic hepatitis C, S2.121

Haemodynamic changes, in liver failure, and NO, S4.20

- Hartmann's procedure**, restoration of intestinal continuity following, S4.36
- Helicobacter pylori***, S4.49-50
associated gastritis, increased epithelial and vascular components of inflammation, S4.42
colonization of intact stomach, and duodenogastric reflux, S4.45
colonization, gastric, decreased lamina propria lymphocyte responses, S1.31
detection in faecal samples from patients with dyspepsia, S1.73
effects on acid-catalysed N-nitrosation in gastric juice, S4.30
eradication
non absorbable bismuth is as effective as De-Nol, S4.45
triple therapy is better than double, S4.45
eradication reduces possibility of rebleeding in peptic ulcer disease, S3.1
growth in vitro, fatty acid inhibition, S4.69
high levels of IgG to, endoscopic findings, S3.2
and IL-6, LTB, and PGE₂ production by monocytes, S3.42
infection
and dental care, S4.70
long term risk of peptic ulcer disease, S1.72
inhibition of growth in-vitro by fatty acids and bile acids, S3.21
and oxygen free radicals, in antral mucosal biopsies, S1.73
possible role of serological screening in reducing endoscopy, S4.17
production of neuraminidase and fucosidase, S1.31
risk factor for cancer, effects of treatment, S3.42
serological response by IEF in gastric carcinoma and dyspepsia, S4.66
stomach/duodenum, S1.3-4, S1.34-37
synthesis of fatty acids from glucose in vitro, S4.17
- Hemodynamic characteristics** of hepatocellular carcinoma observed with Doppler sonography, S3.44
- Hemodynamic events** in peritoneal environment during pneumoperitoneum, dogs, S3.17
- Henoch-Schonlein purpura**, purpuric and prepurpuric, skin biopsy, S3.7
- Heparinoids** stimulate intestinal epithelium proliferation in vitro, mechanisms of action, S1.7
- Hepatectomy**, partial, cell proliferation after, S3.45
- Hepatic 31P magnetic resonance spectroscopy**, in alcoholic liver disease, S1.45
- Hepatic encephalopathy**
acute, lactitol versus vancomycin, S3.46
chronic, oral sodium benzoate, S3.43
latent, effects of flumazenil of cognitive function, S4.5
- Hepatic function**, flow and shunting, measurement, S4.20
- Hepatic metastases**
5-FU targeting to liver, S1.60
percentage hepatic replacement, CT-planimetry, S1.63
- Hepatic metastasis**, sialic acid, and differentiation, colorectal cancer cell lines, S1.5
- Hepatic resection** for colorectal metastases, regional review, S4.55
- Hepatic stimulator substance**, and carbon tetrachloride, stimulate oncogene expression, rat liver, S3.4
- Hepatic VX-2 carcinoma**, selective tumor ablation by high intensity ultrasound, rabbits, S3.45
- Hepatitis**
acute non-A, non-B, IFN alfa-2b treatment, S2.130
chronic
in haemophiliacs, long term treatment with IFN alfa-2b, S2.124
safety of lamivudine, dose ranging study, S4.5
post-transfusion, HCV markers, IFN alfa-2b treatment, S2.62
- Hepatitis A infection**
IgM and IgA detection in saliva, S1.71
nurses' risk, S1.43
- Hepatitis B**
chronic
in anti-HIV positive patients receiving zidovudine, IFN alfa-2b, S2.106
high dose IFN alfa-2b with/without prednisone, S2.91
historical treatment, S2.69
IFN alfa-2b therapy, children, S2.87
low dose IFN alfa-2b, Asian countries, S2.99
low dose IFN alfa-2b treatment, S2.97
chronic active
effects of IFN alfa-2b, S2.101
IFN alfa-2b, effect of six month treatment regimen, S2.102
community acquired, United States, S2.17
and the delta agent, virological and serological aspects, S2.1
diagnostic markers, S2.20
and HDV genomes, hepatic expression after liver transplantation, S4.22
IFN alfa-2b for decompensated liver disease caused by, S2.104
infection, control, progress through immunisation, S2.10
interferon
is there a role? S2.77
US experience, S2.95
- PBMC DNA**, S4.8
recurrence after liver transplantation, role of TNF-alpha, S4.5
short vaccination schedule, S4.68
transmission and natural history, S2.48
treatment algorithms, S2.148
vaccination for all health care workers but not for doctors? S1.59
viral markers, S2.26
- Hepatitis C**
acute, IFN alfa-2b, after transfusion, multicentre randomised controlled trial, S2.141
antibodies
in chronic liver disease, ELISA and RIBA HCV strip immunoblot assay results, S2.61
seroprevalence in pregnant women, France, S2.55
antibody positive blood donors, S2.54
asymptomatic anti-HCV positive subjects, characteristics, S3.12
asymptomatic blood donors, screening, S1.44
chronic
in beta-thalassaemia, IFN alfa-2b treatment, S2.142
in haemophiliacs, IFN alfa-2b, S2.121
historical treatment, S2.69
IFN alfa-2b
clinical and histological evaluation, S2.127
efficacy of different regimens, S2.135
high dose treatment, S2.114
nine months treatment, S2.136
response related factors, S2.139
standard v high dose treatment, Benelux Multicentre Trial, S2.119
and TGF beta-1, S2.146
IFN alfa-2b treatment, S2.126, 128
HCV RNA and liver histology, S2.133
United States, S2.109
chronic active, IFN alfa-2b treatment, S2.112
chronic post-transfusion, lymphoblastoid IFN, 12 months treatment, final report, S3.49
community acquired, United States, S2.17
and cryoglobulinemia, S3.12
culture by Chang cells, S3.12
demonstration in fixed liver tissue with anti double-stranded RNA, S1.45
detection of HCV-RNA in saliva, S2.59
diagnostic markers, S2.20
E2/NS1 protein antibody, in chronic liver disease, S2.64
IFN alfa-2b for decompensated liver disease caused by, S2.104
IFN treatment, S3.13
infection
after liver transplantation, analysis through PCR, S3.22
can mimic type 1 (anticellular antibody positive) autoimmune chronic active hepatitis, S2.66
epidemiology and long term prognosis, Japan, S2.13
and HLA-DR5 allele protection from liver disease, S3.45
in liver transplant recipients, S3.23
renal transplant patients, Greece, S2.57
interferon, is there a role? S2.77
in LKM-1 antibody positive patients, S3.12
looking at a virus that hasn't been seen, S2.6
predominant etiologic role over HBV, in hepatocellular carcinoma, elderly patients, S3.13
recurrence, predictive factors, after alfa IFN treatment, S3.13
treatment algorithms, S2.148
vertical transmission, detected by HCV-RNA analysis, S2.52
viral antibodies, prevalence in general population and selected groups, Limoges, France, S2.50
viral markers, S2.26
- Hepatitis D**, virological and serological aspects, S2.1
- Hepatitis delta virus genomes**, and HBV, hepatic expression after liver transplantation, S4.22
- Hepatitis E**, evidence against intrafamilial transmission, S3.13
- Hepatocellular carcinoma**
and cirrhosis, S4.6
hemodynamic characteristics observed with Doppler sonography, S3.44
liver transplantation, S1.42
orthotopic liver transplantation, S4.21
p53, and correlation to PCNA and HBsAg expression, S3.44
predominant etiologic role of HCV over HBV, elderly patients, S3.13
primary, in PBS, S3.44
transcatheter arterial chemoembolization, S1.42
- Hepatocellular proliferation**, TNF-alpha, and inflammation, in primary biliary cirrhosis, S4.6
- Hepatocyte growth factor**, in human fetal development, S1.33
- Hepatocyte mitochondria**
effect of bile acid structure, S1.22
effect of bile acids, S3.45
- Hepatocyte organelles**, do hydrophobic bile acids damage? S4.7

- Hepatocytes**
 biochemical and 31P-NMR spectroscopic evaluation, S3.4
 influence of taurouridine kinase on DNA synthesis, rat, S3.4
 transplantation, hepatic reconstitution, for gene therapy and liver repopulation, S3.3
- Hepatology**, case studies, S2.81
- Hepatoscintigraphy**, dynamic, in health and chronic liver disease, S1.45
- Hereditary non polyposis colorectal cancer**, diagnosis, vertical transmission of tumors as major independent predictor, S4.31
- Herpesvirus 6 DNA** in gastrointestinal tract and IBD, S4.70
- Highly selective vagotomy**, postoperative symptoms heralding ulcer recurrence, S4.43
- Hirschsprung's disease**
 and aganglionosis, S4.12
 NADPH-diaphorase and neural cell adhesion molecule expression, S1.41
- HIV**
 and chronic active viral hepatitis, zidovudine plus IFN alfa-2b treatment, S2.107
 infected patients, ileal function, comparison with ileal Crohn's disease, S1.73
 related cholangiopathy, biliary tree abnormalities, S4.34
- HLA region** in IBD, study by genetic linkage analysis, S1.11
- Hoarseness**, resulting from cricopharyngeal dysfunction? S4.65
- HT-29 cells**, protecting from injury when exposed to hydrogen peroxide, S1.9
- Hydrocarbon exposure**, and chronic pancreatitis, S1.28
- Hydrogen peroxide**, and IL-1beta, effect on distal colonic smooth muscle function, guinea pig, S4.13
- 5-Hydroxytryptamine**
 assessment of central function in IBS, S1.56
 -like receptors, human colon, subserve relaxation, S3.35
 re-uptake inhibition impairs gallbladder emptying, S4.12
- Hyperamylasemia** induced by endoscopic papillosphincterotomy, prevention, S3.40
- Hypergastrinemia**, long standing, mitogenic but not tumorigenic effect on colonic mucosa, S3.15
- Hypertrophic pyloric stenosis**, NCAM, NO synthase and neurofilament protein expression, S1.16
- Hyposplenism**, functional, in alcoholic liver disease, S4.5
- Hypothalamo-pituitary-adrenal axis**, prednisolone metasulphobenzene foam enemas suppress, S4.53
- Hypovolaemia** and reperfusion in portal hypertension, S3.6
- Hypoxia**, in liver cirrhosis, role of arteriovenous shunting, S3.46
- Idiopathic megarectum and megacolon**, first description of pathology, S4.48
- Ileal break**, on motility and secretion, peptides as mediators, S3.48
- Ileal function** in HIV infected patients, comparison with ileal Crohn's disease, S1.73
- Ileoanal pouch surgery**
 crypt cell proliferation rate, S3.17
 postprandial bile levels, S3.17
 results in patients over 50 years, S3.16
- Ileorectal anastomosis**, for UC, absorption of 5-ASA, S3.9
- Ileostomy** closure, ileo-anal pouch prior to, and prediction of stool frequency, S1.62
- Ileostomy/intact colon** compared, duodenal biliary bile acid profile, S4.40
- Immunisation**, progress on control of hepatitis B infection, S2.10
- Immunglobulin**
 alterations in mucosal response, IBD, S1.10
 high levels to *H. pylori*, endoscopic findings, S3.2
 salivary assay to detect *H. pylori* infection, S1.36
 high levels to *H. pylori* and PGI, blood donors, S1.47
 in saliva, hepatitis A infection, S1.71
- Immunology**, S1.30-31
- Immunology and pathophysiology**, S3.37-38
- Immunosuppression**
 FK 506, after liver transplantation, course of IBD, S3.26
 following major liver resection, S3.22
- Indocyanine green** clearance, early predictor of graft function, S4.22
- Indomethacin-induced**
 caecal diaphragms, in a chronic NSAID study, S1.49
 changes, endoscopic and histologic, experimental gastric ulcer healing, S3.10
 small intestinal enteropathy, activation of mucosal eosinophils is an early step, S1.71
 ulceration, and secondary mycobacterial granulomatous inflammation, in rat caecum, S4.57
- Infection**, S1.71-73, S4.56-57, S4.68-70
- Inferior vena caval bypass** during OLT, effect on renal function, S4.22
- Inflammation**, S1.49-50, S4.60-63
- Inflammatory bowel disease**, S1.10-12, 23-24, 49-50, S3.26-27, 37, S4.27-29, 52-53, 61-63
 accurate assessment using 1 hour Tc99m HMPAO white cell scanning, S1.62
 activity, quantitation using SPECT, S1.49
 and adherent gel layer, colonic mucus, S3.9
 discrimination against patients by insurance companies, S4.14
 disinterest in local self help groups, S1.59
 experimental, L-arginine exacerbates inflammatory response, S4.60
 familial, in relatives of patients with Crohn's disease, S4.9
 fedotuzine, S3.30
 genetic polymorphisms of TNF-alpha and IL-1beta, S1.71
 HHV-6 DNA in gastrointestinal tract, S4.70
 quality of life, morbidity may be greatly underestimated, S4.56
 quantitation of activity using Tc99m HMPAO SPECT, S3.9
 what doctors need to know about their patients, S4.56
- Injection sclerotherapy**, S1.22-23
- Insulin**, and epidermal growth factor, influence on wound repair, gastric ulcer disease, S3.11
- Insulin like growth factor**, is it affected by chronic gastrointestinal disease or the acute phase response? S1.65
- Insurance companies**, discrimination against patients with IBD, S4.14
- Integrin alpha2beta1** controls morphological differentiation of colorectal rumour cells in vivo and in vitro, S3.14
- Integrins**, role in oesophageal epithelium, S1.9
- Intercellular adhesion molecule-1**
 and -2, expression in liver disease, S3.47
 effects of IFN-gamma and TNF-alpha, S1.31
 increased serum levels in UC, S3.26
- Interferon**
 clinical use, biological basis, S2.74
 for hepatitis B, US experience, S2.95
 is there a role in acute viral hepatitis? S2.77
 lymphoblastoid, for chronic post-transfusion hepatitis type C, 12 months treatment, final report, S3.49
- Interferon alfa-2b**
 for acute non-A, non-B hepatitis, S2.130
 for chronic active hepatitis B, effect of six month treatment regimen, S2.102
 for chronic active hepatitis C, S2.112
 in chronic hepatitis B, children, S2.87
 for chronic hepatitis B in anti-HIV positive patients receiving zidovudine, S2.106
 for chronic hepatitis C, S2.128
 after transfusion, multicentre randomised controlled trial, S2.141
 in beta-thalassaemia, S2.142
 clinical and histological evaluation, S2.127
 efficacy of different regimens, S2.135
 in haemophiliacs, S2.121
 HCV RNA and liver histology, S2.133
 nine months treatment, S2.136
 response related factors, S2.139
 and TGF beta-1, S2.146
 United States, S2.109
 in chronic non-A, non-B/type C hepatitis, S2.1126
 for decompensated liver disease caused by either chronic hepatitis B or C, S2.104
 effects on chronic active hepatitis B, S2.101
 high dose
 for chronic hepatitis C, S2.114
 with/without prednisone, chronic hepatitis B, S2.91
 low dose
 in chronic hepatitis B, S2.97
 Asian countries, S2.99
 in mixed cryoglobulinaemia, controlled crossover trial, S2.144
 plus zidovudine, in HIV and chronic active viral hepatitis, S2.107
 standard v high dose treatment for chronic hepatitis C, Benelux Multicentre Trial, S2.119
 treated post-transfusion hepatitis, HCV markers, S2.62
- Interferon-alfa** treatment, HCV recurrence, predictive factors, S3.13
- Interferon-gamma**
 5-ASA inhibits impaired epithelial barrier function induced by, S4.67
 mRNA, detection in mucosa of patients with CD, by ISH, S4.24
 and TNF, effects on ICAM-1, S1.31
- Interferon** treatment for HCV, S3.13
- Interleukin-1beta**
 and hydrogen peroxide, effect on distal colonic smooth muscle function, guinea pig, S4.13
 and TNF-alpha, genetic polymorphisms, in IBD, S1.71
 inhibition of pentagastrin-stimulated gastric acid secretion, NO generation modulates, rat, S3.11
- Interleukin-2**
 123I, in imaging of bowel lymphocytic infiltration in CD, S4.24
 receptor expression, on circulating lymphocytes in alcoholic liver disease, demonstration using flow cytometry, S4.8

- Interleukin-6**
enhanced production in Crohn's disease reflects quantitative not qualitative differences in monocyte function, S1.12
is prognostic indicator or mortality in severe intra-abdominal sepsis, S1.31
modulates suppressive effect of IL-1 on neurotransmitter release from rat myenteric plexus, S3.35
mucosal secretion, in response to T cell stimulation, in UC and controls, S1.12
-receptor mRNA, in rat liver Kupffer cells, S3.3
secretion by colonic mucosa, modulatory effects of anti-inflammatory drugs, S1.24
and TNF-alpha, in CD mucosa, detected by immunohistochemistry and ISH, S4.24
- Interleukin-8**, immunologically and biologically active, secretion by gastric epithelial cell line, S4.15
- Intestinal diseases**, functional and organic, quality of life, S4.14
- Intestinal dysmotility**, erythromycin, infants, S3.7
- Intestinal function** at altitudes above 5000m, S4.42
- Intestinal motility**, intraluminal electric impedance measurement, S3.30
- Intestinal permeability** increases in normal volunteers receiving TPN, S3.29
- Intestinal pseudo-obstruction**, chronic, determinants of response to cisapride, adults, S3.30
- Intestinal transit**, women slower than men, S4.3
- Intestinal trefoil factor (peptide)**
human homologue, S4.41
pS2 and hSP, and EGF receptor, enhanced expression at edges of human gastric ulcers, S4.51
spasmolytic polypeptide, EGF and TGF-alpha mRNAs, are expressed sequentially during healing of cryoprobe-induced gastric ulcers, rats, S4.50
- Intraluminal electric impedance measurement** for intestinal motility investigation, S3.30
- Intravenous nutrition**, impaired splenic function with intestinal failure, S1.33
- Iron transfer**, intestinal, reduced, in diabetes, S4.58
- Irritable bowel syndrome**, S1.55-56
defaecography, S4.12
effect of antidepressants on symptoms, S1.58
role of fibre in pathogenesis, S4.60
symptoms do not correlate with colonic transit abnormalities, S4.4
- Irritable oesophagus**, demonstration, S4.18
- Isosorbide-5-mononitrate**, 10 mg and 40 mg, acute and chronic action on azygos blood flow and portal pressure, alcoholic cirrhosis, S4.20
- Japan**, hepatitis C virus infection, epidemiology and long term prognosis, S2.13
- Jaundice**, obstructive, promotes bacterial translocation, S1.69
- Jejunal mucosal thickness** decreases in normal volunteers receiving TPN and increases after short-term enteral refeeding, S3.8
- Jejunal water** and electrolyte transport in AIDS-related cryptosporidiosis, S4.69
- Jejunoileitis**, and Crohn's disease, management, prognosis and outcome, S1.66
- Kate's video diary**, a patient's perspective of endoscopy, S1.50
- Ketotifen**, decreases capsaicin amplified acetic acid induced colonic damage, S3.38
- Klatskin tumours**, aggressive surgical management, results, S4.33
- Kupffer cell**
-derived 95kD type IV collagenase/gelatinase, regulation by glucocorticoids and prostaglandins, S4.8
function in obstructive jaundice, biliary decompression restores, S4.8
IL-6-receptor mRNA, rat liver, S3.3
- L-arginine**
does it induce intestinal water secretion through formation of NO? S4.60
exacerbates inflammatory response in experimental IBD, S4.60
- Lactase**, intestinal persistence, S1.32
- Lactitol** versus vancomycin in treatment of acute hepatic encephalopathy, S3.46
- Lactoferrin**, selective release from IBD mucosa, S4.28
- Lactose/mannitol test**, to predict Crohn's disease relapses, S1.61
- Lamina propria lymphocyte**, decreased responses to *H. pylori*, S1.31
- Lamivudine**, dose ranging study, and safety in chronic hepatitis, S4.5
- Lanreotide**, slow release, in carcinoid syndrome, S3.36
- Laparoscopic cholecystectomy**
conversions and complications, S4.37
and endoscopic sphincterotomy, impact on gallstone management, S4.34
ERCP following, S4.39
- and ESWL, cost-effectiveness compared, S1.70
iatrogenic bile duct injury complicating, S4.34
influence of obesity on operative difficulty and postoperative complications, S4.37
intravenous cholangiography in preoperative assessment, S4.36
and mini-cholecystectomy comparison of cost, S1.68
return to normal activity after, S1.68
peroperative cholangiography through gall bladder during, S4.33
prior assessment of bile duct, S1.67
prospective audit, west of Scotland, S1.69
relationship to endoscopic bile duct stone removal, S1.67
- Laparoscopic Nissen fundoplication**, S3.16, S4.37
- Laparoscopic surgery**, and open surgery compared, S3.16
- Laparoscopy and laparoscopic ultrasonography**
in evaluation of pancreatic carcinoma, S1.29
in superior staging of liver tumours, S1.43
- Large bowel perforation** in war surgery, one stage treatment in a field hospital, S1.20
- Laxative** effect of bran on small bowel transit, due to its particulate nature? S4.3
- Levamisole**, and 5-FU, adjuvant, effects on T-cell proliferation, S1.62
- Lipiodol**, retention by and effect on liver tumour cells, S4.6
- Lipopolysaccharide**, bacterial, stimulates IL-8 secretion by human colonic epithelial cells, S3.38
- Lithostatin**, expression in pancreatitis, S4.2
- Liver**, S1.21-23, S1.42-45, S3.43-44, S4.5-8
basic, S3.3-4
biopsy
bleeding time, an unpredictable event, S1.47
day case, are they undervalued, S4.58
ultrasound assisted ambulatory percutaneous, S3.43
cancer, S4.21-23
disease
childhood, measuring ranitidine requirements using gastrojet infusion, S3.7
chronic
HCV antibodies, ELISA and RIBA HCV strip immunoblot assay results, S2.61
HCV E2/NS1 protein antibody, S2.64
expression of ICAM-1 and -2, S3.47
failure, haemodynamic changes, and NO, S4.20
injury, following HBV recurrence after liver transplantation, major role for TNF-alpha, S4.5
metastases, colorectal, allele loss and its association with clinical features, S1.8
perfused, regenerating, effect of bile acids on DNA synthesis, S3.47
transplantation, S1.42, 44, S3.22-23, S4.21-23
ERCP following, S1.70
FK 506 immunosuppression after, course of IBD, S3.26
intestinal function and postoperative enteral nutrition following, S1.65
orthotopic, influence on skeleton of patients with chronic liver disease, S3.48
tumour cells, retention and effect of lipiodol, S4.6
tumours, primary, and liver transplantation, S1.44
- Lower gastrointestinal tract**, S3.24-25, S3.35-36
- Lower oesophageal sphincter**
pressure vector volumes correlate with type and severity of acid reflux, S3.41
relaxations, and acid reflux, under ambulant conditions, S1.1
- Luminal bacteria** play a key role in progression of experimental colitis to chronicity, S3.38
- Lymph node micrometastases**, incidence and prognostic significance in Dukes' B colorectal cancer, S4.47
- Lymphocytic gastritis**, and coeliac disease, children, S3.7
- M2 autoantibodies**, PBC specific, in recurrent UTI, using ELISA and purified pyruvate dehydrogenase, S1.30
- Magnetic resonance imaging**, Crohn's disease assessment, S4.47
- Malnutrition**, and diarrhoea, in a developing country, S4.60
- Markers**, prognostic, in pancreatitis, S1.28
- Mast cell distribution** and tumour cell proliferation in colonic carcinoma, S1.5
- Mast cells**, role in pathophysiology of obstructive jaundice, S4.33
- Medium-chain triglycerides** in pancreatic insufficiency, S1.66
- Megacolon**, toxic, in chronic UC is associated with induction of NO synthase, S3.26
- Melaena**, centralised unit is part of 'state of the art' management, S4.55
- Membrane vesicles**, luminal and basolateral, colon, isolation and characterization, S1.6
- Mesalazine**
serum and urinary acetylated and unacetylated 5ASA compared, S1.11
in UC, S1.11

- Mesenchymal interactions**, in intestinal epithelial proliferation in vitro, S1.7
- Microalbuminuria**, marker for IBD, S1.24
- Microfilament associated proteins** in stromal cells of colon tumours, S1.7
- Micronutrient antioxidant status** in controls and in chronic pancreatitis, S4.2
- Microsporidia**, second species causes diarrhoea in AIDS, eliminated by albendazole, S1.73
- Microvascular injury**, intestinal, endotoxin-induced, dual action of NO synthase inhibitor, rat, S4.28
- Migrating motor complex**, intestinal, intensity predicts colonization with Gram negative bacilli in proximal small intestine, S3.25
- Misoprostol**, effect of long term co-administration with NSAIDs, S4.44
- Molecular and cell biology**, S4.26-27
- Monoclonal antibodies**, disease-specific, use to clone cDNAs upregulated in IBD including the complement regulatory protein DAF, S4.27
- Monocyte function**, enhanced IL-6 production in Crohn's disease reflects quantitative not qualitative differences, S1.12
- Mononuclear cells**, release gastrin from cultured G-cells, S1.3
- Morphometric image analysis** and eosinophil counts in human liver allografts, S1.44
- Motility**, S1.54-56, 58-59, S4.11-14
disturbances, in oesophageal cancer, S4.65
gastrointestinal, S4.3-4
oesophageal, normal, S1.1
- Motor neuron disease**, pharyngo-oesophageal pressure profile, analysis, S3.41
- Mucin synthesis**, and epithelial metabolism, in UC and controls, S4.28
- Mucinase**, total, assay, in IBD, S4.61
- Muscarinic receptor inhibitor**, M3, selective inhibition of post-prandial small bowel motility, S1.55
- Mutation analysis** in familial adenomatous polyposis, S4.31
- Mycobacterial protoplasts or spheroplasts** as possible cause of Crohn's disease, S2.27
- Mycobacterium paratuberculosis**
absence, but presence of *M. avium*, in CD, PCR, S4.29
DNA analysis using PCR, S3.10
associated with granulomatous tissue in Crohn's disease, S4.57
not detected by PCR in Crohn's disease tissue, S4.57
- Myenteric neuropathy**, experimental, relationships between neuron number and distension responses following, S1.55
- N-3 fats** reduce experimental colorectal tumourigenesis including perianastomotic tumours, S4.46
- N-3 and N-6 rich oils** compared, effect on inflammation in experimental colitis, rat, S1.10
- N-nitrosation**, acid-catalysed, in gastric juice, effect of *H. pylori*, S4.30
- N-Nitroso compounds**, levels in fresh gastric juice in relation to clinical diagnosis, S4.30
- Na⁺/H⁺ luminal exchange**, in bovine main pancreatic duct, S3.28
- Nadolol** does not improve results of sclerotherapy in prevention of variceal rebleeding, S3.5
- Nafamostat mesilate** promotes pancreatic regeneration after partial pancreatectomy, S3.28
- Near infrared reflectance analyzer**, in detection and quantification of output of faecal nutrients, S4.59
- Needle-knife papillotomy**, endoprosthesis guided, after Billroth II gastrectomy, new technique, S4.17
- Neoplasia**, S4.29-31, 65-68
- Neuraminidase and fucosidase production by *H. pylori***, S1.31
- Neutrophil adherence and mucosal injury induced by NSAIDs**, S3.20
- Nicotine**
effect on distal colon, S1.56
and its metabolite continine, action on distal human colon, S3.24
transdermal treatment for UC, S3.48
- Nissen fundoplication**, laparoscopic, S4.37
- Nitric oxide**
-inhibition and tetrodotoxin in reversion of reduction by endotoxin of pentagastrin-stimulated gastric acid secretion, S3.20
cytotoxic to cultured CACO-2 intestinal cells, S4.27
and diffuse esophageal spasm, S1.1
donor, topical application reduces internal anal sphincter tone, S1.25
donors, gastric mucosal injury provoked by, role of superoxide, S4.15
and ethanol, effects on muscle strip tension in cat lower esophageal sphincter, S3.20
generation modulates inhibition by IL-1beta of pentagastrin-stimulated gastric acid secretion, rat, S3.11
and haemodynamic changes in liver failure, S4.20
increased, in UC, sources, S4.10
and L-arginine induced intestinal water secretion, S4.60
producing neurons in mammalian pancreas, S3.18
and regulation of postprandial gastric motility, S1.54
- synthase**
distribution and action of neurones immunoreactive for, in human intestine, S1.54
- induction, toxic megacolon in chronic UC associated with, S3.26
- inhibition leads to severe bowel ischaemia and water secretion, S3.36
- inhibition in rat jejunum in vivo, S1.32
- inhibitor, dual action on endotoxin-induced intestinal microvascular injury, rat, S4.28
- synthesizing neurons in primate digestive system, distribution and targets of innervation, S3.35
- Non-steroidal anti-inflammatory drug(s)**
-induced neutrophil adherence and mucosal injury, S3.20
and aspirin use, risk of asymptomatic colorectal cancer, S1.52
duodenal histology, ulceration, and *H. pylori*, S1.35
effect of long term co-administration with misoprostol, S4.44
gastrointestinal side effects, S1.57
induced oesophagitis, S1.17
may protect against colorectal cancer, S4.31
and peptic ulcer haemorrhage, outcome, S1.47
prescribing by individual practices and upper gastrointestinal bleeding in their patients, S3.2
- prior use in upper gastrointestinal bleeding presenting to an open-access bleeding unit, S4.39
- and prostaglandin, effects on pepsinogen secretion by dispersed human peptic cells, S3.20
- Nurses**, risk of hepatitis A infection, S1.43
- Nutrition**, S4.58-60
- Nutritional status** in patients receiving home enteral feeding, S4.59
- Obesity**, influence on laparoscopic cholecystectomy and postoperative complications, S4.37
- Obstructive jaundice**
biliary decompression restores Kupffer cell function, S4.8
enteral cholestyramine prevents fall in renal blood flow following surgery, S3.17
impairs neutrophil response to bacterial wall products, S4.11
role of mast cells in pathophysiology, S4.33
with liver metastases, endoscopic stenting, S3.34
- Octreotide**
-induced renal changes, cirrhosis, Echodoppler to assess, S3.6
in control of post-injection sclerotherapy haemorrhage, S1.22
and gallbladder emptying, S4.4
increases proportions of arachidonic acid-rich phospholipids in gall-bladder bile, S3.32
inhibits high pressure waves in isolated perfused distal colon, S1.26
intravenous, in cirrhosis, systemic haemodynamic effects, S1.42
in reduction of liver tumour growth and blood flow, S1.42
- Oesophagogastric varices**, bleeding, combined use of a n-butyl-2 cyanoacrylate and ethanolamine oleate, S3.39
- Oesophagitis**
NSAID induced, S1.17
and reflux symptoms in self medicating patients, S1.2
- Oesophagus, oesophageal**, S1.1-2, 16-19, S4.63-65
cancer, motility disturbances, S4.65
EMG responses evoked by cortical stimulation, effect of swallowing and vagal stimulation, S4.14
epithelium, role of integrins, S1.9
irritable, demonstration, S4.18
metallic stents, preliminary report on 64 cases, S4.19
motility, normal, in response to eating, healthy volunteers, S3.29
mucosa, normal, metaplastic and dysplastic, differential expression of E-Cadherin, a putative biomarker, S4.26
spasm, diffuse, beneficial effect of glyceryl trinitrate, S3.42
stricture, prevention of recurrence, omeprazole and ranitidine compared, S4.19
variceal pressure, measurement using novel endoscopic probe, S4.20
varices, bleeding, variceal banding ligation and injection sclerotherapy compared, S1.22
- Oestrogen**, and growth response of colonic carcinoma, S1.8
- Oestrogen receptor** and oestrogen inducible genes are expressed in gastric mucosa and cancers, S4.30
- Olsalazine**, serum and urinary acetylated and unacetylated 5ASA compared, S1.11
- Olympus SIF 10**, in gastrointestinal disease, clinical evaluation, S1.65
- Omeprazole**
in Barrett's oesophagus, S1.19
different dosages for preventing relapses of duodenal ulcer diseases, S4.43
does not alter plasma gastrin in achlorhydria, S1.57
in DU and prevention of relapse, S3.1
and duodenal ulcer healing, effect on gastrin and pepsinogen A and C basal serum levels, S1.13
effect on gastric emptying, S4.64
in gastric ulcers, S3.48
and impairment of protein-bound cobalamin absorption, S1.14
in inhibitor of *H. pylori* urease, S1.34
inhibits azoxymethane-induced colorectal carcinogenesis, rats, S1.8

- and ranitidine compared, in prevention of recurrence of oesophageal stricture, S4.19
 reverses deleterious effects of indomethacin on experimental gastric ulcer healing, S3.21
- Oncogene expression**, hepatic stimulator substance and carbon tetrachloride stimulate, S3.4
- Ondansetron**
 effects on healthy or IBS subjects, S4.55
 effects on symptoms and motor correlates of postoperative emesis, S4.4
- Open access endoscopy** for acute dyspepsia presenting to an Accident and Emergency department, S1.60
- Opioid peptides**, basic gene expression, in gastrointestinal tract, S3.35
- Orad transport of refluxate**, and Barrett's segment length, S4.18
- Ornithine decarboxylase activity**
 in enterocyte-like cultured cells is increased by *Giardia* trophozoites, S1.72
 is increased in intestinal metaplasia of the gastric antrum, S4.51
- Osteopenia**, in adult CD, biochemical, dietary and anthropometric factors associated with, S4.24
- Oxygen**, mucosal perfusion, new endoscopic probe, preliminary findings, S3.39
- Oxygen derived free radicals**, the missing link in smoking and gastroduodenal disease? S4.62
- Oxygen free radicals**, and *H. pylori*, in antral mucosal biopsies, S1.73
- p53**
 expression in gastric cancer and its correlation with survival, S4.15
 in hepatocellular carcinoma, and correlation to PCNA and HBsAg expression, S3.44
 is detectable in non-neoplastic oesophagus, S1.16
 overexpression in relation to long-term prognosis in colorectal carcinoma, S3.15
- Paediatrics**, S4.31-33
- Pancreas, pancreatic**, S1.27-29, S1.67-71, S3.18-19, S3.28, S4.40-42
 cell line, inhibitory effects of CR2093 on GF stimulated growth, S4.30
 disease, S4.2
 elastase, in feces, new tubeless pancreatic function test, S3.18
 pseudocysts, endoscopic transpapillary drainage, S3.40
 tumors, diagnosis and differentiation by imaging, S3.19
- Pancreatitis**
 acute
 role of PAF, S4.41
 TNF in pancreatic acinar cells, S4.2
 chronic
 EGFR autocrine loop, S3.19
 evidence of heightened free radical activity, South African blacks, S4.2
 micronutrient antioxidant status, S4.2
 experimental, phospholipases-A2, S3.19
 expression of lithostatin, S4.2
 recurrent (non-gallstone), blood antioxidant profiles in relation to pancreatic morphology, S4.40
- Pantoprazole**, and serum gastrin, S4.63
- Papillosphincterotomy**, endoscopic, inducing hyperamylasemia, prevention, S3.40
- Paracetamol**, inhibitor of PGE2 release, and UC relapse, S4.63
- Paragastroesophageal mass lesions**, endoscopy for fine needle aspiration, S3.33
- Partial thoracic stomach patients**, review after twenty years, S1.18
- Patients**, understanding of CD, audit, S4.25
- PBC specific 2 autoantibodies** in recurrent UTI using ELISA and purified pyruvate dehydrogenase, S1.30
- Peanut eating** increases colonic epithelial proliferation, S4.68
- Pediatrics and nutrition**, S3.7-8
- Pelvic floor**, electrical stimulation and alteration of proctographic parameters, S1.25
- Pepsinogen** secretion by dispersed human peptic cells, effects of NSAIDs and prostaglandin, S3.20
- Pepsinogen serum levels**, and omeprazole, S1.13
- Peptic ulcer**
 bleeding
 endoscopic injection therapy, S1.30
 England and Wales, epidemiological trends, S4.43
 disease, long term risk in people with *H. pylori* infection, S1.72
 high Ig levels to *H. pylori* and PGI, blood donors, S1.47
- Peptides**, mediators of ileal break on motility and secretion, S3.48
- Percutaneous cholecystolithotomy**, risks, benefits and long-term outcome, S1.70
- Percutaneous endoscopic gastrostomy**
 for enteral nutrition in acute stroke, audit, S4.58
 tube feeding, children, S3.8
- Perianal fistula** activity, recurrence depends on fecal stream, S3.27
- Perineal rectosigmoidectomy** and abdominal resection rectopexy compared, S1.20
- Peritonitis**, does CO₂ pneumoperitoneum increase bacteraemia, S4.69
- Peyer's patch-associated epithelium**, suppression of enterocyte-specific gene expression, S1.5
- pH**
 antral and fundic surface mucosal, with/without *H. pylori* gastritis, S1.36
 gastric intramucosal, effect of dopamine, S1.13
 gastro-oesophageal acid reflux and gastric alkaline shift, S1.12
 intragastric, fall after postoperative bile vomiting, S4.36
 normal pharyngo-oesophageal profile, S1.18
- Pharyngo-oesophageal pressure profile**, in motor neuron disease, analysis, S3.41
- Phasic peristaltic activity**, and duodenogastric reflux, simultaneous measurement in human stomach, S4.13
- Phospholipases-A2**, in experimental pancreatitis, S3.19
- Phospholipid** secretion, mucus, enhanced, associated with ebrotidine gastroprotection, S3.11
- Photodynamic therapy**
 of colon cancer with 5-ALA, S1.52
 for villous adenomas of rectum and colon, S1.39
- Phytase activity**, small intestinal, S4.42
- Picotamide**, thromboxane synthesis/receptor antagonism, in IBD, S4.29
- Pie electric lithotripter**, for ES-L for bile duct stones, S1.68
- Platelet activating factor**, role in acute pancreatitis model, S4.41
- Platelet activation and volume** in Crohn's disease, S4.63
- Platelet derived growth factor** stimulates anion secretion in mammalian colon, S1.38
- Platelets**
 activated, GMP10 (CD62) and GP53 (CD63) expressing, increased number in IBD, S3.37
 activation in IBD, S1.50
 circulating, are activated in IBD, S1.50
 hyperaggregability in IBD, S1.23
- Pneumatic dilatation**, forceful, for achalasia of the cardia, usingitzel balloon method, S1.50
- Pneumatosis coli**, review of 25 cases, S1.60
- Pneumoperitoneum**
 CO₂, does it increase bacteraemia in peritonitis? S4.69
 hemodynamic events in peritoneal environment during, dogs, S3.17
- Polymerase chain reaction**
 after treatment with IFN alfa-2b in chronic hepatitis C in haemophiliacs, S2.124
 in detection of vertical transmission of HCV, S2.52
 to locate site for amoxycillin/cimetidine evasion in *H. pylori* infection, S1.36
 for viral hepatitis B and C diagnosis, S2.39
- Polymorphonuclear elastase**, new test in ascitic fluid infection, S3.46
- Polypeptide**, spasmolytic, intestinal trefoil factor, EGF and TGF-alpha mRNAs, are expressed sequentially during healing of cryoprobe-induced gastric ulcers, rats, S4.50
- Polyunsaturated fats**, high dietary, and vitamin E deficiency, compromise small intestinal function, S4.25
- Portal colopathy**, endoscopic, hemodynamic and histomorphometric study, S3.47
- Portal hypertension**, S3.5-6, S4.20-21
- Portal hypertensive gastropathy**
 and chronic gastritis are related to different pathogenic factors, S4.43
 effects of injection sclerotherapy on gastric emptying, S1.23
- Postchildbirth/hysterectomy constipation**
 anorectal manometry, S4.48
 colonic motility patterns, S4.3
- Postprandial colonic motility**, serotonergic control, S3.24
- Potassium channels**, from bovine gallbladder epithelium, reconstitution, S1.68
- Pouch**, ileo-anal, prior to ileostomy closure, prediction of stool frequency, S1.62
- Prednisolone metasulphobenzoate foam enemas** suppress HPA axis, S4.53
- Pregnant women**, anti-HCV seroprevalence, France, S2.55
- Pressure gradients**, and dehiscence of distal colonic anastomoses, S1.59
- Preterm infant**, gastric emptying, breast is best, S4.32
- Prevention and treatment of viral hepatitis**, role of screening, S2.45
- Primary biliary cirrhosis**
 hepatocellular proliferation, TNF-alpha, and inflammation, S4.6
 procollagen III propeptide levels and PGA index, S1.21
- Primary response protein TIS 11**, localisation, S1.4
- Primary sclerosing cholangitis**, effect of UDCA, S1.69
- Proctocolectomy**
 restorative, for UC
 long term results, S1.63
 longitudinal distribution of inflammatory changes in ileal reservoir after, S1.66
 totally stapled restorative, functional results outweigh putative risks, S1.26
 urgent restorative, as safe procedure in UC, S1.61
- Proliferating cell nuclear antigen**
 and BrdU immunohistochemistry, in proliferation analysis of preneoplastic colorectal mucosa, S3.14
 prediction of metachronous colonic adenomas? S1.53

- Proliferative patterns**, colonic, patients at risk of hereditary non polyposis colon cancer, S1.53
- Prostaglandins**
and glucocorticoids, in regulation of Kupffer cell-derived 95kD type IV collagenase/gelatinase, S4.8
and NSAIDs, effects on pepsinogen secretion by dispersed human peptic cells, S3.20
in regulation of pancreatic acini, S3.28
- Protein metabolism**, intestinal, in response to postoperative stress, S4.41
- PS2**, expression in normal and malignant pancreas, S1.29
- Psychiatric morbidity**, influence on self-appraisal of symptoms in IBS, S1.56
- Psychological distress** and coping capacity in functional and organic gastrointestinal disease, S4.14
- Push-enteroscope (Olympus SIF 10)**, in gastrointestinal disease, clinical evaluation, S1.65
- Quality of life**
in functional and organic intestinal diseases, S4.14
in IBD, morbidity may be greatly underestimated, S4.56
measurements in specialist undernutrition clinic, S4.26
- Radioimmunosintigraphy**, value in recurrent colorectal carcinoma diagnosis, S4.46
- Ranitidine**
measuring requirements in childhood liver disease using gastrojet infusion, S3.7
and omeprazole compared, in prevention of recurrence of oesophageal stricture, S4.19
in preventing peptic ulceration in arthritic patients receiving diclofenac, S1.14
in prophylaxis against stress ulcer disease, S1.14
ras mutations, detection in faecal materials from colorectal cancer patients, S1.53
- Reactive oxygen metabolites**, in IBD, S4.52
- Rebleeding**, reduction, and *H. pylori* eradication, S3.1
- Rectum, rectal**
adenomas, submucosal transanal resection, S1.21
cancer, survival, and involvement of circumferential margin of excision, S4.9
carcinoma, DXT and anterior resection, S1.20
dialysis, in detection of thromboxane inhibition, S1.24
impaired in patients with Crohn's disease, functional outcome after low anterior resection with colon pouch-anal anastomosis, S4.48
sensitivity, impaired in patients with Crohn's disease, S3.27
- Reflux**
acid, oesophageal manometric patterns preceding, ambulant subjects, S4.65
bile, oesophageal, gastric and oesophageal alkaline shifts do not predict, S4.64
long lasting acid, causes, S4.64
oesophageal, S1.1-2
primary peristalsis as major acid clearance mechanism, S4.64
- Renal blood flow**, enteral cholestyramine prevents fall following surgery in obstructive jaundice, S3.17
- Renal transplant patients**, HCV infection, Greece, S2.57
- Reperfusion** and hypovolaemia in portal hypertension, S3.6
- Restorative proctocolectomy**, and anal sphincter impairment, S4.11
- Resuscitation skills** in endoscopy staff, cause for concern? S1.48
- Retorsine** ingestion prevents neonate liver copper excretion, S4.33
- Saliva**, detection of HCV-RNA, S2.59
- Salivary response**, and acid sensitivity in columnar-lined oesophagus, S1.2
- Salvage surgery** for bile duct stones, outcome, S1.52
- Schistosomiasis** and alcoholic liver cirrhosis, circulating enzyme activities of collagen turnover and undulin, S3.44
- Scid** mouse xenograft model for human intestinal development and function, S4.32
- Scintigraphic defaecography**, the clinician's choice, S1.40
- Scintigraphy**, which type is best for IBD? S4.62
- Scleroderma (systemic sclerosis)**, an unrecognised cause of faecal incontinence, S1.61
- Sclerotherapy**
injection
for bleeding oesophageal varices, S1.22
or oesophageal staple transection, as emergency treatment of variceal bleeding, long term follow-up, S1.23
- post-injection haemorrhage, octreotide in control, S1.22
or TIPS, in variceal rebleeding, S3.5
variceal rebleeding, nadolol ineffective, S3.5
- Screening**, role in viral hepatitis prevention and treatment, S2.45
- Secretor status and coeliac disease**, S4.23
- Selenite** deficiency, and antioxidant and micronutrient intake in dyspepsia, S4.59
- Sepsis**, intra-abdominal, severe, IL-6 is prognostic indicator of mortality, S1.31
- Serine dependent proteinases**, negatively charged, significant increase in UC, S4.10
- Serotonergic control** of postprandial colonic motility, S3.24
- Short chain fatty acids**
reduce human longitudinal colonic motility in vitro, S4.13
reverse colonic secretion induced by enteral feeding, S4.25
- Sialic acid**, hepatic metastasis, and differentiation, colorectal cancer cell lines, S1.5
- Simvastatin**, 40 mg, plus UDCA 750 mg daily, for gallbladder stone dissolution, S4.35
- Skin biopsy** in purpuric and prepurpuric Henoch-Schonlein purpura, S3.7
- Sleep deprivation**, effects on gastric emptying and food intake, healthy volunteers, action of fedotozine, S3.30
- Small bowel**, S1.32-34, S4.40-42
autotransplantation, effect on fatty acid absorption, S4.42
disorders, nutrition, S1.63-66
examination with push type enteroscope, diagnostic, therapeutic and practical advantages, S1.30
motility, abnormal, IBS, S1.55
neomucosal generation by transplantation of stem cells, model, S1.34
proximal, sensory and motor responses to experimental distension, S1.55
stem cell transplantation in generation of neomucosa, S1.34
- Small intestine**
function, vitamin E deficiency and high dietary polyunsaturated fats compromise, S4.25
Gram negative bacilli, and migrating motor complex, S3.25
stem cell transplantation, temporal mucosal morphogenesis after, S4.41
- Smoking**
effect on distal colon, S1.56
and gastroduodenal disease, are oxygen derived free radicals the missing link? S4.62
- Smooth muscle function**, distal colon, effect of hydrogen peroxide and IL-1beta, S4.13
- Sodium benzoate**, oral, in chronic hepatic encephalopathy, S3.43
- Somatostatin**, for acute bleeding from portal hypertensive gastropathy and colopathy, S4.21
- Spermatogenic consequences** and teratogenic side effects of sulphasalazine in men, S4.62
- Sphincter damage**
during sphincterotomy, underestimated, S1.41
forceps/vacuum delivery, S1.41
mucosal and internal, predict incontinence better than external sphincter division after fistula surgery, S4.9
- Sphincter defects**, anal endosonography, S1.26
- Sphincter of Oddi dysfunction** and nondilated bile ducts, endoscopic sphincterotomy more hazardous, S3.33
- Sphincter repair**, anterior obstetric, related to external sphincter function, S1.40
- Sphincterotomy, endoscopic**
monitoring to detect pancreatic damage, S3.40
in the younger patient, success and complications, S1.48
- Spinal cord lesions**
gastric emptying and small intestinal motility abnormalities, S1.58
segmental colonic transit, objective evaluation, S4.11
- Splenectomy**, effects on NK cell function, and radical resection for gastric cancer, S1.15
- Staging of gastric cancer compared**, units with different referral mechanisms, S4.16
- Starch digestion**, effect on gastric emptying and glycemic response to next meal, S4.12
- Stem cells**, transplantation, and small bowel neomucosal generation, model, S1.34
- Stents, stenting**
of common bile duct stones, S1.70
as definitive procedure in benign biliary disease, S4.35
oesophageal, metallic, preliminary report on 64 cases, S4.19
- Stomach**, S4.42-45., 63-65
- Stomach/duodenum**, S1.12-16
- Stress**, postoperative, intestinal protein metabolism in response to, S4.41
- Stress faecal incontinence**, prolonged uncompensated rectoanal inhibition responsible for, S4.48
- Stress ulcer disease**, prophylaxis with ranitidine, sucralfate or placebo, S1.14
- Submucosal transanal resection** of rectal adenomas, S1.21
- Substance P**, increases sphincter of Oddi basal pressure and reduced transsphincteric flow, possum, S4.1

- Sucralfate**
gastric emptying of two radiolabelled forms, S1.13
in prophylaxis against stress ulcer disease, S1.14
reduces incidence of gastric cancer following truncal vagotomy and gastroenterostomy, rats, S4.15
- Sulindac**, influence on recurrent colonic adenomatous polyps, S1.38
- Sulphasalazine**
and 5-ASA, reduce leucocyte adhesion to vascular endothelium, S4.53
and its metabolites, in management of IBD, mode of action, S4.52
serum and urinary acetylated and unacetylated 5ASA compared, S1.11
sporadogenic consequences and teratogenic side effects, S4.62
- Sulphated glycosaminoglycans**, reduction, and intestinal albumin loss, S1.49
- Superior mesenteric artery blood flow** changes after feeding, relationship to calorific content of food, S1.65
- Superoxide**, role in rat gastric mucosal injury provoked by NO donors, S4.15
- Surfactant-like lipid** of human stomach, duodenum and rectum, S4.16
- Surgery**, S4.36–38
- Swallowing**, effect on oesophageal EMG responses evoked by cortical stimulation, S4.14
- Sydney classification** of endoscopic gastritis, histological assessment, S1.29
- T cell**
proliferation, effects of adjuvant 5-FU and levamisole, S1.62
receptor, Vbeta usage in coeliac disease, S1.63
stimulation, mucosal IL-6 secretion in response to, in UC and controls, S1.12
- Telen epine**, inhibition of caerulein-induced gallbladder contraction and PP release, S3.32
- Tetradotoxin** and NO-inhibition in reversion of reduction by endotoxin of pentagastrin-stimulated gastric acid secretion, S3.20
- Thalassaemia-beta**, and chronic hepatitis C, alpha interferon treatment, S2.142
- Thrombin**, an effective treatment for fundal gastric varices? S1.48
- Thromboxane** synthesis inhibition/receptor antagonism with picotamide, in IBD, S4.29
- Through 'scope balloon dilatation** of oesophageal strictures, cost and efficacy, S4.19
- Thyrotropin-releasing hormone**, and its metabolite Cyclo (His-Pro), influence on amylase secretion from isolated exocrine pancreatic acinar cells, rat, S3.18
- TIS 11**, localisation, S1.4
- Tissue inhibitor of metalloproteinase-1**, mRNA is expressed in acute and chronic liver disease, S1.21
- alpha-Tocopherol** antioxidant levels in chronic gastritis, S1.34
- Total parenteral nutrition**
does not predispose to gut translocation in man, S1.64
intestinal permeability increases in normal volunteers, S3.29
- Trace elements**, plasma and tissue levels, and glutathione peroxidase, in UC, S1.10
- Transfemoral liver biopsy**, 100 consecutive procedures of new technique, S4.7
- Transforming growth factor alpha**
and basic fibroblast growth factor, in gastric ulceration, S4.51
and EGF, hepatocyte expression alteration, in chronic liver disease and hepatocellular carcinoma, S4.23
induction at edge of human gastric ulcers demonstrated by immunostaining and quantitative PCR, S4.51
ontogenetic role in developing human stomach, S4.31
spasmodolytic polypeptide, intestinal trefoil factor and EGF mRNAs, are expressed sequentially during healing of cryoprobe-induced gastric ulcers, rats, S4.50
- Transforming growth factor beta-1**, chronic hepatitis C, and alpha interferon treatment, S2.146
- Transit abnormality**, in chronic idiopathic constipation, audit, S4.13
- Transjugular intrahepatic portosystemic shunt**
echodoppler examination of portal circulation after, S3.6
or sclerotherapy, in variceal rebleeding, S3.5
using Strecker stent, for variceal bleeding, S3.5
- Transjugular intrahepatic portosystemic stent shunt**, results of 2 years of follow-up, S4.21
- Transmission**
of *H. pylori*, S1.3
and natural history of viral hepatitis B, S2.48
vertical, of HCV, detected by HCV-RNA analysis, S2.52
- Tri-potassium dicitrato bismuthate**, lack of neurotoxicity evidence, S1.57
- Trinitrobenzene sulfonic acid** induced colitis, effect of bowel decontamination on inflammatory response, S3.10
- Triple therapy** for *H. pylori* eradication, S1.37
- Truncal vagotomy**, villary motility and CCK levels after, S1.51
- Tumour ablation**, selective, by high intensity ultrasound, in rabbits bearing hepatic VX-2 carcinoma, S3.45
- Tumour necrosis factor**
genes, genetic variance, in IBD, S3.37
induces LTB production in epithelial cell line, S1.24
membrane-bound, and increased TNF production, expression in IBD, S3.37
- microsatellite polymorphisms, in coeliac disease, S1.63
in pancreatic acinar cells, acute pancreatitis model, S4.2
- Tumour necrosis factor-alpha**
gene, promoter region, association with CD, S4.23
hepatocellular proliferation, and inflammation, in primary biliary cirrhosis, S4.6
and IFN-gamma, effects on ICAM-1, S1.31
and IL-1beta, genetic polymorphisms, in IBD, S1.71
and IL-6, in CD mucosa, detected by immunohistochemistry and ISH, S4.24
- production, in acute pancreatitis, is related to outcome, S3.28
- role in HBV recurrence after liver transplantation, S4.5
- Tumour suppressor gene p53** in anal transition zone after restorative proctocolectomy for UC, S4.46
- Ulcer disease**, history over past 10–20 years, S4.44
- Ulcer healing drugs**, prior use in upper gastrointestinal bleeding presenting to an open-access bleeding unit, S4.39
- Ulceration**, in arthritic patients receiving diclofenac, ranitidine prevents, S1.14
- Ulcerative colitis**, S1.10–12, S3.26–27, S4.52–53
active distal, budesonide versus prednisolone enema, comparative eight week study, S1.41
colonoscopic surveillance, patients' understanding and tolerance, S1.59
and Crohn's disease compared, for colorectal cancer risk, S1.38
and cytokine gene polymorphisms on chromosome 2, S4.29
epithelial metabolism and mucin synthesis, S4.28
pathophysiology, novel colonic factors, S3.9
restorative proctocolectomy long term results, S1.63
longitudinal distribution of inflammatory changes in ileal reservoir after, S1.66
significant increase in negatively charged serine dependent proteinases, S4.10
sources of increased NO production, S4.10
transdermal nicotine treatment, S3.48
urgent restorative proctocolectomy as safe procedure, S1.61
see also Inflammatory bowel disease
- Ultrasound**, as predictor of ERCP findings, audit, S4.38
- Undernutrition clinic**, anthropometric and quality of life measurements, S4.26
- Undulin**, and collagen turnover, circulating enzyme activities, in schistosomiasis and alcoholic liver cirrhosis, S3.44
- Upper gastrointestinal endoscopy**, inappropriate use, study, S1.27
- Upper gastrointestinal symptoms**, investigating, outpatients or endoscopy direct, S1.46
- Upper gastrointestinal tract**, S3.20–21, S3.41–42
clinical, S3.1–2
- Upper gut transit** in IBS, S4.11
- 14C-Urea breath test**, simplified minidose, for *H. pylori* detection, S4.49
- Ursodeoxycholic acid**
in alcoholic liver disease, S4.7
and chenodeoxycholic acid, effect on human hepatocyte and erythrocyte membranes, S1.45
effect in primary sclerosing cholangitis, S1.69
- Vagal stimulation**, effect on oesophageal EMG responses evoked by cortical stimulation, S4.14
- Variceal banding ligation** for bleeding oesophageal varices, S1.22
- Variceal bleeding**
injection sclerotherapy and oesophageal staple transection compared, S1.23
TIPS using Strecker stent, S3.5
- Variceal haemorrhage**, coughing precipitates, S3.5
- Variceal rebleeding**
sclerotherapy, nadolol ineffective, S3.5
TIPS or sclerotherapy, S3.5
- Vasopressin**, endogenous, in endotoxin-induced acute gastrointestinal injury, rat, S4.61
- Very low birthweight infants**, early full strength enteral feeding, S3.8
- Video diary**, a patient's perspective of endoscopy, S1.50
- Villous adenomas** of rectum and colon, photodynamic therapy, S1.39
- Villus-attached enterocytes**, postnatal inhibition of glucose transport into, S1.6

Viral hepatitis, S3.12-13

B and C, PCR for diagnosis, **S2.39**

chronic active, and HIV, zidovudine plus IFN alfa-2b treatment, **S2.107**

diagnosing, problems, **S2.36**

management: Chairman's introduction, **S2.IV**

management: standards for the future, **S2.1-149**

procollagen III propeptide levels and PGA index, **S1.21**

role of screening in prevention and treatment, **S2.45**

see also Hepatitis B; Hepatitis C

Viral markers

HCV in acute post-transfusion hepatitis treated with IFN alfa-2b, **S2.62**

in hepatitis B and C treatment, **S2.26**

see also Diagnostic markers

Vitamin D receptor mRNA is expressed in normal human colorectal mucosa and neoplasms, **S1.8**

Vitamin E deficiency and high dietary polyunsaturated fats compromise small intestinal function, **S4.25**

War surgery, large bowel perforation, one stage treatment in a field hospital, **S1.20**

Wheat germ agglutinin assay for exocrine pancreatic cancer, **S1.28**

Witzel balloon method, for forceful pneumatic dilatation for achalasia of the cardia, **S1.50**

Wound repair of gastric ulcer disease, influence of epidermal growth factor and insulin, **S3.11**

Zamifenacin, effect on colonic motility in IBS, **S4.4**

Zidovudine

and IFN alfa-2b, in chronic hepatitis B in anti-HIV positive patients, **S2.106, S2.107**

Zileuton, trial in UC, **S3.26**

Gut

*Journal of the British Society of Gastroenterology which
is a registered charity*

VOLUME 34 · 1993

Editor: R N Allan

Technical Editor: Jackie Foulds

Review Editor: D L Wingate

Editorial Assistant: Michelle Dimler

EDITORIAL BOARD

| | | | |
|----------------|-------------|---------------|--|
| D C C Bartolo | T G Cooke | P Quirke | S J W Evans (Statistical adviser) |
| M F Bassendine | C A Hart | D Rampton | |
| R M Batt | C J Hawkey | W D W Rees | Editor <i>British Medical Journal</i> |
| I S Benjamin | J Neuberger | D Swallow | |
| J Calam | D Nolan | I C Talbot | |
| D C A Candy | H O'Connor | B J R Whittle | |
| R Chapman | M E Parsons | | |

INTERNATIONAL ADVISORY BOARD

| | | |
|---|------------------------|--------------------------|
| B S Anand (USA) | D Y Graham (USA) | R Modigliani (France) |
| C Arvanitakis (Greece) | J Hansky (Australia) | T Muto (Japan) |
| G P van Berge Henegouwen (Netherlands) | J Heathcote (Canada) | G Paumgartner (Germany) |
| G Bianchi-Porro (Italy) | R H Hunt (Canada) | E W Pomare (New Zealand) |
| A L Blum (Switzerland) | J R Jass (New Zealand) | D Rachmilewitz (Israel) |
| M van Blankenstein (Netherlands) | S-J Jiang (China) | J Rask-Madsen (Denmark) |
| J P Delmont (France) | S J Konturek (Poland) | E Rene (France) |
| J Dent (Australia) | S K Lam (Hong Kong) | A Torsoli (Italy) |
| | M M Levine (USA) | |
| | J-R Malagelada (Spain) | |

VOLUME 34 · CONTENTS

| No 1 JANUARY 1993 | Page | Leading articles |
|--------------------|------|--|
| | 1 | Recent advances in the molecular biology of hepatitis B virus: mutant virus and the host response <i>G R Foster, H C Thomas</i> |
| | 4 | Ischaemic colitis: two distinct patterns of severity <i>J H Robert, G Mentha, A Rohner</i> |
| | 7 | Complications and limitations of injection sclerotherapy in portal hypertension <i>Nigel D Heaton, Edward R Howard</i> |
| | 11 | Oesophagus Role of intragastric and intraoesophageal alkalinisation in the genesis of complications in Barrett's columnar lined lower oesophagus <i>S E A Attwood, C S Ball, A P Barlow, L Jenkinson, T L Norris, A Watson</i> |
| | 16 | Lower oesophageal sphincter hypersensitivity to opioid receptor stimulation in patients with idiopathic achalasia <i>R Penagini, B Bartesaghi, P Zannini, G Negri, P A Bianchi</i> |
| | 21 | Location of the lower oesophageal sphincter and the squamous columnar mucosal junction in 109 healthy controls and 778 patients with different degrees of endoscopic oesophagitis <i>A Csendes, F Maluenda, I Braghetto, P Csendes, A Henriquez, M S Quesada</i> |
| | 28 | Stomach Gastroscopic follow up of pernicious anaemia patients <i>S M Sjöblom, P Sipponen, H Järvinen</i> |
| | 33 | Cholecystokinin octapeptide stimulates phasic and tonic pyloric motility in healthy controls <i>R Fraser, D Fone, M Horowitz, J Dent</i> |
| | 38 | Small intestine Impaired IgA response to <i>Giardia</i> heat shock antigen in children with persistent diarrhoea and giardiasis <i>S Char, A M Cevallos, P Yanson, P B Sullivan, G Neale, M J G Farthing</i> |
| | 41 | Pancreas Role of interleukin-6 in mediating the acute phase protein response and potential as an early means of severity assessment in acute pancreatitis <i>D I Heath, A Cruickshank, M Gudgeon, A Jehanli, A Shenkin, C W Imrie</i> |
| | 46 | Inflammatory bowel disease Serum antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease are mainly associated with ulcerative colitis. A correlation study between perinuclear antineutrophil cytoplasmic autoantibodies and clinical parameters, medical, and surgical treatment <i>M Oudkerk Pool, P M Ellerbroek, B U Ridwan, R Goldschmeding, B M E von Blomberg, A S Peña, K M Dolman, H Bril, W Dekker, J J Nauta, R O B Gans, H Breed, S G M Meuwissen</i> |
| | 51 | Adsorbents as antiendotoxin agents in experimental colitis <i>K R Gardiner, N H Anderson, M D McCaigue, P J Erwin, M I Halliday, B J Rowlands</i> |
| | 56 | Anti-lactoferrin antibodies and other types of ANCA in ulcerative colitis, primary sclerosing cholangitis, and Crohn's disease <i>E Peen, S Almer, G Bodemar, B-O Rydén, C Sjölin, K Tejle, T Skogh</i> |
| | 63 | Adhesive and hydrophobic properties of <i>Escherichia coli</i> from the rectal mucosa of patients with ulcerative colitis <i>M Gillian Hartley, M J Hudson, E T Swarbrick, A E Gent, M D Hellier, R H Grace</i> |
| | 68 | Quantification of disease activity in Crohn's disease by computer analysis of Tc-99m hexamethyl propylene amine oxime (HMPAO) labelled leucocyte images <i>M H Giaffer, W B Tindale, S Senior, D C Barber, C D Holdsworth</i> |
| | 75 | Factor XIIIa subunit and Crohn's disease <i>M Hudson, A J Wakefield, R A Hutton, E A Sankey, A P Dhillon, L More, R Sim, R E Pounder</i> |
| | 80 | Gastrointestinal cancer Plasminogen activators in normal tissue and carcinomas of the human oesophagus and stomach <i>C F M Sier, H W Verspaget, G Griffioen, S Ganesh, H J M Vloedgraven, C B H W Lamers</i> |
| | 86 | Electron microscopic study of intercellular junctions in human gastric mucosa with special reference to their relationship to gastric ulcer <i>T Ohkusa, M Yamamoto, K Kataoka, T Kyoi, F Ueda, H Fujimoto, M Sasabe, Y Tamura, H Hosoi, S Tokoi, N Sasaki, Y Saito</i> |
| | 90 | Identification of progastrin derived peptides in colorectal carcinoma extracts <i>J Nemeth, B Taylor, S Pauwels, A Varro, G J Dockray</i> |
| | 96 | Feasibility of family based screening for colorectal neoplasia: experience in one general surgical practice <i>B M Stephenson, V A Murday, P J Finan, P Quirke, M F Dixon, D T Bishop</i> |
| | 101 | Distribution of mucosal pathology and an assessment of colonic phenotypic change in the pelvic ileal reservoir <i>N A Shepherd, C J Healey, B F Warren, P I Richman, W H F Thomson, S P Wilkinson</i> |
| | 106 | Microvascular abnormalities in the mucosal prolapse syndrome <i>R N Lonsdale</i> |
| | 110 | Gall stones Effect of phospholipids and their molecular species on cholesterol solubility and nucleation in human and model bile <i>Z Halpern, M Moshkowitz, H Laufer, Y Peled, T Gilat</i> |
| | 116 | Liver Natural history of AIDS related sclerosing cholangitis: a study of 20 cases <i>A Forbes, C Blanshard, B Gazzard</i> |
| | 122 | Technique A laparoscopic technique for full thickness intestinal biopsy and feeding jejunostomy <i>W K Eltringham, A M Roe, S W Galloway, R A Mountford, H J Espiner</i> |
| | 125 | Clinical trial Double blind trial of oral fluticasone propionate v prednisolone in the treatment of active ulcerative colitis <i>A B Hawthorne, C O Record, C D Holdsworth, M H Giaffer, D A Burke, M L Keech, C J Hawkey</i> |
| | 129 | Progress report Contractile activity of the human colon: lessons from 24 hour studies <i>G Bassotti, M D Crowell, W E Whitehead</i> |
| | 134 | Case reports Perforation from endoscopic small bowel biopsy <i>B Scott, G Holmes</i> |
| | 136 | Familial primary gastric lymphoma <i>D Hayoz, M Extermann, B F Odermatt, P Pugin, C Regamey, H Knecht</i> |
| | 141 | Book reviews Notes |
| | 143 | Referees |
| No 2 FEBRUARY 1993 | | Leading articles |
| | 145 | Molecular biology and gastric carcinoma <i>P A Wright, G T Williams</i> |
| | 148 | Achalasia cardia: dilatation or operation? <i>John Spencer</i> |
| | 150 | Clinical and pathological spectrum of coeliac disease – active, silent, latent, potential <i>A Ferguson, E Arranz, S O'Mahony</i> |

- Oesophagus**
- 152 Oesophagitis is as important as oesophageal stricture diameter in determining dysphagia *M Dakkak, R C Hoare, S C Maslin, J R Bennett*
- Stomach**
- 156 Do infiltrating neutrophils contribute to the pathogenesis of indomethacin induced ulceration of the rat gastric antrum? *M A Trevethick, N M Clayton, P Strong, I W Harman*
- 161 Glutathione prevents ethanol induced gastric mucosal damage and depletion of sulphydryl compounds in humans *C Loguercio, D Taranto, F Beneduce, C del Vecchio Blanco, A de Vincentis, G Nardi, M Romano*
- 166 Erythromycin effects on gastric emptying, antral motility and plasma motilin and pancreatic polypeptide concentrations in anorexia nervosa *G Stacher, T L Peeters, H Bergmann, S Wiesnagrotzki, C Schneider, G V Granser-Vacariu, G Gaupmann, A Kugi*
- 173 Real time ultrasonography of the gastric antrum *R Ricci, I Bontempo, E Corazziari, A La Bella, A Torsoli*
- 177 Conjugation of 1-naphthol in human gastric epithelial cells *P Déchelotte, M Vanrentrapp, H J Meyer, M Schwenk*
- 181 Development of a ¹⁴C-urea breath test in ferrets colonised with *Helicobacter mustelae*: effects of treatment with bismuth, antibiotics, and urease inhibitors *A A McColm, J A Bagshaw, C F O'Malley*
- 187 Improving the selection of patients for upper gastrointestinal endoscopy *S A Naji, P W Brunt, S Hagen, N A G Mowat, I T Russell, T S Sinclair, T M H Tang*
- Gastrointestinal infection**
- 192 Culture negative cytotoxin positive stools in community acquired diarrhoea *D Burke, B J Al Jumaili, H Al Mardini, C O Record*
- 194 Concentrations of interleukin 6 and tumour necrosis factor in serum and stools of children with *Shigella dysenteriae* 1 infection *D G Harendra de Silva, L N Mendis, N Sheron, G J M Alexander, D C A Candy, H Chart, B Rowe*
- Paediatrics**
- 199 Antineutrophil antibody: a test for autoimmune primary sclerosing cholangitis in childhood? *S K Lo, R W G Chapman, P Cheeseman, C P J Charlton, J A Walker-Smith, G Mieli-Vergani, K A Fleming*
- 203 Transfer of cow's milk β -lactoglobulin to human serum after a milk load: a pilot study *J A Lovegrove, D L Osman, J B Morgan, S M Hampton*
- Coeliac disease**
- 208 Numbers of T cell receptor (TCR) $\alpha\beta+$ but not of TcR $\gamma\delta+$ intraepithelial lymphocytes correlate with the grade of villous atrophy in coeliac patients on a long term normal diet *T Kutlu, N Brousse, C Rambaud, F Le Deist, J Schmitz, N Cerf-Bensussan*
- Motility**
- 215 Abnormal visceral autonomic innervation in neurogenic faecal incontinence *C T M Speakman, M A Kamm*
- 222 Does the ileocolonic junction differentiate between solids and liquids? *J Hammer, M Camilleri, S F Phillips, A Aggarwal, A M Haddad*
- Gastrointestinal cancer**
- 227 Haemoccult does not reduce the need for colonoscopy in surveillance after curative resection for colorectal cancer *C Hall, J Griffin, P W Dykes, J Alexander Williams, M R B Keighley*
- 230 DNA ploidy in early gastric carcinoma (T1): a flow cytometric study of 100 European cases *M J Brito, M I Filipe, G T Williams, H Thompson, M G Ormerod, J Titley*
- Molecular biology**
- 235 Evaluation of a proposed technique to assess unscheduled DNA synthesis and genotoxicity *R A Goodlad, C Y Lee, M R Alison, C E Sarraf, M A Ghatei, S R Bloom, N A Wright*
- Inflammatory bowel disease**
- 242 Ulcerative colitis disease activity following treatment of associated primary sclerosing cholangitis with cyclosporin *W J Sandborn, R H Wiesner, W J Tremaine, N F Larusso*
- 247 Thromboembolism in inflammatory bowel disease: role of platelets *M J Webberley, M T Hart, V Melikian*
- 252 Inhibition of leucocyte adhesion molecule upregulation by tumour necrosis factor α : a novel mechanism of action of sulphasalazine *S M Greenfield, A S Hamblin, Z S Shakoor, J P Teare, N A Punchard, R P H Thompson*
- 257 Human colonic intraepithelial lymphocytes suppress in vitro immunoglobulin synthesis by autologous peripheral blood lymphocytes and lamina propria lymphocytes *G K Sachdev, H R Dalton, P Hoang, M C DiPaolo, B Crotty, D P Jewell*
- 264 Octreotide effectively decreases mucosal damage in experimental colitis *R Eliakim, F Karmeli, E Okon, D Rachmilewitz*
- Gall stones**
- 270 Effect of octreotide on gall stone prevalence and gall bladder motility in acromegaly *S M Catnach, J V Anderson, P D Fairclough, R C Trembath, P A J Wilson, E Parker, G M Besser, J A H Wass*
- 274 Results of extracorporeal shock wave lithotripsy of gall bladder stones in 693 patients: a plea for restriction to solitary radiolucent stones *A Elewaat, A Crape, M Afschrift, W Pauwels, M De Vos, F Barbier*
- Case report**
- 279 Familial visceral myopathy associated with a mitochondrial myopathy *R Lowsky, G Davidson, S Wolman, K N Jeejeebhoy, R A Hegele*
- Special report**
- 284 Consultant staffing and career prospects in gastroenterology for England and Wales *Graham Neale, Roger Williams, Royal College of Physicians Committee for Gastroenterology and Clinical Services Committee of the British Society of Gastroenterology*
- 288 Letters to the editor

No 3 MARCH 1993

- Leading articles**
- 289 Molecular biology of colorectal neoplasia *N Scott, P Quirke*
- 293 *Helicobacter pylori*: 10th anniversary of its culture in April 1982 *C S Goodwin*
- 295 The changing face of liver transplantation *C Shorrock, J Neuberger*
- Oesophagus**
- 299 Varicella-zoster virus DNA in the oesophageal myenteric plexus in achalasia *C S Robertson, B A B Martin, M Atkinson*
- 303 Mechanisms underlying the antireflux action of fundoplication *A C Ireland, R H Holloway, J Toouli, J Dent*
- 309 Determinants of oesophageal 'alkaline' pH environment in controls and patients with gastro-oesophageal reflux disease: *S Singh, L A Bradley, J E Richter*
- 317 Oesophageal motor response to reflux is not impaired in reflux oesophagitis *R Timmer, R Breumelhof, J H S M Nadorp, A J P M Smout*
- Stomach**
- 321 Cholecystokinin in the control of gastric acid secretion in man *J W Konturek, R Stoll, S J Konturek, W Domschke*
- 329 Role of eicosanoids, nitric oxide, and afferent neurons in antacid induced protection in the rat stomach *N Lambrecht, M Trautmann, R Korolkiewicz, M Liszkay, B M Peskar*

- 338 Effect of ranitidine bismuth citrate on postprandial plasma gastrin and pepsinogens *A G Fraser, W M Lam, Y W Luk, J Sercombe, A M Sawyerr, M Hudson, I M Samloff, R E Pounder*
- 343 Cystic dystrophy of the gastric and duodenal wall developing in heterotopic pancreas: an unrecognised entity *J-F Fléjou, F Potet, G Molas, P Bernades, P Amouyal, F Féchéte*
- Endoscopy**
- 348 Endoscopic injection therapy to prevent rebleeding from peptic ulcers with a protruding vessel: a controlled comparative trial *P Rutgeerts, A M Gevers, M Hiele, L Broeckaert, G Vantrappen*
- Peptic ulcer**
- 351 Secretor status and *Helicobacter pylori* infection are independent risk factors for gastroduodenal disease *W Dickey, J S A Collins, R G P Watson, J M Sloan, K G Porter*
- Small intestine**
- 354 Intestinal permeability in patients with coeliac disease and relatives of patients with coeliac disease *R M van Elburg, J J Uil, C J J Mulder, H S A Heymans*
- 358 Does the fatty acid profile of dietary fat influence its trophic effect on the small intestinal mucosa? *A P Jenkins, R P H Thompson*
- 365 Effects of dietary calcium and phosphate on the intestinal interactions between calcium, phosphate, fatty acids, and bile acids *M J A P Govers, R Van der Meer*
- Inflammatory bowel disease**
- 371 Antibodies to *Mycobacterium paratuberculosis* and nine species of environmental mycobacteria in Crohn's disease and control subjects *K J Stainsby, J R Lowes, R N Allan, J P Ibbotson*
- 375 Early mucosal changes in Crohn's disease *E A Sankey, A P Dhillon, A Anthony, A J Wakefield, R Sim, L More, M Hudson, A M Sawyerr, R E Pounder*
- 382 Diversion colitis and involution of the defunctioned anorectum *A M Roe, B F Warren, A J M Brodribb, C Brown*
- Gastrointestinal cancer**
- 386 Butyrate production from dietary fibre and protection against large bowel cancer in a rat model *A McIntyre, P R Gibson, G P Young*
- 392 High frequency of K-ras mutations in sporadic colorectal adenomas *E A McLellan, R A Owen, K A Stepniewska, J P Sheffield, N R Lemoine*
- Motility**
- 397 Autonomic dysfunction in gastrointestinal motility disorders *A E Bharucha, M Camilleri, P A Low, A R Zinsmeister*
- 402 Radioisotope determination of regional colonic transit in severe constipation: comparison with radio opaque markers *J R M van der Sijp, M A Kamm, J M D Nightingale, K E Britton, S J Mather, G P Morris, L M A Akkermans, J E Lennard-Jones*
- Liver**
- 409 Increased ethane exhalation, an in vivo index of lipid peroxidation, in alcohol-abusers *P Lettéron, V Duchatelle, A Berson, B Fromenty, C Fisch, C Degott, J P Benhamou, D Pessaire*
- Biliary tract**
- 415 Laser lithotripsy of difficult bile duct stones under direct visual control *H Neuhaus, W Hoffmann, C Zillinger, M Classen*
- Special report**
- 422 Organising unrestricted open access gastroscopy in South Tees *M G Bramble, W M Cooke, W A Corbett, P A Cann, D Clarke, B Contractor, A S Hungin*
- 428 Letters to the editor Notes

No 4 APRIL 1993

- Leading articles**
- 433 Single gene disorders affecting the gastrointestinal tract *G R Taylor, S M Farmer*
- 437 Sulphate reducing bacteria and hydrogen metabolism in the human large intestine *G R Gibson, G T Macfarlane, J H Cummings*
- 440 Gall stones and gall bladder motility *L J D O'Donnell, P D Fairclough*
- Oesophagus**
- 444 Pressure events surrounding oesophageal acid reflux episodes and acid clearance in ambulant healthy volunteers *C P Barham, D C Gotley, R Miller, A Mills, D Alderson*
- Acid related diseases**
- 450 Pepsinogen C gene polymorphisms associated with gastric body ulcer *T Azuma, N Teramae, T Hayakumo, K Yasuda, M Nakajima, T Kodama, H Inokuchi, K Hayashi, R T Taggart, K Kawai*
- 456 Phospholipid composition of human gastric mucosa: a study of endoscopic biopsy specimens *G Nardone, P Lacetti, C Civiletti, G Budillon*
- Helicobacter pylori***
- 461 Serological diagnosis of *Helicobacter pylori* – evaluation of four tests in the presence or absence of non-steroidal anti-inflammatory drugs *A S Taha, J Reid, P Boothmann, C G Gemmell, F D Lee, R D Sturrock, R J Russell*
- 466 Short and long term outcome of *Helicobacter pylori* positive resistant duodenal ulcers treated with colloidal bismuth subcitrate plus antibiotics or sucralphate alone *G Bianchi Porro, F Parente, M Lazzaroni*
- Small intestine**
- 470 Laser ablation of upper gastrointestinal vascular ectasias: long term results *I R Sargeant, L A Loizou, D Rampton, M Tulloch, S G Brown*
- 476 Gastrointestinal function in chronic radiation enteritis – effects of loperamide-N-oxide *E K Yeoh, M Horowitz, A Russo, T Muecke, T Robb, B E Chatterton*
- 483 Bile salt inhibition of motility in the isolated perfused rabbit terminal ileum *D N Armstrong, H K Krenz, I M Modlin, G H Ballantyne*
- 489 Presence of N-acyl and acetoxy derivatives of putrescine and cadaverine in the human gut *K E Murray, K J Shaw, R F Adams, P L Conway*
- Gastrointestinal cancer**
- 494 Screening for gastric carcinoma in coal miners *J D Harrison, D L Morris, J D Hardcastle*
- 499 Increased risk of left sided colon cancer in patients with diverticular disease *T Stefánsson, A Ekbom, P Sparén, L Påhlman*
- Inflammatory bowel disease**
- 503 Inter-relationships between inflammatory mediators released from colonic mucosa in ulcerative colitis and their effects on colonic secretion *T D Wardle, L Hall, L A Turnberg*

- 509 Increased absorption of polyethylene glycol 600 deposited in the colon in active ulcerative colitis *S Almer, L Franzén, G Olaison, K Smedh, M Ström*
- 514 Pathology of the defunctioned rectum in ulcerative colitis *B F Warren, N A Shepherd, D C C Bartolo, J W B Bradfield*
- 517 Familial empirical risks for inflammatory bowel disease: differences between Jews and non-Jews *H Yang, C McElree, M-P Roth, F Shanahan, S R Targan, J I Rotter*
- Large intestine**
- 525 Rectal epithelial cell proliferation patterns as predictors of adenomatous colorectal polyp recurrence *M Anti, G Marra, F Armelao, A Percesepe, R Ficarelli, G M Ricciuto, A Valenti, G L Rapaccini, I De Vitis, G D'Agostino, S Brighi, F M Vecchio*
- 531 Sex differences in colonic function: a randomised trial *J W Lampe, S B Fredstrom, J L Slavin, J D Potter*
- 537 Cephalic phase of colonic pressure response to food *J Rogers, A H Raimundo, J J Misiewicz*
- Liver**
- 544 Immunoblotting as a confirmatory test for antimitochondrial antibodies in primary biliary cirrhosis *G Provenzano, O Diquattro, A Craxi, P Almaito, G Pinzello, L Marino, G Fiorentino, F Rinaldi, L Pagliaro*
- 549 GSTM1 null polymorphism at the glutathione S-transferase M1 locus: phenotype and genotype studies in patients with primary biliary cirrhosis *M H Davies, E Elias, S Acharya, W Cotton, G C Faulder, A A Fryer, R C Strange*
- 554 Hepatic perfusion in patients with liver metastases: comparison with those patients with cirrhosis *E Leen, J A Goldberg, J R Anderson, J Robertson, B Moule, T G Cooke, C S McArdle*
- Case reports**
- 558 Diffuse vascular ectasia of the antrum, duodenum, and jejunum in a patient with nodular regenerative hyperplasia. Lack of response to portosystemic shunt or gastrectomy *P Calès, J-J Voigt, J-L Payen, E Bloom, P Berg, J-P Vinel, B Pradère, P Brousy, J-P Pascal*
- 562 Cap polypsis – an unusual cause of diarrhoea *A P Campbell, C A Cobb, R W G Chapman, M Kettlewell, P Hoang, B J Haot, D P Jewell*
- 565 Early acute hepatitis with parenteral amiodarone: a toxic effect of the vehicle? *A Rhodes, J B Eastwood, S A Smith*
- 567 Polymyositis associated with ulcerative colitis *S Chugh, J B Dilawari, I M S Sawhney, N Dang, B D Radotra, Y K Chawla*
- 570 Multisystem Langerhans' cell histiocytosis with pancreatic involvement *R C H Yu, A Attra, C M Quinn, T Krausz, A C Chu*
- 573 **Letters to the editor Notes**

No 5 MAY 1993

- Leading articles**
- 577 Trefoil peptides and the gut *Nicholas A Wright*
- 580 *Helicobacter pylori* and non-steroidal anti-inflammatory drugs: uncomfortable partners in peptic ulcer disease *A S Taha, R I Russell*
- Oesophagus**
- 584 Mucosal polyamine metabolism in the columnar lined oesophagus *M R Gray, H M Wallace, H Goulding, J Hoffman, W E Kenyon, A N Kingsnorth*
- Helicobacter pylori***
- 588 Gastric mucosal barrier: evidence for *Helicobacter pylori* ingesting gastric surfactant and deriving protection from it *B A Hills*
- 594 ¹³C-urea breath test for diagnosis of experimental *Helicobacter pylori* infection in barrier born pigs *K Meyer-Rosberg, S Gustavsson*
- 599 Incidence of *Helicobacter pylori* strains activating neutrophils in patients with peptic ulcer disease *H Rautelin, B Blomberg, H Fredlund, G Järnerot, D Danielsson*
- Gastrointestinal cancer**
- 604 Comparison of computed tomography, endosonography, and intraoperative assessment in TN staging of gastric carcinoma *K Ziegler, C Sanft, T Zimmer, M Zeitz, D Felsenberg, H Stein, C Germer, C Deutschmann, E O Riecken*
- 611 Sex differences in the incidence of colorectal cancer: an exploration of oestrogen and progesterone receptors *Sukhdev Singh, Michael C Sheppard, Michael J S Langman*
- 616 Effect of cytokines on the epithelial function of the human colon carcinoma cell line HT29 cl 19A *A Hiribarren, M Heyman, A L'Helgouac'h, J F Desjeux*
- 621 p53 expression and K-ras mutation in colorectal adenomas *N Scott, S M Bell, P Sagar, G E Blair, M F Dixon, P Quirke*
- 625 Lactate and pH in faeces from patients with colonic adenomas or cancer *H Hove, M Rye Clausen, P Brøbech Mortensen*
- 630 Colonic fermentation of complex carbohydrates in patients with familial adenomatous polyposis *D M Bradburn, J C Mathers, A Gunn, J Burn, P D Chapman, I D A Johnston*
- Small intestine**
- 637 The value of in vivo electrophysiological measurements for monitoring functional adaptation after massive small bowel resection in the rat *M C J Wolwekamp, N M C Durante, M A C Meyssen, J Bijman, H R de Jonge, R L Marquet, E Heineman*
- 643 Absorbed aluminium is found with two cytosolic protein fractions, other than ferritin, in the rat duodenum *M Cochran, G Goddard, G Ramm, N Ludwigson, J Marshall, J Halliday*
- Endoscopy**
- 647 Perioperative endoscopy of the whole small bowel in Crohn's disease *D Lescut, D Vanco, P Bonnière, M Lecomte-Houcke, P Quandalle, A Wurtz, J F Colombel, J S Delmotte, J C Paris, A Cortot*
- Inflammatory bowel disease**
- 650 Epithelial deposits of immunoglobulin GI and activated complement colocalise with the M₁40 kD putative autoantigen in ulcerative colitis *Trond S Halstensen, Kiron M Das, Per Brandtzæg*
- 658 Soluble interleukin-2 receptors, antineutrophil cytoplasmic antibodies, and other autoantibodies in patients with ulcerative colitis *G N Dalekos, M N Manousakis, A C Goussia, E V Tsianos, H M Moutsopoulos*
- 665 Intestinal epithelial cells contribute to the enhanced generation of platelet activating factor in ulcerative colitis *L Ferraris, F Karmeli, R Eliakim, J Klein, C Fiocchi, D Rachmilewitz*
- 669 Oroileal transit of slow release 5-aminosalicylic acid *H Goebell, U Klotz, B Nehlsen, P Layer*
- 676 Comparison of bismuth citrate and 5-aminosalicylic acid enemas in distal ulcerative colitis: a controlled trial *R D Pullan, S Ganesh, V Mani, J Morris, B K Evans, G T Williams, J Rhodes*
- 680 An audit of restorative proctocolectomy *M R B Keighley, S Grobler, I Bain*
- Sphincter function**
- 685 The prevalence of anal sphincter defects in faecal incontinence: a prospective endosonic study *K I Deen, D Kumar, J G Williams, J Olliff, M R B Keighley*
- 689 Nerve mediated relaxation of the human internal anal sphincter: the role of nitric oxide *Terence O'Kelly, Alison Brading, Neil Mortensen*

| | |
|--------------------|--|
| | Liver |
| 694 | Congestive jejunopathy in portal hypertension <i>A S Nagral, A S Joshi, S J Bhatia, P Abraham, F P Mistry, I M Vora</i> |
| | Bile salts |
| 698 | Serum 7α-hydroxy-4-cholesten-3-one concentrations in the evaluation of bile acid malabsorption in patients with diarrhoea: correlation to SeHCAT test <i>S Eusufzai, M Axelson, B Angelin, K Einarsson</i> |
| 702 | Reduced cholesterol metastability of hepatic bile and its further decline in gall bladder bile in patients with cholesterol gall stones <i>K Nakano, K Chijiwa</i> |
| 708 | Fate of oral enzymes in pancreatic insufficiency <i>L Guarner, R Rodríguez, F Guarner, J-R Malagelada</i> |
| 713 | Letters to the editor Book reviews Notes Correction |
| A717 | British Association for the Study of the Liver |
| No 6 JUNE 1993 | |
| | Leading articles |
| 721 | Towards safer endoscopic retrograde cholangiopancreatography <i>John Thornton, Anthony Axon</i> |
| 725 | Progress in determining the nature of bile duct strictures <i>Brian R Davidson</i> |
| | Oesophagus |
| 727 | The role of smoking and alcohol in metaplasia and cancer risk in Barrett's columnar lined oesophagus <i>M R Gray, R J Donnelly, A N Kingsnorth</i> |
| | Stomach |
| 732 | Role of active oxygen, lipid peroxidation, and antioxidants in the pathogenesis of gastric mucosal injury induced by indomethacin in rats <i>T Yoshikawa, Y Naito, A Kishi, T Tomii, T Kaneko, S Inuma, H Ichikawa, M Yasuda, S Takahashi, M Kondo</i> |
| 738 | New non-invasive test of gastric acid secretion for use in children <i>J E Thomas, E J Eastham, L T Weaver</i> |
| 742 | Enhanced gastric mucosal leukotriene B ₄ synthesis in patients taking non-steroidal anti-inflammatory drugs <i>N Hudson, M Balsitis, S Everitt, C J Hawkey</i> |
| | Helicobacter pylori |
| 748 | Effect of <i>Helicobacter pylori</i> colonisation on gastric mucosal eicosanoid synthesis in patients taking non-steroidal anti-inflammatory drugs <i>N Hudson, M Balsitis, F Filipowicz, C J Hawkey</i> |
| 752 | Influence of <i>Helicobacter pylori</i> , sex, and age on serum gastrin and pepsinogen concentrations in subjects without symptoms and patients with duodenal ulcers <i>Sandro Mossi, Beat Meyer-Wyss, Eberhard L Renner, Hans S Merki, Gerdien Gamboni, Christoph Beglinger</i> |
| 757 | <i>Helicobacter pylori</i> related hypergastrinaemia is the result of a selective increase in gastrin 17 <i>G Mulholland, J E S Ardill, D Fillmore, R S Chittajallu, G M Fullarton, K E L McColl</i> |
| 762 | A study of the pathogenesis of <i>Helicobacter pylori</i> negative chronic duodenal ulceration <i>K E L McColl, A M El-Nujumi, R S Chittajallu, S W Dahill, C A Dorrian, E El-Omar, I Penman, E J Fitzsimons, J Drain, H Graham, J E S Ardill, R Bessent</i> |
| | Coeliac disease |
| 769 | Duodenal mucosa and extracellular cyclic nucleotide pattern in coeliac disease <i>M Peracchi, F Bamonti-Catena, P Fagioli, N Molteni, M T Bardella, B Bareggi, P A Bianchi</i> |
| 774 | Is an intestinal permeability test a valid marker for slight dietary transgressions in adolescents with coeliac disease? <i>P Fernandez-Calle, R Codoceo, I Polanco, J Gomez-Cerezo, M Orsi, J M Tenias</i> |
| | Inflammatory bowel disease |
| 778 | Polymeric enteral diets as primary treatment of active Crohn's disease: a prospective steroid controlled trial <i>F González-Huix, R de León, F Fernández-Bañares, M Esteve, E Cabré, D Acero, A Abad-Lacruz, M Figuera, M Guilera, R Planas, M A Gassull</i> |
| 783 | Food intolerance and Crohn's disease <i>M Pearson, K Teahan, A Jonathan Levi, I Bjarnason</i> |
| 788 | Interleukin 2 and interferon-γ augment anticolon antibody dependent cellular cytotoxicity in ulcerative colitis <i>T Hibi, M Ohara, M Watanabe, T Kanai, H Takaishi, A Hayashi, Y Hosoda, H Ogata, Y Iwao, S Aiso, N Watanabe, K Toda, M Tsuchiya</i> |
| | Motility |
| 794 | Effects of serotonin on rat ileocolonic transit and fluid transfer in vivo: possible mechanisms of action <i>L Oosterbosch, M von der Ohe, M A Valdovinos, L J Kost, S F Phillips, M Camilleri</i> |
| 799 | Effect of food and anti-cholinergic drugs on the pattern of rectosigmoid contractions <i>J Daly, A Bergin, W M Sun, N W Read</i> |
| 803 | Colonic manometry in children with chronic intestinal pseudo-obstruction <i>C Di Lorenzo, A F Flores, S N Reddy, W J Snape Jr, G Bazzocchi, P E Hyman</i> |
| 808 | Postprandial gall bladder motility and hormone release during intermittent and continuous subcutaneous octreotide treatment in acromegaly <i>M F J Stolk, K J van Erpecum, H P F Koppeschaar, W I de Bruin, J B M J Jansen, C B H W Lamers, G P van Berge Henegouwen</i> |
| | Large intestine |
| 814 | Relaxation of distal colonic circular smooth muscle by nitric oxide derived from human leucocytes <i>S J Middleton, M Shorthouse, J O Hunter</i> |
| 818 | Colonic hydrogen absorption: quantification of its effect on hydrogen accumulation caused by bacterial fermentation of carbohydrates <i>Heinz F Hammer</i> |
| 823 | Use of the conjugate of disulphated ursodeoxycholic acid with <i>p</i> -aminobenzoic acid for the detection of intestinal bacteria <i>M Takahashi, T Konishi, Y Maeda, Y Matsugu, F Akazawa, T Eto, M Okajima, K Uchida, Y Masuoka, K Okada</i> |
| 829 | Altered glycosylation of integrin adhesion molecules in colorectal cancer cells and decreased adhesion to the extracellular matrix <i>B v Lampe, A Stallmach, E O Riecken</i> |
| | Biliary tract |
| 837 | The percutaneous rotary lithotrite: a new approach to the treatment of symptomatic cholelithiasis <i>A Gillams, J J Donald, R C G Russell, A R W Hatfield, W R Lees</i> |
| | Progress report |
| 843 | Alcohol and gastric acid secretion in humans <i>S Chari, S Teyssen, M V Singer</i> |
| | Technique |
| 848 | Prolonged monitoring of the upper gastrointestinal tract using echo planar magnetic resonance imaging <i>D F Evans, G Lamont, M K Stehling, A M Blamire, P Gibbs, R Coxon, J D Hardcastle, P Mansfield</i> |
| | Case reports |
| 853 | Non-communicating multiseptate gall bladder and choledochal cyst: a case report and review of publications <i>C E L Tan, E R Howard, M Driver, I M Murray-Lyon</i> |

| | |
|------------------|---|
| No 7 JULY 1993 | <p>857 Dieulafoy's disease controlled by Doppler ultrasound endoscopic treatment <i>D Jaspersen</i></p> <p>859 Acute gastric dilatation – a delayed complication of percutaneous endoscopic gastrostomy <i>S Ghosh, M A Eastwood, K R Palmer</i></p> <p>861 Letters to the editor Book reviews Notes</p> <p>Leading articles</p> <p>865 Inflammatory bowel disease – a radical view <i>N J Simmonds, D S Rampton</i></p> <p>869 Crohn's disease: the genetic contribution <i>Jeffrey Sofair</i></p> <p>Upper gastrointestinal tract</p> <p>872 Measurement of bicarbonate output from the intact human oesophagus <i>C M Brown, C F Snowdon, B Slee, L N Sandle, W D W Rees</i></p> <p>881 Fibroblast growth factor in gastropreservation and ulcer healing: interaction with sucralfate <i>Stanislaw J Konturek, Tomasz Brzozowski, Jolanta Majka, Aleksandra Szlachcic, Wladyslaw Bielanski, Jerzy Stachura, Wilhelm Otto</i></p> <p>888 Acid secretion and sensitivity to gastrin in patients with duodenal ulcer: effect of eradication of <i>Helicobacter pylori</i> <i>Steven F Moss, John Calam</i></p> <p>893 Study of the proliferation in human gastric mucosa after <i>in vivo</i> bromodeoxyuridine labelling <i>S Patel, D A Rew, I Taylor, C S Potten, C Owen, S A Roberts</i></p> <p>897 Ablation of capsaicin sensitive afferent nerves impairs defence but not rapid repair of rat gastric mucosa <i>M A Pabst, E Schöninkle, P Holzer</i></p> <p>Motility</p> <p>904 Effect of gastro-oesophageal reflux on upper oesophageal sphincter motility in children <i>J Willing, G P Davidson, J Dent, I Cook</i></p> <p>911 Regulation of gall bladder motility by the arginine-nitric oxide pathway in guinea pigs <i>Marisabel Mourelle, Francisco Guarner, Xavier Molero, Salvador Moncada, Juan-R Malagelada</i></p> <p>916 Isotope gastric emptying tests in clinical practice: expectation, outcome, and utility <i>M A Galil, M Critchley, C R Mackie</i></p> <p>920 Evidence of a dominant role for low osmolality in the efficacy of cereal based oral rehydration solutions: studies in a model of secretory diarrhoea <i>A V Thillainayagam, S Carnaby, J A Dias, M L Clark, M J G Farthing</i></p> <p>Inflammatory bowel disease</p> <p>926 Glycosylation and sulphation of colonic mucus glycoproteins in patients with ulcerative colitis and in healthy subjects <i>H Morita, M G W Kettlewell, D P Jewell, P W Kent</i></p> <p>933 Serum carnitine concentrations in coeliac disease <i>A Lerner, N Gruener, T C Iancu</i></p> <p>936 Location of superoxide anion generation in human colonic mucosa obtained by biopsy <i>N Oshitani, A Kitano, H Okabe, S Nakamura, T Matsumoto, K Kobayashi</i></p> <p>939 Growth and clinical course of children with Crohn's disease <i>Anne M Griffiths, Phuongbich Nguyen, Claire Smith, James H MacMillan, Philip M Sherman</i></p> <p>944 Insulin like growth factor-I, insulin like growth factor binding protein-1, and insulin in childhood Crohn's disease <i>A G Thomas, J M P Holly, F Taylor, V Miller</i></p> <p>948 Restorative proctocolectomy with end to end pouch-anal anastomosis in patients over the age of fifty <i>W G Lewis, P M Sagar, P J Holdsworth, A T R Axon, D Johnston</i></p> <p>Gastrointestinal cancer</p> <p>953 Protein kinase C inhibits cyclic adenosine monophosphate generation by histamine and truncated glucagon like peptide 1 in the human gastric cancer cell line HGT-1 <i>P McKenna, J M Williams, C P Gespach, P J Hanson</i></p> <p>958 Radiation enhancement of laser palliation for advanced rectal and rectosigmoid cancer: a pilot study <i>I R Sargeant, J S Tobias, G Blackman, S Thorpe, S G Bown</i></p> <p>963 Effects of vitamin antioxidant supplementation on cell kinetics of patients with adenomatous polyps <i>R J Cahill, K R O'Sullivan, P M Mathias, S Beattie, H Hamilton, C O'Morain</i></p> <p>Liver</p> <p>968 Transjugular intrahepatic portasystemic stent shunting for control of acute and recurrent upper gastrointestinal haemorrhage related to portal hypertension <i>K J Simpson, N Chalmers, D N Redhead, N D C Finlayson, I A D Bouchier, P C Hayes</i></p> <p>974 Serum concentrations of laminin in cirrhosis of the liver <i>Julio Collazos, Fernando Díaz, José Genollá</i></p> <p>977 Inappropriate expression of blood group antigens on biliary and colonic epithelia in primary sclerosing cholangitis <i>S Bloom, A Heryet, K Fleming, R W Chapman</i></p> <p>Pancreas</p> <p>984 Complex carbohydrate malabsorption in exocrine pancreatic insufficiency <i>Spiros D Ladas, Kostas Giorgiotis, Sotos A Raptis</i></p> <p>988 Pancreatic hypertrophy with acinar cell nodules after longterm fundectomy in the rat <i>M Chu, L Franzén, S Sullivan, S Wingren, J F Rehfeld, K Borch</i></p> <p>Case reports</p> <p>994 Isolated primary oesophageal involvement by lymphoma: a rare cause of dysphagia: two case histories and a review of other published data <i>B G Taal, P Van Heerde, R Somers</i></p> <p>999 Myofibroblasts in hollow visceral myopathy: the origin of gastrointestinal fibrosis? <i>J E Martin, M Benson, M Swash, V Salih, A Gray</i></p> <p>1002 Gold induced enterocolitis complicated by cytomegalovirus infection: a previously unrecognised association <i>V Wong, J Wyatt, F Lewis, P Howdle</i></p> <p>Review article</p> <p>1006 Painful rib syndrome – a review of 76 cases <i>E M Scott, B B Scott</i></p> |
| No 8 AUGUST 1993 | <p>Leading articles</p> <p>1009 Colonic motility: practice or research? <i>J S Jameson, J J Misiewicz</i></p> <p>1013 Non-deglutitive motor activity of the oesophagus <i>Gaston Vantrappen</i></p> <p>Oesophagus</p> <p>1015 Fate of Nissen fundoplication after 20 years. A clinical, endoscopical, and functional analysis <i>M Luostarinen, J Isolauri, J Laitinen, M Koskinen, O Keyriläinen, H Markkula, E Lehtinen, A Uusitalo</i></p> <p>1021 Bursts of non-deglutitive simultaneous contractions may be a normal oesophageal motility pattern <i>J Janssens, V Annese, G Vantrappen</i></p> <p>1025 Effects of ranitidine and cisapride on acid reflux and oesophageal motility in patients with reflux oesophagitis: a 24 hour ambulatory combined pH and manometry study <i>W Inauen, C Emde, B Weber, D Armstrong, H U Bettschen, T Huber, U Scheurer, A L Blum, F Halter, H S Merki</i></p> |

- Peptic ulcer**
- 1032 Effect of age, *Helicobacter pylori* infection, and gastritis with atrophy on serum gastrin and gastric acid secretion in healthy men *P H Katelaris, F Seow, B P C Lin, J Napoli, M C Ngu, D B Jones*
- 1038 Effect of eradication of *Helicobacter pylori* on gastric juice ascorbic acid concentrations *G M Sobala, C J Schorah, S Shires, D A F Lynch, B Gallacher, M F Dixon, A T R Axon*
- 1042 Acid, motility, and ulcers: a comparison of cisapride with placebo in the prevention of duodenal ulcer relapse *D D Kerrigan, M E Taylor, N W Read, A G Johnson*
- 1047 Duodenogastric reflux after gastric surgery and in gastric ulcer disease: continuous measurement with a sodium ion selective electrode *Anne Smythe, Daniel O'Leary, Alan G Johnson*
- 1051 Gastric secretion of platelet activating factor and precursors in healthy humans: effect of pentagastrin *I Sobhani, Y Denizot, S Hochlaf, D Rigaud, J Vatier, J Benveniste, M J Lewin, M Mignot*
- 1057 Immunocytochemical localisation of parietal cells and G cells in the developing human stomach *E J Kelly, M Lagopoulos, J N Primrose*
- 1060 Eradicating *Helicobacter pylori* infection lowers gastrin mediated acid secretion by two thirds in patients with duodenal ulcer *E El-Omar, I Penman, C A Dorrian, J E S Ardill, K E L McColl*
- Small intestine**
- 1066 Mathematical correlation between villus height and the nutritional state in Sprague-Dawley rats *J L Zambonino Infante, J M Rouanet, P Besançon*
- 1069 Comparison of different lipid substrates on intestinal adaptation in the rat *M Galluser, B Czernichow, H Dreyfus, F Gossé, B Guérolé, J Kachelhofer, M Doffoel, F Raul*
- Inflammatory bowel disease**
- 1075 Failure of colonoscopic surveillance in ulcerative colitis *D A F Lynch, A J Lobo, G M Sobala, M F Dixon, A T R Axon*
- 1081 Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience *W R Connell, M A Kamm, J K Ritchie, J E Lennard-Jones*
- Gastrointestinal cancer**
- 1086 Influence of preoperative radiotherapy on DNA ploidy in squamous cell carcinomas of the oesophagus *R Porschen, G Bevers, U Remy, S Schauseil, F Borchard*
- 1091 Effect of histamine on the growth of human gastrointestinal tumours: reversal by cimetidine *S A Watson, L J Wilkinson, J F R Robertson, J D Hardcastle*
- 1097 Transforming growth factor α is trophic to pancreatic cancer in vivo *N Davies, P Kapur, J Gillespie, P J Guillou, G J Poston*
- 1099 Anthranoid laxative abuse – a risk for colorectal cancer? *C-P Siegers, E von Hertzberg-Lottin, M Otte, B Schneider*
- Clinical gastroenterology**
- 1102 Prospective survey of investigations in outpatients referred with iron deficiency anaemia *A S McIntyre, R G Long*
- 1108 Bowel function and irritable bowel symptoms after hysterectomy and cholecystectomy – a population based study *K W Heaton, D Parker, H Cripps*
- Liver**
- 1112 Intestinal glutamine and ammonia metabolism during chronic hyperammonaemia induced by liver insufficiency *Cornelis H C Dejong, Nicolaas E P Deutz, Peter B Soeters*
- 1120 Fibrinolytic activity of ascites caused by alcoholic cirrhosis and peritoneal malignancy *D M Scott-Coombes, S A Whawell, M N Vipond, L Crnojevic, J N Thompson*
- Biliary tract**
- 1123 Erythromycin induces supranormal gall bladder contraction in diabetic autonomic neuropathy *S M Catnach, A B Ballinger, M Stevens, P D Fairclough, R C Trembath, P L Drury, P J Watkins*
- 1128 Effect of acute hyperglycaemia on gall bladder contraction induced by cholecystokinin in humans *S Y de Boer, A A M Masclee, M C W Jebbink, J Schipper, H H P J Lemkes, J B M J Jansen, C B H W Lamers*
- Pancreas**
- 1133 Pancreatic and synovial type phospholipases A2 in serum samples from patients with severe acute pancreatitis *Timo J Nevalainen, Juha M Grönroos, Pirjo T Kortesuo*
- 1137 Intestinal bile acid malabsorption in cystic fibrosis *S O'Brien, H Mulcahy, H Fenlon, A O'Brien, M Casey, A Burke, M X Fitzgerald, J E Hegarty*
- Case reports**
- 1142 Phlegmonous gastritis: an unusual presenting symptom of Sjögren's syndrome *M L van Leeuwen, H L Tjiang, M van Blankenstein, A H Mulder, C M Bakker*
- 1145 Lithotripsy of an impacted calcified stone in the cystic duct accompanied by cholecystitis in severe Crohn's disease *U Stölzel, C Koszka, M Gregor, K Ziegler, T Zimmer, E O Riecken*
- 1148 Colorectal carcinoma in patients with ulcerative colitis and recent colonoscopy *S M Catnach, K R P Rutter, R L Bown*
- 1150 Letters to the editor Book reviews Notes

No 9 SEPTEMBER 1993

- Leading articles**
- 1153 Transplantation of cultured small bowel enterocytes *F C Campbell, I S Tait, N Flint, G S Evans*
- 1156 Treatment of hepatic metastases by cryotherapy and regional cytotoxic perfusion *D L Morris, M D A'C Horton, A V Dilley, A Warlters, P R Clingan*
- Oesophagus**
- 1158 Audit of the role of oesophageal manometry in clinical practice *P W Johnston, B T Johnston, B J Collins, J S A Collins, A H G Love*
- Helicobacter pylori**
- 1162 Duodenal histology, ulceration and *Helicobacter pylori* in the presence or absence of non-steroidal anti-inflammatory drugs *A S Taha, S Dahill, I Nakshabendi, F D Lee, R D Sturrock, R I Russell*
- 1167 Amoxicillin plus omeprazole versus triple therapy for eradication of *Helicobacter pylori* in duodenal ulcer disease: a prospective, randomised, and controlled study *J Labenz, E Gyenes, G H Rühl, G Börsch*
- Gastric emptying**
- 1171 Disturbed gastric emptying in the short bowel syndrome. Evidence for a 'colonic brake' *J M D Nightingale, M A Kamm, J R M van der Sijp, G P Morris, E R Walker, S J Mather, K E Britton, J E Lennard-Jones*
- 1177 The effect of liquid fibre on gastric emptying in the rat and humans and the distribution of small intestinal contents in the rat *J Tomlin, N Brown, A Ellis, A Carlsson, C Bogentoft, N W Read*
- Acid related disease**
- 1182 Is sclerosant injection mandatory after an epinephrine injection for arrest of peptic ulcer haemorrhage? A prospective, randomised, comparative study *Hwai-Jeng Lin, Chin-Lin Perng, Shou-Dong Lee*
- 1186 Inhibition of omeprazole induced hypergastrinaemia by SMS 201-995, a long acting somatostatin analogue in man *J L Meijer, J B M J Jansen, L F S J Crobach, I Biemond, C B H W Lamers*

- Inflammatory bowel diseases**
- 1191 Increased production of luminol enhanced chemiluminescence by the inflamed colonic mucosa in patients with ulcerative colitis *S Sedghi, J Z Fields, M Klamut, G Urban, M Durkin, D Winship, D Fretland, M Olyae, A Keshavarzian*
 - 1198 Initial response and subsequent course of Crohn's disease treated with elemental diet or prednisolone *D A Gorard, J B Hunt, J T Payne-James, K R Palmer, R G P Rees, M L Clark, M J G Farthing, J J Misiewicz, D B A Silk*
 - 1203 Neutrophil mucosal involvement is accompanied by enhanced local production of interleukin-8 in ulcerative colitis *Y Raab, B Gerdin, S Ahlstedt, R Häggren*
 - 1207 Epidemiology of inflammatory bowel disease in the Province of Granada, Spain: a retrospective study from 1979 to 1988 *J F Martínez-Salmerón, M Rodrigo, J de Teresa, F Nogueras, M García-Montero, C de Sola, J Salmerón, M Caballero*
 - 1210 In vivo rectal inflammatory mediator changes with radiotherapy to the pelvis *A T Cole, K Slater, M Sokal, C J Hawkey*
- Large intestine**
- 1215 Colonic dysfunction in acute diarrhoea: the role of luminal short chain fatty acids *B S Ramakrishna, V I Mathan*
 - 1219 Deoxycholate is an important releaser of peptide YY and enteroglucagon from the human colon *T E Adrian, G H Ballantyne, W E Longo, A J Bilchik, S Graham, M D Basson, R P Tierney, I M Modlin*
 - 1225 Morphometric analysis of intestinal mucosa. V Quantitative histological and immunocytochemical studies of rectal mucosae in gluten sensitivity *A Ensari, M N Marsh, D E Loft, S Morgan, K Moriarty*
 - 1230 Selective affective biasing in recognition memory in the irritable bowel syndrome *J E Gomorone, P A Dewsnap, G W Libby, M J G Farthing*
- Colorectal cancer**
- 1234 Xenobiotic metabolising enzyme expression in colonic neoplasia *J A McKay, G I Murray, R J Weaver, S W B Ewen, W T Melvin, M D Burke*
 - 1240 Nuclear DNA content of isolated crypts of background colonic mucosa from patients with familial adenomatous polyposis and sporadic colorectal cancer *S Nakamura, I Kino, S Baba*
- Biliary tree**
- 1245 Intercellular adhesion molecule-1 and MHC antigens on human intrahepatic bile duct cells: effect of pro-inflammatory cytokines *R C S Ayres, J M Neuberger, J Shaw, R Joplin, D H Adams*
 - 1250 Bile duct injury after laparoscopic cholecystectomy: the value of endoscopic retrograde cholangiopancreatography *P H P Davids, J Ringers, E A J Rauws, L Th de Wit, K Huibregtse, M N van der Heyde, G N J Tytgat*
- Pancreatitis**
- 1255 Pancreatitis in Finland between 1970 and 1989 *M Jaakkola, I Nordback*
 - 1261 Duodenal juice total protein and pancreatic enzyme synthesis, turnover, and secretion in patients after acute pancreatitis *J M Ogden, S J D O'Keefe, J A Louw, G Adams, I N Marks*
- Case reports**
- 1267 Reversible bilateral ureteric obstruction due to a pancreatic pseudocyst *G E Gibson, E Tiernan, C C Cronin, J B Ferriss*
 - 1269 Iatrogenic pancreatitis in familial adenomatous polyposis *K P Nugent, A D Spigelman, C B Williams, R K S Phillips*
 - 1271 Thrombosis of splenic artery pseudoaneurysm complicating pancreatitis *Th De Ronde, B Van Beers, L de Cannière, J P Trigaux, M Melange*
 - 1274 Carcinoid tumour of the gall bladder: two case reports and a review of published works *D J Deehan, S D Heys, N Kernohan, O Eremi*
- Special report**
- 1277 Gall stone recurrence and its prevention: the British/Belgian gall stone study group's post-dissolution trial *K A Hood, D Gleeson, D C Ruppin, R H Dowling, and the British Belgian Gall Stone Study Group*
- Letters to the editor Book reviews Notes**
- A1294 **Pancreatic Society of Great Britain and Ireland**

No 10 OCTOBER 1993

- Leading articles**
- 1297 A perspective on iron deficiency anaemia *J M Sayer, R G Long*
 - 1300 Duodenal ulcer pain – the role of acid and inflammation *Kenneth E L McColl, Grant M Fullarton*
- Peptic ulcer**
- 1303 Influence of dietary fat on duodenal resistance to acid *A Lugea, A Salas, F Guarner, J-R Malagelada*
 - 1310 Reduced tissue type plasminogen activator activity of the gastroduodenal mucosa in peptic ulcer disease *M A Wodzinski, K D Bardhan, J T Reilly, P Cooper, F E Preston*
 - 1315 Diagnostic value of serum pepsinogen C in patients with raised serum concentrations of pepsinogen *A I Biemond, J Kreunig, J B M J Jansen, C B H W Lamers*
 - 1319 Prospective multicentre study of risk factors associated with delayed healing of recurrent duodenal ulcers (RUDER) *D Armstrong, R Arnold, M Classen, M Fischer, H Goebell, A L Blum, the RUDER Study Group*
 - 1327 Post-bulbar and coexisting ulceration: unique features of peptic ulcer in Hyderabad *S S C Rao, K V R Murthy*
 - 1331 Properties of a potassium channel in cultured human gastric cells (HGT-1) possessing specific omeprazole binding sites *G I Sandle, G Fraser, K Foggs, G Warhurst*
- Helicobacter pylori**
- 1339 Systemic and mucosal humoral responses to *Helicobacter pylori* in gastric cancer *J E Crabtree, J I Wyatt, G M Sobala, G Miller, D S Tompkins, J N Primrose, A G Morgan*
 - 1344 Acute perforated duodenal ulcer is not associated with *Helicobacter pylori* infection *D H Reinbach, G Cruickshank, K E L McColl*
 - 1348 *Helicobacter pylori*: comparison of DNA fingerprints provides evidence for intrafamilial infection *K B Bamford, J Bickley, J S A Collins, B T Johnston, S Potts, V Boston, R J Owen, J M Sloan*
- Small intestine**
- 1351 Somatostatin binding in human gastrointestinal tissues: effect of cations and somatostatin analogues *G V Miller, S R Preston, L F Woodhouse, S M Farmery, J N Primrose*
 - 1357 Distribution of macrophages and granulocytes expressing L1 protein (calprotectin) in human Peyer's patches compared with normal ileal lamina propria and mesenteric lymph nodes *K Bjerke, T S Halstensen, F Jahnsen, K Pulford, P Brandzaeg*
- Inflammatory bowel disease**
- 1364 Technetium-99m hexamethyl propylene amine oxime granulocyte scintigraphy in Crohn's disease: diagnostic and clinical relevance *G Sciarretta, A Furno, M Mazzoni, C Basile, P Malagutti*
 - 1370 Abnormal plasma polyunsaturated fatty acid pattern in non-active inflammatory bowel disease *M Esteve-Comas, M C Núñez, F Fernández-Bañares, A Abad-Lacruz, A Gil, E Cabré, F González-Huix, X Bertrán, M A Gussull*
 - 1374 Diffuse jeunoileitis of Crohn's disease *W C Tan, R N Allan*

- 1379 Carriage of adhesive *Escherichia coli* after restorative proctocolectomy and pouch anal anastomosis: relation with functional outcome and inflammation *A J Lobo, P M Sagar, J Rothwell, P Quirke, P Godwin, D Johnston, A T R Axon*
- 1384 Outcome of restorative proctocolectomy when the diagnosis is suggestive of Crohn's disease *S P Grobler, K B Hosie, E Affie, H Thompson, M R B Keighley*
- Large intestine**
- 1389 Non-penetrance and late appearance of polyps in families with familial adenomatous polyposis *D G R Evans, S P Guy, N Thakker, J G Armstrong, C Dodd, D R Davies, C Babbs, T Clancy, T Warne, P Sloan, T V Taylor, R Harris*
- 1394 Increased risk of thyroid and pancreatic carcinoma in familial adenomatous polyposis *F M Giardello, G J A Offerhaus, D H Lee, A J Krush, A C Tersmette, S V Booker, N C Kelley, S R Hamilton*
- 1397 Bowel dysfunction in young women with urinary retention *M-C Lemieux, M A Kamm, C J Fowler*
- 1400 Constipation in early childhood: patient characteristics, treatment, and longterm follow up *V Loening-Baucke*
- 1405 Electrogenic colonic ion transport in Hirschsprung's disease: reduced secretion to the neural secretagogues acetylcholine and iloprost *S P Hardy, P M Smith, R Bayston, L Spitz*
- 1412 Intestinal pseudo-obstruction in patients with amyloidosis: clinicopathologic differences between chemical types of amyloid protein *S Tada, M Iida, T Yao, T Kitamoto, T Yao, M Fujishima*
- Endoscopy**
- 1418 Dieulafoy's disease: endoscopic treatment and follow up *B Baettig, W Haecki, F Lammer, R Jost*
- 1422 Transrectal ultrasound study of the pathogenesis of solitary rectal ulcer syndrome *M J Van Outryve, P A Pelckmans, H Fierens, Y M Van Maercke*
- 1427 Iron deficiency anaemia – how far to investigate? *R Sahay, B B Scott*
- 1429 Audit of endoscopic surveillance biopsy specimens in HIV positive patients with gastrointestinal symptoms *S G Lim, M C Lipman, S Squire, D Pillay, S Gillespie, E A Sankey, A P Dhillon, M A Johnson, C A Lee, R E Pounder*
- Liver**
- 1433 Human gastric alcohol dehydrogenase activity: effect of age, sex, and alcoholism *H K Seitz, G Egerer, U A Simanowski, R Waldherr, R Eckey, D P Agarwal, H W Goedde, J-P von Wartburg*
- 1438 Reversal of carbon tetrachloride induced changes in microviscosity and lipid composition of liver plasma membrane by colchicine in rats *J A Solis-Herruzo, M De Gando, M P Ferrer, I Hernandez Muñoz, B Fernandez-Boya, M P De La Torre, M T Muñoz-Yague*
- Biliary tree**
- 1443 Correlation between gall bladder fasting volume and postprandial emptying in patients with gall stones and healthy controls *J Pauletzki, M Cicala, J Holl, T Sauerbruch, A Schafmayer, G Paumgartner*
- 1448 Outcome after cholecystectomy for symptomatic gall stone disease and effect of surgical access: laparoscopic v open approach *G C Vander Velpen, S M Shimi, A Cuschieri*
- Pancreatitis**
- 1452 Expression of major histocompatibility antigens in human chronic pancreatitis *R P Jalleh, J A Gilbertson, R C N Williamson, S D Slater, C S Foster*
- Clinical trial**
- 1458 Improved symptom relief and duodenal ulcer healing with lansoprazole, a new proton pump inhibitor, compared with ranitidine *C J Hawkey, R G Long, K D Bardhan, K G Wormsley, K M Cochran, J Christian, I K Moules*
- Case report**
- 1463 Pleural lymphoma in a patient presenting with malabsorption: an illustration of the clinicopathological behaviour in a case of enteropathy associated T cell lymphoma *G J Doyle, J D G Rose, P J L Kesteven*
- 1467 Letters to the editor Book reviews Notes
- 1470 British Stomach Cancer Group Meeting

No 11 NOVEMBER 1993

- Leading articles**
- 1473 Pioneer in the gluten free diet: William-Karel Dicke 1905–1962, over 50 years of gluten free diet *G P van Berge-Henegouwen, C J J Mulder*
- 1476 Molecular biology. Setting the stage in colorectal cancer? *H E Mulcahy, D P O'Donoghue*
- Oesophageal reflux**
- 1478 Paediatric gastro-oesophageal reflux: prognostic indicators from pH monitoring *K Varty, D Evans, L Kapila*
- 1482 Non-invasive detection of gastro-oesophageal reflux using an ambulatory system *N Washington, H A Moss, C Washington, J L Greaves, R J C Steele, C G Wilson*
- 1487 Acid clearance and oesophageal sensitivity in patients with progressive systemic sclerosis *G Basilisco, R Barbera, M Molgora, M Vanoli, P Bianchi*
- Endoscopy**
- 1492 Effects of supplemental oxygen on cardiac rhythm during upper gastrointestinal endoscopy: a randomised controlled double blind trial *T E Bowling, C L Hadjiminas, R J Polson, J H Baron, R A Foale*
- 1498 Long term results of endoscopic dilatation for corrosive oesophageal strictures *S L Broor, G S Raju, P P Bose, D Lahoti, G N Ramesh, A Kumar, G K Sood*
- 1502 Efficacy of the heater probe in peptic ulcer with a non-bleeding visible vessel. A controlled, randomised study *J L Jaramillo, C Carmona, C Gálvez, M de la Mata, G Miño*
- Helicobacter pylori**
- 1507 Ultrastructural patterns of *Helicobacter pylori* *M Caselli, A Aleotti, P Boldrini, M Ruina, V Alvisi*
- 1510 Gastric metaplasia and *Helicobacter pylori* infection *L A Noach, T M Rolf, N B Bosma, M P Schwartz, J Oosting, E A J Rawws, G N J Tytgat*
- Small intestine**
- 1515 Dose dependent effects of protracted ingestion of small amounts of gliadin in coeliac disease children: a clinical and jejunal morphometric study *C Catassi, M Rossini, I-M Rätsch, I Bearzi, A Santinelli, R Castagnani, E Pisani, G V Coppa, P L Giorgi*
- 1520 Effect of a satiating meal on the concentrations of procolipase propeptide in the serum and urine of normal and morbidly obese subjects *R C Bowyer, W M Rowston, A M T Jehanli, J H Lacey, J Hermon-Taylor*
- 1526 Nerve involvement in fluid transport in the inflamed rat jejunum *M Jodal, U Wingren, M Jansson, M Heidemann, O Lundgren*
- Inflammatory bowel disease**
- 1531 Neoterminal ileal blood flow after ileocolonic resection for Crohn's disease *W J Angerson, M C Allison, J N Baxter, R I Russell*
- 1535 Comparison of leukocyte excretion and blood loss in inflammatory disease of the bowel *K Teahon, I Bjarnason*

- 1539 Refractory pouchitis: does it reflect underlying Crohn's disease? *K Subramani, N Harpaz, J Bilotta, C Bodian, P H Rubin, H D Janowitz, I M Gelernt, D B Sachar*
- 1543 Hormone replacement therapy prevents bone loss in patients with inflammatory bowel disease *D Clements, J E Compston, W D Evans, J Rhodes*
- 1547 Prevalence and family risk of ulcerative colitis and Crohn's disease: an epidemiological study among Europeans and South Asians in Leicestershire *C S J Probert, V Jayanthi, A O Hughes, J R Thompson, A C B Wicks, J F Mayberry*
- 1552 Ileal and colonic epithelial metabolism in quiescent ulcerative colitis: increased glutamine metabolism in distal colon but no defect in butyrate metabolism *I A Finnie, B A Taylor, J M Rhodes*
- Colorectal cancer**
- 1559 Omeprazole inhibits colorectal carcinogenesis induced by azoxymethane in rats *I D Penman, E El-Omar, J R McGregor, K J Hillan, P J O'Dwyer, K E L McColl*
- 1566 DNA densitometry of colorectal cancer *G T Deans, K Williamson, P Hamilton, M Heatley, K Arthurs, C C Patterson, B J Rowlands, T G Parks, R A J Spence*
- Motility**
- 1572 Ambulatory motility patterns of the transposed short segment colon *G Peppas, H R Payne, K Jeyasingham*
- 1576 Liquid stool incontinence with severe urgency: anorectal function and effective biofeedback treatment *G Chiariom, C Scattolini, F Bonfante, I Vantini*
- 1581 Biomechanical wall properties of the human rectum. A study with impedance planimetry *F H Dall, C S Jørgensen, D Houe, H Gregersen, J C Djurhuus*
- Colonic epithelium**
- 1587 Proliferation cell nuclear antigen (clone 19A2) correlates with 5-bromo-2-deoxyuridine labelling in human colonic epithelium *U M Weisgerber, H Boeing, R Nemitz, R Raedsch, R Waldherr*
- 1593 Expression of intercellular adhesion molecule 1 (ICAM-1, CD54) in colonic epithelial cells *W Dippold, B Wittig, W Schwaebel, W Mayet, K-H Meyer zum Büschenfelde*
- Liver**
- 1598 Randomised trial of targeted chemotherapy with lipiodol and 5-epidoxorubicin compared with symptomatic treatment for hepatoma *M V Madden, J E J Krige, S Bailey, S J Beningfield, C Geddes, I D Werner, J Terblanche*
- 1601 Down regulation of epidermal growth factor receptors in liver proliferation induced by a mixture of triiodothyronine, amino acids, glucagon, and heparin (TAGH) *D A Vesey, A C Selden, H J F Hodgson*
- Biliary tree**
- 1607 Postprandial biliary and pancreatic secretion during profound inhibition of gastric secretion in humans *A Lanzini, D Facchinetto, M G Pigozzi, A Wuhrer, A Saleri*
- 1612 Primary culture of bovine gall bladder epithelial cells *J N Plevris, S W Walker, D J Harrison, A Dhariwal, P C Hayes, I A D Bouchier*
- Pancreas**
- 1616 Mechanism of Galanin's inhibitory action on pancreatic enzyme secretion: modulation of cholinergic transmission – studies in vivo and in vitro *K-H Herzig, G Brunke, I Schön, M Schäffer, U R Fölsch*
- 1622 Somatostatin and somatostatin analogues – are they indicated in the management of acute pancreatitis? *C J McKay, C W Imrie, J N Baxter*
- Case reports**
- 1627 Extraintestinal lymphoma in association with Whipple's disease *C D Gillen, R Coddington, P G Monteith, R H Taylor*
- 1630 Inflammatory bowel disease and refractory anaemia (myelodysplasia) *R Sahay, D R Prangnell, B B Scott*
- 1632 Hepatoerythropoietic porphyria precipitated by viral hepatitis *R J Hift, P N Meissner, G Todd*
- 1635 Intraperitoneal ivalon mimicking peritoneal malignancy after plugged percutaneous liver biopsy *N P Thompson, P J Scheuer, R Dick, G Hamilton, A K Burroughs*
- 1636 Crohn's disease with pulmonary involvement in a 3 year old boy *C J Calder, D Lacy, F Raafat, P H Weller, I W Booth*
- 1639 Hormone replacement therapy in chronic active hepatitis; a case report *D Clements, J Rhodes*
- Special report**
- 1641 Aldehyde disinfectants and health in endoscopy units. The report of a working party of the British Society of Gastroenterology Endoscopy Committee *R E Cowan, A P Manning, G A J Ayliffe, A T R Axon, J S Causton, N F Cripps, R Hall, P J V Hanson, J Harrison, R J Leicester, C Neumann, J Wicks*
- 1646 Letters to the editor Book review Notes Correction

No 12 DECEMBER 1993

- Leading articles**
- 1649 Gene expression in Barrett's mucosa: acute and chronic adaptive responses in the oesophagus *Janusz Jankowski*
- 1651 Capturing clinical activity – coming to terms with information *J G Williams, D V Ford, T R Yapp*
- Oesophagus**
- 1653 Nocturnal oesophageal motor activity is dependent on sleep stage *F Castiglione, C Emde, D Armstrong, C Schneider, P Bauerfeind, G Stacher, A L Blum*
- Peptic ulcer**
- 1660 Peptic ulcer, cimetidine, and motor neurone disease – a record linkage study *M P Vessey, M J Goldacre, V Seagroatt, D Yeates*
- 1662 Two year maintenance treatment of duodenal ulcer disease with ranitidine 150 mg: a prospective multicentre randomised study *Ph Ruszniewski, A Slama, M Pappo, M Mignon, GEMUD*
- 1666 Perforated peptic ulcer over 56 years. Time trends in patients and disease characteristics *C Svanes, H Salvesen, L Stangeland, K Svanes, O Søreide*
- Helicobacter pylori**
- 1672 Epidemiology of, and risk factors for, *Helicobacter pylori* infection among 3194 asymptomatic subjects in 17 populations *The EUROGAST Study Group*
- 1677 Prevalence of *Helicobacter pylori* infection and its effect on symptoms and non-steroidal anti-inflammatory drug induced gastrointestinal damage in patients with rheumatoid arthritis *P M Goggin, D A Collins, R P Jazrawi, P A Jackson, C M Corbishley, B E Bourke, T C Northfield*
- 1681 When is *Helicobacter pylori* infection acquired? *D J E Cullen, B J Collins, K J Christiansen, J Epis, J R Warren, I Surveyor, K J Cullen*
- Stomach**
- 1683 DNA damage in the stomach after vagotomy measured by ³P-postlabelling *G W Dyke, J L Craven, R Hall, R C Garner*
- 1688 Chronic nicotine intake causes vascular dysregulation in the rat gastric mucosa *M Battistel, M Plebani, F Di Mario, M Jocić, I T Lippe, P Holzer*

- Small intestine**
1693 Determination of the histological distribution of insulin like growth factor 1 receptors in the rat gut *J Ryan, D C Costigan*
- Inflammatory bowel disease**
1698 Expression of CD45RO on circulating CD19+ B-cells in Crohn's disease *B R Yacyshyn, L M Pilarski*
1705 Location of tumour necrosis factor α by immunohistochemistry in chronic inflammatory bowel disease *S H Murch, C P Braegger, J A Walker-Smith, T T MacDonald*
- Colonic cancer**
1710 Human papillomavirus 16 DNA in NIH3T3 cells transformed by colonic cancer cellular DNA *Jhy-Young Cheng, Ching-Liang Meng, Chung-Faye Chao, Shun-Der Gau, Jih-Chang Lin*
- Liver**
1714 Prediction of the response of chronic hepatitis C to interferon alfa: a statistical analysis of pretreatment variables *J Camps, S Crisóstomo, M García-Granero, J I Riezu-Boj, M P Civeira, J Prieto*
- Biliary tree**
1718 Endoscopic extraction of bile duct stones: management related to stone size *A Lauri, R C Horton, B R Davidson, A K Burroughs, J S Dooley*
- Pancreas**
1722 Comparison of two sialosyl-Tn binding monoclonal antibodies (MLS102 and B72.3) in detecting pancreatic cancer *C K Ching, S W Holmes, G K T Holmes, R G Long*
- Case report**
1726 Toxic megacolon: the knee-elbow position relieves bowel distension *M Z Panos, M J Wood, P Asquith*
- Special report**
1728 Nature and standards of gastrointestinal and liver services in the United Kingdom *Gastroenterology Services Working Party of the Clinical Services Committee of the British Society of Gastroenterology*
- Letters to the editor**
1740
- Author index – Main headings, 1993**
1743
- Subject index – Main headings, 1993**
1758
- Author index – Supplements, 1–4, 1993**
1768
- Subject index – Supplements, 1–4, 1993**
1776

Gut

*Journal of the British Society of Gastroenterology
which is a registered charity*

Gut publishes original papers, short rapid communications, leading articles, and reviews concerned with all aspects of the scientific basis of diseases of the alimentary tract, liver, and pancreas. Case reports will only be accepted if of exceptional merit. Letters related to articles published in *Gut* or with topics of general professional interest are welcomed. Authors should include the names and addresses of four experts whom the authors consider suitable to peer review their work.

COMMUNICATIONS Two copies of the manuscript and figures should be addressed to the Editor, *Gut*, BMA House, Tavistock Square, London WC1H 9JR, UK. Manuscripts should follow the Vancouver conventions (see *BMJ* 1979; i: 532-5. *Gut* 1979; 20: 651-2). They should be in double spaced typewriting on one side of the paper only. The title page should include the name of the author with initials or distinguishing first name only, and the name and address of the hospital or laboratory where the work was performed. The paper must include a precise summary of the work of less than 200 words. Use of abbreviation is discouraged. Short rapid communications should not be more than 10 double spaced A4 pages including references, tables, and figures. These papers will be subject to peer review in the normal way. The interval from acceptance to publication will be much shorter. A covering letter should include a request for the paper to be considered in this category with valid reasons for that request. A separate covering letter signed by all authors must state that the data have not been published elsewhere in whole or in part and that all authors agree to publication in *Gut*. Previous publication in abstract form must be disclosed in a footnote. Papers must not be published elsewhere without prior permission of the Editorial Committee.

ACKNOWLEDGEMENT OF MANUSCRIPTS Manuscripts will only be acknowledged if an addressed postcard is enclosed.

ILLUSTRATIONS *Photographs* Unmounted photographs on glossy paper should be provided. Illustrations should not be inserted in the text but marked on the back with the figure numbers, title of paper and name of author. All photographs, graphs, diagrams should be referred to as figures and should be numbered consecutively in the text in Arabic numerals. The legends for illustrations should be typed on a separate sheet.

ETHICS Ethical aspects will be considered in the assessment of papers (see the Medical Research Council's publications on the ethics of human experimentation, and the World Medical Association's code of ethics, known as the Declaration of Helsinki (see *BMJ* 1964; ii: 177)).

SI UNITS All measurements except blood pressure are expressed in SI units. In tables and illustrations values are given in SI units. For general guidance on the International System of Units and some useful conversion factors, see *The SI for Health Professions* (WHO, 1977).

NB: Such conversion is the responsibility of the author.

REFERENCES These follow the Vancouver system – that is, references numbered consecutively in the text and listed numerically with journal titles abbreviated in the style of *Index Medicus, Standard journal article*. List up to six authors, then add *et al.*

CORRECTIONS other than printers' errors may be charged to the author.

REPRINTS Reprints will be available on payment of the necessary costs; the number of reprints required should be sent to the Publishing Manager on the form provided with the proof.

NOTICE TO ADVERTISERS All applications for advertisement space and rates should be addressed to the Advertisement Manager, *Gut*, BMA House, Tavistock Square, London WC1H 9JR.

NOTICE TO SUBSCRIBERS *Gut* is published monthly. The annual subscription rates are £177.00 (USA \$309.00). Reduced subscriptions of £74.00 available to trainees for one year (direct only). Orders should be sent to the Subscription Manager, *Gut*, BMA House, Tavistock Square, London WC1H 9JR. Orders can also be placed with any leading subscription agent or bookseller. (For the convenience of readers in the USA subscription orders, with or without payment, can be sent to: *British Medical Journal*, Box 560B, Kennebunkport, Maine 04046. All enquiries, however, must be addressed to the Publisher in London.) Subscribers may pay for their subscriptions by Access, Visa, or American Express by quoting on their order the credit or charge card preferred together with the appropriate personal account number and the expiry date of the card. All overseas copies of the journal are sent by accelerated surface post. If required, full air mail rates and enquiries for single copies already published should be addressed to the Publisher in London.

COPYRIGHT © 1993 *Gut*. This publication is copyright under the Berne Convention and the International Copyright Convention. All rights reserved. Apart from any relaxations permitted under national copyright laws, no part of the publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means without the prior permission of the copyright owners. Permission is not, however, required to copy abstracts of papers or articles on condition that a full reference to the source is shown. Multiple copying of the contents of the publication without permission is always illegal.

Second class postage paid, Rahway NJ. Postmaster: send address changes to: *Gut*, c/o Mercury Airfreight International Ltd Inc, 2323 Randolph Avenue, Avenel, NJ 07001, USA. ISSN 0017-5749.